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Abstract
Genetic studies of bipolar disorder and recurrent major depression in a large Scottish family
Bipolar disorder and recurrent major depression are complex psychiatric illnesses 
with a substantial, yet unknown genetic component. Genetic studies have identified linkage 
of bipolar disorder and recurrent major depression with markers on chromosome 4p15-p16 
in a large Scottish family and three smaller families. To focus the search for genetic factors 
for susceptibility to illness two approaches were adopted: a chromosome 4p15-p16 candidate 
gene study and a whole-genome linkage scan.
In the first instance, phosphatidylinositol 4-kinase type-II beta (PI4K2B) was selected 
as a candidate gene. Analysis of haplotypes in the four linked families identified two 
regions, both of which were shared by three families. PI4K2B lies within one of these regions. 
PI4K2B is also a worthy functional candidate as it is a member of the phosphatidylinositol 
pathway, which is targeted by lithium for therapeutic effect in bipolar disorder. Expression 
studies at the allele-specific mRNA and protein level were performed in lymphoblastoid cell 
lines from the large Scottish family. There was no evidence for expression differences 
between affected and non-affected family members. However, a case-control association 
study showed preliminary evidence for association of schizophrenia but not bipolar 
disorder, with tagging single nucleotide polymorphisms from the PI4K2B genomic region.
Second, the linkage evidence for bipolar disorder and recurrent major depression in 
the large Scottish family was re-examined. This was important because additional family 
members had been recruited and advances in technology made it feasible to cover all 
chromosome regions more densely than had been possible ten years ago. Stringent 
genotyping and pedigree error checks were performed to ensure an optimised dataset for 
analysis. Furthermore, the large family was divided in an informative manner for ease of 
analysis using both parametric and non-parametric methods, supplemented by haplotype 
analysis. Genome-wide significant evidence for linkage was observed on chromosome 4p15-
p16 and genome-wide suggestive evidence was observed on chromosomes 8p21 and 1p36. 
The analysis clearly supports the evidence for a susceptibility locus of bipolar disorder and 
recurrent major depression on chromosome 4p15-p16, while identifying other genetic loci 
that may confer risk to psychiatric illness.
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1.1. Bipolar Disorder & Recurrent Major Depression
1.1.1. Diagnosis of the illness
Bipolar disorder is a distressing psychiatric illness. It was originally termed “manic-
depression” to encompass the primary features of the illness: separate episodes of 
mood elevation “mania” and deep disabling depression. The periods of mania are 
marked by feelings of elation, euphoria, irritation and increased activity, whereas 
feelings of sadness, anxiety, guilt, anger and hopelessness are common in 
depression episodes. The duration of the depression periods are longer and more 
frequent than the manic episodes. The illness is defined by these episodes of 
extreme behaviour, which are often inappropriate and unpredictable in nature. 
Accompanying characteristics of the mood disturbances are psychosis, cognitive 
impairment, increasing creative energy, sleep and other periodicity problems (ISBD 
2006). Undoubtedly, bipolar disorder impacts negatively on quality of life (World 
Health Organization 2005).
The criteria for diagnosing mental disorders are defined in the DSM-IV (Diagnostic 
and Statistical Manual of Mental Diseases) from the American Psychiatric 
Association (American Psychiatric Association 2000) and the International 
Classification of Diseases (ICD-10) of the World Health Organisation (WHO) (World 
Health Organization. 1994). In DSM-IV, bipolar disorder is subdivided into two 
classes, bipolar I disorder and bipolar II disorder. In bipolar I disorder, the mania 
episodes consist of mood elevation persisting for longer than one week with social 
impairment. In bipolar II disorder, patients suffer shorter periods of hypomania 
with mood elevation for at least four days. Using DSM-IV or ICD-10 criteria ensures 
that diagnoses of mental disorders are reliable. However, the validity of the 
diagnoses is unknown as there are no biological diagnostic markers for the illness. 
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In particular there are no diagnostic markers that will be considered for inclusion in 
the newly proposed DSM-V (Hyman 2007).
Patients with recurrent major depression, sometimes referred to as unipolar 
disorder, experience episodes of depression but no mania symptoms. Individuals 
diagnosed with recurrent major depression suffer from the same characteristics 
associated with the depression episodes in individuals with bipolar disorder.
Yet another mental illness, namely schizophrenia is also discussed in this study. It is 
regarded as a separate illness to bipolar disorder and recurrent major depression, 
with positive symptoms which are psychological phenomena that do not occur in 
healthy individuals, such as hallucinations and delusions, and negative symptoms 
which arise from deficits in normal functions, such as lack of motivation and blunt 
emotional responses. Cognitive deficits, including impairments in working memory 
and executive functions, are found in both schizophrenia and bipolar disorder 
(Hyman 2007). 
1.1.2. Prevalence of the illness
The lifetime prevalence of bipolar disorder in the general population is 0.5-1.5% for 
both males and females, as shown in Table 1.1 and the mean age of onset is
estimated to be 21 years (Smith and Weissmann 1992). Recurrent major depression 
is more common in the population, but there are varying reports of the prevalence. 
The large US multi-site Epidemiological Catchment Area (ECA) study reported a 
lifetime population prevalence for DSM-III major depression of 4.4% (Weissman, 
Leaf et al. 1988) whereas the US National Comorbidity Survey estimated the lifetime 
prevalence of DSM-III major depression to 17% (Kessler, McGonagle et al. 1994). In 
addition, the lifetime rate for recurrent major depression in women (21.3%) is twice 
that for men (12.7%) (Kessler, McGonagle et al. 1994). Nevertheless, it is widely 
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regarded that recurrent major depression is common in the population (McGuffin, 




RISK OF BIPOLAR 
DISORDER (%)
ADDITIONAL RISK OF 
RECURRENT MAJOR 
DEPRESSION
Monozygotic co-twin 40-70 15-25
First degree relation 5-10 10-20
General population 0.5-1.5 5-10
Table 1.1 The approximate lifetime rates for bipolar disorder and recurrent 
major depression. This table is adapted from (McGuffin, Owen et al. 2002). The 
lifetime risk for a mood disorder in a relation is obtained by adding the risk of bipolar 
disorder and the risk of recurrent major depression.
Table 1.1 summarises classical genetic studies of bipolar disorder to show that there 
is an increase in risk of bipolar disorder and recurrent major depression with an 
affected relation; the risk of a bipolar disorder diagnosis is 5-10% when the 
individual has an affected first degree relation and 40-70% for an affected 
monozygotic twin. One particular study of 2.1 million individuals from the Danish 
population, of whom 2,229 were diagnosed with bipolar disorder, showed a nearly 
14-fold increase in risk of bipolar disorder, when an individual had a first-degree 
relation with bipolar disorder (Mortensen, Pedersen et al. 2003). The risk of a 
recurrent major depression is 10-20% for those with a first degree relation with 
bipolar disorder and 15-25% for a monozygotic twin with bipolar disorder. 
Twin and adoption studies also demonstrate heritability of bipolar disorder, and to 
some degree in recurrent major depression. The largest bipolar disorder twin study 
used the Danish Twin Register and found that the probandwise concordance (the 
proportion of proband twins with bipolar disorder who had a twin with bipolar 
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disorder) in monozygotic twins was 0.62, and for dizygotic twins was 0.08 
(Bertelsen, Harvald et al. 1977). As there was not full concordance (100%) in 
monozygotic twins, it suggests the existence of “environmental” risk factors in 
addition to genetic risk factors.  While the estimation of a genetic component in 
recurrent major depression is not so clear-cut due to unknown diagnostic validity, 
ascertainment problems and gender differences, a meta-analysis of twin studies 
illustrates a significant additive genetic effect and an estimated heritability or 
recurrent major depression of 37% (95%CI 31-42%) (Sullivan, Neale et al. 2000).
Further evidence supporting genetic risk factors for bipolar disorder has been 
provided by adoption studies. Adoption studies are useful to distinguish post-natal 
environment and genetic risk factors, as the affected individuals inherit genetic risk 
factors from their biological parents but their environmental exposure from a 
different family. A bipolar disorder adoption study showed that the biological 
relations of bipolar disorder adoptees were at a greater risk for bipolar disorder than 
were the adoptive relations. The risk in biological relations of bipolar adoptees was 
similar to that in the biological relations of bipolar non-adoptees (Mendlewicz and 
Rainer 1977).
1.1.1. Treatment for the illness
The WHO publishes a list of essential medicines that satisfy the priority health care 
needs of the population (WHO Model List of Essential Medicines, 15th edition, 
revised March 2007). The core list presents an index of the minimum medicine 
needs for a basic health care system, cataloguing the most efficacious, safe and 
cost‐effective medicines for priority conditions. Priority conditions are selected on 
the basis of current and estimated future public health relevance, and potential for 
safe and cost‐effective treatment. For the treatment of bipolar disorder, the WHO 
recommends lithium carbonate and the anticonvulsants: carbamazepine and 
valproate. For the treatment of depression, the tricyclic antidepressant, amitriptyline 
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and the selective serotonin reuptake inhibitor (SSRI) class antidepressant, fluoxetine 
are recommended. However, the mood-stabilising treatments are often not fully 
effective, have many reported adverse side-effects and can be toxic at doses close to 
the therapeutic range (Moller and Nasrallah 2003).
1.2. Genetic Analysis
In the following section, I would like to introduce basic genetic concepts. These are 
important to understand when genetic mapping studies for bipolar disorder are 
discussed. Ensuing this, I will present a more detailed explanation of case-control 
association analysis and linkage analysis. While it is not essential reading to 
introduce this study, readers will find it helpful as it directly introduces methods
used in chapters 4, 5 and 6 of this thesis.
1.2.1. Genetic concepts
The concept behind the two genetic mapping approaches, linkage and association, is 
shown in Figure 1.1. Association compares the frequency of the markers between 
the cases with the disease and the unaffected controls. For example, marker “C” 
occurs more frequently in cases than the controls in Figure 1.1a. Linkage analysis 
searches for two loci that are inherited together, for example the disease and marker 
“C” in Figure 1.1b. Both approaches search for the same genetic determinant for 
disease, however there are notable differences between the two methods. 
Association is observed in unrelated individuals, whereas linkage is only in related
individuals. Also, association only occurs when the marker is extremely close to the 




Figure 1.1 Association and linkage mapping. Association mapping is illustrated in 
a. The affected individuals share the C allele identical by descent (IBD) from a 
common ancestor in the past marked by the arrow. Linkage mapping is illustrated in 
(b) and shows that the affected individuals share the C allele IBD from a common 
ancestor, three generations in the past (Personal communication, Chad Garner, 23rd
July 2006, University of California, US (Weeks, Lathrop et al. 2006)).
1.2.2. Hardy-Weinberg equilibrium
An important feature of genetic studies is Hardy-Weinberg equilibrium, which 
ensures the markers under investigation for linkage or association analysis behave 
in a non-biased manner. Hardy–Weinberg distribution describes the simple 
relationship between gene frequencies and genotype frequencies that is found in a 
population under certain conditions. In the presence of random mating, the alleles 
at a neutral locus are independent such that the genotype frequencies are given by 
the product of the allele frequencies. For example, in a biallelic marker having 
alleles A and a, 
o the allele frequencies are Pr(A)=p and Pr(a)=q=(1-p)
o the genotype frequencies are Pr(AA)=p2, Pr(Aa)=2pq, Pr(aa)=q2
o which sum to one  p2+2pq+q2=1
Hardy Weinberg distribution can break down due to a variety of reasons including 
systematic genotyping errors, inbreeding, random sampling, sampling of affected 












Another important characteristic is linkage disequilibrium (LD). LD, also called 
allelic association, is the non-random association of markers at different loci, 
whether or not the loci are physically linked. Markers are in LD if they are inherited 
together more often than expected by chance. LD can be created through mutation, 
drift in small populations, population bottlenecks, founder effects or selection. 
Conversely, LD decays as a function of the recombination rate, the effective 
population size, time and mutation. There are conventionally three ways to measure 
LD between markers: D’, r2 and LOD. The co-efficient D is, in short, the equivalent 
to the co-variance between loci (Lewontin 1964).  D’ is the normalised measure of 
Lewontin and is the absolute value of the difference between observed and expected 
probabilities. An advantage of this method is that it is related to recombination rate; 
however a disadvantage is that it is biased in small sample sizes. A D’ value of one 
means complete LD between two markers, such that there is no evidence for an 
ancestral recombination event between two markers. r2 looks at the statistical 
association between markers by the correlation coefficient between markers. One 
advantage of r2 is that it is more reliable than D’ for markers with low allele 
frequencies. An r2 of one means perfect LD between two markers, no recombination 
between the markers or they have the same allele frequencies. Also, either of the 
markers are redundant and can act as “perfect proxies” to each other (Pritchard and 
Przeworski 2001). The third measure is the logarithm of the odds (LOD score) for 
linkage disequilibrium between a given marker pair, and is commonly used in 
HapMap (section 1.3.6) as an LD measure (www.hapmap.org).
1.2.4. Identity by descent
The labelling of genetic markers as identical by descent (IBD) or identical by state 
(IBS) is an important concept in genetics. Related individuals are similar to each 
other because they have variants that are IBD, which are copies of the same variant
from a common ancestor, as illustrated with the red circles in Figure 1.2. IBD 
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variants are of the same allelic type whereas non-IBD variants are of independent 
types and are illustrated by the purple circles in Figure 1.2. For alleles that are the 
same, but it is unclear whether they are IBD, are termed identical by state (IBS), 
shown by the green circles in Figure 1.2. To date, many useful applications of IBD 
estimation have been devised, for example: relatedness analysis, case-control 
association studies and non-parametric linkage analysis and are discussed in the 
upcoming sections.
Figure 1.2 Allele-sharing. Definition of identity by descent (IBD) and identity by 
state (IBS) is illustrated with two pedigrees on a three-allele (A, C, G) marker.  IBD 
alleles are highlighted in red, IBS alleles in green and non-IBD alleles in purple.
1.2.5. Relatedness analysis
The estimation of IBD and IBS is central to relatedness analysis between individuals
in a family. A pedigree or relationship determines probabilities of IBD, which then
determines probabilities of joint genotypes. This is equivalent to similarity among 
relations. The identification of alleles that are IBS is also informative over a large 
number of markers, shared by a pair of individuals to detect full-siblings, half-
siblings and unrelated individuals (Ehm and Wagner 1998).  IBD sharing between 
related individuals is measured as the probability of a relationship-pair sharing 0, 1 




PAIRWISE RELATIONSHIP Κ 0 Κ 1 Κ 2 Ψ
Unrelated 1.00 0 0 0
Parent-Offspring 0 1.00 0 0.25
Monozygous twin 0 0 1.00 0.5
Full sibling 0.25 0.5 0.25 0.25
Half sib, grandparent, aunt 0.5 0.5 0.00 0.125
First cousin 0.75 0.25 0 0.0625
Double first cousin 0.5625 0.375 0.0625 0.125
Quadruple half first cousin 0.5312 0.4375 0.0312 0.125
Table 1.2 Identity by descent sharing relationship between relations. κ is the 
probability of 0, 1, or 2 markers shared identical by descent (IBD) (pi = Pr (i genes 
IBD), κ2+ κ1+ κ0=1.ψ is the kinship coefficient which measures IBD between two 
markers. This table is adapted from (Thompson 2000; Weir, Anderson et al. 2006)
ψ is the kinship coefficient which measures IBD between two markers. Kinship 
coefficients can be theoretical, derived from assumed levels of marker sharing in a 
pedigree as shown in Table 1.2, or conditional, which use marker data. The 
theoretical kinship coefficient ψ ij is the probability that a randomly sampled gene 
from j is IBD to a randomly sampled gene from the same arbitrary locus of i. For 
example, ψ ij = 1/2 if i = j and ψ ij = 1/4 if i and j are first degree relatives. In both 
cases, no inbreeding is allowed.
1.3. Case-Control Association Studies
1.3.1. Concept of association studies
In an influential paper, Risch and Merikangas advised that the “future of genetics 
requires large-scale testing by association analysis” (Risch and Merikangas 1996). 
Case-control association studies are commonly used to detect variants causing 
susceptibility to common complex disorders. In the present day literature, 
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association studies fall into two categories; candidate gene studies and whole-
genome association. Candidate gene studies are hypothesis-driven, that focus on a 
particular biological function or area of the genome. Whole genome association 
studies are performed without a prior hypothesis, as susceptibility genes are often 
not obvious biological candidates, and comprehensively cover the whole genome 
with a dense marker set. However, those whole genome association studies 
performed searching for common bipolar disorder variants have met with a mixed 
success rate, as will be described in section 1.5.3.
1.3.2. Methods of association analysis
Figure 1.3 depicts the calculations used for association study analysis methods, 
utilising χ2 contingency models at the allele level and genotype level, incorporating 
the dominant, recessive and additive models (Lewis 2006). An additive model 
(Armitage’s test for trend) is specified by assigning to the heterozygous genotype, a 
value that is halfway between the values of the two homozygous genotypes.
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Figure 1.3 Contingency table calculations for case-control association study 
analysis. AA, BB and AB represent the genotypes at certain SNPs. a is the number 
of cases with a particular genotype. N is the number of controls with a particular 
genotype.
The χ2 statistic tests the null hypothesis that there is no difference between observed 
and expected results and is calculated as follows
o χ²=Σ(obsi-expi)2/expi
o Degrees of Freedom, df = (number of columns-1)*(number of rows-1) where 
the observed counts are the number of alleles/genotypes and the expected 
results in each cell 
o Expi = column total*row total/total
The Odds Ratio (OR) is a measure of relative risk derived from case-control 
association studies; it is the ratio of odds of disease in the exposed group over the 
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non-exposed group (Zondervan and Cardon 2007). The OR can also be defined as 
the ratio of the odds of an event occurring in one group (cases) to the odds of it 
occurring in another group (controls) is also calculated with 95% confidence 
intervals.
The Odds Ratio of the AB genotype
o OR AB genotype baseline AA = (nAA*aAB)/(nAB*aAA)
o OR BB genotype baseline AA = (nAA*aBB)/(nAA*nBB)
o OR AB genotype baseline BB = (nBB*aAB)/(nAB*aBB)
o OR AA genotype baseline BB = (nBB*aAA)/(nAA*aBB)
The 95% Confidence Intervals are calculated as 
o 95%CI = OR/EF OR*EF 
o Error Factor (EF) = exp[1.96*s.e.(logOR)]
o s.e.(logOR) = √[1/nAA + 1/aAB + 1/nAB +1/aAA) 
as an example for OR AB (Kirkwood and Sterne 2003).
The expected genotype frequencies, as calculated above, are compared to the 
observed genotype frequencies, using the χ2 statistic and corresponding P-value.
1.3.3. Haplotype analysis in association studies
Analytic methods for association studies can be extended beyond the allele level 
and genotype level. Association analysis performed on haplotypes can improve the 
information content of the genomic region under investigation (Ott and Rabinowitz 
1997; Chapman and Wijsman 1998), with an aim to detect chromosomal segments 
that carry the true functional variant. UNPHASED (Dudbridge 2003) is a selection of 
programmes for association analysis of multilocus haplotypes from unphased 
genotype data. UNPHASED includes a program COCAPHASE v2.43 which 
performs case-control association study analysis and is used here to first, perform 
haplotype frequency estimation and then perform association analysis of such 
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haplotypes to illness. This software uses the expectation maximisation (EM) 
algorithm, which is a numerical method to find the maximum likelihood estimates 
of parameters and is applicable in situations where there are more categories than 
can be distinguished, such as known genotype data but incomplete haplotype data. 
The EM algorithm estimates the haplotype frequencies of unphased genotype data 
and standard unconditional logistic regression analysis, applying the likelihood 
ratio test under a log-linear model, to ultimately compare haplotype frequencies 
between cases and controls. Potential problems caused by rare haplotypes are 
circumvented by declaring all haplotypes rare, that have a frequency less than or 
equal to 5% in both the cases and the controls, and clumping them together for 
testing the null hypothesis. The maximum-likelihood frequencies are re-computed 
after identification of rare haplotypes. 
1.3.4. Reporting evidence for association studies
To report positive association results, the number of tests performed must be taken 
into account. The range of tests must be considered; at the genotype level, from 
multiple polymorphisms in candidate gene studies to whole genome association 
studies; at the phenotype level, from multiple phenotypes definitions to multiple 
endophenotypes and; at the analysis level, from single allele analysis to multiple-
marker haplotype analysis. The traditional critical significance level (α<0.05) is not 
thought to be sufficient to avoid false positive results. There are many options to 
account for the number of tests, such as Bonferroni correction, that corrects the 
critical significance level by the number of tests (n) performed (α=0.05/n) and 
Nyholts, which is based on spectral decomposition (Nyholt 2004). However, they 
may be both overly conservative for non-independent tests (Perneger 1998; 
Salyakina, Seaman et al. 2005). A preferred option is permutation analysis, which 
permutes the affection status of both cases and controls within the particular study, 
recalculates the tests for association, records the smallest P-value and repeats this to 
obtain empirical distribution of the smallest P-values. This method is 
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computationally intensive but provides a clearer picture to the degree of 
significance for the association results. 
1.3.5. Features of association studies
There are many ways to improve the power to detect a real positive association 
result. For example, increasing sample size and marker density, improving accuracy 
of phenotype and genotype measurements, rigorous quality control and error 
checking and selecting individuals with highest genetic loading as cases, and 
individuals with lowest genetic loading as controls can provide substantial 
improvements. At the analysis stage, power can be improved with a through 
analysis plan; incorporating all phenotype and genotype information, allowing for 
heterogeneity and population substructure (Sham 1998). Cautious interpretation of 
results and a replication study are also recommended. 
Additionally, there are many population genetic assumptions made in association 
analysis. Firstly, Hardy-Weinberg equilibrium is assumed. Secondly, the same 
mating patterns are assumed between cases and controls and this is especially 
important if genotype frequencies are tested. Thirdly, it is assumed that the search is 
for common alleles, which arose from old mutations in founder individuals, as 
illustrated in Figure 1.1. Linkage disequilibrium is also assumed, as is no population 
admixture or stratification. Finally, it is assumed there is little or no allelic 
heterogeneity (where a single trait is caused by different mutations within one gene) 
within the disease gene. The disease gene will have one common mutation, where 
this functional variant, within the gene will influence the phenotype. 
Indeed, case-control association studies have many advantages over linkage 
analysis. One major benefit of case-control association studies is the ease of 
collection of large sample sizes. Also, there is no correlation between individuals so 
the statistics are simpler. Association studies are also more efficient than linkage 
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studies in narrowing down the region of interest, as linkage studies do not localise 
the phenotype and genotype to a small chromosomal location. However, there are 
many factors that influence the power of association studies such as the mode of 
inheritance of the illness, population sub-structure, the age of the disease mutation, 
allele frequency, distance of marker to the trait, the mutation rate and genotyping 
errors. In addition, the risk allele must be common to have high power in 
association studies and hence rare risk variants are extremely difficult to detect. 
There are also disadvantages related to association studies. One potential bias in 
case-control association studies, which is not present in linkage studies, is the 
presence of confounding in the control population. Confounding exists when an 
unmeasured confounder variable is associated with both the risk factor and the 
outcome, causing an apparent association between the measured risk factor and the 
outcome. Alcohol consumption was reported to be risk factor for lung cancer 
because a significant association was observed. However, this association was not 
true and was due to a confounding factor, smoking, as the fact that individuals who 
smoked were also more likely to drink larger amounts of alcohol (Personal 
communication, Chad Garner, 23rd July 2006, University of California, US (Weeks, 
Lathrop et al. 2006)). 
It is important that the control population is representative of the same population 
that the cases are from, to reduce false positive findings due to information and 
selection biases. However, the most important bias is confounding due to 
population stratification, which is related to the ethnic origin of cases and controls. 
Population stratification occurs when the comparison of the frequency of the genetic 
variant between cases and controls shows a significant difference due to the 
underlying sampling of the population and not due to a disease risk variant.  This 
spurious association can occur in a population with different proportions of 
ethnicity to cause the confounding effects of population admixture. For example, 
population admixture affected the outcome of an association study which detected a 
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mutation that was protective against diabetes in an Indian population. The 
association did not hold when population stratification was taken into account 
(Cardon and Palmer 2003). This can be avoided by carefully matching the ethnicity 
of the control population to that of the case population.
1.3.6. HapMap
The International HapMap Project is a very important resource. The aim of the 
HapMap is to determine the common patterns of DNA sequence variation in the 
human genome, by characterising sequence variants, their frequencies and 
correlations between them (HapMap 2003). Phase II of HapMap provides 
information on the location of ~4 million common SNPs across the genome in four 
populations of different ethnic origin (Caucasians of Northern and Western 
European origin, Japanese from Tokyo, Han Chinese from Beijing and Yoruba from 
Nigeria) (Frazer, Ballinger et al. 2007). Furthermore, within each population 
HapMap provides information on the allelic association of SNPs in the same 
genomic region. This is advantageous because knowledge of the LD structure of a 
specific region helps to select SNPs that capture the majority of all common genetic 
variation, because one SNP can predict the allelic status of other nearby SNPs 
without having to genotype these variants themselves. A method available to 
visualise haplotypes is “Haploview” (Barrett, Fry et al. 2005). LD between markers 
can be visualised using the standard LD measurements D’, r2 and LOD. One method 
in Haploview is the “Solid Spine of LD”. This method searches for a "spine" of 
strong LD running from one marker to another along the triangle in the figure of 
LD. This implies that the first and last markers in a block are in strong LD with all 




1.4. Family-Based Linkage Studies
Genetic linkage analysis is a method to study the inheritance of traits in families, by 
mapping the relative positions of two or more loci using genetic markers. Linkage 
was described by Morgan in 1911 in the model organism, the fruit fly (Drosophila 
melanogaster), and the first gene mapping paper was written by Sturtevant in 1913. 
Both reports demonstrated the basis of genetic linkage; when a recombination event 
occurs between two genetic loci, it does so at a rate related to the distance between 
the two loci, on the same chromosome. Thus, loci that are physically close together, 
tend to be inherited together. The aim of linkage analysis is to determine whether 
two loci tend to cosegregate more often than they should if they are not physically 
close together on the same chromosome (Ott 1999).
There are many approaches to detect linkage to a phenotype in a family. The main 
two methods are i) the traditional model-based parametric linkage analysis and ii) 
the model-free non-parametric linkage analysis method based on allele sharing. 
Parametric and non-parametric linkage methods follow the same experimental 
procedure by examining the pedigree structure, determining the expected pattern 
(of recombination fraction or allele sharing respectively) and comparing the 
difference to that expected by chance. Both methods can provide the approximate 
location of the disease marker, the placement of the disease loci relative to other loci 
and the exclusion of other loci that do not contain the disease marker.
1.4.1. Parametric linkage analysis
Traditional linkage analysis is based on Mendel’s second law of independent 
assortment that states “genes controlling different characters segregate 
independently.” For example as shown in Figure 1.4, if a person is heterozygous at 
two loci, A/a at one loci and B/b at the other loci, there are four possible gametes: 
AB, Ab, aB and ab and all are equally likely, if under independent assortment.
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Figure 1.4 Illustration of Mendel's second law of independent assortment. 
There are two loci shown on each chromosome, A and B. There are four possible 
gametes. Two are non-recombinants (NR) and two are recombinants (R). 
However, if the two loci, one a marker and the other one a hypothetical disease 
locus, are tightly linked, and recombination between loci does not take place, then 
the only chromosomes will be AB and ab which are the parental, non-recombinant 
(NR) gametes. The recombinants (R) or non-parental gametes Ab and aB will be 
rare. Meioses are informative for linkage, if the gamete can be identified as a 
recombinant or non-recombinant. If θ is the recombination fraction, which is a 
measure of the genetic distance between two loci as discussed in more detail in 
1.4.1, between locus A and B, then for a person with AB|ab phased genotypes, the 
gamete probabilities are as Table 1.3.

















Table 1.3 Gamete probabilities. Here are the gamete probabilities from the phased 
genotypes AB|ab. There are four possible gametes. Θ is the recombination fraction. 
NR is non-recombinant and R is recombinant.
The possibility of crossover between non-sister chromatids is illustrated in Figure
1.4. One crossover results in 50% recombinant chromosomes or two crossovers 
results in either no recombinants or all recombinants. The maximum recombination 
fraction is 50%, when the two loci are not linked, as a consequence of independent 
assortment. 
These calculations can be applied to pedigrees to test for linkage; the likelihood (L) 
of recombination event occurring between two loci (θR) or not [(1-θ)NR]
o L(data|θ)= θR(1-θ)NR
and compared to the null hypothesis that loci A and B are not linked, such that θ0 = 
0.5. A likelihood ratio test compares a general θ1 against the null θ0: 
o L( data| θ1)/L (data | 0.5).
This is the odds for θ1 compared to the Null hypothesis. The next step is to calculate 
the likelihood ratio test (odds) at various values for θ. The value θ that maximizes 
the odds is the Maximum Likelihood Estimate (MLE) of θ. This is the best estimate 
for θ, given the data. LOD is the logarithm base 10 of the odds 
o LOD (θ) =log10 [L (θ) / L (0.5)]
In general, the Null hypothesis is rejected when LOD (θ1)>3 for whole genome scans 
and there is evidence for linkage between two loci.  Conversely, linkage can be 
excluded at θ1 when LOD (θ1) <-2. The thresholds for significant and suggestive 
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linkage are discussed later in section 1.4.6.3. LOD scores can be added across 
independent families, also discussed in section 1.4.1.3.
1.4.1.1. Genetic distance
The recombination fraction (θ) is a measure of the genetic distance between two loci, 
such that it is the expected number of crossovers between the two loci per gamete. 
Recombination fractions define genetic distance rather than physical distance. Two 
loci that show 1% recombination are defined as being 1 centiMorgan (cM) apart on a 
genetic map. Recombination fractions are not additive across a genetic map. To 
describe the relationship between recombination fractions and genetic map distance, 
a mapping function is used. There are several different map functions such as the 
Morgan map function, the Haldane map function and the Kosambi map function. 
The simplest one is the Morgan map function that assumes a maximum of one 
crossover but which only works for small genetic distances. The Haldane map 
function assumes any number of random, independent crossovers but does not 
allow for interference. The Kosambi map function takes into account that over short 
distances a crossover at one location reduces the chance of a second crossover 
nearby due to physical proximity, namely interference. A STR (short tandem repeat) 
high resolution genetic map by deCODE genetics (Kong, Gudbjartsson et al. 2002) is 
now commonly used in linkage studies and also in this study.
For small distances, genetic distance (Morgans) is similar to recombination fraction 
(θ). Also, genetic distance is additive whereas recombination fractions are not 
additive.  There is a complex relationship between recombination and genetic 
distance, and further again in relation to physical distance measured in base pairs 
(bp). The female human genetic map is generally longer that the male map. On 
some small regions ~10:1, and more rarely the converse ~1:10 for example on the 
pseudo-autosomal region on chromosome X that is 19cM in males but 2.7cM in 
females.  Sex-specific maps should ideally be used for linkage analysis but although 
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this area is undergoing continuous research, this is not yet possible for the whole 
genome. 
1.4.1.2. Genetic model of inheritance
Traditional parametric linkage analysis requires a model of inheritance to specify 
how the genotype at the trait locus influences the trait phenotype. The model is 
specified as a penetrance function, the probability of a genotype given a certain 
phenotype: Pr (phenotype|genotype). To explain penetrance further, it is useful to 
consider the disease allele, D, and the wild-type allele, d. For a simple, fully 
penetrant recessive disease the genotypes Dd and dd have penetrances of 0 and the 
genotype DD has penetrance 1. The set of penetrances for the genotypes at a locus 
are referred to as the penetrance vector, (fdd, fDd, fDD). For the example of a recessive 
disease, the penetrance vector is (0, 0, 1). For a simple dominant disease the 
penetrance vector is (0, 1, 1).  A value of fDD less than one indicates that some 
individuals homozygous for the disease allele do not express the disease, and such 
is termed reduced penetrance. A greater than zero value for fdd allows for 
phenocopies, which are affected individuals without the disease allele, where 
disease is presumed to have a different cause. The number of phenocopies assumed 
in a genetic model is a function of the penetrance vector and the gene frequency of 
the disease allele in the population. The relationship between fDd and fDD specifies 
the dominance of the disease gene (Terwilliger and Ott 1994).
In some diseases, including bipolar disorder and recurrent major depression, 
penetrance varies with age. To account for this, linkage analysis can include age-
dependent penetrances where individuals are grouped according to age and 
assigned liability classes depending on age. A penetrance vector is then applied to 
each liability class. The simplest method is directly from age at onset within the 
family. These values can be estimated approximately from cumulative age of onset 
distributions for sets of affected individuals (Ott 1999).
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In short, linkage analysis tests how close two loci are on a chromosome. Parametric 
linkage analysis is based on a model of inheritance that defines parameters to 
describe genotypes at a trait locus influencing a trait phenotype. The resulting 
output estimates the degree of linkage to show how far apart the loci are from each 
other.  
1.4.1.3. Features of parametric linkage analysis
As with any statistical test, there are many important assumptions to be considered 
in parametric linkage analysis. It is assumed that all markers are in Hardy-Weinberg 
equilibrium and in linkage equilibrium, which assumes that two alleles at different 
loci are independent of each other. Random mating is also assumed. Additionally, 
in the search for a single locus, it is assumed there is no interaction between alleles 
at different loci and, in fact, there is less power to detect if such epistasis (genetic 
interaction) is present. 
There are many advantages to parametric linkage analysis. Firstly, the method is not 
sensitive to allelic heterogeneity or population history. Also population substructure 
can be problematic in population case-control association studies but not in family 
linkage studies. Additionally, there are no candidate genes, regulatory regions or 
transcription factor binding sites to propose, as one might need to focus on if 
resources are restricted in performing association studies. Thirdly, linkage analysis 
is performed within pedigrees and results from many pedigrees can be combined to 
obtain an overall result. Finally, a linkage signal with a marker can be detected up to 
20cM away from the proposed disease locus, so markers separated by 10cM 
(microsatellites) or 2cM (SNPs) have a good chance of detecting linkage (Terwilliger 
and Ott 1994; Ott 1999).  
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There are however, disadvantages to linkage mapping. The first deterrent is that 
families are difficult to collect for late-onset traits and the power of linkage analysis 
is low to detect genes of modest effect (Risch and Merikangas 1996). A second 
complication in parametric linkage analysis is sensitivity to bilinearity, where illness 
introduced into the family from outside, can mask the true inheritance pattern of the 
disease within the family. A third limitation is that generally, the localised region 
will not be finely-defined unless the family is very large but narrowed to a region >3 
Mb wide with wide confidence intervals, dependent on the number of meioses 
(Terwilliger and Ott 1994). Linkage analysis employs the concept of linkage 
disequilibrium (LD). However, LD regions in families are large, but between 
unrelated individuals it is smaller and this allows the fine-mapping of LD regions in 
case-control association studies. A final obstacle is locus heterogeneity. Locus 
heterogeneity occurs where more than one trait loci is suspected when examining 
linkage to a disease in a group of families. The disease may be due to one locus in 
one family and a different locus in other families. This can be overcome by testing 
for locus heterogeneity (α<1) as the probability that a pedigree is segregating a 
disease gene at any given θ. θ and α can be simultaneously estimated in an 
unbiased fashion using parametric linkage analysis. In addition, at each θ a 
Heterogeneous LOD (HLOD) can be obtained which is maximised over all value of 
α. It is sometimes advised to use this HLOD score for complex traits. However, this 
is not relevant when a single family is analysed. 
1.4.2. Non-parametric linkage analysis
An alternative method to parametric linkage analysis is non-parametric linkage 
analysis. The aim of non-parametric linkage analysis is to identify the disease locus, 
by identifying chromosomal markers where affected individuals with a disease are 
more alike at a location, than expected by chance. The main advantage of this 
linkage analysis method is that it is a model-free test, with no model-dependent 
inferences about underlying disease genotypes. Furthermore, this analysis can 
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increase power to detect linkage if the model is not known, or imprecisely specified, 
which can be the case in complex diseases (Clerget-Darpoux, Bonaiti-Pellie et al. 
1986).
Essentially, non-parametric linkage analysis is based on the affected sib pair method 
which looks at a measure of sharing IBD (as explained in Figure 1.2) and compares 
the observed and expected sharing, over the sharing standard deviation (SD) with a 
Mean Sharing Test, Z = Mean sharing – Expected sharing / SD (sharing). The best 
method of detecting genetic sharing between relations within a pedigree would be 
to completely specify the gene flow throughout the whole pedigree, such that an 
inheritance vector would completely specify the inheritance pattern of all the alleles 
in a family. The number of these inheritance vectors for a specific family is a 
function of the number of meioses and increases exponentially with pedigree size. 
To circumvent this problem, there are computational methods that estimate IBD 
sharing. The MERLIN programme was chosen to estimate the Sall sharing statistic, 
which sums the numbers of non-trivial permutations of all possible sets consisting 
of one allele from each affected individual. This favours the sharing of a single allele 
by a large number of affected individuals as hypothesised in this study. The SALL
statistic is commonly used in linkage studies of complex disease and performs well 
(Davis, Schroeder et al. 1996; Sengul, Weeks et al. 2001).
In order to evaluate the level of IBD sharing, Kong and Cox have a single parameter 
alternative model using the δ parameter. The δ parameter measures the amount of 
deviation of the inheritance vector distribution from its null distribution, in one 
direction, such that the null hypothesis, H0: δ = 0 vs. δ ≥ 0. There are two types of 
alternative directions; linear (upper bound of δ) and exponential. The linear model 
is the standard method to identify small increases in allele sharing spread across a
large number of families. The exponential model is designed to identify a large 
increase in allele sharing in a small number of families, and is a better test if a large 
increase in allele sharing among affected individuals is expected. It is, however, 
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more computationally intensive (Abecasis, Cherny et al. 2002). The Kong and Cox 
approach generates more accurate P-values than those obtained by other methods 
and is commonly reported (McGuffin, Knight et al. 2005; Shugart, Samuels et al. 
2006).
There are certain limitations to non-parametric linkage analysis in a single pedigree. 
There is a decrease in power compared to parametric linkage analysis if the model is 
correctly specified in parametric linkage analysis (Terwilliger and Ott 1994).  Also, 
the results are particularly sensitive to marker allele frequencies. Furthermore, 
genetic heterogeneity is not taken into account and recombination fraction is not 
estimated (Kong and Cox 1997; Sengul, Weeks et al. 2001; Shih and Whittemore 
2001; Abecasis, Cherny et al. 2002; Weeks, Lathrop et al. 2006). A suggestion in the 
literature is to weight different sub-pedigrees according to their size (Sengul, Weeks 
et al. 2001). However, with multiple pedigrees, each of a different size, there is no 
single optimal way to weight the contributions from different pedigrees. 
Furthermore, if this is performed then the non-parametric test is no longer truly 
“model-free” (Sham 1998).
1.4.3. Linkage analysis programmes
Currently, there are many general linkage analysis programmes. These programmes 
can be classified into three different groups depending on the algorithm used for 
analysis: i) Elston-Stewart algorithm on which the classic linkage analysis 
programmes are based, for example FastLink, Linkage, Mendel and Vitesse (Elston 
and Stewart 1971). ii) Lander-Green algorithm on which Allegro, GeneHunter, 
Mendel and MERLIN are based (Lander and Green 1987) iii) Markov chain Monte 
Carlo (MCMC) algorithm on which Simwalk2 and Loki are based (Sobel and Lange 
1996). There are drawbacks for each algorithm. The Elston-Stewart is limited by 
marker number (~8 loci), the Lander-Green is restricted by pedigree size (~20 
people) and the MCMC provides only an estimated solution (Weeks, Lathrop et al. 
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2006). Although the MCMC methods are not restricted by pedigree size or marker 
number the computational time is a huge burden and is unsuitable for analysis of a 
large number of markers.
Since its publication in 2002, MERLIN (Multipoint Engine for Rapid Likelihood 
INference) has been highly cited and widely-used because it permits quicker 
analysis of larger pedigrees, while reducing memory constraints. The algorithms 
that MERLIN uses are based on sparse binary trees that summarise the gene flow 
within pedigrees. The reasons for MERLIN’s speed are twofold i) it explores the 
symmetries in the pedigree structures and data to derive a family of related 
algorithms for examining the pedigree and ii) reduces the inheritance-vector space 
by eliminating classes of vectors that are not compatible with observed genotypes 
(Nicolae and Cox 2002). Furthermore, MERLIN can perform many applications such 
as rapid genotype error detection, parametric and non-parametric linkage analysis 
and haplotyping, with a large number of markers (Abecasis, Cherny et al. 2002). 
Since the advent of dense marker sets there has been development of linkage 
programmes that can accommodate analysis of large families for linkage on a large 
number of markers, for example Superlink (Fishelson and Geiger 2002) and a 
multipoint non-parametric technique (Thomson, Quinn et al. 2007). However, none 
match the range of features, the ease of execution and the reliability offered by 
MERLIN.
1.4.4. Multipoint linkage analysis
As linkage analysis in anything other than a simple small pedigree with many 
markers requires a computer, algorithms have been developed, as described in 
section 1.4.3. One such algorithm is the Lander-Green algorithm which considers an 
entire pedigree one locus at a time and combines this information to produce a 
multipoint LOD score by combining information from all loci (Lander and Green 
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1987). This is an extension of 2-point analysis in which linkage of a disease marker is 
tested not just to a single marker, but to an entire map of markers and is reported in 
this study. 
The Lander-Green method computes the probability of marker genotypes, given an 
inheritance vector. For example, at a single marker, the linkage information of each 
non-founding member can be summarised by two binary digits, one for the allele in 
the parental haplotype and one for the allele in the maternal haplotype. A pedigree 
with n-f non-founders contains 2(n-f) potentially informative gametes so that the 
pattern of inheritance at a single locus can be described by a vector of 2(n-f) 
elements. Each element is the inheritance vector, v, which describes the parental 
status of the allele at the locus in one gamete. There are 22(n-f) possible inheritance 
vectors, each describing a different pattern of allele transmissions at the locus (Sham 
1998). For each possible inheritance vector at the locus, P(Mi|Vi) at locus I, where P 
is the probability, Mi is the marker data at this locus (evidence) and Vi is a certain 
inheritance vector. In brief, if “a” is a vector of alleles assigned to founders of the 
pedigree. There are restrictions imposed by the observed marker genotypes on the 
vector “a” that can be assigned to the founder genes. The Lander-Green algorithm 
extracts only vectors “a” compatible with the marker data.  P [m|v] is obtained by 
summing all compatible vectors “a”. 
Multipoint analysis uses binary digits, 0/1 notation, to describe the parental origin of 
an allele in relation of the first allele, where 0 is no recombination with respect to the 
first allele, 1 is recombination with respect to the first allele, the first allele is not 
coded (0). These values are then related to haplotype frequencies via θ and the 
probability of each haplotype determined under the Haldane map function. The 
next step is the calculation of haplotype counts to obtain the maximum likelihood 
estimate of haplotype probabilities. Following that, the haplotype probabilities are 
transformed into recombination fractions (θ) where the sizes suggest the order of 
loci. In order to map the disease, fixed marker loci are moved through test positions. 
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The multilocus likelihood at each test position Lx is then compared to the multilocus 
likelihood at unlinked Linf.
o 2(ln Lx- ln Linf)=location score=4.6*multipoint LOD score.
There are many advantages to multipoint analysis. Firstly, it is a more informative 
measure as genotype information can be imputed at an originally uninformative 
locus via haplotype information. Secondly, the location of the disease gene can be 
fine-mapped by evaluating many locations along a chromosome. However, it is 
critical that the order of markers and the distances between the markers are 
correctly specified (Haines and Pericak-Vance 1998). Finally, multipoint linkage 
analysis can increase power to detect to detect linkage and uncover minor gene 
effects (Baron 2001).
1.4.5. Potential sources of error in linkage analysis
Despite the availability of robust methods that test for linkage, their success 
depends on high-quality data. There are numerous potential sources of error in the 
experimental flow-chart from pedigree collation, DNA preparation, genotype 
calling and data file preparation. Errors in these areas can greatly affect the power of 
linkage analysis. Pedigree errors can decrease the power to detect linkage or 
produce false positive results (McPeek and Sun 2000). Genotyping errors can also 
have a severe consequence in linkage analysis. Errors can affect haplotype 
frequencies (Kirk and Cardon 2002) and lead to an inflation of genetic map length 
(Hackett and Broadfoot 2003). A 1% error rate can generate a loss of 53-58% of the 
linkage information for a trait locus (Douglas, Boehnke et al. 2000). 
Genotyping errors can occur due to DNA of poor quality or quantity. For example, a 
small quantity of DNA molecules remaining in a sample may have resulted from a 
very high dilution of DNA or degradation. This can lead to both allelic dropout, 
which is the stochastic non-amplification of an allele; such that one of the two alleles 
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present at a heterozygous locus is amplified and a false allele, which is an allele-like 
artefact that is generated by PCR (Taberlet, Griffin et al. 1996). Low quantity of 
DNA also increases the risk of contamination because there is a higher probability of 
amplifying contaminant molecules when the DNA sample is of low concentration 
(Taberlet, Griffin et al. 1996; Pompanon, Bonin et al. 2005). Recently, whole genome 
amplification of DNA is regarded as a practical method to conserve DNA, while 
also maintaining the integrity of the DNA. Amplified DNA samples have been used 
successfully in whole-genome scans for complex genetic diseases, for example in the 
neurodegenerative disease amyotrophic lateral sclerosis (ALS) (Kasperaviciute, 
Weale et al. 2007).
1.4.6. Reporting evidence for linkage
1.4.6.1. Power
Power is defined as the probability of a study to obtain a significant result, if this 
result is true in the underlying population from which the study subjects were 
sampled (Zondervan and Cardon 2007). The power to detect linkage depends 
strongly on the magnitude of the contribution that the disease locus makes to the 
genetic variation of the trait. There are other complicating factors that influence 
power of both parametric and non-parametric linkage analysis. The distance of 
markers from disease loci, phenocopy rate, genetic heterogeneity and magnitude of 
the genetic effect cannot be accounted for and may affect the power of the study. A 
study can be optimised by seeking a pedigree of a suitable size and structure tested 
with informative markers.
Simulation can also be used to compute the power of a linkage study, where 
replicates of datasets are simulated under the alternative hypothesis of linkage. 
However, the simulation process is very time-consuming, the simple assumptions 
are non-realistic for complex models and there is difficulty in determining an 
appropriate alternative hypothesis. 
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1.4.6.2. LOD support intervals
Support intervals for LOD scores are difficult to obtain analytically (Terwilliger and 
Ott 1994). Originally a 1-LOD support interval was recommended (Conneally, 
Edwards et al. 1985) which is obtained by constructing a horizontal straight line at 1 
unit LOD score below the maximum LOD score, provided that LOD max ≥ 3 
(otherwise, no support interval is constructed). The endpoints are the intersection of 
this horizontal line with the LOD score curve (Ott 1999). The width of the 1-LOD
support interval is R-L, where L and R are the first positions at which the LOD score 
is less than the maximum LOD score minus 1 to the left and right of the position of 
the maximum LOD score respectively. However, an inconsistency occurs when 
constructing 1-LOD-unit support intervals between the statistical test and the 
support intervals when 1<ZMAX<3, where no support interval should be constructed 
when ZMAX<3 (Terwilliger and Ott 1994).  Terwilliger and Ott recommend the use of 
3-LOD-unit support intervals. However, 1-LOD unit rule is widely accepted and is 
the current method of reporting linkage support intervals.
1.4.6.3. Significance
Thresholds of significance are an important consideration to avoid reporting false 
positive linkage results (Strachan and Read 1999). The higher the LOD scores the 
greater the evidence for linkage. Traditionally, a score of 3 was regarded as 
significant evidence of linkage in a classical two-point linkage study of simple 
Mendelian traits corresponding to a P=10-4. LOD -2 was regarded as evidence 
against linkage. 
Widely acceptable significance thresholds are based on the classic paper by Lander 
and Kruglyak in 1995, who proposed a series of thresholds as criteria for suggestive 
and significantly linkage for complex diseases. Suggestive linkage is a LOD score or 
P-value that would be expected to occur once by chance in a whole genome scan. 
Significant linkage is statistical evidence that would be expected to occur by chance 
0.05 times in a whole genome scan. Highly suggestive linkage is a LOD score or P-
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value that would be expected to occur by chance 0.001 times in a whole genome 
scan. Confirmed linkage is the confirmation of significant linkage in a further 
sample, preferably by an independent group of investigators. Table 1.4 shows the 
thresholds calculated by Lander and Kruglyak for mapping loci underlying 
complex traits. For suggestive linkage, a LOD of 1.9 is recommended and for






P value LOD P value LOD
LOD score analysis in human 1.7x10-3 1.9 4.9x10-5 3.3
Allele-sharing methods in 
human (sibs and half-sibs)
7.4x10-4 2.2 2.2x10-5 3.6
Table 1.4 Thresholds for evidence of linkage in complex traits. This table is 
adapted from Lander and Kruglyak, 1995. It shows the classification based on the 
number of times that one would expect to see a results at random in a dense 
genome scan.
The thresholds for allele-sharing methods depend on the relationship measures. A
weighted average for a mixture of different relative types should be used. At the sib-
pair level, the P-value and for suggestive linkage are 7.4x10-4 and 2.2, and significant 
linkage are 2.2x10-5 and 3.6. The LOD scores for genome-wide significance should be 
in the range 3.3-4.0, depending on study design according to Lander and Kruglyak 
criteria.  Suggestive linkage results may be wrong, but are fworth reporting if 
accompanied with a warning. Lander and Kruglyak also advocate reporting all 
regions with a nominal P value of P=0.05 encountered in a complete genome scan, 
but without any claims of linkage.
There are some difficulties in estimating significance levels for example using 
multiple diagnostic schemes to define affection status. Strictly, a Bonferroni 
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correction should be applied so the P values are multiplied by the number of 
models. This is, however, overly stringent as the models are closely related and are 
not statistically independent.
Another difficulty with estimating linkage thresholds is the addition of extra 
markers to regions of linkage, leading to an increase in the false positive rate. 
Lander and Kruglyak initial criteria in 1995 were based on a dense map of markers 
covering the whole genome. Sawcer et al in 1997 argued this point stating that such 
stringent measures were not required for initial linkage scans with sparse coverage 
of the genome, where linkage peaks were followed up with increased marker 
coverage. Their simulations showed that follow up of interesting linkage peaks with 
more markers did not inflate the false positive rate (Sawcer, Jones et al. 1997). 
However, problems were found in their simulation method (Kruglyak and Daly 
1998). When increasing the marker density to simulate adding extra markers around 
linkage peaks, they did this on the peak of their interest, not on the simulated false-
positive peaks. In conclusion, the original recommendations to use dense-map 
thresholds still holds as shown in Table 1.4 and are regularly reported for whole-
genome linkage scans; for example in a bipolar disorder whole-genome linkage scan 
(Park, Juo et al. 2004). However, simulations are sometimes required to take into 
account specific features of studies, such as the family structure. These simulations 
must model the experimental parameters precisely, including the follow-up of 
interesting regions. This should avoid under-estimating the false positive rate 
(Kruglyak and Daly 1998). 
1.4.6.4. Simulation
Computer simulation is important to assess the significance of a result by generating 
realistic artificial data. This is achieved by obtaining random numbers from a 
deterministic computer by a “seed”. This seed determines a starting point in a 
sequence, then uses a different seed for generating each dataset and thus creates 
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random datasets. A genotype can be simulated while taking account of the allele
frequency. This can be extended by a process called “gene-dropping” (Jean W. 
MacCluer 1986). Gene-dropping generates random founder genotypes according to 
allele frequencies at each marker, using random numbers as explained above.  Once 
all founders are assigned genotypes, the offspring’s alleles are “dropped” down the 
pedigree at random from the parental genotypes. These random genotypes are then 
segregated through the pedigree, using the relationships as specified in the 
pedigree. If the random seed is changed, a different dataset of founder genotypes 
and segregation pattern is generated. Furthermore, the simulated genotype data 
mirrors the pattern of the original data in terms of missing data, marker 
informativeness, marker spacing and phenotype status. 
The advantages to “gene-dropping” are many. The method is fast, conditional on a 
known pedigree structure and unconditional on any known disease status. 
Consequently, this method is useful for this study, as the pedigree structure was 
known and limited by available DNA. A disadvantage of the method is with larger 
pedigrees, the proportion of simulated outcomes compatible with the data becomes 
very small and most of the generated observations are discarded. There are many 
assumptions in the “gene-dropping” method. For example, it is assumed that the 
parents are chosen randomly from population, the markers are in Hardy-Weinberg 
equilibrium, there is no segregation distortion such that there are 50:50 transmission 
probabilities, there are no mutations and no genotyping error. 
MERLIN is a useful programme for simulating data. It generates random datasets 
based on the gene-dropping method described above. The genotype data is 
simulated under the null hypothesis of no linkage to the observed phenotypes. The 
resulting data is a random genome that is unlinked to the trait of interest and is 
useful for examining false positive rates due to peculiarities in marker 




Simulation of random datasets allows the calculation of empirical threshold to find 
the desired significance level (Sawcer, Jones et al. 1997).  To estimate the threshold 
T, a replicate dataset is simulated under the null hypothesis, linkage analysis is 
computed and a LOD is recorded. This is performed numerous times. The genome-
wide threshold of significance T is then estimated so that the number of times the 
LOD score is equalled or exceeded divided by the number of simulations 
(#>T)/(Total #) = 0.05 (Weeks, Lathrop et al. 2006). The threshold for highly 
suggestive linkage is a LOD score that would be expected to occur by chance 1/1,000 
times in a whole genome scan. 
1.4.7. Haplotype analysis
A haplotype is a combination of genetic markers such as SNPs or microsatellites that
are located closely together on the same chromosome and tend to be inherited 
together. Haplotype analysis aims to describe the inheritance of genetic information 
descending through a family. More specifically, a haplotype for an individual at a 
certain loci is defined as the set of alleles inherited from one parent at a series of 
markers. Each individual has two haplotypes, one of maternal origin and the other 
of paternal origin. Traditionally haplotype analysis aimed to estimate the “best” 
haplotype for each of the two haplotypes for every individual in a family. This 
analysis is improved by considering multiple generations in a family to construct 
haplotypes that segregate through the family. 
Haplotype analysis is important for many reasons. Firstly, it can help to identify 
genotyping errors that comply with Mendelian inheritance, but when considered as 
a haplotype that would require a double recombination event over a close distance, 
which is very rare. Secondly, it can make linkage analysis more informative by 
combining loci that are uninformative as individual markers to use as a single point. 
This can often improve standard linkage analysis. Haplotype analysis can narrow 
down a region of a putative trait locus. Examination of haplotypes under linkage 
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peaks can be used to check for inheritance of a consistent chromosomal region by all 
affected individuals. This is particularly important in single large families, such as 
the family in this study. 
It can be hypothesised in an isolated population that a trait is introduced by 
mutation for example, in a founder individual and the proceeding generations have 
inherited this mutation from the single founder. Haplotype analysis of all affected 
individuals could reveal a conserved haplotype inherited with the trait through 
many generations. This conserved haplotype will be surrounded by areas not 
inherited from the founder individual. These areas are evidence of recombination 
events that have occurred with transmission of the haplotype through generations. 
The section of the haplotype that is common to all affected individuals may contain 
the trait locus.  This localisation technique has been successful in isolating the gene 
“ATM” for the autosomal disorder ataxia-telangiectasia (A-T) by supplementing 
classical linkage analysis in 176 pedigrees, with pedigrees from Britain and Costa 
Rica (Savitsky, Bar-Shira et al. 1995). 
Undoubtedly, defining the origin of haplotypes is a complex process. The main 
problem is missing genotype data, which can substantially increase the number of 
haplotypes that are consistent with the observed data. This problem is confounded 
by uninformative markers, such as biallelic SNPs. However, these problems can be 
reduced in large pedigrees when the majority of people are genotyped, by 
providing information on the homozygosity in the founders and informative 
matings. There are many computer programs available for haplotype analysis, each 
with their own advantages and drawbacks. For this study, the chosen method of 
haplotype analysis is based on the Lander-Green algorithm that searches for gene 
flow representation in a pedigree using MERLIN. 
It is important to note that haplotype construction is based on estimations and may 
not reveal the true haplotype. This is particularly important with respect to widely 
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spaced markers and large amounts of missing data. Manuel inspection of 
haplotypes at key regions can resolve some of these problems. Furthermore, the 
most likely haplotype may not in fact be the actual true haplotype (Sobel and Lange 
1996). However, in the search for the true haplotype, adding more information may 
actually uncover the true haplotype.
1.4.8. Importance of single large families in genetic studies
There are many advantages to studying single large families. Firstly, the mode of 
inheritance of a phenotype can be hypothesised with a genetic model and this 
model can be refined, depending on how the trait segregates through the family. 
The risk of the illness can also be estimated within the family which makes the 
genetic model more accurate.  Linkage analysis can help decipher whether the 
signal detected is either indicating the presence of a causative factor in a genomic 
region or the actual disease causing variant. This was discussed in Clerget-Darpoux 
and Elston 2007, specifying two examples: the VNTR locus flanking the insulin gene 
in type-1 diabetes and the PTP22 gene in rheumatoid arthritis. In both cases, 
examining IBD sharing in affected siblings, showed the variant under investigation 
to be the causal variant (Hodge 1993). 
Secondly, the study of single families is recommended to avoid allelic heterogeneity 
(Clerget-Darpoux and Elston 2007).  In fact, a disease that appears to be 
multifactorial may be due to single gene effects. One example is the identification of 
BRCA1 by segregation analysis in large sample of families. For example, a four-fold 
reduction in sample size was achieved by enriching a cohort with cases who had 
two or more other family members with the illness, making a more efficient and 
cost-effective study of a risk allele BRCA1 for breast cancer (Easton, Pooley et al. 
2007). Thirdly, another advantage is that large families can be investigated to assess 
complex genetic effects, for example imprinting, anticipation and epigenetics. 
Finally, genotyping errors, genomic mutations and copy number variants are easier 
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to detect or validate in family data. Certainly, the larger the family, the more power 
is available to detect any of the above effects. However, studies in single families 
also have drawbacks as the larger the family, the greater the chance that more than 
one genetic risk factor is represented, but this is negligible in comparison to a large 
collection of small families or population-based cohorts.
1.4.9. Benefits of re-analysis
Many experts in the field advocate the re-analysis of linkage studies, due to the 
current generation of newer, high-resolution data (Evans and Cardon 2004). A map 
of closely spaced SNPs may offer many advantages over low-density microsatellite 
maps, including increased information content, greater power to detect linkage, and 
may improve the localisation of the disease locus (Evans and Cardon 2004; John, 
Shephard et al. 2004; Thalamuthu, Mukhopadhyay et al. 2005). Evans and Cardon 
(2004) suggest that “previous linkage studies that employed sparse microsatellite 
maps could benefit substantially from reanalysis by use of a denser map of 
markers” (Evans and Cardon 2004). For example, reanalysing the 1996 UK multiple 
sclerosis whole genome linkage screen showed that high density SNP linkage 
mapping sets can extract significantly more information and achieve higher rates of 
genotyping success and accuracy than previous studies (Sawcer, Maranian et al. 
2004).  Other technological advancements are a more accurate marker map and
greater genotyping success rate. These improvements are vital, as missing and
incorrect data can severely reduce the power to detect linkage (Pompanon, Bonin et 
al. 2005). Hence, re-analysis of single large families in genetic studies, with high-
resolution data is then certainly recommended twofold.
1.5. Genetic Studies of Bipolar Disorder
As the characteristics of both bipolar disorder and genetic mapping have been 




1.5.1. Genetic mechanism of bipolar disorder
Many methods have been undertaken to elucidate the genetic mechanism of bipolar 
disorder: collecting single affected individuals for cytogenetic studies, families for 
linkage studies and population cohorts for association studies. Each method has a 
specific advantage, cytogenetic and linkage studies may detect single, rare variants 
that could highlight candidate genes or pathways or association studies can detect 
multiple, common susceptibly variants. Early linkage studies assumed single gene 
inheritance and large, apparently autosomal dominant, pedigrees were studied.
Unfortunately, consistent evidence of single, major gene effects in bipolar disorder 
has not been forthcoming (Segurado, Detera-Wadleigh et al. 2003). 
The primary deterrent in the gene search is that the precise mode of the inheritance 
of bipolar disorder is unknown. Segregation analyses on large pedigrees have 
produced mixed results, where some studies are consistent with single gene models
(Rice, Reich et al. 1987) and others unable to demonstrate major locus transmission.
The observed very rapid decrease in recurrence risk, as shown in Table 1.1,  from
identical co-twins (40-70%) to first degree relatives (5-10%) and to the general 
population (0.5-1%) is not consistent with a single gene mode of inheritance
(Craddock, Khodel et al. 1995). It may be suggestive of a polygenic pattern, where a 
number of genes with small, additive effects provide an underlying genetic 
predisposition to disease, an epistatic interaction of multiple genes or a more 
complex genetic mechanism. Complex genetic mechanisms suggested in bipolar 
disorder include locus heterogeneity, imprinting, anticipation, mitochondrial 
inheritance (McGuffin, Owen et al. 2002) or disruption of alternative splicing 
mechanisms (Wang and Cooper 2007). Albeit, the lack of agreement in segregation 
analyses, to determine a single gene model of inheritance or complex mechanisms, 
could be due to the difficulties in defining a phenotype and a reflection of the 
number of assumptions required for segregation analysis. It is evident, 
undoubtedly, that the pattern of inheritance for bipolar disorder in some large 
pedigrees follows simple or quasi-Mendelian inheritance, consistent with a single 
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gene contributing to susceptibility to bipolar disorder in that family, and may yet 
prove fruitful in revealing a single genetic disease-susceptibility variant. 
Nonetheless, it must be assumed that no single pattern of inheritance underlies all 
of bipolar disorder. It is likely that cases may be sporadic or inherited, and that 
heritable forms of illness may include single and multiple genes.
1.5.2. Cytogenetic & linkage studies of bipolar disorder
Rare variants of large effect have indeed been identified as contributing to bipolar 
disorder and related disorders. Cytogenetic studies examine individual 
chromosomes for evidence of abnormalities which may cause gene disruption and 
linkage studies search for greater than expected, cosegregation of an illness and a 
chromosomal region. In a linkage study of a large Scottish family with bipolar 
disorder (1 case), schizophrenia (7 cases) and recurrent major depression (10 cases),
a balanced translocation was found to segregate with illness (maximum LOD=7.1)
(St Clair, Blackwood et al. 1990; Blackwood, Fordyce et al. 2001). The translocation 
between chromosomes 1 and 11 lead to the identification of a candidate 
susceptibility gene “Disrupted In Schizophrenia” (DISC1) (Millar, Wilson-Annan et 
al. 2000). Molecular genetic studies have also begun to achieve success in 
uncovering susceptibility genes for complex diseases by their chromosomal 
location. Significant linkage regions for bipolar disorder have been reported in 
extended pedigrees on chromosomes 1q, 4p, 6p, 10p, 10q, 11p, 12q, 13q, 18p, 18q, 
21q, 22q and Xp (Baron 2002). A meta-analysis performed on whole-genome linkage 
scans of bipolar disorder found the strongest evidence for susceptibility loci on 
chromosome 13q (P<6x10-6) and 22q (P<1x10-5) (Badner and Gershon 2002).
1.5.3. Association studies of bipolar disorder
In contrast to linkage and cytogenetic studies that identify rare variants for disease, 
allelic-association studies have made important genetic contributions by identifying 
common susceptibility variants for bipolar disorder and other related psychiatric 
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illnesses (McGuffin, Owen et al. 2002). Allelic association refers to the co-occurrence 
of an allele at a particular locus and a disease, above the level of chance. This co-
occurrence can suggest causation or that the marker is in linkage disequilibrium 
(LD) with the causative variant. The case-control association study compares
individuals with a psychiatric illness (cases) with unaffected subjects from the same 
population (controls) for differences in allele, genotype or haplotype frequencies.  
Association analysis considering multiple, linked markers can often be more 
informative, as illness may be associated with a particular haplotype, more strongly 
than a single allele.
The results of the first three whole-genome association studies in bipolar disorder 
have been recently reported. The first whole-genome association study for bipolar 
disorder was performed by genotyping over 550,000 single nucleotide 
polymorphisms (SNPs), on the Illumina HumanHap550, in two independent case-
control samples of European origin. The first cohort was 461 cases and 563 controls 
individuals of European origin from the NIMH Genetics Initiative and the second 
collection was 772 cases and 876 controls from the German population. The study 
incorporated a two-stage study design by performing the initial association screen 
using pooled DNA, and then the selected SNPs were confirmed by individual 
genotyping. There were 88 SNPs that met the criteria for replication in both 
samples. There were no reports of a single SNP of large effect. The strongest 
association signal was detected at a SNP in the first intron of diacylglycerol kinase eta
(DGKH; P=1.5x10-8, experiment-wide P<0.01, Odds ratio (OR) =1.59). An association 
signal was also reported at a marker on chromosome 4p16.1 in intron 2 of a VPS10 
domain-containing receptor (SORCS2) that is predominantly expressed in the 
developing brain (SORCS2; P=1.4x10-5, OR=1.67). As this association study shows 
evidence for several genes each of modest effect, the authors advocate a polygenic 
disease model influencing bipolar disorder risk (Baum, Akula et al. 2007). 
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A second whole genome association study was reported by the Wellcome Trust 
Case-Control Consortium (WTCCC) by genotyping 500,000 SNPs on 2,000 
individuals affected with bipolar disorder and 3,000 controls from Great Britain. 
Again, there were no reports of powerful associations. The strongest association 
signal was to a marker on chromosome 16p12 (genotypic test P=6.3x10-8, OR=2.1). 
There were four other regions showing association at P<5x10-7 on chromosomes 
1p31, 2q31, 12q21 and 22q12. The associated markers were not within previously
studied candidate genes for bipolar disorder (WTCCC 2007). 
A third genome wide association scan was reported in 1,461 patients with bipolar I 
disorder and 2,008 controls from the US and UK with genotyping for >370,000 SNPs 
(Sklar 2008). The genotyping was performed on the same Affymetrix Gene Chip 
Human Mapping 500K Array platform as the WTCCC. Once more, there was no 
evidence for association that did not meet either the criteria for genome-wide 
significance (5x10-8) nor that replicated in two independent sample sets. The 
strongest results were in two brain-expressed genes; myosin5B (MYO5B; P=1.66x10-7-, 
OR=1.51) and tetraspanin-8 (TSPAN8; P=6.11x10-7, OR=0.58). No associations were 
replicated from the other two genome-wide scans for bipolar disorder. The authors 
hypothesise the reason for the lack of agreement between studies was because the 
susceptibility alleles for bipolar disorder are likely to be modest in effect size and 
therefore require larger cohorts to detect such effects. Other reasons for non-
replication of significant association results between studies may include 
phenotypic and genotypic heterogeneity, population specific alleles or epistatic 
interactions of multiple modest effect genes.
1.5.4. Candidate susceptibility genes for bipolar disorder
Studies of rare chromosomal rearrangements also reveal candidate genes for bipolar 
disorder and schizophrenia. For example, Glutamate Receptor, Ionotropic, Kainate, type 
4 (GRIK4) originally found to be disrupted at a chromosomal breakpoint in a patient 
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with schizophrenia, was also found to be associated with bipolar disorder 
(P=0.0002) and schizophrenia (P=0.0005) in a Scottish population (368 bipolar 
disorder cases, 386 schizophrenia cases and 458 controls) (Pickard, Malloy et al. 
2006). Another example of a gene identified at a balanced chromosomal 
translocation, t(9,14)(q34.2;q13) is a neuronal transcription factor called NPAS3,
initially associated with schizophrenia and learning difficulties (Pickard, Malloy et 
al. 2005). A further study showed that NPAS3 is associated with bipolar disorder 
(P=0.0000010) and schizophrenia (P=0.0000012) at the haplotype level by calculating 
the “net genetic load” incorporating genetic heterogeneity, in the same Scottish 
population (Pickard, Christofororou et al. 2008).
Linkage studies, followed by meta-analyses have identified and confirmed 
candidate regions, which were refined by linkage disequilibrium mapping to 
identify promising candidate genes for bipolar disorder and also to schizophrenia.
These include: G72 (a brain expressed protein) on chromosome 13q34, DISC1 on 
chromosome 1q42, neuregulin-1 (NRG1) on chromosome 8p21, a regulator of G-
protein signalling (RGS4) on chromosome 1q, a cell adhesion molecule (NCAM1) on 
chromosome 11q23.1, a D-Amino acid oxydase (DAO) on chromosome 12q24, 
metabotropic glutamate receptor 3 (GRM3) and GRM4 on chromosomes 7q21 and 
6p21 respectively, an N-methyl-D-asparate receptor subunit 2B (GRIN2B) on 
chromosome 12p12, a WKL1, cation channel (MLC1) on chromosome 22q13, a 
synaptogyrin 1 (SYNGR1) on chromosome 22q13, a potassium chloride co-
transported (SLC12A6) on chromosome 15q13 and catechol-O-methyltransferase
(COMT) on 22q11 (Kato 2007). There are other genes also found using the candidate 
gene approach that show association to bipolar disorder, including a G-protein 
coupled receptor (GPR50) on chromosome Xq28 (Thomson, Wray et al. 2005). 
Emerging evidence has also supported an association between 
methylenetetrahydrofolate reductase (MTHFR) on chromosome 1p36 and bipolar 
disorder, recurrent major depression and schizophrenia (Gilbody, Lewis et al. 2007).  
In addition, there are several candidate genes in the circadian rhythm pathway that 
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are associated with bipolar disorder; TIMELESS on chromosome 12q12 and
PERIOD3 on chromosome 1p36. Further, genes that have been implicated in more 
than one study are the dopamine D1 receptor (DRD1) on chromosome 5q35 and
inositol(myo)-1-monophosphatase 2 (IMPA2) on chromosome 18p11 (reviewed in Kato 
2007). Despite the number of candidate genes studied, there has been no causative 
gene or genetic risk factor implicit for bipolar disorder and recurrent major 
depression.
1.5.5. Genetic overlap between bipolar disorder & 
schizophrenia
Despite clear differences in the definition of the phenotype, there is evidence for a 
genetic overlap between bipolar disorder and schizophrenia. A twin study 
examining the relationship between bipolar disorder, schizophrenia and
schizoaffective (an illness with features of both schizophrenia and bipolar disorder 
symptoms) suggested that there is a set of genes that contribute to all three 
syndromes (Cardno, Rijsdijk et al. 2002). Other studies also include families with 
both bipolar disorder and schizophrenia such as that which identified DISC1 
(Blackwood, Fordyce et al. 2001) and suggested the candidate genes NRG1 and 
GRIK4 (reviewed in (Blackwood, Pickard et al. 2007). In addition, the loci 
highlighted for bipolar disorder in a meta-analysis of genome-wide linkage scans, 
suggested evidence for linkage to chromosome 13q and 22q, regions previously 
implicated in schizophrenia (Badner and Gershon 2002). Also, promising candidate 
genes for bipolar disorder were originally identified in molecular genetic studies of 
schizophrenia are a positional G-protein receptor kinase 3 on 22q, the G72/G30 locus 
on 13q34 and brain-derived neurotrophic factor (BDNF) on 11p13 (McGuffin, Owen et 
al. 2002). Furthermore, there are many signalling pathways and cellular mechanisms 
where evidence converges for bipolar disorder and schizophrenia: phosphoinositide 
3-kinase (PI3K) and serine/threonine-specific protein kinase (AKT) signalling, 
growth factors, N-methyl-D-aspartic acid (NMDA) and glutamate-related, 
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dopaminergic and serotonergic pathways, circadian genes, cytokines, oxidative and 
other stress pathways and endoplasmic reticulum stress (Carter 2006)
(www.polygenicpathways.co.uk). Collating this evidence suggests common genetic 
risk factors for bipolar disorder and schizophrenia.
1.6. Large Scottish Family in a Genetic Study of Bipolar 
Disorder
In the following section, I would like to describe the family that is investigated in 
genetic studies of bipolar disorder in chapters 3, 5 and 6 of this thesis.
1.6.1. Family description
The Scottish family in this study is a valuable and rare genetic resource, particularly 
with respect to the size of the pedigree and the clear diagnosis of bipolar disorder 
and recurrent major depression in the family. The pedigree was originally reported 
in 1996 as F22, with 11 individuals with bipolar disorder and 16 with recurrent 
major depression in a 132 member pedigree (Blackwood, He et al. 1996). The family 
was recruited through two probands: individuals 21 and 29. A follow-up of this 
family was subsequently reported with 32 cases, 12 of which were bipolar disorder 
and 20 of which were diagnosed with recurrent major depression (Le Hellard, Lee et 
al. 2007). Further follow-up of this family is reported here.
Figure 1.5 clearly illustrates the expanse of the present day pedigree. Table 1.5 lists
the number of affected individuals at the time of the original study in 1996, and at 
the present day. There are 180 members that span five generations. Of the 180 
members, 45 are founders and 135 are non-founders. Founders are individuals that 







































































Figure 1.5 The pedigree The pedigree is a representation of the large Scottish family in this study. For confidentiality, a selection of 
extraneous individuals was removed and the genders are hidden. The filled symbols denote bipolar disorder and half-filled symbols 
represent recurrent major depression. The numbers under the symbols is the numbering system used in this thesis. The generations 




















Prior to this study, the diagnosis for all affected individuals were re-evaluated and 
reached by consensus between two psychiatrists (Prof. D. Blackwood, Dr. W. Muir) 
using clinical information collected by direct interview based on the Schedule for 
Affective Disorders and Schizophrenia-Life Time Version (SADS-L) (Endicott and 
Spitzer 1978) supplemented by case-note review, further information from general 
practice or hospital case records, and collateral information from relations. Twelve
individuals have been diagnosed with bipolar disorder and 24 with recurrent major 
depression. The key numbers are shown in Table 1.5. Eight individuals were 
diagnosed with other psychiatric illness including anxiety states, alcoholism, single 
episode depression or minor depression.
DIAGNOSIS 1996 STUDY PRESENT STUDY
Bipolar disorder 11 12
Recurrent major depression 16 23




Table 1.5 Number of affected individuals in the family in 1996 and in this study 
For each psychiatric diagnosis, the number of affected individuals in the family is 
listed. 
The changes to diagnoses are listed in Table 1.6.  The diagnosis for 18 individuals 
was changed from the original classification.  A change in diagnosis occurred for 
example, from bipolar disorder (at initial assessment) to recurrent major depression 
(at review ten years later) because the information about manic symptoms obtained 
at the initial assessment was considered inconclusive and was not supported by 
subsequent follow-up, when the case was reviewed.
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INDIVIDUAL PREVIOUS DIAGNOSIS UPDATED DIAGNOSIS
12 Other psychiatric illness Recurrent major depression
15 Other psychiatric illness Recurrent major depression
20 Other psychiatric illness Unknown
27 Other psychiatric illness Unaffected
30 Recurrent major depression Other psychiatric illness
35 Other psychiatric illness Unaffected
55 Bipolar disorder Recurrent major depression
65 Recurrent major depression Other psychiatric illness
69 Other psychiatric illness Unaffected
71 Unaffected Unknown
83 Other psychiatric illness Recurrent major depression
84 Other psychiatric illness Recurrent major depression
97 Other psychiatric illness Unaffected
124 Other psychiatric illness Recurrent major depression
130 Unaffected Recurrent major depression
157 Recurrent major depression Other psychiatric illness
165 Other psychiatric illness Unknown
166 Recurrent major depression Other psychiatric illness
Table 1.6 Diagnoses updates. The diagnoses for individuals in the Scottish family 
were updated as above in February 2006. Other psychiatric diagnosis includes 
single episode depression, anxiety or alcoholism. 
One individual was changed from bipolar disorder to recurrent major depression. 
Four individuals were updated from recurrent major depression to other psychiatric 
illness. Six individuals were altered in the opposite direction from other psychiatric 
illness to recurrent major depression. Three individuals’ other psychiatric diagnosis 
became unaffected and two individuals became unknown. Two individuals whose 
diagnoses were previously unaffected were updated: one as unknown and the other 
as recurrent major depression. 
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1.7. Evidence for a Bipolar Disorder Susceptibility Region 
on Chromosome 4
1.7.1. Linkage evidence on chromosome 4p15-p16 from a 
large Scottish family
A genome-wide linkage study was performed on the aforementioned large Scottish 
family. There were 11 individuals diagnosed with bipolar disorder and 16 with 
recurrent major depression, both classified together as major affective disorder. 
Significant linkage of bipolar disorder to chromosome 4p15-16 was found with a 
maximum LOD of 4.1 (Blackwood, He et al. 1996). Additional statistical evidence is 
based on a significant result (LOD=3.7) using a variance component method of 
analysis (Visscher, Haley et al. 1999). Genetic analysis was updated by re-evaluating 
family members and increasing the number of markers in the chromosome 4p15-p16 
region, resulting in a maximum LOD score of 4.4 (Le Hellard, Lee et al. 2007). This 
significant LOD score implies this region is likely to contain a susceptibility locus for 
bipolar disorder.
1.7.2. Further evidence for chromosome 4p15-p16 from 
other families
Evidence for psychiatric illness, including bipolar disorder, schizophrenia and 
related phenotypes to this region on chromosome 4 has been confirmed in other 









Scotland F22 BP & RMD LOD 4.4
(Blackwood, He et al. 
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Wales F50 SCZ & SA LOD 2
(Asherson, Mant et al. 
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Scotland F59 BP & RMD LOD 0.9
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(Underwood, 
Christoforou et al. 
2006)




Hellard et al. 2007)
Table 1.7 Genetic evidence for psychiatric illness on chromosome 4p14-p16.
This table lists the studies that show genetic evidence for a mental illness locus on 
chromosome 4p14-p16. The table is grouped according to the type of genetic 
evidence: linkage studies, cytogenetic studies and association studies, respectively. 
Details of the study origin, the study samples, their diagnosis and the genetic 
evidence from the study and related references are listed. BP is bipolar disorder, 
RMD is recurrent major depression, SCZ is schizophrenia, SA is schizoaffective 
disorder. US is United States of America. Inv is a chromosomal inversion.
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The primary evidence for linkage for bipolar disorder on chromosome 4p14-p16 
stems from the Scottish family in this study, a maximum LOD 4.1 with marker 
D4S394 and a maximum multipoint LOD 4.8 with markers D4S431, D4S394 and 
D4S403 on chromosome 4p15.33-4p16.1. There are eight additional sources of 
linkage evidence to chromosome 4p14-16; i) in a Welsh family, a maximum LOD 
1.97 with marker D4S403 on chromosome 4p15.33 was reported (Asherson, Mant et 
al. 1998) ii) in another Scottish family, a LOD 0.9 with marker D4S394 on 
chromosome 4p16.1  was reported, (LOD 0.9, (Blackwood, He et al. 1996)) iii)  in a 
large family from the United States (one family of the 22 families studies) a LOD 3.2 
with marker D42632 on chromosome 4p16 was reported (Detera-Wadleigh, Badner 
et al. 1999)) iv) in two Danish families a LOD 2 with marker D4S394 on chromosome 
4p16 was reported (Ewald, Degn et al. 1998) v) in a 154 pedigree sample set with 
psychosis and suicidal behaviour a LOD 1.8 with D4S2366 on chromosome 4p16.1 
was reported (Cheng, Juo et al. 2006)) vi) an increase sharing to chromosome 4p16.1 
in Welsh schizophrenia sib-pairs [LOD 1.73, (Williams, Rees et al. 1999)] vii) in 
Arab-Israeli families with schizophrenia and schizoaffective disorder (non-
parametric LOD 2.2 to D4S394, (Lerer, Segman et al. 2003)) viii) in an Italian sample 
of 16 families affected by bipolar disorder and schizophrenia (non-parametric LOD 
1.5 to D4S405 on chromosome 4p14 (Vazza, Bertolin et al. 2007))
Three studies of single individuals provide further support for chromosome 4p14-
16; two schizophrenia affected individuals, one with a balanced translocation t(4;13) 
(p16.1;q21.31) (Itokawa, Kasuga et al. 2004) and another with a chromosomal 
inversion, [inv 4 (p15.2;q21.3)] (Palmour, Miller et al. 1994). A third study on an 
individual with mild mental retardation and physical anomalies has a balanced 
translocation t(1;4) (p21;p14).
From population based cohorts, there are three studies that support this genomic 
region. A report on individuals from the Faroe Islands with bipolar disorder (17) 
and schizophrenia (11) describes excess haplotype sharing to chromosome 4p16.1 
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(best P value, P=0.00007, Als, Dahl et al. 2004). Preliminary evidence suggests 
association of the orphan G-protein coupled receptor (GPR78) on chromosome 4p16.1, 
in females with bipolar disorder and schizophrenia from a total of 377 bipolar 
disorder, 392 schizophrenia cases and 470 controls from the Scottish population 
(Underwood, Christoforou et al. 2006).  The other association study will be 
described in section 1.7.3, as it was involved in refining the chromosome 4p15-p16 
locus.
1.7.3. Refinement of chromosome 4p15-16 region 
1.7.3.1. High-resolution haplotype analysis
Figure 1.6 illustrates recombination mapping in the abovementioned large Scottish 
family and three other families which are listed in Table 1.7. The aim was to narrow
the linkage region that segregates with illness in three of the four families. There 
were two families of Scottish origin [F22 & F59 (Blackwood, He et al. 1996)], a Welsh 
family [F50 (Asherson, Mant et al. 1998)] and a large US family of Ashkenazi Jewish 
origin [F48 (Detera-Wadleigh, Badner et al. 1999)]. Both F22 and F48 are large 
families and the linkage regions are broad (22Mb for F22 and 10Mb for F48) with 
endpoints defined by recombination breakpoints in single affected individuals. 
Families F59 and F50 are smaller and do not have significant LOD scores. Therefore, 
they do not necessarily supply reliable data, as the possibility that affected members 
share common haplotypes, by chance across the genome is increased. However, 
their inclusion can be helpful if they are used to prioritise sub-regions of the large 
regions identified in the other families.
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Figure 1.6 Definition of haplotypes shared by affected members in four 
families on chromosome 4. This diagram is taken from (Le Hellard, Lee et al. 
2007). It illustrates the extent of the disease related haplotype on chromosome 
4p15-p16 that is linked to affective illness. F22 is the large Scottish family under 
investigation in this study with individuals affected with bipolar disorder and 
recurrent major depression, combined as major affected disorder (AFD). F59 is 
another Scottish family with bipolar disorder and recurrent major depression (AFD). 
F50 is a Welsh family with schizophrenia and schizoaffective disorder (SCZAFF). 
F48 is a large family from the United States of Ashkenazi Jewish origin with major 
mental illness including bipolar disorder and schizophrenia (SCZAFD). Regions of 
overlap in four families are Region B and Region D. The co-ordinates are from 
UCSC May 04, NCBI build 35.
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To date, haplotype analysis and allele sharing analysis highlight two regions in the 
20Mb linked region, where three of the four linkage regions overlap, namely region 
B and region D (Le Hellard, Lee et al. 2007). Haplotypes that segregated with illness 
in the four families were determined at high-resolution, and are represented by the 
black bars in Figure 1.6 that overlap at region B and region D. In these two regions, 
allele sharing between linked haplotypes from the four families, which were 
assumed to be distantly related, was compared to that between control 
chromosomes from the four families. The proposed disease-causing locus will be 
shared in common between the families, as the original mutation occurred in a 
common ancestor. This is derived from the assumption in population genetics that 
affected individuals from a founder population will share a mutation at the disease 
locus, with a large genomic haplotype surrounding the disease locus. 
Recombination events specific to each family, will reduce the length of the genomic 
haplotype, surrounding the disease locus shared between the families. The number 
of consecutive markers that comprised a region of sharing was counted. A region of 
significant excess allele sharing was discovered in region B (P=0.009). 
In addition, as listed in Table 1.7, an association study of region B and region D was 
performed (Christoforou, Le Hellard et al. 2007). 408 haplotype tagging SNPs were 
selected on a block-by-block basis and tested on 368 bipolar disorder samples, 386 
schizophrenia samples and 458 control samples. In this study, a tagging SNP was 
one chosen to represent a haplotype block, as it is in high LD with other SNPs in the 
block. There were two clusters of markers and/or haplotypes that met significant 
levels: two in region B and another two in region D. In region B, overlapping SNPs 
and haplotypes met the criteria for significance specific to that region (P<0.0005) at 
the global and individual haplotype test level and clustered in two regions, 
chromosome 4p16.1 and chromosome 4p15.33. For region D, there were no 
individual significant SNPs, but certain global and individual haplotypes were 
associated with bipolar disorder and/or schizophrenia (region-wide threshold, 
P<0.0003). These overlapping haplotypes fell into two regions on chromosome 
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4p15.2. There were no reported known RefSeq genes in these four regions, there 
were however predicted transcripts and genes marked nearby. In addition to the 
four clusters, there were other less significant associations, but potentially true 
associations, that did not exceed the nominal significance thresholds determined by 
principal component analysis. Thus, this study was successful in identifying 
significant associations between bipolar disorder and markers on chromosome 
4p15-p16 that are worthy of further investigation, but which of course, await 
replication. 
Overall, region D appeared an attractive region for further study, from the strength 
of the linkage evidence emerging from the larger families of F22 (LOD 4.4) and F48
(LOD 3.2). Region B was also favourable as the three families, two Scottish and one 
Welsh, share a common Celtic heritage and may potentially share a common 
ancestral origin. To investigate the regions further, candidate genes for 
susceptibility to bipolar disorder were considered. There were 20 genes in regions B 
and D, as listed in Table 1 (Le Hellard, Lee et al. 2007). There were seven known 
genes in region B, including GPR78 that has shown preliminary association in 
females with bipolar disorder and schizophrenia (Underwood, Christoforou et al. 
2006). Of the thirteen known genes in region D (Le Hellard, Lee et al. 2007), there is 
biological and neuropharmacological evidence, to prioritise PI4K2B as a candidate 
gene. This evidence is discussed below.
1.8. PI4K2B 
As I have introduced genetic studies of bipolar disorder, a large Scottish family 
where bipolar disorder segregates and the genetic evidence originating from this 
family to chromosome 4p15, I would now like to introduce a candidate gene study 
on PI4K2B, using expression analysis in a large Scottish family.
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1.8.1. Candidate Susceptibility Gene for Bipolar Disorder 
Popular candidate genes for bipolar disorder are selected based on positional 
evidence, from linkage and association studies or on functional evidence, often 
focussing on neurotransmitter systems. Functional candidate genes have been 
chosen for several reasons: involvement in the serotonin, dopamine and 
norepinephrine/noradrenaline neurotransmitter pathways, the GABAergic system, 
circadian rhythm-related pathways or cytokines. Dysfunction of these systems has 
been proposed as possible biochemical mechanisms in bipolar disorder. 
Additionally, popular functional candidates are target molecules of lithium, such as
the phosphoinositide (PI) signalling pathway as lithium and an alternative drug for 
bipolar disorder, valproate, act on this pathway for therapeutic effect (reviewed in 
(Farmer, Elkin et al. 2007; Kato 2007)). A phosphatidylinositol-4 kinase type 2 beta, 
PI4K2B fulfils both positional and functional criteria as a candidate susceptibility 
gene for bipolar disorder, based on its position on chromosome 4p15, in region D 
shown in Figure 1.6, and its involvement in the PI pathway, illustrated in Figure 1.7.
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Figure 1.7 Functional evidence for PI4K2B in inositol signalling. This simplified 
figure highlights the action of bipolar disorder treatment drugs; lithium and valproate 
on the phosphatidylinositol (PI) signalling pathway. Activation of some G proteins 
induces hydrolysis of phosphoinositide-4,5-bisphosphate (PIP2) to diacylglycerol 
(DAG) and inositol-1,4,5-triphosphate (IP3) via phospholipase C (PLC). DAG 
activates protein kinase C (PKC) which inhibits glycogen synthase kinase-3 (GSK-
3). IP3 is recycled back to PIP2 by inositol monophosphatase (IMPase) and inositol 
polyphosphatase phosphatase (IPPase); both of which are inhibited by lithium 
(Majerus 1992). Valproate inhibits inositol synthase (Ino-1) that is involved in the 
production of inositol-4,5-diphosphate (IP2), alongside inositol-4 phosphate (IP1). 
The recycling steps also involve the phosphorylation of phosphatidylinositol (PI) to 
phosphatidylinositol-4-phosphate (PIP) via phosphatidylinositol 4-kinase (PI4K), and 





As the genetic evidence supporting the role of a chromosome 4p15 locus in bipolar 
disorder has been discussed, I will now consider the genetic evidence to support 
genes involved in PI signalling in bipolar disorder, the functional evidence that 
implicates abnormal PI signalling in bipolar disorder and then focus specifically on 
the characteristics, function and cellular location of PI4K2B.
1.8.2. Genetic evidence for phosphoinositide genes in 
psychiatric illness
Table 1.8 lists a number of genes in the PI pathway that map to candidate regions 
for susceptibility to bipolar disorder, schizophrenia and other major affective 
disorders. It is notable that including PI4K2B, there are four phosphatidylinositol 
kinases in candidate susceptibility regions (PIP5K2A, PIK3C3 and PIK4CA).
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CHROMOSOME PI GENE              DESCRIPTION             REFERENCE
3q13 GSK3β
Glycogen synthase kinase 3, 
beta
(Benedetti, Bernasconi 
et al. 2004; Lachman, 
Pedrosa et al. 2007; 




kinase type 2 Beta
(Blackwood, He et al. 




phosphate 5-kinase, type II 
A
(Stopkova, Saito et al. 
2003; Schwab, Knapp 
et al. 2006; Bakker, 
Hoogendoorn et al.
2007)
13q14 DGKH Diacylglycerol kinase eta
(Baum, Akula et al. 
2007)
15q13 cPLA2




18p11.2 IMPA2 Inositol monophosphatase 2
(Sjoholt, Ebstein et al. 
2004; Ohnishi, 




(Stopkova, Saito et al. 










kinase a type II









(Lachman, Kelsoe et 
al. 1997)
22q12 Synapsin III
synaptic vesicle membrane 
phosphoprotein
(Lachman, Stopkova 
et al. 2005; WTCCC 
2007)
Table 1.8 Phosphoinositide genes and psychiatric illness. Genes involved in the 
phosphoinositide pathway that are mapped to chromosomal regions linked to 
psychiatric illness, including bipolar disorder and schizophrenia (Bennett and 
Horrobin 2000; Saito, Stopkova et al. 2003) (www.polygenicpathways.co.uk). The 
references for each gene are listed, except for PIB5PA and PITPNB on 22q12 
where the linkage evidence to the region is referenced. Further detail on each study 




The bipolar disorder treatment, lithium, inhibits Glycogen Synthase Kinase 3, beta 
(GSK3as illustrated in Figure 1.7.  This suggests that manipulating GSK3may 
have a therapeutic value in treating bipolar disorder. Concomitant with functional 
evidence reviewed for this candidate gene (Rowe, Wiest et al. 2007), there is also 
genetic evidence from separate studies.  In a sample of 185 Italian patients with 
bipolar disorder, a SNP in the promoter region of GSK3did not show association. 
However in the same study, homozygotes for the wild-type variant (T/T) showed an 
earlier age at onset than carriers of the mutant allele (F=5.53, d.f.=2,182, P=0.0047) 
(Benedetti, Bernasconi et al. 2004) A second study on bipolar disorder cohorts from 
the Czech Republic and the US, has reported evidence for a submicroscopic copy 
number variations (CNVs) in the GSK3locus that appears to disrupt the gene's 3'-
coding elements. The CNV also affects two other annotated genes. They report that 
patients with bipolar disorder have an increased frequency of this CNV, primarily 
the duplication variant, compared with controls (P=0.002) (Lachman, Pedrosa et al. 
2007).
1.8.2.2. PIP5K2A
A gene in the phosphatidylinositol 4-phosphate 5-kinase family, PIP5K2A was 
screened for polymorphisms in a cohort of bipolar disorder samples (118) and 
schizophrenia (96) from the US, Czech Republic and Israel. This study revealed the 
existence of an imperfect CT repeat polymorphism (disruption of CT repeat) located 
in an intronic region. The distribution of alleles from this highly polymorphic 
variant was modestly different between bipolar disorder and schizophrenia patients  
(P=0.03) (Stopkova, Saito et al. 2003). Another polymorphism screening of PIP5K2A
revealed that a SNP in the same intronic region shows evidence of association
(Stopkova, Saito et al. 2003). Furthermore, in a sample of 65 sib-pair families from 
Germany (56) and Israel (9) affected with schizophrenia, evidence for an association 
was reported for SNP rs10828317 in exon seven of PIP5K2A. This SNP, which causes 
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a non-synonymous amino-acid exchange (asparagine/serine) produced a P-value of 
0.001 (experiment-wide significance level 0.00275) for over-transmission of the 
major allele coding for serine, analysed by transmission disequilibrium test
(Schwab, Knapp et al. 2006). In addition, association of this SNP with schizophrenia 
has been also described in a sample of 273 Dutch schizophrenic patients and 580 
controls (P=0.0004) (Bakker, Hoogendoorn et al. 2007). A negative association to 
PIP5K2A has also been reported in 260 bipolar disorder cases, 268 schizophrenia 
cases and 325 controls (Jamra, Klein et al. 2006). Aside from the positional genetic 
evidence, there is also alternative functional evidence to implicate PIP5K2A in 
bipolar disorder. In a microarray study that profiled lithium-modulated gene 
expression in human neuronal cells, PIP5K2A was upregulated upon lithium 
treatment (1.2 fold change, P=0.02) (Seelan, Khalyfa et al. 2007)
1.8.2.3. DGKH
One genome-wide bipolar disorder association study in two independent case-
control cohorts of European origin revealed association to DGKH; P=1.5x10-8, 
experiment-wide P<0.01, OR=1.59) (Baum, Akula et al. 2007).  The DGKH protein 
has an important role in the PI pathway by metabolising diacylglycerol (DAG). 
Figure 1.7 illustrates the position of DAG in the PI pathway.
1.8.2.4. cPLA2
Evidence for the cytosolic phospholipase A2 Beta (cPLA2) and psychiatric illness is 
provided by a survey of linkage analysis to the chromosomal region 15q12 
(Craddock and Lendon 1999), which was originally identified in two genome scans 




Other genes involved in the PI pathway have undergone association analysis for 
susceptibility to bipolar disorder, namely the myo-inositol monophosphatase genes, 
IMPA1 (Sjoholt, Molven et al. 1997) and IMPA2 (Yoshikawa, Kikuchi et al. 2001). 
IMPA2 maps to 18p11.2, a genomic locus for which evidence of linkage to bipolar 
disorder has been supported by several reports. A case-control association study
was reported in a large Japanese cohort with three IMPA2 SNPs. All three SNPs 
showed significant genotypic association (nominal P=0.031-0.0001) with 
schizophrenia, but not with bipolar disorder (Yoshikawa, Kikuchi et al. 2001). 
Another study investigated DNA variants in IMPA1 and IMPA2 genes in 
Norwegian bipolar disorder patients (44) and controls (48), followed by examination 
of selected polymorphisms and haplotypes in a family-based bipolar sample of 
Palestinian Arab proband-parent trios (75 nuclear families, 95 affected offspring). 
Two SNPs in the IMPA2 promoter sequence and their corresponding haplotypes 
showed transmission disequilibrium in the Palestinian Arab trios. The -461C and -
207T alleles were significantly more often transmitted than not transmitted to 
bipolar offspring (P=0.006 and 0.002 respectively, uncorrected). No association was 
found between the IMPA1 polymorphisms and bipolar disorder in the Norwegian 
cohort, neither with respect to disease susceptibility nor with variation in lithium 
treatment response (Sjoholt, Ebstein et al. 2004). Evidence for IMPA2 was 
strengthened by a report of a replication study in a Japanese cohort (496 patients 
with bipolar disorder and 543 control subjects). Association of the same IMPA2 
promoter SNPs was detected (-461C (P-value 0.042) and -207T (P-value=0.046)) with 
bipolar disorder in a Japanese cohort (496 bipolar disorder cases and 543 controls)
(Ohnishi, Yamada et al. 2007). However, this association was not supported for 
bipolar disorder, in a study involving 237 parent-offspring trios and in 174 cases 




The chromosome 18q12 gene, PIK3C3 encodes phosphoinositide-3-kinase, class 
three, which is highly expressed throughout the brain. A promoter variant in this 
gene has been associated with bipolar disorder and schizophrenia in two studies to 
date. Firstly, studies on 83 bipolar disorder patients from the Czech Republic 
showed a statistically significant difference in -432T allele distribution (P=0.008) and 
in 124 schizophrenia patients from Israel (P=0.0003) (Stopkova, Saito et al. 2004). 
Secondly, in a Chinese family-based study of schizophrenia in a sample of 235 trios 
there was significant evidence of preferential transmission at the same position of -
432C allele (P=0.0036, global significance P=0.0092) (Duan, Gao et al. 2005).  A 
negative association in the Danish population (310 schizophrenia cases and 880 
controls) has also been reported (Jungerius, Hoogendoorn et al. 2007). In addition, 
this region on chromosome 18q12 has been highlighted in a whole-genome 
homozygosity association study where the gene is located adjacent to a 
homozygosity run that is overrepresented in schizophrenia individuals (P=0.0012) 
(Lencz, Lambert et al. 2007).
1.8.2.7. SYNJ1
Several rare promoter and splice junction polymorphisms were found only in 
bipolar disorder patients in the SYNJ1 gene but this finding was not considered 
significant due to the small sample number (Saito, Guan et al. 2001). An ensuing 
study in a cohort of 84 bipolar disorder patients did not detect any rare variants, but 
showed in increase of an intron 12 polymorphism that was again not significant but 
may have been underpowered (Stopkova, Vevera et al. 2004).
1.8.2.8. PIK4CA
A screening of PIK4CA for polymorphisms identified rare variants at a splice site 
and the promoter region in three patients from the United States with bipolar 
disorder, three patients with schizophrenia and one control. There was no difference 
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between patients with a psychiatric diagnosis and controls for the variants, however 
the authors report a trend towards significance in the distribution of promoter 
genotypes in bipolar disorder patients (Saito, Stopkova et al. 2003). 
1.8.2.9. Synapsin III
Another PI candidate gene is synapsin III, which encodes for an intrinsic synaptic 
vesicle membrane protein. Synapsin III was highlighted in the genome-wide 
association study, previously described in section 1.5.3, performed by the WT-CCC 
on 2,000 bipolar disorder cases and 3,000 controls, as SNP rs11089599 in synapsin III
was among one of the higher ranked signals (P=7.2x10-5) (WTCCC 2007). Previous 
linkage studies in families with schizophrenia have shown evidence for 
chromosome 22q12-p13, where synapsin III is located (reviewed in (McGuffin, Owen 
et al. 2002) but this result was not supported by a multicentre linkage study 
(Mowry, Holmans et al. 2004). An association study has reported an increase in the 
number of  African American individuals (124) with schizophrenia that are 
homozygous for a SNP in synapsin III, compared to homozygous controls (P=0.04) 
(Lachman, Stopkova et al. 2005).
1.8.2.10. PI4K2B 
Finally, genetic evidence suggesting PI4K2B, the focus of this research, as a 
candidate gene in psychiatric illness was provided by results of a large-scale 
association study, as described in section 1.7.3 (Christoforou, Le Hellard et al. 2007).  
Tagging SNPs from the genomic region containing PI4K2B were used in the case-
control association study on 368 bipolar disorder individuals, 386 individuals 
diagnosed with schizophrenia and 458 control individuals. The association study 
identified SNP rs1093903, which is located in the same haplotype block as PI4K2B, 
100kb upstream of the coding region, as a potentially important variant in 
schizophrenia (allele P=0.006, odds ratios: 1.314, 95% CI 1.08-1.59), but not bipolar 
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disorder. This result did not meet the region-wide nominal significance threshold, 
P≤0.0003 but warranted further investigation.
Incompatible with the above genetic evidence suggesting a role of PI genes in 
susceptibility to bipolar disorder, a recent family-based association study of lithium-
related and other candidate genes in bipolar disorder has not supported this notion. 
This study examined a dense set of haplotype-tagging SNPs using a gene-based test 
of association in 379 US trios. No genes that were specifically chosen to probe 
lithium were associated with bipolar disorder and hence, found that no variants in 
lithium-related genes contribute to susceptibility to bipolar disorder.  However, 
only two of the genes listed in Table 1.8 were tested, namely GSK3β and IMPA2 and 
did not show association (Perlis, Purcell et al. 2008). 
In summary, the above positional genetic evidence for PI4K2B, IMPA2, PIP5K2A,
SYNJ1 and PIK4CA support a possible role for PI genes as bipolar disorder 
susceptibility genes. Further evidence from functional studies also supports this 
notion. 
1.8.3. Functional evidence for phosphoinositide genes in 
bipolar disorder
1.8.3.1. Phosphoinositide expression differences in bipolar 
disorder
Several investigations in bipolar disorder patients have suggested abnormalities in 
the PI pathway. One study reported that levels of the scaffolding molecule PIP2 are 
significantly increased in platelet membranes of drug-free depressed bipolar 
disorder patients. However, there was no difference in the levels of PI and PIP in 
bipolar disorder patients and healthy individuals (Soares, Dippold et al. 2001). A 
second study showed that a decrease in PIP2 resulted in synaptic vesicle defects (Di 
Paolo, Moskowitz et al. 2004). Other studies show altered inositol monophosphatase 
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(IMPase) enzyme activity and IMPA1 and IMPA2 expression levels in 
lymphoblastoid cell lines of bipolar patients, particularly in lithium responders 
(Shamir, Ebstein et al. 1998; Nemanov, Ebstein et al. 1999; Yoon, Li et al. 2001). 
Notably, these studies are in platelet membranes (Soares, Dippold et al. 2001) and 
lymphoblastoid cell lines (Shamir, Ebstein et al. 1998) and may not truly represent 
neuronal function. 
1.8.3.2. Effect of lithium on phosphoinositide signalling
Lithium is recommended by the WHO as a prophylaxis against bipolar disorder and 
can be effective in reducing the frequency and severity of manic and depressive 
episodes. Despite its chemical simplicity, the complex pharmacology and molecular 
mechanisms underlying the therapeutic actions of lithium have not been elucidated. 
The primary hypothesis of the lithium effect is the inositol hypothesis (Berridge, 
Downes et al. 1989). This idea proposes that lithium affects the PI signal 
transduction pathway to deplete inositol, as illustrated in Figure 1.7. It has been 
shown that lithium acts as a potent non-competitive inhibitor of myo-inositol 
monophosphatase (IMPase) (the rate limiting enzyme in inositol recycling) leading 
to inositol depletion (Hallcher and Sherman 1980; Berridge, Downes et al. 1989). 
This possibly causes abnormal activation of Calcium (Ca) Ca2+-mobilizing receptors. 
The upstream inositol polyphosphate-1 phosphatase (IPPase) has also been 
identified as an additional target for lithium (Majerus 1992; Acharya, Labarca et al. 
1998). This in turn, decreases the amount of phosphatidylinositol-4, 5-bisphosphate 
(PIP2), available for signalling cascades that rely upon this pathway, for example
synaptic vesicle trafficking. The signalling lipid, PI(3,5)P2 is also critical for survival 
of neural cells (Zhang, Zolov et al. 2007). A recent study has shown that lithium 
regulates Akt/glycogen synthase kinase 3 (GSK3) signalling by disrupting a 
signalling complex composed to Akt, β-arrestin 2 and protein phosphatase 2A. This 
is interesting as β-arrestin 2 promotes formation of signalling complexes allowing G 
protein-coupled receptors (GPCR) to signal independently from G proteins, and as 
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the authors suggest, the β-arrestin complex may represent a target for drug 
intervention aimed at the regulation of GPCR signalling (Beaulieu, Marion et al. 
2008)
Valproate, also a mood stabiliser recommended by the WHO, is proposed to act by 
the similar mechanism of inositol depletion, as illustrated in Figure 1.7. Functional 
evidence shows that chronic valproate treatment decreases inositol and increases 
inositol monophosphate (IP1) concentration in the rat brain (O'Donnell, Rotzinger et 
al. 2000), by inhibiting inositol synthase (ino-1) (Williams, Cheng et al. 2002). 
Additionally, lithium, valproate and another mood stabilising drug, carbamazepine, 
have been shown to inhibit the collapse of growth cones and increase the growth 
cone area in sensory neurons. These effects were reversed by inositol 
supplementation, again suggesting inositol depletion, as an important target for the
treatment of bipolar disorder (Williams, Cheng et al. 2002). 
1.8.3.3. Phosphoinositide signalling in neuronal physiology
The phosphorylation of inositol phospholipids is important in cellular regulation 
and synaptic vesicle trafficking for normal neuronal physiology. The generation of 
PIP from PI is an important precursor step. On synaptic vesicles, the membrane 
associated α isoform of PI4K, PI4KIIα is responsible for the majority of PI 4-kinase 
activity in the brain and is concentrated at the synapse and in the region of the Golgi 
complex in neuronal perikarya (Guo, Wenk et al. 2003). PI4KIIα is thought to be 
important in synaptic vesicle trafficking and downstream PI intracellular signalling
(Guo, Wenk et al. 2003). The important signalling and scaffolding molecule, PIP2, 
has been shown to regulate synaptic transmission by modulating Ca2+ signalling 
through its metabolic products, inositol triphosphate (IP3) and diacylglycerol 
(DAG). A decrease in PIP2 levels in the brain and impairment of PIP2 synthesis in 
nerve terminals has been shown to cause postnatal lethality and synaptic defects in 
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mice, including enhanced synaptic depression and delayed endocytosis (Di Paolo, 
Moskowitz et al. 2004). 
Therefore, the above positional and functional evidence support a possible role for 
PI genes as bipolar disorder susceptibility genes. In addition, the studies on PI genes 
and the lithium hypothesis suggest a model where functional mutations in genes 
affecting PI signalling pathway may cause an abnormality in neuronal PI4K 
homeostasis. On the basis of this hypothesis, further research in the genes involved 
in PI metabolism as candidates for psychiatric illness is reasonable, in particular the 
positional and functional candidate PI4K2B. In addition, it validates my approach to 
perform expression analysis, to examine the polymorphisms and resulting 
haplotypes for association analysis on this positional candidate gene involved in the 
PI pathway.
1.8.4. Phosphatidylinositol 4 kinases
1.8.4.1. Characteristics of PI4K2B
Four phosphatidylinositol 4 kinases (PI4K) have been identified. The four PI4K 
RefSeq genes are PI4K2B (NM_018323), PI4K2A (NM_018425), PI4KA (NM_058004) 
and PI4KB (NM_002651). Figure 1.8 illustrates PI4K2B as a gene of 45,000 base pairs 
(bp) with ten exons. The mRNA is 3458 bases long, the protein size is 481 amino 
acids and 54,754 Daltons (Da). Figure 1.8 also depicts the position of the 
PI3_PI4_kinase domain from amino acid 167 to amino acid 415. 
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Figure 1.8 PI4K2B gene. The blue bars represent the 10 exons of PI4K2B in 
proportion to their actual size. The dark blue scale bar represents 100bp. The 
phosphatidylinositol (PI) kinase domain is highlighted.
PIK42B is a type II kinase and is highly homologous (58% identical and 75% 
homologous) to PI4KII apart from a unique N-terminal 100 amino acid sequence. 
1.8.4.2. Function of PI4K2B
PI4K2Bis phosphatidylinositol 4-kinase and a member of the PI signal transduction 
pathway, as illustrated in Figure 1.7. Its primary function is phosphorylation of
phosphatidylinositol (PI) to generate phosphatidylinositol 4-phosphate (PIP). PIP is 
an immediate precursor of important signalling and scaffolding molecules, such as 
phosphatidylinositol 4,5-bisphosphate (PIP2) (Wei, Sun et al. 2002). The 
phosphoinositide cascade mediates the transmission of numerous hormonal signals 
through second messengers, diacylglycerol (DAG) and inositol-1,4,5-triphosphate 
(IP3), stimulating the release of the calcium ion (Ca2+). This in turn, modulates the 
activity of many intracellular events (Gould, Quiroz et al. 2004) to spatially and 
temporally regulate signalling, cytoskeletal dynamics and membrane trafficking
(Wei, Sun et al. 2002). However, there is controversy over the enzymatic ability of 
PI4K2B as “membrane-associated PI4K2B is as active as membrane-associated 
PI4K2 and has essentially identical kinetic properties” (Wei, Sun et al. 2002) to the 
contrary “most striking thing about PI4K2 is that it seems to be virtually inactive 
enzymatically compared to the  isoform.” (Shane Minogue, Personal 




1.8.4.3. Location of PI4K2B
Balla et al, 2002 have cloned PI4K2 and showed that over-expression of PI4K2B co-
localises with overexpressedPI4KIIin endosomal vesicles, but not in the plasma 
membrane or the Golgi apparatus (Balla, Tuymetova et al. 2002). Their data also 
indicate the existence of multiple forms of PI4K2B in mammalian cells (Balla, 
Tuymetova et al. 2002). Contrary to this, Wei et al have shown that PI4K2Bis a 
predominantly cytosolic protein and is recruited to the plasma membrane by the 
platelet-derived growth factor (PDGF) and mediated through the small GTPase, Rac 
in a Guanosine-5'-triphosphate (GTP)-dependent manner (Wei, Sun et al. 2002). Rac
simultaneously recruits and activates PI4K2Band PIP5K, a phosphatidylinositol 4-
phosphate 5-kinase, which converts PIP to PIP2, at the membrane. This pathway is 
very important in intracellular second messenger signalling, for example through
Ca2+ and for receptor dependent phospholipase C (PLC) and PI3K signalling. This 
suggests that PI4K2Bsynthesizes PIP and PIP2 to increase cellular trafficking in
membrane ruffling, endocytosis and exocytosis (Wei, Sun et al. 2002).
1.9. Expression Analysis 
1.9.1. Allele-specific expression
Allele-specific differences in gene expression have been reported in epigenetic 
phenomena of X-chromosome inactivation and genomic imprinting. Investigations 
on the extent of gene expression in populations, have suggested that allele-specific 
expression is also common in non-imprinted autosomal genes and that these allele-
specific differences are heritable (Lo, Wang et al. 2003; Pastinen, Sladek et al. 2004). 
Allele-specific differences in gene expression can be explained by cis-acting genetic 
variations causing differential expression between alleles. A cis-regulatory region is 
a segment of DNA that regulates transcription of a gene. For example, segments can 
typically lie immediately 5’- of the start site of transcription, or can be discontinuous 
or individual segments within introns, 5’- and 3’-untranslated regions (UTRs) or 
tens of kilobases on either side of the gene they regulate (Wray 2007). The search for 
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these genomic variations is helped when the haplotype structure of the locus has 
been defined (Pastinen, Ge et al. 2005). The differences can be determined using 
variation within the coding regions, to distinguish the relative abundance of 
transcript arising from the two alleles. For example, when cells from an individual 
who is heterozygote for a SNP are analysed, the allelic origin of the transcript can be 
identified. It is unlikely that the coding SNP will be functional but it may be used as 
a marker to distinguish the relative abundance of the two alleles. 
A screen for allele-specific differences in transcript abundance in human fetal liver 
and kidney tissue was reported using a microarray platform (Lo, Wang et al. 2003). 
This high-throughput analysis showed a twofold difference in transcript abundance 
between alleles in at least one individual, out of seven individuals, in 54% of the 602 
genes studied, and a fourfold difference in 28% of the genes. The majority of the 
differentially expressed genes were not in known imprinting domains and were 
distributed throughout the genome. The authors suggested that variation of gene 
expression between alleles is common, and this variation may contribute to human 
variability (Lo, Wang et al. 2003).
Pastinen et al, 2003 similarly reported differential expression of transcripts in 
heterozygous samples by quantifying intragenic marker alleles in messenger 
(mRNA) or heteronuclear RNA (hnRNA). In the study, they used 193 SNPs from 
129 genes expressed in lymphoblastoid cell lines, to identify 23 genes (18%) with 
common transcripts whose expression from the two alleles deviated from the 
expected equimolar ratio. Further study of three genes, in samples from a three-
generation pedigree showed patterns of transmission, including co-segregation of 
allelic skewing across generations, compatible with Mendelian inheritance and 
random monoallelic expression (Pastinen, Sladek et al. 2004). Thus, the authors 
provide evidence for widespread allele-specific differential gene expression and 
inheritance of this variation in some instances.
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Allelic differences in expression have been reported in candidate genes for bipolar 
disorder and schizophrenia. First, the bipolar disorder candidate gene encoding the 
winged-helix transcription factor RFX2, has shown evidence for significant allelic 
differences in expression (P<0.001) in post-mortem brain tissue cDNA (Glaser, Kirov 
et al. 2005). Second, assays of allelic expression on the schizophrenia susceptibility 
gene dystrobrevin binding protein 1, DTNBP1, have shown a relative reduction in 
mRNA expression in human cerebral cortex (P<0.0001), possibly mediated through 
cis-acting variants tagged by defined schizophrenia risk haplotypes (Bray, Preece et 
al. 2005). Last, allelic expression analysis on the schizophrenia candidate gene 
GNB1L, a G-protein beta-subunit-like polypeptide, showed evidence for differential 
allelic expression of GNB1L transcripts (P=0.0006) in post-mortem brain tissue 
cDNA. The study also found evidence that markers associated with psychosis are 
also correlated with the presence of cis-acting influences on alterations in GNB1L
expression (Williams, Glaser et al. 2008).
Moreover, expression differences can also be detected at the protein level. For 
example, a microarray study which investigated the effect of lithium on gene 
expression in a human neuronal cell line identified as Peroxiredoxin 2 (PRDX2), an 
antioxidant enzyme, as the most upregulated gene and tribbles homolog 3 (TRB3), a 
pro-apoptotic protein, as the most down-regulated gene upon lithium treatment. 
This difference was also detected at the protein level by Western blotting technique, 
ensuring greater confidence in the result (Seelan, Khalyfa et al. 2007).
1.9.2. Lymphoblastoid cell lines as a cellular model
The ability to perform expression analysis studies depends on the availability of 
pertinent biological tissue. Fortunately, lymphoblastoid cell lines were available 
from 50 individuals in the aforementioned large Scottish family. There are many 
advantages to using lymphoblastoid cell lines as an experimental resource. Firstly, 
this resource is exceptional because of the number of cell lines available within one 
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family. Secondly, they provide immense experimental potential, including a 
limitless supply of DNA. Thirdly, a postulated advantage is minimising the 
influence of medication, as the cell lines can be cultured for more than one month
(Washizuka, Kakiuchi et al. 2005). 
Importantly, expression analysis on these blood-derived cell lines can be extended 
to model brain tissue. There is evidence for altered expression of neuronal receptor 
proteins and neurotransmitter systems in lymphocytes, and for similarities of 
hormonal effects on nervous system processes and lymphocyte physiology in 
schizophrenia, recurrent major depression and related phenotypes (Gladkevich, 
Kauffman et al. 2004). Microarray expression analysis between brain and whole 
blood samples shows that whole blood shares significant gene expression 
similarities with multiple CNS tissues, which is useful for gene expression studies. 
For example, from a total of 45 schizophrenia candidate genes studied, the 
expression was correlated in 21 genes between the blood and prefrontal cortex of 
the brain. This research also showed that correlation between blood and brain 
tissues was good for certain processes: including axon guidance, neurogenesis, G-
protein coupled receptor protein signalling and intracellular signalling cascade and 
would be useful (Sullivan, Fan et al. 2006). Finally, lymphoblastoid cell lines have 
been used as a cellular model to study complex human diseases such as bipolar 
disorder, hypertension, diabetes mellitus, Alzheimer’s disease and Huntington’s 
disease [as reviewed in (Gladkevich, Kauffman et al. 2004; Iwamoto, Kakiuchi et al. 
2004).
However, there are disadvantages associated with lymphoblastoid cell lines such as
a risk of structural genomic alterations due to the Epstein Barr Virus (EBV) 
immortalisation process, lymphoblastoid cell lines creation or prolonged cell 
culturing (Simon-Sanchez, Scholz et al. 2007). Another drawback is not all genes are 
expressed in lymphoblastoid cell lines or behave as they would in vivo. 
Furthermore, lymphoblastoid cell lines are non-neuronal cells so it is difficult to 
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extend any finding in lymphoblastoid cell lines to brain disorders such as bipolar 
disorder. The aforementioned microarray expression study between brain and 
whole blood samples also showed that correlation in gene expression was not good 
for certain processes. For example, the study of brain oxygen transport, RNA 
binding and DNA binding in blood tissue would not reflect the processes in brain 
tissue (Sullivan, Fan et al. 2006). Thus, when the relevant gene is expressed in both 
blood and brain, any interpretation of experimental data from lymphoblastoid cell 
lines should be cautious.
Several intermediate phenotypes of bipolar disorder have been reported at the 
lymphoblastoid cell level. Many reports relate to abnormal intracellular calcium 
metabolism, phosphoinositides and cAMP signalling (Kato, Ishiwata et al. 2003). 
This suggests that certain biochemical pathways involved in bipolar disorder can be 
studied using non-neuronal lymphoblastoid cell lines. Furthermore, differentially 
expressed genes (IMPA2, TRPC7, NDUFV2) have been reported in lymphoblastoid 
cell lines from patients with bipolar disorder (Washizuka, Kakiuchi et al. 2003; 
Washizuka, Kakiuchi et al. 2005). Also, candidate genes HSPF1 and LIM showed 
altered gene expression in both post-mortem brains and lymphoblastoid cell lines 
from Japanese patients with bipolar disorder (Iwamoto, Bundo et al. 2004). A 
reported association of a mitochondrial complex I subunit gene, NDUFV2 at 
chromosome 18p11 with bipolar disorder (Washizuka, Kakiuchi et al. 2003), was 
substantiated by a decrease in NDUFV2 and other mitochondria-related genes 
mRNA expression in lymphoblastoid cell lines from patients with bipolar disorder 
(21) compared with controls (11) (Washizuka, Kakiuchi et al. 2005). Lymphoblastoid 
cell lines can also be used to investigate the effects of bipolar disorder treatment 
such as lithium. A examination of in vitro activity of a target of lithium, IMPase 
activity in lymphoblastoid cell lines derived from individuals with bipolar disorder
with a positive response to lithium (56), with a poor response to lithium (11) and 
control samples (29) found that levels of IMPase indicate susceptibility to bipolar 
disorder and response to lithium treatment (Shamir, Ebstein et al. 1998). A study on 
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bipolar disorder affected individuals currently treated with lithium (9), lithium-free 
individuals (13) and healthy control subjects (23) found that  levels of the lithium 
target, GSK3β, previously discussed in section 1.8.2.1, were eightfold higher in 
peripheral blood mononuclear cells from lithium-treated bipolar disorder 
individuals than healthy control individuals (Li, Friedman et al. 2007).
Investigations of the allelic expression of PI4K2B in lymphoblastoid cell lines were 
used to test the hypothesis of this study, that impairment of phosphatidylinositol 
phosphorylation by altered expression levels may lead to disturbances in cell 
signalling implicated in development of bipolar disorder.
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1.10. Aim of the Study
This study tested the hypothesis that there is a genetic risk factor for susceptibility 
to the psychiatric illnesses, bipolar disorder and recurrent major depression in a 
large Scottish family. The aims were twofold i) investigation of a candidate gene, 
PI4K2B, for susceptibility to bipolar disorder using expression studies in the family 
and in a case-control association study and ii) whole genome linkage analysis of the 
family with increased marker coverage and updated diagnoses.
o In Chapter 3, expression analysis of PI4K2B was conducted in
lymphoblastoid cell lines from the family, at the allele-specific RNA level 
and the protein level.
o In Chapter 4, a case-control association study tested association of markers 
in the PI4K2B region with bipolar disorder and schizophrenia in the Scottish 
population
o In Chapter 5, the data for the whole genome linkage scan was prepared and 
verified, by performing relatedness analysis on the family, error-checking 
the genotyping data and sub-dividing the large family to allow linkage 
analysis.
o In Chapter 6, the linkage evidence for bipolar disorder and recurrent major 
depression in the family was evaluated by parametric linkage analysis, non-
parametric linkage analysis and haplotype analysis.
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2. Material & Methods
2.1. General Molecular Biology Material
A collection of cell lines and DNA samples were available for this study and are 
detailed in section 2.1.1. For the molecular biology methods detailed in section 2.2, 
the general chemicals were obtained from Sigma, unless otherwise noted. All PCR 
primers, cell culture media and supplements were supplied by Invitrogen. Section 
2.1.2 details the protocol for preparing solutions, buffers and materials. Table 2.1
lists the kits used for molecular biology techniques.
2.1.1. DNA
The DNA samples available to this study are detailed in this section. There were 
DNA samples from a large Scottish family, lymphoblastoid cell lines from the same 
Scottish family, a panel of DNA samples from four families, a selection of trios and a 
cohort of unrelated cases and controls. The details of the collection method are listed 
below. The phenotyping methods for all patients was through interview using the 
semi-structured instrument “Schedule for Affective Disorder and Schizophrenia-
Lifetime” version (SADS-L) (Endicott and Spitzer 1978) and supplementary clinical 
information was also available from hospital case notes and from relations of cases.
Diagnosis was determined by criteria from the Diagnostic and Statistical Manual of 
Mental Disorders (4th Edition) (DSM-IV) for bipolar disorder and schizophrenia. All 
diagnoses were reviewed independently by two experienced psychiatrists and a 
consensus diagnosis was reached where necessary. A peripheral venous blood 
sample (20ml) was obtained for DNA extraction and separation of lymphocytes to 
establish transformed cell lines by European Collection of Cell Cultures (ECACC). 
DNA samples were stored on 96-well plates and archived in the Wellcome Trust 
Core Research Facility (WT-CRF), Western General Hospital, Edinburgh.
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2.1.1.1. DNA samples from Scottish family
DNA samples, extracted from blood samples prior to this study, were available 
from the large Scottish family, which has previously named as F22 (Blackwood, He 
et al. 1996). The family was ascertained at a local psychiatric hospital where an aunt 
and niece had been admitted at the same time, each with bipolar disorder. The 
researchers obtained informed consent from both probands to contact other family 
members. The whole family was gradually recruited over several years. Some 
individuals were interviewed on more than one occasion. Linkage analyses were 
performed under two definitions of the disease phenotype: broad and narrow. For 
the broad definition, the phenotype included bipolar I disorder, bipolar II disorder 
and recurrent major depression cases. The narrow definition included only cases 
with a bipolar I disorder and bipolar II disorder diagnosis and all other psychiatric 
diagnoses were labelled as unknown
2.1.1.2. Lymphoblastoid cell lines
Lymphoblastoid cell lines were established from members of the large Scottish 
family. The cell lines were available from ECACC. All individuals gave consent to 
take part in these studies. 
2.1.1.3. Allele sharing panel
The Allele Sharing Panel was a collection of 46 DNA samples from individuals in 
the four families that show linkage of bipolar disorder on chromosome 4. There 
were 31 samples from the large Scottish family (F22), seven samples from F50, three 
samples from F48, five samples from F59 (Blackwood, He et al. 1996) a control DNA 
pool and a negative control. This represented multiple copies of the linked 
haplotype to chromosome 4p15-16. This enabled unambiguous determination of the 
linked haplotype and 38 control chromosomes in region B and 37 control 
chromosomes in region D (defined as all non-disease chromosomes). Please refer to 
Figure 1.6.
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2.1.1.4. Trio bipolar panel
The Trio Bipolar Panel is a collection of DNA samples from 96 individuals that 
comprise 32 proband-parent trios. A trio is an affected offspring (bipolar disorder) 
and both parents. The panel were recruited from the south Scottish population and 
are all of North European ancestry.
2.1.1.5. Association study sample
The study sample consists of DNA from 444 control individuals, 362 bipolar 
disorder patients and 383 schizophrenia patients. These studies were approved by 
the Scottish MultiCentre Research Ethics Committee (MREC) and patients and 
controls gave written informed consent. Individuals suffering from bipolar disorder 
and schizophrenia were recruited from The Royal Edinburgh Hospital and other 
Scottish psychiatric hospitals by trained psychiatrists. Samples were also obtained 
from Fyffe, The Borders and Lanackshire through collaborations with psychiatrists 
based in these regions. 
Control subjects were drawn from the same population in South East and South 
Central Scotland. The majority (391) were recruited through the Scottish National 
Blood Transfusion service. Although the blood donors were not screened by 
interview for personal or family history of psychiatric illness, donors are only 
allowed to donate blood if they are not currently on medication and had no chronic 
illness. The remaining controls (79) were recruited from the local population and
from hospital staff. These controls were briefly screened by interview to exclude 
anyone currently on medication or with a history of treatment for psychiatric illness. 
The samples were drawn from the Scottish population.
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RPMI or DMEM depending on cell type
10% Fetal Bovine Serum
10% DMSO
Aliquot and store at -20°C.
Coomassie Brilliant Blue protein stain
Coomassie stain 0.25g
Methonal: Water (1:1 v/v) 90ml
Glacial acetic acid* 10ml
Filter solution and store at room temperature (RT)
*Always add acid to water
Coomassie de-stain (Methanol:Acetic acid)
Glacial acetic acid 100ml
Methanol 300ml





5ml of deionised water (dH20) added to 95ml ethanol (99.7-100% v/v), mixed and stored at 
room temperature (RT).
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70% Ethanol
30ml dH20 added to 70ml ethanol (99.7-100% v/v), mixed and stored at RT.
10μg/100ml Ethidium Bromide
1μl of 10mg/ml ethidium bromide solution was added to 100ml dH20. The solution was 
mixed and stored at RT.
Orange G Loading Dye
Ficoll 400 3g (15%)
SDS (20% solution) 50µl (0.05%)
EDTA (0.5M) 800µl (20mM)
Orange G 0.125%
Qs (Quantity sufficient) to 20ml dH20, store at RT.
PBS/BSA




Qs 100ml, store at RT.
PBST blocking buffer (Western Blotting)
1x PBS, 5% semi-skimmed milk (Marvel) 0.2% Tween20.
Protease inhibitors (Complete)
1 tablet dissolved in 1 ml dH20, aliquot and store at -20°C.
Protein sample buffer (2X Laemmli)
Tris (hydroxymethyl)-methylamine (0.5M, pH6.8) 2ml (100mM)
Glycerol 2ml (20%)
SDS (20% solution) 2ml (4%)
Bromophenol Blue 0.2g (0.02%)
Qs 10ml dH20, store at RT. Add 100mM DTT before use.
RIPA buffer 
Tris (hydroxymethyl)-methylamine (50mM, pH7.4) 0.61g
Sodium chloride (NaCl, 150mM) 0.9g
dH20 80ml
Stirred to dissolve, pH7.4 with 5M HCl
1% Trition 1ml
Sodium deoxycholate (10% solution) 2.5ml
Sodium dodecyl sulphate (20% solution) 250µl
Stirred to dissolve
1mM EGTA (100mM solution) 1ml
Qs 100ml dH20, 5ml aliquots, store at 4°C. Add 100µl protease inhibitors to 5ml RIPA lysis 
buffer before use.
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REPA lysis buffer
10% Sodium deoxycholate 2.5ml
Nonidet p40 (aka IGEPAL CA-630) 0.5ml
20% SDS 250µl
Qs PBS 50ml




20% Sodium dodecyl sulphate (0.04%) 2ml
Methanol (20%) 200ml
Qs to 1L dH20, pH9-9.4, store at 4°C.
3M Sodium Acetate
8.16g sodium acetate qs 20ml dH20.  *adjust the pH to 5.2. 
Sodium azide
5g NaN3 in 50ml dH2O.
Use at 1:100 PBS
1x TBST (Tris buffered saline with Tween)
1MTris, pH 7.5 50ml
Sodium chloride 8.75g
Qs 1L dH20, add 1ml Tween20 (0.1%)
TBST blocking buffer
1X TBST with 1% Marvel




1.5M Tris pH 8.8
181.5g Tris (hydroxymethyl)–methylamine in 1L dH20, *adjust pH and store at RT.
0.5M Tris pH 6.8





Qs 1L ml dH20. The buffer was autoclaved to sterilise before use and stored at RT.





The solution was mixed and stored at RT.
2.1.3. Kits 
METHOD KIT SOURCE
cDNA preparation First Strand cDNA Kit Roche




















PCR Amplification 10X PCR Enhancer Invitrogen
PCR Amplification PCR Core Kit Sigma

























REPLI-g Midi Kit Qiagen
Table 2.1 Kits used in molecular biology techniques.
Chapter 2 Material & Methods
85
2.2. General Molecular Biology Methods
Molecular biology techniques were developed from Sambrook et al, 1989, 
(Sambrook, Fritsch et al. 1989) unless otherwise stated. 
2.2.1. Cell culture
2.2.1.1. General cell culture
All mammalian cells were classified as containment level one and were manipulated 
using aseptic technique in Envair Bio2+ Class II safety cabinets. Cells were grown 
under humid conditions (37°C, 5% Carbon dioxide) in the appropriate growth 
medium. T.25, T.75 and T.175 tissue culture flasks with filter caps were used to 
maintain cell cultures (CellStar®, Greiner Bio-One). 
2.2.1.2. Lymphoblastoid cell culture
Lymphoblastoid cell lines were cultured with RPMI 1640 (Sigma) containing 10% 
Fetal Calf Serum (Invitrogen), 1:100 penicillin/streptomycin (Invitrogen), 1:100 L-
Glutamine, 1:500 1.25M MOPS (Sigma). Cells were maintained by feeding every 
three-four days. It is recommended that lymphoblastoid cell cultures be maintained 
at a density of 3-9x104 cells per ml (www.ecacc.org.uk). For three days prior to
harvesting cells, the culture medium was changed every day in order to randomise 
the cell cycle (Washizuka, Kakiuchi et al. 2005). Healthy lymphoblastoid cells grew 
in aggregates which settled at the bottom of the tissue culture flask. To replenish 
medium or passage cells, the flasks were removed from the incubator into the safety 
cabinet with minimum agitation to avoid disrupting the cell aggregates. The 
medium was removed using a sterile glass pipette. The medium was then either 
replenished or the cells were split by removing an appropriate amount of cells and 
placing them into a new flask of fresh medium. Once in fresh medium, the cells 
were agitated to dissociate clumps and promote growth. All cell lines were 
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subjected to the same cell culture and experimental conditions, to minimise any 
changes to gene or protein expression. 
2.2.1.3. Adherent cell culture
COS7 cells were cultured. These adherent cells were from monkey kidney 
fibroblasts (Medical Genetics, Molecular Medicine Centre). Cell medium (DMEM, 
10% FBS) was replenished every three-four days as required. Cells were passaged at 
70-90% confluency. To passage cells, growth medium was aspirated using a sterile 
glass pipette and cells were washed in D-PBS (GIBCO®) to remove any remaining 
serum. Cells were incubated with a 1:1 solution of versene plus trypsin (GIBCO) at 
37°C to lift them from the flask surface. The versene:trypsin solution was inactivated 
by adding an equal volume of growth medium containing 10% fetal bovine serum. 
Cells were centrifuged gently at 1,000rpm for five minutes (CR312 Jouan centrifuge) 
at RT and then re-seeded into new medium. Cells were re-seeded at 1 in 10 to 1 in 50 
dilutions. 
2.2.1.4. Preparation and recovery of cell stocks
Frozen cell stocks were prepared by centrifuging an appropriate amount of cells (4-
9x106 lymphoblastoid cells or 1-2x106 adherent) for five minutes at 1,000rpm. Cell 
pellets were resuspended in 1ml cell freezing medium and placed in a CryoTube™ 
(NUNC™). Cells were frozen using a Cryo 1°C freezing container (NALGENE). The 
freezing chamber was filled with 100% ethanol or propan-2-ol and the CryoTube 
was placed in the holder provided. This was stored at -70°C overnight. Using this 
container, the cells were frozen slowly at a rate of -1°C/minute. The cells were then 
placed in liquid nitrogen for long term storage. Frozen cells were recovered by 
thawing quickly at 37°C and placing into a T.25 tissue culture flask with 5ml growth 
media. Cells were incubated overnight at 37°C, 5% CO2 to recover. Following this, 
cells were resuspended in fresh medium and grown as normal.
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2.2.1.5. Haemocytometer counting to determine cell number
The haemocytometer (Improved Neubar) was cleaned with 70% ethanol. A 
coverslip was placed over the haemocytometer chamber. Confluent cell suspensions 
were diluted 1 in 10 for counting. Each chamber of the haemocytometer was filled 
by capillary action using a Pasteur pipette to place a drop of the cell suspension on 
the chambers edge. A minimum of four 1mm square (divided into 16 smaller 
squares) were counted and the average cell number was calculated. Each square 
represented the number of cells x104/ml.
2.2.1.6. Mycoplasma test with Hoechst 33258
Lymphoblastoid cell lines were incubated with an equal volume of MeOH/Acetic 
Acid fix for five minutes. The cells were spun down, washed, resuspended in a 
small quantity of fix and placed on a glass slide. The slide was stained with 1µg/ml 
Hoechst 33258 (Invitrogen, Spectra) for 10 minutes and washed with dH20. A 
coverslip with Vectashield mounting media (Vector labs, H-1400) covered the glass 
slide, secured with rubber sealant. The stained slides were analysed by fluorescent 
microscopy. Uncontaminated cultures showed only cell nuclei staining and there 
was no evidence of small cocci or filaments of mycoplasma-positive cultures. 
2.2.1.7. Chemical transfection of mammalian cell lines
Transfection of Cos7 cells was performed by Lipofectamine™ 2000 (Invitrogen) 
according to the manufacturer’s instructions, in duplicate, in 6-well COSTAR® flat 
bottom plates. There were controls included in the transfection procedure of 
PI4K2B-HA; no DNA, HA 14-3-3, MYC 14-3-3 and HA. PCR amplification of these 
preparations did not produce a product with PI4K2B specific primers.
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2.2.2. Nucleic acid preparation
2.2.2.1. Genomic DNA preparation
Genomic DNA (gDNA) was isolated using the DNeasy Tissue Kit (Qiagen) as per 
the manufacturer’s instructions. A maximum of 5x106 cells were used. Briefly, cells 
were lysed using proteinase K, ethanol was added to the lysate, which was then 
applied to a spin column with a specialised silica-gel membrane that binds DNA. 
The contaminants were removed by washing the column and the DNA was eluted.
DNA was eluted twice using 2x200µl volumes of AE buffer provided. The extracted 
gDNA was stored temporarily at 4°C or at -20°C for long-term storage.
2.2.2.2. RNA preparation
RNA was prepared using RNeasy Mini Kit (Qiagen) as per the manufacturer’s 
instructions. Briefly, samples were lysed and homogenized in the presence of a 
highly denaturing guanidine-thiocyanate–containing buffer, which immediately 
inactivates RNases to ensure purification of intact RNA. Ethanol was added to 
provide appropriate binding conditions, and the sample was then applied to an 
RNeasy Mini spin column, where the total RNA bound to the membrane and 
contaminants were washed away. RNA was then eluted in 30–100μl dH20. With this 
protocol, all RNA molecules longer than 200 nucleotides were purified, enriching 
for mRNA since most RNAs <200 nucleotides (such as 5.8S rRNA, 5S rRNA, and 
tRNAs, which together comprise 15–20% of total RNA) were excluded. The RNA 
was DNase treated to remove genomic DNA, by incubating DNaseI directly on the 
membrane at RT for 15 minutes. RNA preparations were immediately frozen on dry 
ice and stored at -70°C.  
2.2.2.3. cDNA preparation
mRNA was reverse transcribed to cDNA with First Strand cDNA Kit (Roche) using 
random primers. This method produces single stranded RNA using AMV (Avian 
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myeloblastosis virus) reverse transcriptase. A typical cDNA synthesis reaction is 
described in Table 2.2.
REAGENT VOLUME FINAL CONCENTRATION
10X reaction buffer 4µl 1X
25mM Magnesium 
chloride 8µl 5mM
10mM dNTPs 4µl 1mM
Random Primers 
p(dN)6 4µl 3.2µg
RNase inhibitor 2.5µl 50 units
AMV reverse 
transcriptase 1.6µl 20 units
Total RNA X µl <1µg total RNA
dH20 X µl
20µl
Table 2.2 cDNA synthesis reaction
A master mix containing the appropriate reagents was prepared, mixed and 
centrifuged before aliquoting into 0.5ml RNase free thin walled tubes. The reactions 
were then cycled on a thermal cycler (Peltier PTC-225) or separately on a heating 
block as shown in Table 2.3.
TEMPERATURE TIME PURPOSE
25°C 10 minutes Primer annealing
42°C 60 minutes Reverse transcription
99°C 5 minutes AMV inactivation
4°C 5 minutes
Table 2.3 cDNA incubation times
The cDNA was stored at -20°C. For all cDNA preparations a negative control 
reaction was prepared. This control included RNA, but did not include the reverse 
transcriptase enzyme. This was to ensure that no DNA contamination was present 
in the RNA sample which would interfere with downstream PCR applications. 
Negative controls containing dH20 and reverse transcriptase were also prepared to 
ensure all reagents were free of contamination.
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The cDNA was tested for genomic contamination by PCR with intron-spanning 
housekeeping primers [ANAPC4, WDR1, DDX15 (Invitrogen)] as the Sigma 
protocol. The cDNA sample without reverse transcriptase was also tested with the 
three Taqman assays used for PI4K2B expression analysis in chapter 3. Please see 
Table 2.4 for primer sequences.
2.2.2.4. Gel extraction of DNA
DNA was extracted from agarose gel to isolate PCR products for sequence analysis. 
PCR products were extracted from low melting point (LMP) agarose gels using the 
QIAquick gel extraction kit (Qiagen) with the microfuge, according to the 
manufacturers’ instructions.  In brief, gel slices containing the desired PCR product 
were dissolved at 50°C in the appropriate buffer. An appropriate volume of 
isopropanol was added and the mixture was then applied to a spin column where 
the DNA bound to a silica membrane. After impurities such as salt and agarose 
were washed away, the DNA was eluted and ready for use. 
2.2.2.5. Transformation of PI4K2B-HA plasmid
The DNA was provided by Tamas Balla on 6th December 2005, NICHD, Bethesda, 
MD, USA. The DNA was extracted from filter paper with 20µl sterile water 
(Invitrogen) and incubated for 14 hours. The DNA was transformed into Subcloning 
Efficiency™ DH5α™ competent cells (Invitrogen) using the heat shock protocol, as 
per manufacturers’ instructions. Briefly, the DH5α cells were thawed on ice, 25l 
per reaction. 2l DNA was added and mixed with the cells. The samples were 
incubated on ice for 30 minutes. The cells were heat-shocked for 20 seconds in a 
42°C water bath, then on ice for 2 minutes. The cells recovered in 1ml L-broth with 
glucose at 37°C for 30 minutes before spreading the transformed DNA on plates. 
The transformed DNA was plated on kanamycin (50mg/ml). DNA was prepared 
from one colony. The DNA plasmid was purified by EndoFree Plasmid Maxi Kit
(Qiagen) as per manufacturers’ instructions. In brief, the EndoFree plasmid 
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purification procedure was based on the selectivity of QIAGEN Resin that purified 
ultrapure supercoiled plasmid DNA with high yields. The plasmid purification 
protocol was based on a modified alkaline lysis procedure, followed by binding of 
plasmid DNA to QIAGEN Anion-Exchange Resin under appropriate low-salt and 
pH conditions. RNA, proteins, dyes and low-molecular weight impurities were 
removed by a medium-salt wash. Plasmid DNA was eluted in a high salt buffer and 
then concentrated and desalted by isopropanol precipitation. Finally, the correct 
plasmid was verified by digest with EcoRI and XmaI. The restriction sites were 
determined using NEBcutter version 2, Table 2.8.
2.2.3. Polymerase chain reaction
2.2.3.1. Primer design
Genomic sequence information was obtained from the University College Santa 
Cruz (UCSC) genome browser. Information on features of chromosome 4p14-p16 
sequence was obtained from the in-house browser ACeDB. The Primer3 design 
programme was used (Rozen and Skaletsky 2000). Primers were designed from 
repeat and SNP free regions of sequence. The repetitive sequences were screened 
out using Repeat Masker. Specificity of the primer sequence was checked using 
UCSC In-silico PCR (Kent, Sugnet et al. 2002) which searches a sequence database 
with a pair of PCR primers. The primers were synthesized by Invitrogen Life 
Technologies. The primers were tested to establish optimal PCR conditions on DNA 
samples using Sigma, Invitrogen and Applied Biosystems methods. Primer details 
and specific PCR conditions are listed in Table 2.4. All primers were diluted to 
100µM with dH20, then to a 10µM working stock and stored at -20°C.
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NAME PRIMER SEQUENCE CONDITIONS
Microsatellites
D1S439 F CACAGACTTCATTAGAGGGG Sigma, TD55
D1S439 R GTTGAAATGGTGAATTTGGA
D1S103 F ACGAACATTCTACAAGTTAC Sigma, TD55
D1S103 R TTTCAGAGAAACTGACCTGT
D1S225 F GCCTGGGTGACAAAGCA Sigma,15uM (normal 
is 20µM) TD55
D1S225 R TGGCCTGAATAGACCATAAAAA
D1S229 F GCTTGTTTCCATTTATTGTG Sigma, TD55
D1S229 R ACTCTAGTTGTGTGTGAATGTATG
D1S1621 F TATAACCACTGCATCCTGACC Sigma, TD55
D1S1621 R TTTCTCACCTTTAAATGTCATCA
D4S1599 F CCTTAAAAGTATCCAGTAAAGCACA Sigma, TD55
D4S1599 R CAAGGTTGTCCTGTGTCTGCST
D4S1533 F TCTCTCTCTTGCTCTTCCC Sigma, TD55ext x32
D4S1533 R TCAGGCTTGTATGTGTGTTG
STB131K9 F GCTGAGCTTGCTCACTCTGTTA Sigma, TD 55ext x32
STB131K9 R GTGGCTTAAGGGAATTGTGTTC
D4S1609 F TCTGAAAATGCCCTTGACC Sigma, TD55ext x32
D4S1609 R CATCATTACTGCTGGGATGC
D4S2408 F AATAAACTTCAACTTCAATTCATCC Sigma, TD55ext x30
D4S2408 R AGGTAAAGGCTCTTCTTGGC
D4S1546 F CTACCGACTAGAATCACATGGG Sigma, TD55ext x30
D4S1546 R GACCTGTCCAAACGCCT
3’ RACE
3' RACE Outer Primer GCGAGCACAGAATTAATACGACT As 3’ RACE Protocol
3' RACE Inner Primer CGCGGATCCGAATTAATACGACTCACTATAGG As 3’ RACE Protocol
3' RACE Control Primer CAGGGACATTTTCCAGCAAATTC As 3’ RACE Protocol
5' PCR Control Primer CAAGTCTGGTTCTTCTCCTCTT As 3’ RACE Protocol
PI4K2B-specific for detection of alternative splicing
stcPI4K2B.ex1aF GAGGTGGCGTCCGTTCTAC Invitrogen/AB/Sigma, 
TD55
stcPI4K2B.ex1bF GGTCTCCCGGAGTTCGTC Invitrogen/AB/Sigma, 
TD55




AACGCAGTCAAGGTGGAAGT As 3’ RACE Protocol
stcPI4K2B.ex10_inner 
(aka exon10_inner)
GTCAATTGCAGGAAGCCATT As 3’ RACE Protocol
End of 3’ 1kb sequence 
(aka 3’UTRend)
AGCAATGTTGCCTTAATTTCAAAAGCT As 3’ RACE Protocol
Table 2.4 Primer list. Continued on the next page.
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PI4K2B CDNA SPECIFIC
PI4K2B F GGGGGTCTCCCGGAGTTCG Invitrogen/Sigma, TD55
PI4K2B R CCATAAGGCTCTTCTGATTTGG
Intron spanning primers 
WDR1 F AAGGCCCACGACGGTGGGATTTAC Sigma, TD65
WDR1 R GGAGTTCACGCTGACGTCCCAAAT
DDX15 F AACACCTATCCTGAGATTTTGCGTTCT AB, TD65
DDX15 R TTCCAGGGCTCTCATCAGAGTTTC
ANAPC4 exon 27_30 F GCTAGATGAACAGTGTAGTGCTATTCC AB, TD55
ANAPC4 exon 27_30 R ACACACACAATAATGGCAAGC
PeakPicker primers
stePI4K2B.ex10eF CCTTTGAGGATGCCTACGTC Sigma, TD55
stePI4K2B.ex10eR TGAACAAGGCCAGTACTCTGAA
stPI4K_ex2 F AGAAGTGGGGGTTGTTAGGC Sigma, TD55
stPI4K_ex2 R CCTTTGTTTTGGAAAAGAGGTT
stePI4K2B.int1 F TGATGGATGCATTGACGTTT Invitrogen, TD55
stePI4K2B.int1 R ATGGGGATCTCGCTATGTTG
Table 2.4 Primer list Abbreviations; AB is Applied Biosystems, F is forward primer, 
R is reverse primer, TD is touchdown PCR amplification conditions.
2.2.3.2. Non-quantitative PCR
PCRs were carried out using Sigma, Invitrogen or Applied Biosystems methods, in a 
total volume of 20µl as follows: Sigma; 2µl 10xSigma Buffer, 0.2µl Sigma Taq 
Polymerase, 0.6µl 10mM dNTPs (Sigma), 0.5µl 20mM Primers, 1µl DNA, 15.7µl
dH2O as per Sigma protocol: Invitrogen; 2 µl 10x Invitrogen Buffer, 0.08µl Invitrogen 
Taq Polymerase, 0.6µl 10mM dNTPs, 0.5µl 20mM Primers, 0.52µl MgSO4/MgCl2, 
0.6µl 10%BSA (New England Biolabs), 0.6µl DMSO, 2µl Invitrogen PCR Enhancer, 
1µl DNA, 14.7µl dH2O as per Invitrogen protocol: and Applied Biosystems; 2 µl 10x
ABI Buffer, 0.2µl In-house Taq Polymerase, 0.6µl 10mM dNTPs, 0.5µl 20mM 
Primers, 1.2µl MgCl2, 1-2µl DNA (20ng), 13µl dH2O as per Applied Biosystems 
protocol. For whole genome amplified products that failed initial genotyping, a 
HotStar Taq PCR method was attempted (+/- 2µl MgCl2 and 4µl 5X Q Solution) as 
recommended by Qiagen for higher PCR specificity. HotStarTaq Qiagen protocol 
was 2µl 10x Buffer, 0.1µl Taq Polymerase, 0.6µl 10mM dNTPs, 0.5µl 20mM Primers,
2µl MgCl2, 1-2µl DNA (20ng), 4µl Q-solution, 8.8µl dH2O. The amplification 
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occurred in a Peltier Thermal Cycler, PTC-225 (MJ Research) using TD55 & TD58 
programmes at an initial denaturation of 93oC for 1 min, followed by 10 cycles of 
93oC for 20s, touch down annealing from 65oC to 55oC (or 65oC to 58oC) for 30s over 
10 cycles (-1oC/cycle) and 72oC for 1min followed by 30 cycles of 93oC for 20s, 55oC 
for 30s, 72oC for 1min and a final extension of 72oC for 10mins. 3µl PCR products 
were resolved on 2% agarose gel stained with SYBR Stain (Invitrogen). The primers 
for PCR amplification are shown in Table 2.4.
2.2.3.3. Rapid amplification of cDNA Ends (RACE)
The 3’ RACE FirstChoice® RNA-Ligase-Mediated (RLM) RACE-Ready cDNA 
method was used according to manufacturers’ instructions (Ambion 3200). RACE 
ready human heart cDNA was used (Ambion). Both inner and outer PCR was 
performed. SUPER TAQ plus (HT Biotechnology) was used with this method. 
Direct sequencing of the PCR products was chosen as the optimum method for 
sequencing products. To perform this, RACE products were excised from a low 
melting point gel, purified and sequenced as previously described in section 2.2.2.4.
2.2.4. Sequencing
All DNA intended for sequencing was subjected to agarose gel electrophoresis to 
check for integrity of DNA or PCR products. Occasionally, the DNA was gel 
extracted before use in sequencing procedures.
2.2.4.1. ExoSAP-IT treatment of DNA
Exo-SAP-IT™ (GE Healthcare) contains exonuclease I and alkaline shrimp 
phosphatase which removes all excess primers and dNTPs respectively before 
sequencing. 1-2µl PCR product, 2µl dH2O and 1µl ExoSAP-IT™ were incubated on 
the thermal cycler for 60 minutes at 37°C followed by 20 minutes at 80°C.
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2.2.4.2. PCR direct sequencing
The PCR Sequencing reactions were performed in a thermo-fast non-skirted plate, 
using BigDye® Terminator Ready Reaction Mix v3.1 with 1μl BDv3.1, 1µl 
sequencing buffer, 1µl primer 3.2pmol, 3µl dH20, added to the ExoSAP-IT treated 
PCR. The primers used for sequencing are listed in Table 2.4. Sequencing reactions 
were performed on a Peltier PTC-225 thermal cycler. The thermal profile of the 
sequencing reaction is detailed in Table 2.5.
TEMPERATURE TIME CYCLE
96°C 1 minute 1
96°C 10s 25
50°C 5s 1
60°C 4 minutes 1
4°C ∞ 1
Table 2.5 Thermal profile of BDv3.1 sequencing reaction
2.2.4.3. Ethanol/EDTA precipitation of sequencing reactions
EDTA stabilised the extension products during precipitation and washed out 
unincorporated dyes from the completed reaction. After sequencing, the DNA was 
briefly spun at 3,000rpm for 3 minutes. 2.5µl of 125mM EDTA and 30µl 100% BDH 
absolute ethanol were added to each sample and mixed four times. This was 
incubated at RT for 15 minutes followed by centrifugation at 3,000rpm for 30 
minutes. All ethanol was removed and a further 30µl 70% ethanol was added. This 
was centrifuged at 3,000rpm for 15 minutes and the ethanol was removed. The 
samples were stored at -20°C. Samples were analysed using Applied Biosystems 
3730 DNA Analyser by Alison Condie at the WT-CRF and sequences were 
examined using CONSED (Gordon, Abajian et al. 1998), Chromas (McCarthy 1998)
or Geneious (Drummond, Ashton et al. 2007).




Genotyping of microsatellites was performed with 1µl of 1:10 dilution (PCR product 
with dH2O) added to 10µl of 1:200 dilution of Tamra-350 (Applied Biosystems) with 
HiDi (Applied Biosystems) and stored at -20°C. Genotyping was performed on
Applied Biosystems 3730 DNA Analyser at the WT-CRF and analysed with 
Genemapper v3 (Applied Biosystems). The results were scored by two different 
individuals.
2.2.5.2. Linkage study
96 DNA samples from the family were genotyped in the linkage study. The DNA 
samples were stored at the Medical Genetics Section, Molecular Medicine Centre 
and the WT-CRF. I prepared and quality control tested the 33 samples from the 
Medical Genetics Section. Two of these DNA samples were whole genome 
amplified. Replicates of whole genome amplified sample from each original aliquot 
were pooled for genotyping to avoid allelic-amplification bias. The concentration 
and quality of each DNA sample was determined by DNA gel electrophoresis. The 
preparation of DNA aliquots and dilutions were performed under supervision to 
minimise sample mix-up. The samples from the WT-CRF were originally extracted 
from blood sample by GenVar (56 samples) or in-house at the WT-CRF (7 samples). 
The final DNA concentration was determined by the WT-CRF using picogreen
analysis. The concentration of DNA used for genotyping was 50ng/µl, except for 
sample 37 @ 10ng/µl, sample 44 @ 20ng/µl and sample 160 @ 30ng/µl.  As these 
samples were important for linkage analysis, they were included in the study
despite the reduced concentration of DNA.
The DNA samples were genotyped by the Illumina Linkage IVb panel using 
Illumina BeadArray technology on an Illumina BeadStation in the WT-CRF.  The 
GoldenGate assay protocol was used incorporating Linkage IVb panel. This panel is 
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a set of 6,008 SNPs, split into four OPAs (Oligo Pool All) containing all of the SNP-
specific primers.
2.2.6. Whole genome amplification
2.2.6.1. Template preparation for amplification
Genomic DNA was available as previously published (Blackwood, He et al. 1996). 
In tubes with no visible DNA solution, 7.5µl RNAase free water was added to the 
eppendorf, incubated at 37°C for 15 min and 4°C for 48 hours. Genomic DNA from 
lymphoblastoid cell lines sample 34 or sample 29 were prepared as described in 
section 2.2.2.1 and used as positive controls. 
2.2.6.2. Whole genome amplification
Whole genome amplification was carried out as per manufacturer’s instructions for 
“Amplification of Purified Genomic DNA using the REPLI-g Midi Kit” (REPLI-g 
Midi Kit, Qiagen, UK). In brief, Buffer D1 (denaturation buffer) and Buffer N1 
(neutralization buffer) were prepared by adding sufficient nuclease-free water for 
the required number of whole genome amplification reactions. 2.5µl (10ng) of 
template DNA was placed into a microcentrifuge tube. 2.5µl Buffer D1 was added to 
the DNA, prior to vortexing and brief centrifugation. The samples were incubated at 
RT for 3 min. 5µl of Buffer N1 was added to the samples to stop the denaturing 
process, mixed by vortexing and centrifuged briefly. The REPLI-g Midi DNA 
Polymerase was thawed on ice and the other components were thawed at RT, mixed 
by vortexing and centrifuged briefly. A master mix was prepared, mixed by 
vortexing and centrifuged briefly. The master mix comprised of 10µl nuclease-free 
water, 29µl REPLI-g Midi reaction buffer and 1µl REPLI-g Midi DNA Polymerase 
per reaction. 40µl of the master mix was then added to 10µl of denatured DNA and 
incubated at 30°C for 16 hours for the isothermal amplification reaction. The REPLI-
g Midi DNA polymerase was inactivated by heating the sample for 3 minutes at 
65°C. The amplified products were aliquoted and stored at -20°C. For samples that 
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failed, the amplification procedure was repeated with more DNA (20ng) or with 
DNA dissolved in H2O at 65°C for 1 hour prior to amplification.
2.2.7. Analysis of amplification products 
2.2.7.1. Preparation of DNA for quantification
Before quantifying DNA, it must be fully in solution. A 1 in 10 dilution of DNA with 
TE in a total volume 100µl was dissolved at RT for ~1 hour, and incubated for 48 
hours at 4°C to dissolve DNA. Cut-off pipette tips were used to avoid shearing the 
DNA.
2.2.7.2. DNA quantification by picogreen
 “Quant-iT PicoGreen dsDNA Reagent and Kit” (Molecular Probes) was used to 
quantify DNA. A high-range standard curve was prepared with λ DNA standard to 
detect a final DNA concentration from 1µg/ml to 1ng/ml.  This was diluted 50 fold 
in TE to give 2µg/ml DNA stock (18µl of 100µg/ml λ DNA stock and 882µl TE). The 
standards were prepared in duplicate, as described in Table 2.6.
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FINAL DNA CONCENTRATION WHEN MIXED 1:1
WITH PICOGREEN REAGENT (NG/ML)
0 500 Blank





Table 2.6 Preparation of λ DNA standards for DNA quantification by picogreen 
reagent.
For each sample, a 200 fold dilution of 100µl PicoGreen Reagent was prepared using 
TE and protected from light by covering with foil. A final DNA dilution (10µl 
diluted DNA and 90µl TE) was prepared in duplicate for each sample in a
Microfluor plate (Dynex Microfluor 1, 96 well black plate, flat-bottom, Thermo Life 
Sciences). 100µl PicoGreen reagent was added to the diluted DNA and mixed by 
inverting.  The fluorescence was measured on a Cytofluor fluorimeter (Cytofluor 
Series 4000 fluorescence Multi-Well Reader (Applied Biosystems)) with the 
following settings; Excitation = 485/20nm, emission = 530/25nm, centre only, 4 
readings/well, mix time = 10s, plate type = DynaTech 96 well, gain = 45. These 
settings allowed accurate reading by ensuring the sample with the highest DNA 
concentration gave a reading close to fluorimeters maximum. The data were
analysed by firstly subtracting the fluorescence value of the reagent blank from each 
of the standards and samples. A standard curve was generated from the corrected 
values, and the equation and correlation (r2) of the line were calculated. This 
enabled the concentration of the samples and the validity of the line to be 
determined respectively. 
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2.2.7.3. DNA quantification by agarose gel electrophoresis
DNA was quantified by agarose gel electrophoresis with 1μl DNA (1μl DNA, 8μl 
H2O, 1μl 10X Orange G loading buffer) compared to various concentrations of 
λHindIII on the same gel, 500ng was 10μl of 50ng/μl (Invitrogen). The gel was run 
for five minutes. The concentration of the DNA sample was determined by 
comparing the band of the DNA sample with a band of most similar intensity from 
the various concentrations of λHindIII.
2.2.7.4. Agarose gel electrophoresis
Standard agarose gels of 1-1.5% were used to separate fragments of size 0.2kb-0.5kb 
and 0.8-1% gels were used to resolve fragments of size 0.5kb or greater. Gels were 
prepared and run using 1XTris buffer. Samples were loaded using 10X Orange 
buffer. Electrophoresis was carried out using Hybaid Electro-4 gel tanks. Voltage 
applied (usually 80-100V) creates an electric current causing the DNA to migrate 
through the agarose from the cathode (-ve) to the anode (+ve) due to the negatively 
charged phosphate backbone of the DNA. Amplified DNA products were diluted to 
100ng/µl as calculated from expected yields and 1µl was visualised on a 0.8% 
agarose gel, stained with SyberStain in 0.5X TE buffer. This allowed a rough 
estimation of DNA quantity. 
In general, DNA was stained with SYBR Safe™ (1µl/100ml molten agarose, 
Invitrogen) or occasionally with Ethidium Bromide (0.5µg/ml molten agarose, 
SIGMA). Fragments were visualised using a UV transilluminator (Thistle Scientific) 
with an uvidoc (Uvitec, DOC-CF08.XD). The molecular weight of each fragment 
was determined by comparing its mobility to a 1Kb DNA ladder (Invitrogen) or a 
λHindIII (Invitrogen) marker for larger fragments of up to 23Kb in size. 
DNA fragments were also run on low melting point (LMP) agarose gels to allow for 
recovery of the DNA after electrophoresis. LMP agarose gels were prepared using 
1XTAE and usually run at 80V. 
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2.2.8. Taqman Assays
2.2.8.1. Taqman assay design
Two SNPs, rs313548 and rs313567 were available by pre-designed Taqman SNP 
genotyping assays (c_764549, c_764538 respectively) while rs6834255 was a custom 
designed Taqman SNP genotyping Assay (Applied Biosystems). The Taqman SNP 
genotyping assay uses a 5’ nuclease assay to discriminate between two alleles of a 
specific SNP. Assays for rs313548 and rs313567 were 20x mix and a 40x mix for 
rs6834255, of forward primer, reverse primer, FAM™ dye - MGB labelled probe, 
and VIC® dye - MGB labelled probe. Each probe binds preferentially to one of the 
two alleles. 
2.2.8.2. gDNA standard curve preparation
A standard curve of dilutions from homozygous lymphoblastoid cell line samples 
was prepared to evaluate the contribution of each allele in the heterozygote 
samples.  Genomic DNA prepared from homozygote samples was used at a 
concentration of 5ng/µl. gDNA was mixed from two homozygotes of the SNP, e.g. 
genotype AA was mixed in dilutions 90:10 with genotype GG, and so on to make a 
standard curve 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90. The optimal 
reaction was 10µg of mixed gDNA in a total volume of 5µl, 2ul gDNA, 0.25µl 
Taqman SNP Genotyping Assay, 2.5µl Taqman® Universal PCR Master Mix, 0.25µl 
dH2O. Three standard curves with six different homozygotes were prepared to test 
the precision of each assay. Two standard curves with four different homozygotes 
were prepared to test the precision of rs313548 and rs6834255 assays. Three 
standard curves with four different homozygotes in different combinations were 
prepared to test rs313567 assay; 132 (CC) & 86 (TT), 132 (CC) & 35 (TT), T3445 (CC) 
& 86 (TT). For assays rs313548 and rs6834255, there were an insufficient number of 
lymphoblastoid cell line sample homozygote individuals so it was necessary to use 
homozygote individuals typed from the Trio Bipolar Panel. Each homozygote mix 
was assayed in quadruplicate. 
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2.2.8.3. Taqman SNP genotyping assay
For the heterozygote DNA, 4ng cDNA or 10ng gDNA was amplified; 2µl cDNA
(2ng/µl) or 2µl gDNA (5ng/µl), 0.25µl Taqman SNP Genotyping Assay, 2.5µl 
Taqman® Universal PCR Master Mix, 0.25µl dH2O. Each sample was prepared in 
quadruplicate and each assay was performed in triplicate from the same RNA 
preparation. The assays were performed in ABgene Thermo Fast 384 well PCR 
plates (Applied Biosystems) and covered with a Clear Seal Diamond heat seal 
(Applied Biosystems). The Allelic Discrimination PCR reaction (initial step is hold 
for 10 minutes 95°C, denaturing step is 15s 92°C X 40 cycles, and annealing step is 1 
minute 60°C X 40 cycles) was performed in the ABI PRISM 7900HT sequence 
detection system (Applied Biosystems) available at the WT-CRF.
2.2.9. Protein preparation
2.2.9.1. Protein lysate preparation
All lymphoblastoid cell line protein extractions were performed at the same time to 
optimise protein concentration estimation and minimise varying degradation 
effects. The lymphoblastoid cell line pellets were centrifuged 2,000rpm for 5 
minutes, the supernatant removed and washed in PBS. The cell pellet was 
resuspended in ice-cold lysis buffer (50mM Tris, 150mM NaCl, 1% Trition, 0.25% 
Sodium deoxycholate, 1mM EDTA, 2% Complete Protease Inhibitors) for 30 minutes 
on a rotor.  Lysates were sonicated three times for three seconds at 20 revs (MSC 
Sonicator), centrifuged and supernatant saved. The protein concentration was 
determined immediately, the samples were aliquoted and/or prepared to 10μg 
aliquots in SDS buffer and stored at -80°C until use. 
2.2.9.2. Protein concentration estimation
The protein concentrations of lymphoblastoid cell line lysates were estimated using 
the BCA Analysis (Pierce) as per manufacturers’ instructions. In brief, protein
samples of unknown concentration were prepared in duplicate at 1:20 dilution 
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(100l Total Volume = 5l protein + 95l dH2O) and a 1:10 dilution (100l Total 
Volume = 10l protein + 90l dH2O). The diluted albumin (BSA) standards were 
prepared as Table 2.7.
BCA PROTEIN ASSAY
Vial
Volume of Diluent 
(H2O)
Volume & Source of BSA
Final BSA 
Concentration
A 0 250µl Stock 2,000µg/ml
B 125µl 375µl Stock 1,500µg/ml
C 325µl 325µl Stock 1, 000µg/ml
D 175µl 175µl of vial B dilution 750µg/ml
E 325µl 325µl of vial C dilution 500µg/ml
F 325µl 325µl of vial E dilution 250µg/ml
G 325µl 325µl of vial F dilution 125µg/ml
H 400µl 100µl of vial G dilution 25µg/ml
I 400µl 0 0µg/ml (Blank)
Table 2.7 Standard curve for protein concentration estimation
The BCA Working Reagent (WR) was prepared following this equation;
o (# standards +# unknowns ) x (# replicates) x (volume of WR per sample) = 
total volume WR required, adding 50 parts Reagent A to 1 part Reagent B.
2ml working reagent was added to each sample tube and standard tube and mixed 
well. The samples were incubated for 30 minutes in a 37°C water bath and then 
cooled to RT. The absorbance of the samples was read at OD 562nm from a 
spectrophotometer (GeneQuant) in plastic cuvettes (1cm path length, Fischerbrand). 
A standard curve was prepared using a regression line from the duplicate standard 
samples. The concentrations of the samples were estimated from the standard curve.
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2.2.10. Quantitative protein assays
2.2.10.1. Protein gel electrophoresis
The Western blotting procedure was performed on 5µg protein lysates using 
NuPAGE® Electrophoresis System, as per manufacturer’s instructions with the 17-
well 4-12% Bis-Tris Gels. Western blotting was also performed using Mini-
PROTEAN® 3 Cell (Bio-Rad) according to manufacturers instructions, with the 
following specifications: separating protein samples with gel electrophoresis on a 
10% SDS-PAGE gel at 100V for 10 minutes, 150V for approximately 90 minutes.
2.2.10.2. Staining & drying protein gels
Proteins were stained after electrophoresis with SimplyBlue™ SafeStain as per 
manufacturers’ instructions (Invitrogen) or Coomassie Brilliant Blue stain (as 
Section 2.1.2). This method checked the equal protein loading in each well and also 
determined the successful transfer of proteins after western blotting. The stained 
gels were dried using DryEase® Mini-Gel Drying System as per manufacturer’s 
instructions.
2.2.10.3. Immobilising proteins on membrane
The protein gels were transferred with X-Cell SureLock™ MiniCell (Invitrogen) as
manufacturer’s instructions to PVDF membrane (Hybond-P PVDF Membrane, 
Amersham Biosciences). Semi-dry transfer was also performed at 20V, 250A for 60 
minutes with Trans-blot SD Semi Dry Transfer Cell (Bio-Rad) according to 
manufacturer’s instructions. This method was used in conjunction with 10% 
acrylamide gels, transferred to PVDF membrane with blotting paper either side of 
the PVDF membrane (Whatman® paper).
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2.2.10.4. Ponceau S staining membranes
Ponceau’s stain was used to determine successful protein transfer onto PVDF 
membranes. After transfer, membranes were rinsed in dH20 followed by five 
minutes incubation in Ponceau S. The membranes were destained in dH20.
2.2.10.5. Immunoblotting
All membranes were incubated in 10% Marvel PBS overnight at 4°C to block non-
specific sites on the protein-containing membrane. For fluorescent antibody 
detection, the membranes were blocked in 5% Gelatin from cold water fish skin
(Sigma-Aldrich) overnight at 4°C. The antibodies were used at the following 
conditions; PI4K2B (all three antibodies are discussed in section 3.7.1) at 1:1000 for 
two hours, α-tubulin (Sigma) at 1:3000 for one hour, GAPDH (Abcam) at 1:3000 for 
one hour, -actin (Sigma) at 1:1000 for one hour, R47, Pig α-Rabbit (Dako) at 1:3000 
for twenty minutes and Rabbit α-mouse (Sigma) at 1:1000 for 30 minutes. The 
membranes were detected as per manufacturers’ instructions (Amersham 
Biosciences ECL Plus Western Blotting Detection System) and visualised on X-ray 
film. 
2.2.10.6. Stripping immunoblots
Immunoblots were stripped with Restore Western Blotting Stripping Buffer (Pierce), 
according to manufacturer’s instructions.
2.3. Analysis of Molecular Biology Data
2.3.1. Sequence trace analysis
Sequence trace was visualised using Consed (Gordon, Abajian et al. 1998), Chromas 
or Geneious (Drummond, Ashton et al. 2007). The peak heights of the sequence 
trace were measured using PeakPicker software as per authors’ instructions (Ge, 
Gurd et al. 2005).
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2.3.2. Analysis of allele-specific assays
After the PCR amplification and end point read performed by the ABI 7900HT, it 
was necessary to assess three parameters for each assay; baseline, threshold, Ct 
value, in order for accuracy and precision to be optimal. The baseline read may 
fluctuate from assay to assay, due to changes in the reaction mix so it was important 
to ensure the amplification was sufficiently higher than the background signal. The 
threshold is a numerical value assigned for each run and shows a statistically 
significant point above the calculated baseline.  The threshold cycle (Ct) reflects the 
cycle number at which the fluorescence generated within a reaction crosses the 
threshold. The Ct value assigned to each well is the point during the reaction where 
a sufficient number of amplifications have accumulated to be at a statistically 
significant point above the baseline. The same settings were used in repeats of the 
same assay, to improve precision and to make the data comparable. Outliers of the 
four replicates in each experiment were determined by displaying the data as CT vs. 
Well position and they were removed from further analysis. A reading was 
constituted as an outlier if one of the four replicates did not cluster with the other 
three replicates. After the appropriate settings were determined, the allele types 
were scored by ABI PRISM® SDS software v. 1.7 using the fluorescence readings 
(Rn) from the endpoint read. Rn is the reporter signal normalized to the Passive 
Reference for a given reaction. The delta Rn value is the Rn value minus the Rn 
value for the No Template Control. The Rn values from the FAM™ reporter dye and 
VIC® reporter dye tagged to each allele were used for statistical analysis.  
After the PCR amplification, an end point read was analysed and the allele types 
called using ABI PRISM® SDS software v. 1.7. From the endpoint read, the ratio of 
the fluorescence reading from the FAM™ reporter dye and VIC® reporter dye was 
calculated. The mean of all replicates was calculated for each DNA sample and the 
range of values is shown by errors bars of 95% Confidence Intervals (CI). A 
standard curve (linear regression line) was established for the LOG of the 
fluorescent intensity ratio (FAM™/VIC®) versus the LOG of the allele ratio i.e. the 
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LOG2 ratio of the dilution of each homozygote, from which the ratio of cDNA 
samples from heterozygote individuals were deduced. The transformation of the 
data to LOG2 was performed to normalise the data, enabling further analysis. This 
allowed the deduction of the ratios of gene expression between the two 
heterozygote alleles from the standard curve, by measuring the fluorescent intensity 
(LOG2 FAM™/VIC® reporter dye intensity) of the two alleles in cDNA samples. 
The sensitivity of the assays and variation between results was checked with basic 
statistical analysis using the mean of the replicates, measuring the variability by 
standard deviation, measuring the amount of variability in the sample mean by 
standard error and measuring the range of plausible values for population mean 
with a 95% and 99% confidence interval. The confidence interval was added or 
subtracted to each mean to have a low and high confidence interval range and was 
plotted with results from standard curve replicates (please refer to Appendix A 
(Kirkwood and Sterne 2003)).
Experimental consistency was tested within each assay looking at the coefficient of 
variation between replicates and reproducibility between assays was tested with an
average coefficient of variation.
As it was assumed that genomic DNA samples have an allele ratio of 1:1, but 
because of differences in fluorescent emissions from the two dyes tags (FAM and 
VIC) the measured ratios for gDNA samples deviated from 1:1 sample. Thus, cDNA
values were calculated by the cDNA/gDNA ratio from the mean value of DNA from 
the same individual. Variation within and between experiments was measured by 
the coefficient of variation (standard deviation/mean). To test a difference between 
groups, the Students T-test was used.
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2.3.3. Analysis of sequence data with PeakPicker
The amplification and sequencing of duplicate cDNA and gDNA samples was 
attempted for the PI4K2B genomic region surrounding the three SNPs. For each 
sample heterozygous at the particular SNP, two cDNA and two gDNA sequences 
surrounding the SNP were imported into the PeakPicker programme and analysis 
was performed according to the author’s instructions (Ge, Gurd et al. 2005). In brief, 
each heterozygote was analysed separately. Firstly a gDNA sequence was set as the 
reference sequence for alignment and peak selection. PeakPicker performed a 
multiple pairwise alignment of the imported sequences starting from the first base 
of each. A sequence length of 250bp-300bp and a 70% identity cut-off was used.
Only sequence traces of good quality were analysed.
The peaks comprising the SNP were selected in the reference sequence 
automatically. Reference peaks of the same genotype of the SNP, were chosen from 
the same region at positions in the reference sequence where there was 100% 
consensus amongst all imported sequences. 
Once the appropriate set of reference peaks had been chosen, PeakPicker calculated 
the trace heights at these positions in all sequences. It then normalised the heights of 
the peaks relative to the mean height of their corresponding reference peaks within 
each sequence. The output was a normalized peak ratio which could be compared 
across sequences.
2.3.4. Analysis of protein quantity
Densitometry analysis was performed using Scion Image or ImageJ v 1.37
(Abramoff 2004) to quantify the immunoreactive protein in each lane. The pixel 
value of the peak corresponded to the intensity of the band from the image in 
greyscale. PI4K2B expression was analysed as PI4K2B intensity:house-keeping 
protein intensity ratio. If more than one housekeeping gene or Ponceau S stained 
membrane was quantified, an average of the control intensities was used. 
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2.3.5. Investigation of SNP effects
The SIFT programme, as detailed in Table 2.8, was used to obtain positional and 
coding information about particular SNPs. This incorporates a BLAST search with 
the protein sequence to align with similar proteins, and utilising the Sorting 
Intolerant from Tolerant (SIFT) (Ng and Henikoff 2003) algorithm to find functional 
domains of the protein, and if the amino acid change falls in an important 
regulatory region.
2.4. Bioinformatics
The online resources used for bioinformatic analysis are listed in Table 2.8.
RESOURCE WEBSITE
Allen Brain Atlas http://www.brainatlas.org/aba/
Chromas – Chromatogram Viewer http://www.technelysium.com.au/chromas_lite.html
Database of Chromosomal Imbalance & Phenotype in Humans 
using Ensembl  Resources (DECIPHER)
http://decipher.sanger.ac.uk
DNA & Protein Sequence Analysis http://www.geneious.com/
Haploview http://www.broad.mit.edu/mpg/haploview/
HapMap http://www.hapmap.org/





SIFT (Sorting intolerant from tolerant) http://blocks.fhcrc.org/sift/SIFT.html
UCSC Human Genome Browser http://genome.ucsc.edu/index.html?org=Human
UCSC In silico primer http://genome.ucsc.edu/cgi-bin/hgPcr
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2.5. Statistical Methods
Standard statistics were calculated using MS Excel 2003, SPSS 14.0 (SPSS_Inc. 2005), 
R version 2.4.0 (R_Development_Core_Team 2006) or GraphPad Prism 
(GraphPad_Software version 4.03 ). The statistical analysis programmes used in this 




FULL NAME AIM SOURCE VERSION REFERENCE
CARTOGR Cartographer Estimates genetic position of 
markers by interpolation from 
neighbouring markers based 
on your map of choice 
(deCODE)










LD and haplotype block 
analysis single SNP 
association tests.





Data manipulation and file 
preparation
http://watson.hgen.pitt.edu/register/ 3, 4 (Mukhopadhyay, 
Almasy et al. 2005)
MERLIN Multipoint Engine 
for Rapid Likelihood 
Inference
Linkage analysis, error 






PedCheck Pedigree Check Detecting marker typing 
incompatibilities in pedigree 
data
http://watson.hgen.pitt.edu/register/ 1.1 (O'Connell and 
Weeks 1998)
















Summary statistics and basic 
quality assessments for gene-
mapping





Detection of pedigree errors by 
use of genome-screen data




Infers the relationships of pairs 
of individuals based on genetic 
marker data, either within 
families or across an entire 
sample
http://csg.sph.umich.edu/boehnke/relpair.php 2.0.1 (Boehnke and Cox 
1997; Epstein, Duren 
et al. 2000; Duren 





Association analysis of 
multilocus haplotypes from 
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2.5.1. Case-control association study
2.5.1.1. Selection of markers
SNP genotype data was downloaded for the 30 CEPH trios (Utah residents with 
ancestry from northern and western Europe) from 100kb upstream and downstream 
of the PI4K2B genomic region (24,745,440bp-24,986,687bp, NCBI build 35, May 2004 
UCSC)  from HapMap Phase II build 125 (http://www.hapmap.org) on 7th February 
2006. This HapMap data was uploaded to the Haploview version 3.2 programme 
(http://www.broad.mit.edu/mpg/haploview/). The parameters chosen for 
construction of the LD map were as follows: pair-wise comparisons of markers more
than 500kb apart were ignored, minor allele frequency ≥0.1, Hardy Weinberg 
Equilibrium >0.01, genotyping success rate of >85%, and a maximum number of 
Mendelian errors =1. The haplotype blocks were defined by the solid spine of LD 
(D’>0.8). Adjacent LD blocks were then merged if MAD (Hedrick’s Multi Allelic D’) 
≥0.95 (Hedrick 1987). Tagging SNPs were then selected to tag the common 
haplotypes (>5%) within each haplotype block using Haploview’s internal tagging 
programme. Tagging SNPs were replaced by other SNPs that equally tag the 
haplotypes if the SNPs had been genotyped previously, if pre-designed assays were 
available from the supplier or if the SNPs were included in the PI4K2B expression 
study.
2.5.1.2. Genotyping
Genotyping was performed using pre-designed Taqman assays on demand or 
assays by design from Applied Biosystems. The genotyping was performed on the 
ABI PRISM 7900HT sequence detection system at the WT-CRF.
2.5.1.3. Data quality control
The quality of the SNP assays was validated by checking Mendelian inheritance and 
genotype success rate on DNA from 30 trios (father, mother and affected offspring).
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The results of the genotyping were processed by the Computing Support 
Department (Euan Adie and Stewart Morris). This involved formatting the results 
as per standard linkage format described in section 2.5.3, checking duplicates, 
confirming diagnoses and merging results from original study with the newly 
chosen SNPs.
2.5.1.4. Analysis
The standard Χ2 test of independence was used to examine all markers for 
deviations from Hardy Weinberg Equilibrium (HWE) in the control samples. The 
Haploview default HW significance threshold of p=0.001 was selected as a cut-off to 
exclude potentially erroneous markers due to for example, genotyping error. Single-
marker analysis was performed using in-house software developed by Naomi Wray 
that calculates basic association analysis “BasicAS”, with the Χ2 test of independence 
to look for differences in allele and genotype frequencies between cases and 
controls.  Haplotype analysis was performed separately on bipolar disorder and 
schizophrenia cases using CoCaphase, with a sliding-windows approach to test 
haplotypes of 2 marker length. Rare haplotypes with a frequency ≤0.05 in both cases 
and controls were clumped together. The maximum-likelihood frequencies are re-
computed after identification of rare haplotypes.
2.5.1.5. Permutation
To estimate the significance of the association study result, taking the number of 
markers and haplotypes tested into account, permutation analysis was performed 
using CoCaphase. CoCaphase reassigns the diagnosis labels (case versus control) of 
the individuals in 1,000 simulations of the data. All of the markers within the 
specified window size are tested and the most significant P-value is stored. Based 
on the distribution of the most significant P-values resulting from each test of the 
permuted data, a significance level is provided for the P-value of interest. 
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2.5.1.6. Bioinformatic analysis
Analysis of human genome sequence data was performed using the University 
College of Santa Cruz (UCSC) genome browser (Kent, Sugnet et al. 2002). For 
bioinformatic analysis, the most updated version March 2006 human reference 
sequence (NCBI Build 36.1) was used. Otherwise, the May 2004 human reference 
sequence (NCBI Build 35) was used, as these were the co-ordinates used by Illumina 
to compute the genetic position for the markers tested in the linkage study. 
2.5.2. Pedigree drawing
Pedigrees were drawn using Progeny Desktop Version 6 (Progeny Software LLC, 
South Bend, IN, www.progenygenetics.com) or HaploPainter v.029.5 (Thiele and 
Nurnberg 2005) according to the authors’ instructions. Standard pedigree symbols 
were used (Bennett and Steinhaus 1995). Each diamond symbol represents an 
individual from the family. Individuals with a diagnosis of bipolar disorder were 
designated a filled symbol, those with recurrent major depression by a half-filled 
symbol and those with other related psychiatric diagnosis including single episode 
depression, anxiety states or alcoholism are marked by a quarter-filled symbol. 
Individuals that were genotyped for the linkage study have a central blue circle. To 
preserve anonymity, individuals who were known to the research team and who 
had been interviewed but made no contribution to linkage analysis, were not 
included in the pedigree drawing.
2.5.3. Linkage data preparation & analysis
The software programmes used for linkage analysis are listed in Table 2.9.
2.5.3.1. Linkage file preparation
The raw genotyping data for each of the 96 samples genotyped with 6,008 SNPs 
from the Illumina Linkage IVb panel were processed into standard linkage format 
by Stewart Morris. Standard linkage format (Terwilliger and Ott 1994) is required 
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for most statistical genetics programmes and can easily be converted to other 
formats. The following files necessary for linkage analysis were prepared. The 
”pedigree” file contains the  pedigree structure, trait phenotypes and genetic marker 
data in a numerical file, tab-delimited, with a separate line for each individual, with
the information as follows: Pedigree number, Individual ID, Father ID, Mother ID, 
Gender, Affection status, Liability class, Genotype allele 1, Genotype allele 2, etc. 
The “names” file lists the names of all genetic loci in map order. The “map” file lists
the marker names with their NCBI’s Build 35 chromosomal location and the 
deCODE genetic distance in centiMorgans (cM). To adjust data in the “pedigree” 
file, an “omit” file was prepared. This is a list of all erroneous genotypes which are 
removed from the linkage analysis files. This bypasses the error-prone method of 
adjusting the large “pedigree” file.
2.5.3.2. Genetic map
The genetic map position for each SNP was provided by Illumina and was 
determined by linear interpolation using NCBI’s build 35 physical map position and 
a high-resolution STR genetic map constructed by deCODE genetics (Kong, 
Gudbjartsson et al. 2002). This map was a sex-averaged map. The marker list and 
position are available from the Illumina website 
(http://www.illumina.com/pages.ilmn?ID=191).  For supplementary chromosome 4 
microsatellite markers, the genetic distance was estimated by deCODE genetics, 
using the Cartographer programme or by linear interpolation from flanking 
markers. Table 2.10 lists the name and genetic position of the microsatellite markers.
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Table 2.10 Chromosome 4 microsatellite markers. The 24 markers were used in 
the linkage study. The physical position of each marker is according to July 2003 
human reference sequence (NCBI Build 34), the genetic position was estimated by 
deCODE genetics (not shaded), using the Cartographer programme (grey diagonal 
lines) or by linear interpolation from flanking markers (dark-grey shaded).
Chapter 2 Material & Methods
119
2.5.3.3. Preparation of input files for statistical analysis 
programmes
MEGA2 was used to prepare input files in various formats for different statistical 
packages (Mukhopadhyay, Almasy et al. 2005; Mukhopadhyay N 2006). The 
pedigree, names, map and omit files described in section 2.5.3 were input into
MEGA2 and transformed to the desired format. Allele frequencies for the locus data 
files were determined using the RECODE feature in MEGA2, which determined the 
allele frequencies from all genotyped members of the family. With the help of 
Stewart Morris, allele frequency files were also prepared from the Caucasian 
population that were generated from 60 unrelated samples from the HapMap CEPH 
population (Jim Acierno, Personal Communication, 21st August 2007, Illumina 
(http://www.hapmap.org)).
2.5.3.4. Genotyping data description
The quality of the genotyping data and Hardy Weinberg Equilibrium testing was 
checked and described using Pedstats according to the author’s instructions 
(Wigginton and Abecasis 2005). Mendelian inconsistencies in the pedigree data
were identified by PedCheck according to the authors instructions (O'Connell and 
Weeks 1998). Further genotypes that implied excessive and unlikely recombination 
events between tightly linked markers were detected as erroneous by MERLIN
according to the authors’ instructions (Abecasis, Cherny et al. 2002). These errors 
were collected in the “omit” file, which is an input file for MEGA2 to exclude the 
erroneous genotypes from further analysis, as described in section 2.2.3.1.
2.5.3.5. Detection of marker linkage disequilibrium
LD between markers from the Illumina Linkage IVb panel was detected in the 
family using Haploview (Barrett, Fry et al. 2005). Haploview chose a maximum 
unrelated subset of individuals to detect LD. These were 12 unrelated individuals 
(samples 11, 13, 20, 38, 46, 49, 98, 104, 146, 149, 160, 180) and one trio (samples 29, 33, 
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35). LD was detected using default parameters: solid spine of LD D’≥0.8 for markers 
≤ 500kb apart. SNPs were said to be in LD, if D’≥0.8 and LOD ≥ 2.
2.5.4. Pedigree splitting
As the pedigree was too large to be analysed for whole genome linkage analysis, it
was split into sub-pedigrees using GREFFA (Genetic Relationship Explorer for 
Familiality Aggregation) software, according to the authors’ instructions (Falchi, 
Forabosco et al. 2004). The input files were in standard linkage format, and the 
genotyped individuals to be clustered were labelled “2” and those not genotyped 
were labelled “0”. The pedigree was split before and after adjustment for 
relationship errors. Splitting was based on a kinship coefficient pairwise-
relationship measure at the level of first-cousin relationships (1/16), ψ ≥ 0.0625. The 
software automatically determined the minimum number of generations to 
reconstruct the pedigrees and extracted a pedigree for the largest set of individuals 
as the most informative pedigree. It also extracted more pedigrees for all sets of 
individuals. The number of permutations was 999, which was the number of 
maximum trials for the shuffling algorithm to search for the best clique, which is a 
cluster of individuals, according to the selected parameters.
2.5.5. Relatedness analysis
2.5.5.1. PREST
The programme PREST was used to detect pedigree errors (McPeek and Sun 2000). 
PREST estimates the probabilities κ0, κ1 and κ2 of two individuals sharing 0, 1 and 2 
alleles IBD respectively.  The input files were converted from standard linkage 
format to PREST format using MEGA2, with setting of option 25 “PREST” and all 
defaults, except genotyping errors were not set to zero. This ensured that Mendelian 
inconsistencies were not removed before performing relationship testing. Analysis 
with PREST was performed as suggested, calculating IBD over eleven relationship 
pairs (parent-offspring, full-sibs, half-sib, avuncular, first-cousins, grandparent-
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grandchild, half-avuncular, half-first cousin, half-sib plus first cousin, monozygotic 
twins and unrelated) within the family.  Pedigree errors were detected by PREST’s 
statistical tests: conditional estimated identity by descent (EIBD), adjusted identity 
by state (AIBS) and IBS, in that order and where applicable, at  = 0.0001, to 
highlight more significant problems. The pedigree errors that were detected were 
examined again using PREST’s accompanying programme ALTERTEST that tests 
two individuals for each of the eleven relationship classes, using a default 100,000 
replicates to calculate the empirical P-values for the EIBD, AIBS, IBS and MLLR test. 
PREST output data was displayed using an “R” script written by Prof. Dan Weeks, 
which was provided with the programme package. This script was adapted with the 
help of Dr. Andy McLeod to create a scatter diagram of IBDs on a relationship 
triangle, similar to a diagram showing pedigree errors in the Framingham Heart 
Study (Brush and Almasy 2003). Nine of the eleven tested relationships were 
applicable to the family.
2.5.5.2. Relpair
Relpair checks for pedigree errors by inferring relationships between individuals in 
a pedigree (Epstein, Duren et al. 2000). The input files required for Relpair were a 
“control” file specifying output file names and parameter settings, a “locus” file 
specifying marker names, positions and allele frequencies and a “pedigree” file 
specifying pedigree structure and individual genotypes. The input files were 
converted from standard linkage format to Relpair format using MEGA2; with 
option 2 “Relpair” using all MEGA2 default options, except that genotyping errors 
were not set to zero. The default parameters for the Relpair analysis were used with 
the following exceptions: within the family, with a minimum of 100 shared 
genotypes, a genotyping error rate of 0.1% and a critical value of 1000 to be 
reported. The default settings were used for compiling the programme Relpair, with 
the following exceptions to the parameter file as described in Table 2.11. This 
changed the allocation of memory in the programme to accommodate running large 
number of SNPs.
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PARAMETER CHROMOSOME 1 CHROMOSOME 13 & 16 CHROMOSOME X
MAXALL 2 2 2
cMAXFAM 1 1 1
MAXLOC 500 200 300
MAXPEO 182 182 182
MAXREL 8 8 8
MXPTOT 182 182 182
Table 2.11 Adjustments to parameter files for Relpair programme. The following 
adjustments were made to the source code for Relpair to change the memory 
allocation such that it would analyse a large number of SNPs. The markers were 
biallelic SNPs thus the number of alleles was two.  The analysis was performed on 
one pedigree with 182 individuals on four different chromosomes, chromosome 1, 
13, 16 and X. Each chromosome has a different number of SNPs (chr1=489 SNPs,
chr13=191 SNPs, chr16=197 SNPs, chrX=301 SNPs). Eight SNPs with zero allele 
frequency were removed from X chromosome analysis. The MAXLOC parameter 
was changed to accommodate the different number of SNPs per chromosome. The 
parameters are MAXALL=maximum number of alleles, MAXFAM=maximum number 
of families, MAXLOC=maximum number of markers (loci), MAXPEO=maximum 
number of people per family, MAXREL=maximum number of relationships tested, 
MXPTOT=maximum number of people in total in all families.
2.5.6. Simulation analysis
Simulation of the family genotype data was performed using the –simulate option 
in MERLIN. The input files were created using MEGA2 for each chromosome for 
two phenotype classes, broad and narrow. The simulation of repeated datasets was 
repeated 10,000 (broad model) or 1,000 (narrow model) times with a different seed 
using the –rerun option. Non-parametric linkage analysis was performed on the 
data. A histogram was prepared with counts of the highest LOD scores obtained on 
whole genome analysis per replicate. The 95 and 99 percentiles were calculated. 
Empirical P-values were computed by dividing the number of replicates that 
exceeded the observed Z-score or LOD score by the number of replicates.
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2.5.7. Parametric linkage analysis
Parametric linkage analysis was performed on the sub-pedigrees using MERLIN. 
The input files were prepared using MEGA2, to create a “pedin”, “map”, “omit” 
and a “names” file with option “L” to take into account the binary trait and the 
liability classes. Each individual was assigned a trait class of unknown affection 
status, well or affected; equivalent to 0, 1 or 2 respectively. Each individual was also 
assigned a liability class. For individuals who are well, there were four age-
dependent liability classes; 1 = <20 years, 2 = 20-30 years, 3 = 31-40 years and 4 = > 40 
years. The other liability classes denote married-in individual as 5, 6 is bipolar 
disorder, 7 is recurrent major depression and 8 is other minor psychiatric illness. 
The disease locus parameters were specified in a separate text file and are shown in 
full in Appendix B, and are explained in section 1.4.1 and 6.2.1. The results of the 
parametric linkage analysis are the estimated multipoint LOD score at a particular 
location, followed by the estimate proportion of linked families (α) and the 
corresponding maximum heterogeneity LOD score (HLOD).
2.5.8. Non-parametric linkage analysis
Non-parametric linkage analysis was performed on the sub-pedigrees using 
MERLIN, according to the authors’ instructions. The input files were prepared using 
MEGA2.  The calculation of both the Whittemore and Halpern non-parametric 
linkage (NPL) pairs and NPL-all statistics were performed. The evidence for linkage 
was evaluated using both the Kong and Cox linear and exponential model. The 
output details the maximum possible scores for the dataset followed by analysis 
results at each location (cM position, Z score, P-value assuming normal 
approximation, Kong and Cox delta, Kong and Cox LOD score and Kong and Cox 
P-value).
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2.5.9. Haplotype analysis
Construction of haplotypes from the family genotype data on regions of suggestive 
linkage were performed using the –best option in MERLIN. The input files were 
created using MEGA2. This created an output of the most likely haplotype vector. 
The haplotypes in each sub-pedigree were visualised using HaploPainter software.
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3. PI4K2B Expression Studies
3.1. Preface
There are solid arguments to suggest PI4K2B as a good positional and functional 
candidate susceptibility gene for bipolar disorder, as described in detail in section 
1.8. The reasons are based, in brief, on genetic evidence from a linkage study 
(Blackwood, He et al. 1996), an association study (Christoforou, Le Hellard et al. 
2007) and haplotype analysis (Le Hellard, Lee et al. 2007) that prioritised region D 
on chromosome 4p15, within which PI4K2B is located. The involvement of PI4K2B
in the phosphoinositide (PI) pathway, that is targeted by lithium and valproate for 
therapeutic effect in bipolar disorder, provides functional evidence (Berridge, 
Downes et al. 1989). 
The hypothesis of this present study was that PI4K2B could confer susceptibility to 
bipolar disorder and recurrent major depression through altered expression levels. 
PI4K2B expression was measured at the RNA and protein level in lymphoblastoid 
cell lines from a large Scottish family. Some members of the family have a defined 
haplotype on chromosome 4p15-16, referred to as “linked haplotype” that 
segregates with the majority of cases of bipolar disorder and recurrent major 
depression. At inception of this study, there was no evidence for coding variants in 
PI4K2B in family members that carry the linked haplotype. However, the presence 
of variants in regulatory regions that alter gene expression can be detected by 
measuring allele specific expression (Pastinen and Hudson 2004). In this study, it 
was hypothesised that there was a difference in PI4K2B expression related to the 
linked haplotype, and that this difference could be detected in lymphoblastoid cell 
lines by allele-specific expression analysis. 
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RNA expression of PI4K2B was assessed in lymphoblastoid cell lines by allele-
specific quantitative RT-PCR using Taqman technology. Three SNPs were used to 
quantify the relative levels of PI4K2B alleles in cDNA from linked haplotype 
carriers. The advantage to this method was the sensitivity obtained by comparing 
the linked haplotype to a series of different control alleles within the one family. 
This method could reveal the presence of cis-acting regulatory variants, which may 
contribute to susceptibility for bipolar disorder.  Cis–acting variation has been 
reported to account for 25 –35% of inter-individual differences in gene expression 
throughout the human genome (Pastinen and Hudson 2004). In order to compare 
methodologies, allele-specific expression was also measured by PeakPicker analysis 
of sequence data (Ge, Gurd et al. 2005). Furthermore, as any disruption of PI4K2B
gene regulation may manifest in protein expression abnormalities, it was important 
to investigate PI4K2B protein expression by quantitative Western blotting.
3.1.1. Lymphoblastoid cell lines available
Table 3.1 lists the 50 lymphoblastoid cell lines that were available for expression 
analysis. There were 20 samples with the “linked haplotype”. Of these 20 samples, 
six samples were from individuals with a diagnosis of bipolar disorder, five samples 
were from individuals with a recurrent major depression diagnosis, one had another 
psychiatric diagnosis and eight samples were from individuals without a 
psychiatric diagnosis. For the samples without the disease haplotype, there were 
three samples from individuals with a recurrent major depression diagnosis, one 
with another psychiatric diagnosis, one sample was unknown, 15 samples were 
from individuals without a psychiatric diagnosis and 10 samples were from 
individuals outside of the family and were without a psychiatric diagnosis. 
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29 Yes Bipolar disorder
47 Yes Bipolar disorder Yes
57 Yes Bipolar disorder Yes
61 Yes Bipolar disorder Yes
99 Yes Bipolar disorder Yes




















30 Yes Other 
36 Yes Well Yes
54 Yes Well
58 Yes Well Yes
69 Yes Well Yes
73 Yes Well Yes
76 Yes Well Yes
97 Yes Well
103 Yes Well Yes















35 No Well Yes
42 No Well Yes Yes
56 No Well
72 No Well Yes
86 No Well Yes
113 No Well Yes Yes
127 No Well Yes Yes
128 No Well





11 No Well & married-in Yes Yes
Table 3.1 Lymphoblastoid cell lines information. Continued on the next page.
Chapter 3 PI4K2B Expression Studies
129
13 No Well & married-in Yes
33 No Well & married-in Yes Yes
38 No Well & married-in
39 No Well & married-in
46 No Well & married-in Yes Yes
49 No Well & married-in
70 No Well & married-in Yes
98 No Well & married-in
141 No Well & married-in
Table 3.1 Lymphoblastoid cell lines information. The ID number is according to 
the pedigree. The psychiatric diagnosis is listed for all samples; other psychiatric 
diagnosis can mean a single episode depression, anxiety etc. The presence or 
absence of the chromosome 4p15-16 “linked haplotype” is marked. Samples that 
were heterozygous for the markers used in the allele-specific expression studies are 
labelled. The same individuals are heterozygote for both SNPs rs313567 and 
rs6834255. The table is ordered according to “linked haplotype” status and then by 
diagnosis.
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The methods used for RNA, DNA and protein preparations from the 
lymphoblastoid cell lines are described in section 2.2. Each lymphoblastoid cell line 
was cultured in the same way and the RNA extractions and cDNA preparations 
were prepared in a consistent manner. The RNA was quantified using the Agilent 
2100 Bioanalyser. This method also determined the quality of the RNA. The Agilent 
RNA 6000 Nano kit was used. This was performed by Margaret McLean in the WT-
CRF. All the lymphoblastoid cell lines were tested and found to be negative for 
mycoplasma infection, as contamination can affect uptake across cell membranes, 
interfere with membrane receptor function, cause morphological change, influence 
amino acid and nucleic acid metabolism and induce cell transformation 
(www.ecacc.org.uk). Consequently, these could have substantial effects on the 
reproducibility of results, in particular gene expression.
3.2. No Sequence Variants in PI4K2B
Primers were designed from repeat-free intronic regions to incorporate ~100bp 
either side of the exon, to include possible splice site SNPs and to amplify ~600bp 
genomic DNA fragments. PI4K2B was sequenced in 46 samples from individuals in 
four linked families, please refer to section 2.1.1.3 allele sharing panel. There was no 
evidence of a mutation in the coding region of PI4K2B. 
3.3. PI4K2B Expressed in Lymphoblastoid Cell Lines
Figure 3.1 showed that the PI4K2B gene was expressed in two lymphoblastoid cell 
line samples, 58 and 55. PI4K2B cDNA was amplified using RT-PCR (reverse 
transcription-polymerase chain reaction) technique with gene specific primers and 
sequenced to check PI4K2B specificity. This was an important first step for future 
experiments, as not all genes are expressed in lymphoblastoid cell lines.
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Figure 3.1 PI4K2B is expressed in lymphoblastoid cell lines. PI4K2B was 
amplified by RT-PCR on cDNA from lymphoblastoid cell lines. The intron spanning 
primers ensured there was no band in the gDNA control. The water control was 
used to test for contaminants in the PCR reaction mix. Two reaction mixes from 
Invitrogen and Sigma were tested. The band of expected size 255bp was present.




Three SNPs were chosen to measure PI4K2B allele expression and Taqman assays 
were designed to amplify the SNPs. TaqMan® SNP Genotyping Assays consisted of 
unlabelled PCR primers and TaqMan® MGB probes (FAM™ and VIC® dye-
labelled) that were designed for the allelic discrimination of the specific SNPs. Table
3.2 details the features of the TaqMan® SNP Genotyping Assays. Two of the assays
were premade, off-the-shelf assays “assays on demand” (c____764549 and 
c____764538) and one assay was an “assay by design” (rs6834255).  SNP assays were 
chosen for an exonic coding region, an intron and in the 3’UTR region to look for a 
difference in expression between two alleles. The intronic assay was included as 
studies have reported the detection of allele-specific expression from heterogeneous 
nuclear RNA (hnRNA), which is the unprocessed precursor of the mature, 
functional mRNA (Pastinen, Sladek et al. 2004). Allele specific expression was 
























rs313548 c____764549 24,913,660 Intron 1 Minus CT AG G None known G 13 10
rs313567 c____764538 24,930,264 Exon 2 Positive CT CT T
Synonymous, 
no change in 
peptide 
T 2 12
rs6834255 rs6834255 24,955,589 Exon 10 Positive AG AG A
None known, in 




Table 3.2 PI4K2B SNPs used in allele-specific assays. The rs number refers to the name of the SNP as www.hapmap.org. The 
Applied Biosystems (ABI) reference is the name of the assay provided to amplify the specific SNP. rs6834255 does not have a specific 
ABI reference as it was designed for this study ABD (assay by design). The physical and genomic locations of the SNPs were provided 
by the UCSC genome browser (May 2004). The strand information, the observed genotypes, the assay genotypes and the particular 
allele labelled with FAM dye were provided by ABI. The effect of the SNP shows the potential action the SNP may have on peptide 
sequence. UTR was the Untranslated Region. The genotype of the linked haplotype is listed, as Figure 3.10. The number of samples 
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3.4.1.1. Quality control of SNP assays
The three SNP assays were quality controlled by checking for ease and reliability of 
scoring and Mendelian segregation, using samples from 46 individuals from four 
linked families and samples from 32 trios, as described in section 2.1.1.3 and 2.1.1.4 
respectively. The three assays fully passed these quality control measures. The 
markers rs313567, rs313548 and rs6834255 were also genotyped in 444 members of 
the Scottish population. This was the same population used for the control group in 
the PI4K2B case control association study in chapter 4. This allowed additional 
quality control analysis to be carried out. The genotyping success for the three SNPs 
was >97%. The three markers also passed the Haploview recommended Hardy-
Weinberg equilibrium significance threshold (P=0.001) at P=0.57, 0.18 and 0.15 for 
rs313567, rs313548 and rs6834255 respectively. Furthermore, as shown in Table 3.3
the three SNPs were in complete LD with each other, based on D’=1, which implied 
there was no evidence for ancestral recombination event between two SNPs.
MARKER 1 MARKER 2 D' LOD R2 CILOW CIHI DIST(BP)
rs313548 rs313567 1 69.66 0.627 0.96 1 16,604
rs313548 rs6834255 1 67.89 0.618 0.96 1 41,929
rs313567 rs6834255 1 115.41 1 0.98 1 25,325
Table 3.3 Linkage disequilibrium between PI4K2B SNPs.  D' is the value of D 
prime between the two loci, LOD is the log of the likelihood odds ratio, a measure of 
confidence in the value of D', r2 is the correlation coefficient between the two loci, 
CIlow is 95% confidence lower bound on D', CIhi is the 95% confidence upper 
bound on D'. Dist is the distance in bases between the loci. 
Only rs313567 and rs6834255 are in perfect LD, based on r2=1. Perfect LD means r2 = 
1, where the SNPs are redundant and act as “perfect proxies”. This was reflected by 
the genotypes observed in all sample sets genotyped: lymphoblastoid cell line 
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samples, 46 samples from four-linked families and 32 trios. Individuals were 
consistently heterozygous or homozygous at both rs313567 and rs6834255, but this 
correlation did not extend to rs313548.
Having passed these quality control checks, the markers were genotyped on all
available lymphoblastoid cell lines. There was no information for eight 
lymphoblastoid cell lines due to either genotyping failure or unavailability of the 
cell line at that time. These samples were 32, 30, 132, 97, 98, 164, 38 and 153. Of the 
available 42 samples, those heterozygous for specific SNPs were used, so the 
relative contribution of the two alleles could be compared. There were 23 samples 
heterozygote for rs313548, 13 of which have the linked haplotype (five bipolar 
disorder, four recurrent major depression, four well) and 10 have a control 
haplotype (one recurrent major depression, six well, three well and married-in). 
There were 14 samples heterozygote for both rs313567 and rs6834255, two samples 
had the linked haplotype and are well, 12 samples had the control haplotype (two 
recurrent major depression, five well, five married-in and well). All of these 
heterozygote samples were tested for allelic imbalance according to the optimised 
experimental procedure, as outlined in section 2.2.8.
3.4.2. Taqman Assays
3.4.2.1. Standard curves of genomic DNA dilutions
The initial experimental design was to prepare a standard curve made from a series 
of genomic DNA (gDNA) homozygote dilutions. This standard curve could then be 
used to read the expression of each allele from the cDNA for each individual. This 
approach was first reported by Pastinen et al, and has been used by Kimura et al and 
Lo et al.(Lo, Wang et al. 2003; Pastinen, Sladek et al. 2004; Kimura, Nishioka et al. 
2005). Several stages of the experimental procedure were optimised to improve the 
quality of the standard curves: pipetting accuracy was improved with electronic 
pipettes, DNA concentration was estimated by picogreen reagent, steps were taken 
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to ensure that DNA dilutions were fully dissolved, the DNA concentration required 
for each particular assay was investigated, the number of replicates was increased 
and the most appropriate analysis method was sought. Standard curves with 
different homozygotes mixes were prepared to test the precision of each assay.
Three standard curves with four different homozygotes in different combinations 
were prepared to test rs313567 assay, and two standard curves with four different 
homozygotes were prepared to test the precision of rs313548 and rs6834255 assays. 
Each homozygote mix was assayed in quadruplicate.
Figure 3.2 shows the optimised standard curve for rs313567 obtained using the 
LOG2 ratio of FAM allele:VIC allele against the LOG2 Ratio of FAM™ /VIC® 
reporter dye intensity. The data was transformed for normal distribution (Bland and 
Altman 1996). A linear regression line was drawn for each standard curve to report 
on the linearity of the ratios and accuracy of the triplicate assays. The correlation 
within the four replicates of each standard curve was good, r2>0.97, as was the 
correlation between the three standard curves, r2>0.99. However, for each 
homozygote dilution, represented in Figure 3.2, the 95% confidence intervals
overlapped. This showed that a difference could not be confidently determined 
between neighbouring homozygote dilutions. Figure 3.3 and Figure 3.4 show the 
standard curve data for assays rs313548 and rs6834255 respectively. The correlation 
within the three replicates for each standard curves was also good, r2>0.95 and 
r2>0.98 respectively, as was the correlation between two standard curves for both 
assays, r2>0.98. For both of these assays, the 95% confidence intervals also 
overlapped between neighbouring homozygote dilutions and a difference could not 
be confidently determined.
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Figure 3.2 Standard curve of gDNA dilutions at rs313567. The graph shows the 
known homozygote dilutions allele ratio on the x-axis against the intensity value 
from the assay on the y-axis. FAM and VIC labelled the two alleles. There were nine 
homozygote dilutions tested, from left to right on the graph diluted according to the 
following ratios: 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. 
The box shows the mean value of three standard curves for each homozygote 
dilution. There were four different homozygote gDNA samples mixed; 132 (CC) & 86 
(TT), 132 (CC) & 35 (TT), T3445 (CC) & 86 (TT). There were four replicates of each 
mix. The error bars show 95% CI range. The grey dotted lines from the 50:50 
homozygote mix (log2=0) show the limit of estimating allelic imbalance from the 
standard curve.
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Figure 3.3 Standard curve of gDNA dilutions at rs313548. The graph shows the 
known homozygotes allele ratio on the x-axis against the intensity value of the assay 
on the y-axis.  FAM and VIC labelled the different alleles. There were nine 
homozygote dilutions tested, from left to right on the graph diluted according to the 
following ratios: 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. 
The triangle represents the mean value of three replicates for one standard curve; 
131 (AA) & 70 (GG). The box represents the mean value of three replicates for 
another standard curve 56 (AA) & 72 (GG). The error bars show 95% CI range. 
Each standard curve was correlated, r2>0.95. The grey dotted lines from the 50:50 
homozygote mix (log2=0) show the limit of estimating allelic imbalance from the 
standard curve.
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Figure 3.4 Standard curve of gDNA dilutions at rs6834255. The graph shows the 
known homozygotes allele ratio on the x-axis against the intensity value of the assay 
on the y-axis.  FAM and VIC labelled the different alleles. There were nine 
homozygote dilutions tested, from left to right on the graph diluted according to the 
following ratios: 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. 
The box represents the mean value of three replicates for one standard curve; 
samples 132 (AA) & 86 (GG). The triangle represents the mean value of three 
replicates for another standard curve; samples 132 (AA) & 86 (GG). The error bars 
show 95% CI range. Each standard curve was correlated, r2>0.98. The grey dotted 
lines from the 50:50 homozygote mix (log2=0) show the limit of estimating allelic 
imbalance from the standard curve. 
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3.4.2.2. Estimation of allelic imbalance from standard curves
cDNA from each heterozygote lymphoblastoid cell line was assayed with four 
replicates from the same RNA preparation in each assay. The four replicates within 
the three assays showed good reproducibility of individual cDNA ratios with an 
average coefficient of variation (SD/mean) of <0.037. A cut-off average coefficient of 
variation <0.05 is often used (Bray, Preece et al. 2005). Each assay was repeated three 
times with the same preparation of cDNA and these assays showed good 
reproducibility with average coefficient of variation <0.034. The intensity of the 
cDNA heterozygotes was then compared to the relevant standard curve. The grey 
dotted lines on Figure 3.2, Figure 3.3 and Figure 3.4 show the only difference that 
could be reliably detected from equal expression from both alleles (50:50) was a 
80:20 allele ratio at rs313567, a 90:10 allele ratio at rs313548 and a 70:30 allele ratio at 
rs6834255, respectively. This was not as sensitive, as previous studies have shown a 
threshold for detecting allelic imbalance at a 63:37 allelic ratio (Pastinen, Sladek et al. 
2004)
The allelic imbalances observed for the heterozygote cDNA samples did not reach 
the detection threshold. The mean LOG2FAM/VIC intensity for 14 heterozygotes at 
rs313567 = 0.5 (minimum 0.47 - maximum 0.55, 95%CI 0.01), for 23 heterozygotes at 
rs313548 = 0.64 (minimum 0.57 - maximum 0.69, 95%CI 0.01) and for 14 
heterozygotes rs6834255 = 1.15 (maximum 1.24 – minimum 1.05, 95% CI 0.02). 
Figure 3.2, Figure 3.3 and Figure 3.4 show that these mean cDNA allelic values lie in 
the middle of each of the standard curves and do not extend past the confidence 
intervals for allelic imbalance beyond 50:50. Thus, no allelic over-expression was 
observed to this degree for any of the three assays. Moreover, the standard curves 
were not sensitive enough to detect a small difference between disease haplotype 
carriers and controls. 
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Proof of this is shown in Figure 3.5, which illustrates a comparison with gDNA from 
heterozygotes to that of gDNA equal homozyogote mixes, 50:50. The gDNA equal 
homozygote mixes should mimic the real heterozygotes. The gDNA heterozygotes 
cluster whereas the homozygote mixes have a greater spread. This illustrates the 
technical difficulties with creating accurate mixtures of DNA, and thus the lack of 
sensitivity of the standard curve method. 
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Figure 3.5 Comparison of gDNA from heterozygotes with 50:50 homozygote 
mixes for rs313567.  There were four replicates for each sample. There were 
fourteen heterozygote (het) gDNA and four different standard curves. The standard 
curve homozygote mixes were 132 & 86, 132 & 35, T3445 & 86, F119 T3195 & 56. 
The mean value is represented by the horizontal bar and the error bars show the 
95% confidence interval.
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3.4.2.3. Direct comparison method
As the creation of accurate standard curves was unsuccessful, I adopted another 
method, which incorporated gDNA measurements from heterozygotes, which 
represented equal expression from each allele, as a control. This method has been 
used in many studies (Hoogendoorn, Norton et al. 2000; Bray, Jehu et al. 2004; 
Hannula-Jouppi, Kaminen-Ahola et al. 2005; Li, Grupe et al. 2006; Williams, Glaser 
et al. 2008). Each of the three assays was performed. gDNA and cDNA samples 
were assayed from 23 heterozygote samples for rs313548 and 14 heterozygotes 
samples for both rs313567 and rs6834255. The data was analysed as described in 
section 2.3.2. In brief, the ratio of cDNA:gDNA was calculated, as genomic DNA 
represents a 1:1 ratio of the two alleles. The ratio allows any assay specific and PCR 
amplification bias to be taken into account. For example, the FAM label was 
detected at a greater intensity than the VIC label intensity (Angie Fawkes, Personal 
Communication, 30th May 2005, Wellcome-Trust Clinical Research Facility) and 
incorporating both gDNA and cDNA in the same assay will cancel any intensity 
bias. Figure 3.6 and Figure 3.7 (a and b) showed the cDNA:gDNA ratios for 




















Figure 3.6 PI4K2B allelic expression at rs313548 between linked haplotype carriers and controls. The heterozygote 
lymphoblastoid cell line samples are shown on the x-axis. The cDNA/gDNA ratio for each sample is shown on the y-axis. This ratio is 
the mean of 3 assays, each with 4 replicates, calculated as intensity FAM/intensity VIC. The error bars show 95% Confidence Interval. 
The dark blue bars represent samples with the PI4K2B linked haplotype that are heterozygote at this SNP. The light blue bars 































































Figure 3.7 Allelic expression between linked haplotype carriers and controls at 
rs313567 and rs6834255. The heterozygote lymphoblastoid cell line samples are 
shown on the x-axis. The cDNA/gDNA ratio is shown on the y-axis for rs313567 (a) 
and rs6834255 (b). This ratio is the mean of 3 assays, each with 4 replicates, 
calculated as intensity FAM/intensity VIC. Error bars show 95% Confidence Interval. 
The dark blue bars represent samples with the linked haplotype that are 
heterozygote at these SNPs. The light blue bars represent samples without the 
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It was possible to test for a difference in allelic expression between samples that are 
heterozygote for rs313548. There were 13 heterozygote individuals with the PI4K2B
linked haplotype and 10 individuals without. Allelic expression was compared 
between the two groups using a T Test. The Student-T test, with a two-tailed 
distribution, determined whether two samples are likely to have come from the 
same two underlying populations that have the same mean. The result was non-
significant, P=0.28, thus I was unable to reject the Null Hypothesis that there was no 
difference in allele expression between individuals with the PI4K2B linked 
haplotype and those who do not have the haplotype.
A difference in allelic expression was also tested in the other two SNP assays, 
rs313548 and rs6834255. It was evident from Figure 3.7 that the cDNA/gDNA ratio 
of the samples with the linked haplotype, 69 and 73, did not differ from the other 12 
samples without. However, it would be difficult to detect a difference in only two 
samples with the linked haplotype. The T-test did not suggest a significant 
difference between PI4K2B linked haplotype samples and the control samples, 
P=0.36 (rs313548) and P=0.98 (rs6834255). 
3.4.3. PeakPicker assays
A second technique for measuring allele expression, namely the “PeakPicker” 
method was also attempted (Ge, Gurd et al. 2005). This method had previously 
shown to be successful in detecting allelic expression differences (Pastinen, Ge et al. 
2005). This technique investigated the sequence trace produced by amplification of 
the DNA surrounding the SNP and measured the peak height ratios of the two 
alleles of the SNP, and used the peak heights of the surrounding sequence to 
calculate the level of expression of the two alleles. The peak height ratios for both 
gDNA and cDNA were measured and compared. Figure 3.8 illustrates an example 
on samples 69 and 70. 
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Figure 3.8 Peak heights of the SNP in cDNA & gDNA using PeakPicker 
software. Sequence trace for cDNA and gDNA for two lymphoblastoid cell line 
samples are shown surrounding the marker rs6834255. The arrows point to the two 
alleles of rs6834255. The peaks correspond to different bases: green peaks are 
adenine (A), blue peaks are cytosine (C), black peaks are guanine (G) and red 
peaks are thymine (T). 
This method was attempted for the three SNPs in duplicate for both cDNA and 
gDNA from all heterozygote lymphoblastoid cell line samples. The cDNA was 
prepared from a single RNA sample that was also used in the Taqman assays. Each 
DNA sample was sequenced twice. Peak height ratios of the SNP from the sequence 
traces were measured and normalised based on the surrounding sequence using 
PeakPicker software, according to the authors instructions (Ge, Gurd et al. 2005).
This method was successfully completed for SNP rs6834255. However, reliable peak 
estimates surrounding rs313548 in PI4K2B intron 1 could not be obtained as there 
was double sequence in both cDNA and gDNA. Also, the sequence surrounding 
rs313567 was only of good quality in three out of fourteen samples of gDNA and in 
thirteen out of fourteen samples of cDNA, thus a valid comparison between cDNA 
and gDNA could not be made. The problems in obtaining good quality sequence 
traces may have occurred due to poor DNA quality, poor primer design which may 
have caused the primer to bind to two or more sites on the template, unsuitable PCR 
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amplification conditions or insufficient clean-up reaction. The sequence 
surrounding rs6834255 was successfully obtained for 13 gDNA samples (12 samples 
in duplicate and one singly) and 13 cDNA samples (nine in duplicate and four 
singly). Analysis was performed on this data. 
Figure 3.9a shows level of allelic imbalance at rs6834255 for 13 heterozygotes. The 
samples with the linked haplotype, 69 and 73, lie in the range of middle of allelic 
expression ratios of samples with the control haplotype. A student T-test, with a 
two-tailed distribution, was performed and showed no evidence for a difference 
between the two samples with the linked haplotype and those samples without 
(P=0.91). 




































Figure 3.9 PI4K2B allelic imbalance by Taqman and PeakPicker methods. The 
x-axis shows the lymphoblastoid cell line samples that were heterozygous for the 
PI4K2B 3’UTR SNP, rs6834255. The y-axis shows the cDNA/gDNA ratio. Figure (a) 
shows the DNA ratio estimated by the PeakPicker method by the pink bars. This 
ratio was the mean of two amplifications from each individual, sequenced once.  
Figure (b) shows the DNA ratio as the PeakPicker method (pink bars) beside the 
ratio obtained by the Taqman method (blue bars). The Taqman ratio was the mean 
of 3 assays, each with 4 replicates, calculated as VIC/FAM. Error bars show 95% 
Confidence Interval for the replicate Taqman Assays. The mean coefficient of 
variation experiment-wide is 0.03 (Taqman assays) and 0.06 (PeakPicker 
analysis).The dark bars represent samples with the linked haplotype (69 and 73) 
that are heterozygous at rs6834255. The dotted line at 1 on the y-axis represents 
equal expression of both alleles and labels the direction of expression of each allele 
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Figure 3.9b compares the allelic expression at this marker for the PeakPicker data to 
the Taqman data. In general, the allelic expression detected by both the PeakPicker 
and Taqman methods showed the same direction to the A allele, except for sample 
34 measured by the Taqman method and for sample 42 measured by the PeakPicker 
method. However, the measurements of expression were not the same between the 
PeakPicker and Taqman method. In fact, the majority of the PeakPicker
measurements did not overlap with the 95% confidence intervals from the Taqman 
measurements. Sample 46 was the only one that displayed the same expression 
levels by both methods. 
There were many caveats to this analysis. Firstly, the number of replicates in the 
PeakPicker method was less than the Taqman assays. Technical difficulties curbed 
further experiments to increase the number of replicates and so confidence intervals 
could not be calculated. Secondly, the mean experiment-wide coefficient of variation 
for the PeakPicker method, CV=0.06, was greater than both the Taqman assays, 
CV=0.03, and the recommended cut-off, CV=0.05. Finally, experiments by other 
members in the laboratory showed unacceptable levels of variability in the 
PeakPicker method (Susan Anderson and Helen Torrance, Personal communication, 
26th July 2006, Molecular Medicine Centre, University of Edinburgh). Thus, the 
PeakPicker method did not prove a reliable manner to measure allele-specific 
expression levels for this study.
3.4.4. Haplotype analysis
To investigate PI4K2B expression at the haplotype level, the allele-specific analysis 
by Taqman of the three SNPs was combined. In theory, the linked allele at each of 
the three SNPs should show the same strength and direction of allelic expression. 
Firstly, it was possible, through segregation analysis to determine haplotypes at the 
three SNPs in the individuals tested. Secondly, the data was combined to determine 
the expression of the haplotype.
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3.4.4.1. Determining phase of the SNPS 
From Table 3.2 the possible genotypes for SNPs rs313548, rs313567 and rs6834255 
are A/G, C/T and A/G respectively. The number of possible haplotypes is 23
haplotypes (8 haplotypes). It was firstly determined that the markers showed 
Mendelian segregation through the family. Previous work completed by our group 
identified the individuals that carry the linked haplotype, as listed in Table 3.1. This 
information was used to identify the linked haplotype for the three PI4K2B SNPs. 
For example, Figure 3.10 shows that for SNP, rs313548 the genotype on the linked 
haplotype must be G, and for rs313567 and rs6834255 the genotype must be TG. 
Thus, the linked haplotype was GTG. All genotyped samples with the linked 
haplotype have the haplotype G-T-G.
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Figure 3.10  Determination of haplotype phase of PI4K2B SNPs. Two branches 
of the large family are shown here. The genotypes for each sample are listed in the 
following order; rs313548, rs313567 and rs6834255. The red-filled triangle shows a 
sample from an individual with a bipolar disorder diagnosis. The small black circle 
means the sample was from an individual with the linked haplotype.
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Figure 3.11 illustrates the aim of combining the analysis to compare expression at 
the haplotype level of the linked haplotype versus the control haplotype.
Figure 3.11 Illustration of haplotype of SNPs used in allele-specific expression 
assays. The PI4K2B gene structure is shown here with boxes that represent exons 
and lines that represent introns. The SNP markers are rs313548, rs313567 and 
rs6834255 in intron 1, exon 2 and 3’UTR region of PI4K2B, respectively. The control 
haplotype is defined as A-C-A and the disease haplotype is defined as G-T-G.
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3.4.4.2. Haplotype analysis of Taqman data
The expression data was combined for the three assays to measure the PI4K2B
linked haplotype; G-T-G for rs313548-rs313567-rs6834255. There are eight samples 
who were heterozygous at all three SNPs and for whom the haplotype could 
therefore, be investigated using mean cDNA/gDNA ratios. Although sample 11 was 
heterozygous for the three markers, this sample was not included, as one haplotype 
was A-T-G and the other haplotype was G-C-A for rs313548, rs313567 and 
rs6834255, respectively, as determined by segregation analysis. For the other seven 
samples, their haplotypes were the same, namely G-T-G and A-C-A for rs313548, 
rs313567 and rs6834255, respectively. 
Figure 3.12 shows the haplotype analysis for seven individuals who were 
heterozygous for the three SNP markers. In general, SNPs rs313567 and rs313548 
show the same direction of allelic expression, while SNP rs6834255 shows the 
opposite direction. Thus, the same expression pattern was not detected at all three 
SNPs. This analysis was not used to investigate linked haplotype versus control as 
none of the eight samples that were heterozygous at all three markers had the 
linked haplotype. 





















Figure 3.12 Haplotype analysis of PI4K2B allelic expression. The x-axis shows 
the lymphoblastoid cell line samples. The y-axis shows the cDNA/gDNA ratio. This 
ratio is the mean of three assays, each with four replicates, calculated as VIC/FAM 
(rs3131548 A/G and rs6834255 G/A) and FAM/VIC (rs313567 T/C). Error bars show 
95% Confidence Interval. The dotted line that crosses the y-axis at one represents 
equal expression from both alleles.
G-T-G
A-C-A
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3.5. Alternative Splicing of PI4K2B
3.5.1. Preface
A hypothesis to explain the discordance of PI4K2B allele-expression at the 
haplotype level shown in Figure 3.11 was alternative splicing of PI4K2B. In theory, 
there may be several PI4K2B isoforms, some of which may not contain all three
SNPs in this study. Alternatively, the intronic SNP may be contained in a 
pseudoexon. A pseudoexon is an intronic sequence that resembles an exon because 
it matches 3’ and 5’ splice sites that are not normally spliced. The hypothesised 
variants could regulate PI4K2B transcript levels in an isoform-specific manner. 
Conversely, there may be differential regulation of particular isoforms that could 
include the SNPs in question. 
Here, the three SNPs used in measuring allele-specific expression in PI4K2B were
examined to see if they were contained in different isoforms. Two approaches were 
employed i) bioinformatics using the UCSC genome browser and ii) PCR techniques 
using both RT-PCR and 3’ Rapid Amplification of cDNA Ends (RACE) on cDNA 
from lymphoblastoid cell lines. The second experimental approach was undertaken 
because, despite thorough analysis using EST, cDNA and gene-prediction 
approaches on genome browsers, a significant fraction of alternative 5’- or 3’-
terminal exons and internal alternative splicing can be missed (Wang and Cooper 
2007). 
The UCSC human genome browser was used to search for evidence of alternative 
transcripts, such as multiple transcription initiation sites (first exons), 
polyadenylation sites and alternatively spliced internal and terminal exons. Figure
3.13 illustrates the CpG islands and polyadenylation sites that suggest the 5’ and 3’ 
boundary of the PI4K2B gene, respectively.
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Figure 3.13 Genomic structure of PI4K2B. The graphic was produced from the 
UCSC Genome Browser, using the March 2006 build and the custom tracks option. 
The physical position on chromosome 4 in base pairs is noted on the top. The tracks 
show the position of PI4K2B (NM_018323). The thickest parts of the track indicate 
the coding exon regions within the gene. The slightly thinner portions at the leading 
and trailing ends of the gene track show the 5' and 3' UTRs. Introns are depicted as 
lines with arrows indicating the direction of transcription. The PI4K2B genomic 
region is shown by four tracks; Known Genes Based on Swiss-Prot, TrEMBL, mRNA 
and RefSef, RefSeq Genes, Mammalian Gene Collection Full ORF mRNAs and 
Aceview Gene Models with Alt-splicing. The 5’- start of the PI4K2B is shown by the 
CpG Islands track. The 3’- end of PI4K2B is shown by two tracks: Reported Poly(A) 
sites from PolyA_DB and Predicted Poly(A) Sites using an SVM. 
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3.5.2. No evidence for alternative transcripts at rs313548 
Analysis of the human genome browser data showed that there was no evidence for 
alternative transcripts that would include the intronic SNP, rs313548. The 
investigations carried out on the UCSC genome browser included all gene 
prediction tracks from human and non-human sources, six human mRNAs from 
GenBank and 22 human ESTs that covered this region. None showed evidence for 
rs313548 in a coding region. 
The intronic sequence containing rs313548 may be spliced into the exon. This was
checked by amplifying and sequencing PI4K2B exon 1 to exon 4 and searching for
extra sequence, double sequence or sequence mis-match. Primers were designed to 
amplify exon1 and exon4 of PI4K2B in cDNA samples, namely stcPI4K2B.ex1aF and 
stcPI4K2B.ex4R as listed in Table 2.4. This would detect a sequence if rs313548 was 
spliced into a transcript. Amplification of cDNA produced a single band of expected 
size, 756bp in the two cDNA samples tested (47 and 49). Two of these cDNA 
samples were sequenced with both forward and reverse primers. Figure 3.14 shows 
analysis of the sequence data, with no evidence of an alternative transcript that 
would contain rs313548.
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Figure 3.14 No evidence for alternative transcripts in lymphoblastoid cell lines 
of rs313548. The graphic was produced from the UCSC Genome Browser, using 
the March 2006 build and the custom tracks option. The physical position on 
chromosome 4 in base pairs is noted on the top. Two cDNA samples (47 and 49) 
were amplified and sequenced with forward (F) and reverse (R) primers, 
stcPI4K2B.ex1aF and stcPI4K2B.ex4R respectively. Their transcript is coloured in 
black. The thickest parts of the track indicate the coding exon regions within the 
gene. The slightly thinner portions at the leading and trailing ends of the gene track 
show the 5' and 3' UTRs. Introns are depicted as lines with arrows indicating the 
direction of transcription. The position of PI4K2B according to the UCSC genome 
browser is shown by blue lines. The position of SNPs in the region is shown below. 
The SNP rs313548 is highlighted with a green square. It is located outside of the 
exon.
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3.5.3. Evidence for alternative splicing at rs313567
There were two sources of evidence for alternative splicing of exon 2 in PI4K2B.  
Firstly, collating information on the UCSC genome browser from human genes, 
non-human genes, gene-prediction tracks, mRNA tracks and EST tracks showed 
evidence of alternative splicing. In the non-human RefSeq gene track, exon 2 was 
shorter in the mouse, rat, frog and fruit fly sequence, although it covered rs313567.
Also, of the 25 human ESTs covering exon 2, one human EST, DA744687 (from NT2 
cell line, a neuronally committed human teratocarcinoma cell line) does not cover 
exon 2 and of the 21 non-human mRNAs, two mouse mRNAs, AK106754 and 
AY148879 do not cover exon 2. Also, of >100 non-human ESTs, several showed 
transcripts of exon 2 without rs313567. In particular, out of 20 mouse ESTs, five 
spliced out rs313567: BY710975, BF162501, BI691138, BI691138 and BF162501.
Secondly, evidence for exon 2 alternative splicing came from sequence data.
Lymphoblastoid cell line cDNA was amplified using primers to exon 1 and exon 4 
PI4K2B, stcPI4K2B.ex1bF and stcPI4K2B.ex4R respectively, as described in Table 4. 
Figure 3.15 illustrates amplification of PI4K2B using the Invitrogen and Sigma 
methods. Using the Invitrogen system, a band of approximately 750bp was 
detected, which was most likely derived from the most common PI4K2B isoform at 
the expected size of 756bp. There were two different sized products in the two 
different lymphoblastoid cell line samples amplified using the Sigma system, 
sample 47 with a band at ~400bp and 49 at ~520bp. 
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Figure 3.15 Alternative isoforms at PI4K2B exon2. The picture shows the 
amplification of PI4K2B exon2 from lymphoblastoid cell line cDNA samples, 47 and 
49. gDNA from lymphoblastoid cell line sample, 29 and distilled water were used as 
controls. Both the Invitrogen and Sigma methods were used for PCR amplification. 
The bands at ~750bp amplified with the Invitrogen system were the expected size. 
The bands amplified by the Sigma system at ~400bp and ~500bp were not 
expected.
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All lymphoblastoid cell line cDNA samples were amplified using primers to exon 1 
and exon 4 PI4K2B, stcPI4K2B.ex1bF and stcPI4K2B.ex4R respectively (as Table 4) 
with Invitrogen, Sigma and Applied Biosystems methods. In all cDNA samples, a 
band of ~750bp was detected using the Invitrogen system. Sequence analysis of the 
~750bp product from the Invitrogen system showed the expected coverage of exons 
one to four of PI4K2B.  
Products of various sizes (350bp, 400bp and 520bp) were obtained with the Sigma 
and Applied Biosystems amplification methods. PCR products were extracted from 
the agarose gel and sequenced. Figure 3.16 illustrates the sequence obtained from 
four cDNA samples, using stcPI4K2B.ex4R primer. There were three different 
alternative exons that did not contain the SNP rs313567. For sample 49, the full 
155bp of exon 2 was covered.  The other three isoforms amplified were shorter:
sample 47 (99bp) sample 70 (31bp) and sample 133 (78bp). 
Figure 3.16 Alternative splicing of exon 2 of PI4K2B. The graphic was produced from the UCSC Genome Browser, using the March 
2006 build and the custom tracks option. The physical position on chromosome 4 in base pairs is noted on the top. The four black lines 
were sequence data from amplified products from three lymphoblastoid cell lines: 47, 49, 70 and 133. The thickest parts of the line 
indicate the coding exon regions within the gene. Introns are depicted as lines with arrows indicating the direction of transcription. The 
position of PI4K2B according to the UCSC gene prediction tracks are shown by blue lines. The position of SNPs in the region is shown 
below.  The SNP used in the allele-specific expression studies is in green, rs313567. A green dotted horizontal line shows the SNP is 
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The products amplified from samples 47 and 49 by the Sigma system, as shown in 
Figure 3.15, suggest they are different splice isoforms due to their different size 
(400bp and 520bp respectively). Upon analysis of sequence data, there was evidence 
for exon 2 splice forms for 47 and not for 49. However, the difference in size, from 
the expected 750bp in sample 49, was due to splicing of PI4K2B exon 1. 
Pertinent to this study, was that the SNP, rs313567 used in PI4K2B allelic expression 
assays, was spliced out of exon 2 in some isoforms, as illustrated in Figure 3.17. 
Identification of alternative transcribed transcripts of PI4K2B explains why the 
allelic imbalance data was not consistent across three SNPs on the same haplotype. 
In addition, alternative splice isoforms were detected in cDNA samples that were 
used in the Taqman expression assays. Sample 47 was used as a heterozygote for the 
allelic assay in PI4K2B intron 1 and sample 70 was also heterozygous for another 
SNP in the 3’UTR region that was used in the haplotype analysis. Finally, it was 
notable that the splicing of exon2 in PI4K2B was in-frame, as examined at the base-
level on the UCSC genome browser, and consequently would not affect protein 
production.
Figure 3.17 Illustration of alternative splicing of exon 2 of PI4K2B. This schematic shows four different PI4K2B isoforms, one with all 
of exon 2 and three others with exon 2 spliced out to different degrees as shown in Figure 3.16.
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3.5.4. No evidence for alternative transcripts at the 3’end 
The search of alternative transcripts at the 3’ end of PI4K2B incorporated two 
methods. Firstly, searching the UCSC genome browser for current sequence data 
and ESTs showed there was no evidence for alternative splicing at the 3’ end of 
PI4K2B. From the predicted gene sequence track on the human genome browser 
there was no evidence for an alternative 3’ end of PI4K2B from human data. Also, all 
five human mRNAs covered the SNP rs6834255. However, the mouse Pi4k2b Non-
human RefSeq track did not cover rs6834255
Secondly, 3’ RACE was used to look for alternative transcripts at the 3’ end of 
PI4K2B. Human heart RACE ready cDNA was tested, as described in section 2.2.3.3. 
PI4K2B had previously been shown to be expressed in the heart by Northern Blot 
analysis (Balla, Tuymetova et al. 2002) and by microarray expression analysis (GNF 
Expression Atlas 2 Data from U133A and GNF1H Chips, UCSC human genome 
browser). This validated the use of heart-specific cDNA for this experiment. Figure
3.18 shows the amplification of the 3’ end of PI4K2B by RACE. 
Chapter 3 PI4K2B Expression Studies
167
Figure 3.18 3'RACE amplification. Human heart RACE ready cDNA was amplified 
using a PI4K2B specific assay (stcPI4K2B.ex10_inner and 3’ RACE inner), 3’ RACE 
control primers (3’ RACE outer and 3’ RACE control) and PCR control primers (5’ 
RACE Inner and 5’ PCR Control). The products with the PI4K2B specific primers 
were bands at 2kb and 170bp. There was no clear band in the negative control after 
amplication with the PI4K2B specific primers. The expected products for the 3’ 
RACE control and PCR control were amplified, 733bp and 236bp respectively. 
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Both the 2kb and 200bp products from the PI4K2B specific primers were gel 
extracted and sequenced. The following primers were used to amplifiy the products; 
stcPI4K2B.exon10_outer, stcPI4K2B.ex10_inner and End of 3’ 1kb sequence as listed 
in Table 2.4. The 2kb band was successfully sequenced and matched the known 3’-
sequence of PI4K2B as shown by the black bar in Figure 3.19. Importantly, the 
sequence coverage included the SNP rs6834255, as highlighted in yellow in Figure
3.19.  Reliable sequence was not obtained from the 200bp product. Thus it was likely 
a spurious result and was not considered further. 
Figure 3.19  No evidence for alternative splicing of PI4K2B at 3'end. The graphic was produced from the UCSC Genome Browser, 
using the March 2006 build and the custom tracks option. The physical position on chromosome 4 in base pairs is noted on the top. 
Under “Your Sequence from Blat Search” is the sequence obtained from 3’ RACE amplification of PI4K2B, shown by three black 
boxes: 2kb_3start, 2kb_PI4K_F and 2kb_3UTRend. The primers used for sequencing are also shown by smaller black boxes; 
exon10_inner, 3start_primer and 3’UTRend respectively. The position of PI4K2B according to the UCSC gene prediction tracks for 
human and non-human are shown by blue lines. They show exon 10 of PI4K2B as the thick blue line, which is extended by a slightly 
thinner blue line to show the 3’UTR end. Introns are depicted as lines with arrows indicating the direction of transcription. The position 



















Chapter 3 PI4K2B Expression Studies
170
3.6. Protein Expression
The aim of this study was to determine if there was a difference in PI4K2B protein 
expression, between those individuals with the chromosome 4p15-p16 linked 
haplotype and those without, in protein lysate samples from lymphoblastoid cell 
lines. A difference in protein expression could indicate abnormalities in protein 
translation or protein modification, due to altered translational or posttranslational 
processing, which could consequently affect signalling pathways or synaptic vesicle 
trafficking. First, the choice of PI4K2B antibody to detect protein expression and the 
quality-control measures to determine the specificity of the antibody are described. 
Second, the optimisation of the protein detection and quantification techniques is 
detailed. Last, comparison of PI4K2B protein expression in samples with and 
without the chromosome 4p15-p16 linked haplotype, are reported.
3.6.1. PI4K2B antibodies
There were three antibodies available that were reported to be specific for PI4K2B 
detection; one raised against the entire protein (Minogue, Anderson et al. 2001), one 
specific to the N-terminus and one specific to the C-terminus. Table 3.4 lists the 
specificity and source of the three antibodies.
ANTIBODY SPECIFICITY SOURCE
PI4K2B





PI4K2B N-Terminal 1-17  Abgent
PI4K2B C-Terminal 319-336  Abcam
Table 3.4 PI4K2B antibodies. There are three PI4K2B specific antibodies 
available. αα are the amino-acids to epitopes which the antibody is raised, GST is 
glutathione-S-transferase.
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The first PI4K2B antibody listed in Table 3.4, was raised against a recombinant GST 
fusion protein expressed in Escherichia coli (E.coli) and will be referred to here as 
“PI4K2B (Minogue)”. Figure 3.20 highlights the peptide epitopes used to raise the 
antibodies specific to the N-terminal and C-terminal PI4K2B, on a protein alignment 
of PI4K2B and PI4K2A. PI4K2B is highly homologous (58% identical and 75% 
homologous) to PI4K2A, apart from a unique N-terminal 100 amino acid sequence.
PI4K2B protein (NP_060793) is 481 amino acids in length and encoded on 
chromosome 4p15.2, whereas the slightly smaller PI4K2A (NP_060895) is 479 amino 
acids in length and is encoded on chromosome 10q24. The phosphatidylinositol 3-
and 4- kinase domain was identified from NCBI conserved domain analysis and 
spanned amino acids 167-415 in PI4K2B and 172-438 in PI4K2A. The three 
antibodies were specific for PI4K2B.
Figure 3.20 PI4K2B Antibodies. The alignment of PI4K2A and PI4K2B is shown. The residues in red are different between the alpha 
and beta isoform. The epitopes used to raise the antibodies are highlighted in purple (N-terminal) and orange (C-terminal). The 
phosphatidylinositol 3- and 4- kinase domain is shown in light blue. The alignment was performed using Clustal W (1.82) and the 
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3.6.2. Quality control of PI4K2B antibodies
The specificity of the three antibodies to PI4K2B was tested using two different 
positive control protein lysates. One positive control sample was prepared in this 
study as described in section 2.2.2.5, by transforming the N-terminal PI4K2B specific 
HA-epitope tagged DNA (Balla, Tuymetova et al. 2002), into DH5 competent cells, 
purifying the plasmid, which was then chemically transfected into COS-7 cells. This 
positive control was named “Tfn PI4K2B” and a negative control for the transfection 
procedure was named “Tfn No DNA”. A second control sample was provided for 
this study and consisted of human HT1080 cells stably expressing GFP-PI4K2B 
(Minogue, Anderson et al. 2001). This control was named “+ve Ctrl”. Detection of 
PI4K2B in two lymphoblastoid cell line protein lysates was also tested. The protein 
lysates were prepared as section 2.2.9. The gel electrophoresis and immunoblotting 
of the samples was performed as section 2.2.10. Figure 3.21 shows three replicate 
immunoblots of the above described control samples and lymphoblastoid cell line 
samples. Each immunoblot was detected with one of the three PI4K2B antibodies as 
listed in Table 3.4, according to the conditions detailed in section 2.2.10.5.
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Figure 3.21 Quality control of PI4K2B antibodies by Western blot analysis.
Three replicate gels were processed by gel electrophoresis, followed by 
immunoblotting. Each membrane was probed with one of the three antibodies to 
PI4K2B: α PI4K2B Minogue (a), α PI4K2B N-terminal (b), α PI4K2B C-terminal (c). 
There are two positive controls in each panel; i) protein extract from COS-7 cells 
that were transfected with PI4K2B-HA plasmid which was specific to N-terminal 
PI4K2B, labelled “Tfn PI4K2B” and a related negative transfection control labelled 
“Tfn No DNA” and ii) total cell lysate from human HT1080 cells stably expressing 
GFP-PI4K2B, labelled “+ve Ctrl”. There are two protein lysates from lymphoblastoid 
cell lines (LCL), labelled “LCL 49” and “LCL 142” and one protein lysate prepared 
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 A band size of ~55kDa was expected for PI4K2B. Detection by the PI4K2B 
(Minogue) antibody of the first positive control, shown in Figure 3.21a, produced a 
band of greater intensity in the “PI4K2B” transfected sample compared to the “no 
DNA” transfected sample. This was the expected result, of increased PI4K2B 
expression from the PI4K2B transfection control sample. However, a differential 
signal was not detected between the control and the transfected samples, by 
antibodies specific to the N-terminal or C-terminal domain of PI4K2B, in Figure 3.21
b and c. However, a slight band was detected by the N-terminal antibody in the 
“PI4K2B” transfected sample ~50kDa, in Figure 3.21b panel 2.
A band at 60kDa was also detected in two lymphoblastoid cell line protein lysates 
by the three antibodies to PI4K2B, but was barely detected in the lymphoblastoid 
cell line pellet. This shows that the protein lysate preparation extracted PI4K2B from 
the lymphoblastoid cell line sample, which partitioned to the soluble fraction. 
For the second PI4K2B positive control (GFP-PI4K2B), a band of expected size of 
79kDa was only detected by the PI4K2B (Minogue) antibody. Weak, likely non-
specific, bands were detected at ~65kDa, by the N-terminal and C-terminal 
antibodies and at ~55kDa, by the PI4K2B (Minogue) antibody in this positive control 
sample. 
The other, likely non-specific, bands detected by the PI4K2B (Minogue) antibody 
may be explained as follows: the band of ~44kDa detected in the PI4K2B transfected 
sample may be a breakdown product or as a result of translation initiation from 
internal ATG; the lower band at ~40kDa detected in all five samples (except the LCL 
cell pellet sample) may be due to non-specific antibody binding interactions, such as
an unreported novel protein from the same protein family, a different splice variant 
that shares a similar epitope or the PI4K2B antibody epitope may be common to 
another peptide, of a different molecular weight; the band detected at 80kDa may be 
a multimer of PI4K2B protein.
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The three antibodies were also tested for cross-reactivity. Immunoblots were probed 
with either the primary or secondary antibodies only and no signal was detected. 
The aim of this experiment was to identify an antibody that specifically detected 
PI4K2B. It is clear that the PI4K2B (Minogue) antibody was favourable in two 
respects; i) it was the only antibody of the three tested, that efficiently detected 
transfected PI4K2B ii) it correctly detected the positive control signal, GFP-PI4K2B, 
at 79kDa from the cells stably expressing it. Thus, this antibody was chosen to 
quantify PI4K2B expression in lymphoblastoid cell line protein lysates. 
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3.6.3.  PI4K2B protein expression in brain tissue
Although the expression analysis in this study was performed in lymphoblastoid 
cell line samples, it was important to test for PI4K2B expression in brain tissue 
because both bipolar disorder and recurrent major depression are disorders of the 
brain. The expression studies were not conducted in brain tissue as post-mortem 
brain tissues from the family could not be obtained. Figure 3.22 demonstrates that 
PI4K2B protein was detected in neuronal tissue, by the PI4K2B (Minogue) antibody. 
The neuronal tissue samples were a whole brain homogenate sample and a sample 
prepared from SH-SY5Y cells which are human brain neuroblastoma cells (provided 
by Jennifer Chubb, Molecular Medicine Centre, University of Edinburgh). A band of 
~50kDa was detected. This was 5kDa smaller than the species detected in 
lymphoblastoid cell line samples and control transfection samples. This molecular 
weight discrepancy possibly indicates alternate splicing, post-translational 
modification or post-translational cleavage of PI4K2B. Figure 3.22 also has protein 
lysates from the transfected control samples, from lymphoblastoid cell lines and 
from the positive control, with the expected band pattern as previously shown in 
Figure 3.21. No protein signal, including from the GAPDH the loading control, was 
detected in the PBL sample, which may have degraded during processing. The PBL 
sample was included to ascertain whether PI4K2B was expressed in blood cells. 
Additionally, detection of GAPDH, was used as a loading control and is shown 
below the PI4K2B panel in Figure 3.22.
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Figure 3.22 PI4K2B detection in brain tissue. Protein lysates prepared from two 
lymphoblastoid cell lines; 61 and 141, a peripheral blood lymphocyte sample (PBL), 
SH-SY5Y cells and whole brain homogenate were processed by SDS-PAGE 
followed by immunoblotting.  The positive control is human HT1080 cells, stably 
expressing GFP-PI4K2B and the transfection samples with and without PI4K2B 
plasmid DNA are also shown for band size comparison were also processed. The 
immunoblot was probed with the PI4K2B (Minogue) antibody. The loadings were 
controlled by probing with the GAPDH antibody.
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The detection of PI4K2B protein expression in brain tissue in Figure 3.22 was
contrary to other reports. First, a report showed that PI4K2B was not present in the 
brain (Guo, Wenk et al. 2003) and that PI4K2A accounted for the majority of PI4-
kinase activity in the brain. This conflicting result may be due, however, to 
underexposure of Western Blot pictures in the original report. Second, evidence for
PI4K2B protein expression in the brain was not detected by bioinformatic analysis 
performed in this study using the Allen Brain Atlas (Lein, Hawrylycz et al. 2007). 
However, non-detection of protein expression in the Allen Brain Atlas resource may 
be due to experimental variability and should not be considered a definitive 
negative result. 
3.6.4. Optimisation of PI4K2B protein detection technique
The aim of optimising the PI4K2B protein detection technique was to achieve a 
reproducible and quantifiable pattern of protein detection, which would enable 
quantifiable expression analysis in protein lysate preparations from lymphoblastoid 
cell lines. Adjustments were made to every step of the Western blotting procedure 
as listed in Table 3.5.
In brief, the amount of protein loaded into each lane of a gel and the concentration 
of antibody used for detection was optimised. This prevented an excess amount of 
protein masking any detectable difference or an insufficient amount of protein 
escaping detection by antibody. A selection of sample buffers, electrophoresis gels 
and gel-transfer methods were trialled. This improved the appearance of the protein 
detection signal. Gels with more lanes were used, so that all protein lysate samples 
were on the same gel. This reduced the problem of gel to gel variation, which 
occurred when samples were divided into two or more gels. Different blocking 
buffers and antibody diluents were used to minimise signals from non-specific 
binding. In addition, more than one loading control was used, for detection of 
proteins that were constitutively expressed in all tissues at high levels, for example 
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GAPDH, α-tubulin and β-actin.  The use of accurate loading controls was 
imperative for this study to obtain reliable information on any expression level 
changes in PI4K2B. In addition, the loading controls checked that the lanes in the 
gels were evenly loaded with protein lysate sample and that there was even-transfer 
between the gel and membrane across the whole gel. They were used to quantify the 
amount of protein in each lane by using the density of the loading control band to 
correct for differences in loading.  Various detection methods were also tested, such 
as infrared fluorescent detection by the Odyssey Infrared Imaging system that
provides quantification accuracy and simultaneous two colour detection 
(http://www.licor.com/bio/odyssey/). However, this strategy was unsuccessful due 
to the failure of the secondary antibody [IRDye® 800 Conjugated Affinity Purified 
Anti-RABBIT IgG (H&L) (GOAT)] to bind specifically to the PI4K2B primary 
antibody. The final technique for optimised PI4K2B protein detection in 
lymphoblastoid cell line samples by immunoblotting, is listed in Table 3.5 and 
described in section 2.2.9.
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METHOD INITIAL OPTIMISED OUTCOME
Sample preparation
Sample Buffer (0.5M Tris 
pH6.8, 20% Glycerol, 20% 
SDS, H20, bromophenol 
blue)
Protein Sample (Lysate, 1M 
DTT (10%), Sample Buffer 
(2x), H20) 100°C/5 minutes.
Invitrogen LDS Sample 
Buffer (141mM Tris base, 
2%LDS, 10& Glycerol, 
0.51mM EDTA, SERVA Blue, 
Phenol Red, pH8.5) 1M DTT, 
Lysate, H20.
72°C/10 minutes.
Complete lysis, ease of 
loading
Protein concentration 10-15µg 5µg
Sufficient antigen for 
detection but not 
overload
Gel electrophoresis BioRad Invitrogen 4-12% 10/17 well Bis-Tris gels
Clearer bands, 17 wells, 
more reproducible
Well position According to group According to group & random
No difference in 
variability
Gel transfer BioRad semidry & wet Invitrogen wet transfer
Even transfer across 
whole membrane, 
improved consistency 
between gels and 
between lanes within a 
gel.
Gel staining Coomassie Simply Blue
Ensured equal loading 
of gel resulting in 
increased sensitivity
Membrane





greater transfer of 
protein
Blocking agent
5% Marvel in PBS-Tween, 
5% fish gelatine in PBS, 
sodium azide
5% Marvel in PBS
Blocking incubation time 2 hours to 64 hours. 16hours
Blocked non-specific 
binding & reduced 
background signal
Antibody storage Aliquots at -80°C, -20°C, 4°C 0.01% sodium azide
Prolonged effectiveness 
of antibody
Antibody dilution PBS-Tween, 5% Marvel in PBS-Tween PBS-Tween
Avoided cross-reaction 
between blocking agent 
& antibody
Antibody concentration 1:100 – 1:2,500 1:1000 Titrated antibody to optimal concentration
Detection ECL, Odyssey Scanner ECL+
Varying the time that 
the film was exposed to  
membrane 
Densitometry UVITech, Scion Image, ImageJv1.33 ImageJv1.37 User-friendly
Table 3.5 Alterations to immunoblotting procedure for optimised protein 
detection. Each aspect of the immunoblotting (Western blotting) technique was 
optimised. This table is ordered according to the sequence of the Western blotting 
procedure.
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3.6.5. No evidence for a difference in PI4K2B protein 
expression 
PI4K2B protein expression was detected in lymphoblastoid cell lines derived from 
the large Scottish family as listed in Table 3.1. The most informative lymphoblastoid 
cell line protein samples were used and fell into two groups; twelve samples with a 
“linked haplotype” and a psychiatric diagnosis [four with bipolar disorder (29, 47, 
57, 61), four with recurrent major depression (36, 45, 48, 63), four that were well (58, 
69, 73, 89)] and four samples from individuals that were married-in to the family 
with no psychiatric diagnosis (11, 13, 39, 49). Every effort was made to ensure 
consistency between samples: all cell lines were cultured in the same manner, all 
lysates were prepared by the same protocol and all protein concentrations were 
determined at the same time. Figure 3.23a illustrates an example of PI4K2B protein 
expression detected by PI4K2B (Minogue) antibody, in lymphoblastoid cell line 
samples. This procedure was repeated five times under optimised conditions as 
Table 3.5.
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Figure 3.23 No evidence for a PI4K2B protein expression difference between 
linked haplotype carriers and controls. PI4K2B protein expression (a) was 
detected at 55kDa in 5µg protein preparations from lymphoblastoid cell lines 
(Minogue, Anderson et al. 2001). Detection of α-tubulin, β-actin and GAPDH at 
50kDa, 42kDa and 40kDa respectively were used as a loading control. Protein 
expression levels were measured by densitometry (Abramoff 2004). PI4K2B
expression level was normalised against the mean expression level from the protein 
loading controls. The box and whiskers plot (b) shows the five-number summary; 
lower quartile, median, upper quartile, and largest observation of five replicate gels. 
The dark grey bars represent individuals with a linked haplotype and light grey bars 
represent married-in control individuals. 
a)
b)
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Visual inspection of the immunoblots did not suggest a quantitative difference in 
PI4K2B expression between the two groups (linked haplotype and control). 
Therefore, densitometry analysis was performed on the replicate gels for more 
sensitive quantification of protein expression. This technique measured the intensity 
of each band representing PI4K2B expression from each sample on each of the five 
gels. PI4K2B expression was compared to the expression of three loading controls:
α-tubulin, GAPDH and β-actin. The expression levels from the three housekeeping 
genes were correlated within each replicate gel and only used where the correlation 
value was r2>0.9.Figure 3.23 b shows the result of PI4K2B expression corrected for 
loading, for each sample from the five replicate gels by a box and whiskers plot. The 
box-and-whisker plot was a convenient way of graphically depicting groups of 
numerical data through their five-number summaries; the smallest observation, 
lower quartile, median, upper quartile, and largest observation. 
Further statistical analyses were performed on this data. A student T-test, with a 
two-tailed distribution, was used to compare between groups within gels, one-way 
ANOVA (Analysis of Variance) were used to compare between three groups (linked 
haplotype and ill, linked haplotype and well, and controls) within gels and two way 
ANOVA were used to compare between gels. The statistical equations are detailed 
in Appendix B. There was no evidence to suggest a significant difference between 
groups of linked haplotype and controls on five replicate gels (T test; P=0.51, P=0.33, 
P=0.16, P=0.33, P=0.79). In addition, there was no evidence to suggest a difference 
between linked haplotype and ill, linked haplotype and well, and controls groups 
(One way ANOVA; P=0.83, P=0.64, P=0.07, P=0.69, P=0.78). Combining the five 
replicate gels, there was no evidence to suggest a difference within the three groups 
from the five gels (Two way ANOVA; P=0.155).
Another method of quantifying protein expression was to consider only PI4K2B 
expression in the five replicate gels. This avoided using loading controls which may 
be unreliable as some physiological factors can alter expression of these proteins in 
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certain cell types. It also allowed for experimental error that may have occurred 
during the immunoblotting procedure. From the five replicate gels, detection of 
PI4K2B from three gels (gel 2, 4 and 5) correlated well, with a Pearson’s correlation 
coefficient, r2>0.69. Using these three sets of data, the PI4K2B expression of each 
sample was ranked and the position of the rank for each sample in the three gels 
was noted. This avoided using the absolute PI4K2B expression level that may not be 
consistent due to inter-experimental variability. Figure 3.24 shows the rank of 
PI4K2B within each gel for each lymphoblastoid sample. It is evident that the rank 
of each sample correlated well between the three gels. However, there was no 
difference in PI4K2B expression between the three groups of linked haplotype and 
ill, linked haplotype and well and control individuals. 































Gel #2 Gel #5 Gel #4
Figure 3.24 Rank analysis of PI4K2B protein gels. Expression of PI4K2B was 
measured in five replicate gels. The five replicate gels were correlated.  Gel 2, 4 and 
5 correlated well, r2 >0.69. For each sample, the rank of PI4K2B expression in each 
gel was measured and compared between each gel. 
Linked haplotype Controls
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3.7. Discussion
This study of PI4K2B expression levels has shown that there was no evidence to 
suggest a difference in PI4K2B expression in lymphoblastoid cell line samples with 
the “linked haplotype” and those without. This was demonstrated at the allele-
specific level by Taqman assays and at the protein level by quantitative
immunoblotting techniques. One interesting finding from the study was the 
detection of PI4K2B alternate splice isoforms.  Initial bioinformatic analysis at the 
start of this project showed no evidence for alternative splicing of PI4K2B. Over that 
short time period, substantially more information became available on the UCSC 
genome browser, some of which suggested PI4K2B alternative splicing. 
Additionally, PCR amplification techniques confirmed PI4K2B splice isoforms that 
varied in whether they included the exon 2 SNP. 
The caveats pertinent to this expression study were primarily technical. Despite 
every effort to minimise this by rigorous standard protocols, variability may have 
been introduced during cell culture, RNA preparation and cDNA extraction. As one 
of the SNP markers was intronic (rs313548) it may have been preferential to purify 
nuclei to enrich for intronic RNA and then prepare cDNA, as performed in a recent 
study (Gimelbrant, Hutchinson et al. 2007).
Another source of error may be the technique used for allele-specific expression. 
While many researchers use this technique for sensitive detection of allelic 
imbalance, this study has found that many standard curves of gDNA must be 
constructed to be confident of allelic imbalance. One published study only 
generated one standard curve and determined their DNA concentration in a less 
sensitive manner, by the spectrophotometer method. (Maxwell Lee, Personal 
Communication, 26th April 2005, National Cancer Institute, USA) (Lo, Wang et al. 
2003). This study showed that multiple standard curves must be generated and 
shown to be sufficiently similar before the standard curve can be deemed to be 
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reliable. Accurate DNA dilutions are a key factor. The analytical approach in this 
study, to compare heterozygous cDNA samples to gDNA samples, was supported 
by the recent study of the schizophrenia candidate gene, dystrobrevin binding protein 
1 (DTNBP1). Specific susceptibility variants were not defined, but a risk haplotype 
tagged one or more variants that resulted in a relative reduction in DTNBP1 mRNA 
expression in human cerebral cortex, conferring susceptibility to schizophrenia
(Bray, Preece et al. 2005).
Quantification of protein expression was also a technique not amenable for sensitive 
detection. Variability may be introduced at many levels of the immunoblotting 
procedure and so the technique can only be confident of detecting large 
translational effects. The use of loading controls for protein expression was also 
uncertain. In proteomics experiments, the widely-used loading control antibody, 
GAPDH, bound not only to itself, GAPDH, but to three other non-related proteins 
(Dolores Cahill, Personal Communication, 14th May 2007, 2nd Paris Workshop on 
Molecular and Statistical Genomic Epidemiology), casting doubts on its specificity.
An important caveat to this study was the use of lymphoblastoid cell lines. 
Although they supply large amounts of DNA, RNA and protein, it is questionable 
whether they effectively model pathogenic processes in the brain (Gladkevich, 
Kauffman et al. 2004) (Tsuang, Nossova et al. 2005).  Studies have shown that whole 
blood does share significant gene expression similarities with multiple central 
nervous system tissues (Sullivan, Fan et al. 2006). There is also evidence to suggest 
that gene expression profiles and functional effects in blood lymphocytes do 
correlate with psychiatric illness (Gladkevich, Kauffman et al. 2004; Iwamoto, 
Kakiuchi et al. 2004; Vawter, Ferran et al. 2004; Tsuang, Nossova et al. 2005; 
Marazziti, Dell'Osso et al. 2006)
Other drawbacks of lymphoblastoid cell lines are that prolonged culturing of cells is 
known to alter gene expression profiles, while establishment of lymphoblastoid cell 
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lines and culture passage can lead to the appearance of structural genomic variation 
(Simon-Sanchez, Scholz et al. 2007). In theory, these disadvantages could be 
overcome by validating assays in lymphoblasts from fresh blood, in different 
accessible tissue types, such as adipose tissue or in extracts from the same blood 
samples that were used in the immortalisation to lymphoblastoid cell lines. 
However, certainty in the accuracy of allele-specific gene expression would be 
difficult to obtain due to the extreme context-specificity of differential allelic 
expression, as it cannot be assumed that allelic expression is conserved across 
different tissues, or even across different cell types of the same tissue (Wilkins, 
Southam et al. 2007).
An important limitation to this study was the small number of lymphoblastoid 
samples that were heterozygote for two of the three PI4K2B SNPs. This reduced the 
ability of the study to detect expression differences. Future studies should choose 
SNPs based on the maximum number of heterozygotes available or use another 
allele measuring method such as Real-time RT PCR or microarray analysis.
This study was not a complete survey of PI4K2B alternative transcripts, as it was 
only concerned with the markers involved in the expression assay. Further 
investigations may yield evidence of additional PI4K2B transcripts. This may be a 
potentially interesting approach to locate the bipolar disorder susceptibility 
causative factor in the future. To date, susceptibility mediated through splicing 
effects has been reported for bipolar disorder and schizophrenia. One example is in 
the candidate gene, NCAM1, where two SNPs have shown a cis-effect associated
with bipolar disorder. One of the SNPs is within a cluster of alternative exons that 
shows association to decreased expression of secreted splice variants in post-
mortem brain tissue (Atz, Rollins et al. 2007). Another candidate gene, ErbB4 has a 
reported cis-effect in schizophrenia for one SNP in intron 12 and SNPs near exon 3  
that are linked with splicing of exons 16 and 26 respectively, and leads to increased 
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use of exons 16 and 26 and underlies the genetic association of the gene to 
schizophrenia (Law, Kleinman et al. 2007). 
Although there is no difference detected at the allele and protein level for PI4K2B, it 
cannot be implied that there would be no difference at the activity level. A case in 
point is the MDR1 gene product, where a multidrug resistance synonymous SNP 
does not change the coding sequence, but results in altered drug and inhibitor 
interactions. In this case, there were normal mRNA and protein levels, but altered 
conformations which affected the co-translational folding and insertion of P-gp into 
the membrane, thereby altering the structure of substrate and inhibitor interaction 
sites (Kimchi-Sarfaty, Oh et al. 2007). Another example are haplotypes of 
synonymous SNPs in the human Catechol-O-Methyltransferase (COMT) that have a 
regulatory function, stabilising RNA transcripts and decreasing the amount of 
translated protein (Nackley, Shabalina et al. 2006). A third example are synonymous 
mutations in the human dopamine receptor D2 (DRD2) that affect mRNA stability 
and synthesis of the receptor (Duan, Wainwright et al. 2003). However, this level of 
investigation was not a priority for PI4K2B as: “The most striking thing about 
[PI4K2] beta is that it seems to be virtually inactive enzymatically compared to the 
alpha isoform.” (Shane Minogue, Personal Communication, 31st January 2006, 
University College London)
The hypothesis of this study was that there was PI4K2B expression differences 
between chromosome 4p15-p16 linked haplotype carriers and controls that would 
be a cause or consequence of bipolar disorder and recurrent major depression. 
However, the techniques utilised in this expression study did not detect a difference
in PI4K2B expression levels between those with and without the linked haplotype. 
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4. PI4K2B Association Study
4.1. Preface
Before this study, a case-control association study was performed on 362 bipolar 
disorder cases, 383 schizophrenia cases and 444 controls from the Scottish 
population, using 408 haplotype tagging SNPs from chromosome 4p15-p16.  This 
association study identified SNP rs10939038, as a potentially important variant in 
schizophrenia cases (allele P=0.006, odds ratio (OR)=1.314, 95%CI:1.08-1.59)
(Christoforou, Le Hellard et al. 2007). This result was of interest as the marker, 
rs10939038 was located in the same linkage disequilibrium (LD) block as the gene 
PI4K2B, 120kb upstream from the coding region. In addition, PI4K2B was a worthy 
functional candidate gene based on pharmacological theory. PI4K2B is implicated in 
the therapeutic effect of the bipolar disorder drug, lithium, as illustrated in Figure 
1.7. Furthermore, there was prior statistical evidence of linkage and association of 
phosphoinositol genes to bipolar disorder, as discussed in section 1.8.2. Due to the 
strength of the positional and functional evidence for PI4K2B, further study was 
warranted. Other benefits for re-examining the PI4K2B genomic region were the 
increase in the number of variants available on HapMap and the increase in the 
information on the human genome sequence, since the original study. 
The premise of this study was that rs10939038 was in LD with one or more PI4K2B
functional variants that influence susceptibility to disease, justifying further detailed 
association analysis of the region, on the same sample set as the original study. The 
cohort comprised of 362 bipolar disorder cases, 383 schizophrenia cases and 444 
controls and was described in full in section 2.1.1. In brief, diagnoses were made 
according to DSM-IV criteria based on case note review and personal interview 
using SADS-L. Final diagnoses were reached by consensus between two 
experienced psychiatrists. Control subjects were drawn from the same population in 
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South East and South Central Scotland. Genomic DNA was extracted from venous 
blood samples using standard protocols. 
This association study is described below: by first estimating the power of the study, 
then describing the selection of SNP markers to tag predicted haplotypes, 
presenting the results of association analysis at the allele, genotype and haplotype 




It is wise to estimate the power of a study before embarking upon what might be a 
valueless exercise, to determine if a potential benefit can be achieved from the 
study. The power of this study was calculated by estimating the probability of 
rejecting the null hypothesis when the specified alternative hypothesis is true. Here, 
power was investigated as the chance of observing significant association when 
there is true LD between a disease locus and a SNP marker (alternative hypothesis).
The calculation of power depends on the threshold (significance level), the 
underlying model assumptions, the specification of the alternative, the test statistic
and the sample size.
Genetic power calculations were performed on the Genetic Power Calculator 
(Purcell, Cherny et al. 2003), using the “case-control for discrete traits program.”  
Table 4.1 shows the parameters of the tests for multiplicative (allele counts), 
dominant and recessive models. Power was calculated in two respects i) the level of 
power attainable, given the parameters of the study as Table 4.1 and ii) the sample 
size required for 80% power.




Frequency of the high-risk allele 0.1 0.1 0.1
Prevalence of disease 0.01 0.01 0.01
Genotype-relative risks of Aa 2 2 1
Genotype-relative risks of AA 4 2 2
LD (D’) between tested marker and disease allele 1 1 1
Marker allele frequency* 0.1 0.1 0.1
Number of cases 362 362 362
Control:case ratio 1.227 1.227 1.227
Accepted type I error rate 0.05 0.05 0.05
Power to detect a true effect 0.8 0.8 0.8
Table 4.1 Parameters for estimation of power in the case-control association 
study. This table lists the case-control parameters used in the power calculations 
for an association study with 362 cases and 444 controls. The “Genetic Power 
Calculator” (Purcell, Cherny et al. 2003) was used to determine power. *As generally 
assumed, the disease allele equals the marker allele.
The parameters chosen for power calculations were assumptions based on 
population data. It was assumed that the high risk allele frequency for bipolar 
disorder or schizophrenia were typically rare, with a frequency below 10%. The 
lifetime prevalence in the general population for bipolar disorder is 0.5-1.5% (Smith 
and Weissmann 1992) and the lifetime morbid risk in the general population for 
schizophrenia is 1% (Gottesman 1991), so a value of 1% was used. To specify power 
at the test locus, the LD measure was D’=1 and the frequencies of the disease allele 
and the marker allele were equal. This combination, D’=1 and equal allele 
frequencies between the disease and the marker allele, implies an r2=1, ensuring that 
the power to search for the actual disease variant, or any marker in complete LD 
with the disease variant, was calculated. 
Table 4.2 shows the results of the power calculations. The available power was 
estimated for various levels of significance that may be required. These power 
calculations incorporated the sample size in question here and other sample sizes at 
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specified alpha levels (=0.05). The test also assumes that the marker tested is the 
true disease variant.
MULTIPLICATIVE MODEL




















Table 4.2 Power estimations for the PI4K2B association study. The power 
calculations for this association study were performed using the Genetic Power 
Calculator (Purcell, Cherny et al. 2003). Three models were tested. Alpha is the 
required significance level. N is the number of cases required for 80% power.
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The power calculations showed that this study had sufficient cases of bipolar 
disorder (362) and schizophrenia (383) to reach a significance level α=0.01, with 
>93% power for both dominant and multiplicative models but not for a recessive 
model. There was only 9% power to detect a recessive model at a significance level 
α=0.05. An extremely large cohort of over 8,224 individuals would be required to 
detect any variants that would follow a recessive model at a significance level 
α=0.05.
Power calculations are dependent upon the use of correct parameters to model the 
disease. Variation in the frequency of the high-risk allele can change the power of 
the study and the sample size required. For example, if the PI4K2B variant in 
question caused 1% of the disease, and the disease itself had a prevalence of 1%, the 
frequency of the high-risk allele would be 0.01. Using this value for a rare high-risk 
allele, while maintaining the other assumptions regarding the disease as Table 4.1,
power was calculated for the multiplicative model using the Genetic Power 
Calculator. Unsurprisingly, there was little power (9%) to detect a significant result 
( =0.05). Also, a greater number of cases (8,189) would be required to have 80% 
power to detect a result (=0.05). Thus, power calculations were useful to 
investigate the limits of this study, that although there was ample power to detect a 
relatively frequent variant, this power decreases if a very rare variant is the 
causative disease variant.
4.2.2. SNP selection
The SNP selection procedure was described in section 2.5.1.1, the final selection of 
chosen markers are illustrated in Figure 4.1 and listed in Table 4.3.
Figure 4.1 Location of tagging SNPs on linkage disequilibrium map of PI4K2B genomic region. LD map of the SNPs in the genomic region of 
PI4K2B on chromosome 4p15.2 from rs13148169 to rs6448347 (24,745,440bp-24,986,687bp). The locations of the tagging SNPs are marked by 
green stars and their names are marked by the green squares. The blue bar marks the location of SLA/LP (24,799,991bp-24,838,254bp) and the 
orange bar marks the PI4K2B [24,911,944bp-24,956,979bp (UCSC May 2004, NCBI build 35)]. The LD map of the region was defined by solid spine 
of LD (D’>0.8) using HapMap CEU trios downloaded on 7th February 2006, phase II b125. Haplotype blocks were merged at MAD≥0.95. Tagging 
SNPs were then selected to tag the common haplotypes (>5%) within each haplotype block.  The three LD blocks are marked by black lines.  The 
LD map was created using Haploview and shows the pairwise LD statistics for each marker in this region.  The colour scheme is the standard 
Haploview colour scheme: when D’<1, the squares are white for LOD <2 and pink/red for LOD≥ 2, when D’=1, the squares are blue for LOD <2 and 
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The SNPs were chosen from HapMap Data Release 20/Phase II Jan06 (February 
2006). This was an updated version compared with HapMap Release 7 (May 2004), 
which was used in the original study. For this study, the SNPs were selected to 
cover haplotypes frequencies ≥0.05, than the original study which represented 
haplotypes of frequencies ≥0.10. Figure 4.1 shows the three LD blocks surrounding 
PI4K2B and the location of the markers in relation to the PI4K2B genomic region. 
The position of eleven SNP markers is marked by stars on the LD plot of the PI4K2B
region. These markers tag common haplotypes >5% in each of the three haplotype 
blocks. The three LD blocks in the PI4K2B genomic region are evident in Figure 4.1:
block one is 37,944bp long (rs13148169-rs759243, 24,745,440-24,783,384bp), block two 
is 174,202bp (rs6852497-rs10433834, 24,787,656-24,961,858bp) and block three is 
24,505bp (rs12649921-rs6448347, 24,962,182-24,986,687bp) covering a total area of 
236,651bp, which is ~166kbp upstream and ~29kbp downstream of PI4K2B genomic 
region (24,911,943-24,956,979bp; an area of 45,036bp). There was one other RefSeq 
gene (NM_153825) in this region, a soluble liver antigen/liver pancreas antigen 
(SLA/LP), also known as SEPSECS [Sep (O-phosphoserine) tRNA:Sec 
(selenocysteine) tRNA synthase] at 24,799,991bp-24,838,254bp. The function of this 
gene is to convert O-phosphoseryl-tRNA (Sec) to selenocysteinyl-tRNA (Sec) which 
is required for selenoprotein biosynthesis. This may be relevant to the phenotype 
under study, as it has been shown that the main functional sites of selenium in 
mammals are restricted to specific neurons in the brain (Zhang, Zhou et al. 2007). 
However, there was little known about this specific gene apart from a proposed role 
in autoimmune hepatitis (Strassburg and Manns 2002).
Table 4.3 shows the eleven SNPs that tag haplotypes in the PI4K2B region. 











1 rs2324654 24,748,920 1 Illumina SNP 0.5 0.29
2 rs730061 24,754,154 1 Illumina SNP 0.3 0.26
3 rs17408391 24,777,853 1 Taqman SNP 0.52 0.21
4 rs10939038 24,790,933 2 Illumina SNP 0.71 0.47
5 rs3756207 24,809,633 2 Illumina SNP 0.25 0.19
6 rs313548 24,913,660 2 *Taqman SNP 0.57 0.24
7 rs313567 24,930,264 2 *Taqman SNP 0.18 0.17
8 rs6834255 24,955,589 2 *Taqman SNP 0.15 0.17
9 rs1033102 24,971,539 3 Taqman SNP 0.46 0.3
10 rs953305 24,977,611 3 Taqman SNP 0.16 0.42
11 rs13133104 24,986,084 3 Taqman SNP 0.02 0.1
Table 4.3 Marker selection for PI4K2B association study. This is a list of the
eleven SNPs used in the case-control association study. Their physical position is 
according to NCBI build 35 of the May 2004 UCSC genome browser. Their position 
according to the LD blocks relates to Figure 4.1 and the three LD blocks around 
PI4K2B. The note for each marker gives further information; if the marker was 
included in the original study “Illumina SNP”, a newly chosen “Taqman SNP” or a 
SNP used in the allele-specific expression assays in chapter 3 “ *Taqman SNP”. 
The markers tag all haplotypes >5% frequency in HapMap population. The deviation 
from Hardy-Weinberg equilibrium (HWE) and the minor allele frequency (MAF) were 
measured from the Scottish control population (444 individuals).
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Seven of these SNPs were selected specifically for this study and the remaining four 
SNPs were used in the original association study. All of these markers are tagging 
haplotypes. In Table 4.3, if the marker was also used in the expression study as 
described in Chapter 3 they are labelled “*Taqman SNP”. Otherwise the markers are 
labelled “Taqman SNP”, as genotyping the seven extra markers was performed 
using Taqman assays, as explained in section 2.5.1.2. The remaining four markers
are labelled “Illumina SNP” as they were genotyped by Illumina Inc. (San Diego, 
CA, USA), using the high-throughput Bead-Array platform technology, for the 
original study. This genotyping information was included in the association 
analysis. All markers passed the Haploview recommended Hardy-Weinberg 
significance threshold (P =0.001).
Table 4.4 shows the LD between the markers as measured in Haploview from the 
444 individuals in the control population. Both measures of LD are displayed i) the 
r2 values are on upper diagonal of the table and ii) the D’ values are on the lower 
diagonal the table. It is clear that the five markers in LD block 2 are in LD with the 
three markers in LD block 3, D>0.77.
                                            
MARKER RS2324654 RS730061 RS17408391 RS10939038 RS3756207 RS313548 RS313567 RS6834255 RS1033102 RS953305 RS13133104
rs2324654 - 0.12 0.113 0.095 0.073 0.041 0.059 0.058 0.065 0.014 0.01
rs730061 0.93 - 0.082 0.028 0.042 0.067 0.049 0.049 0.041 0.007 0
rs17408391 1 0.949 - 0.178 0.184 0.175 0.17 0.165 0.231 0.127 0.02
rs10939038 0.447 0.274 0.859 - 0.21 0.189 0.169 0.167 0.279 0.49 0.105
rs3756207 0.857 0.728 0.458 1 - 0.55 0.79 0.787 0.45 0.268 0.026
rs313548 0.563 0.801 0.456 0.824 0.86 - 0.627 0.618 0.66 0.355 0.022
rs313567 0.836 0.855 0.48 0.973 0.969 1 - 1 0.462 0.278 0.023
rs6834255 0.836 0.859 0.473 0.972 0.969 1 1 - 0.457 0.277 0.022
rs1033102 0.599 0.539 0.609 0.859 0.899 0.948 1 1 - 0.563 0.029
rs953305 0.215 0.167 0.588 0.873 0.905 0.903 1 1 0.974 - 0.077
rs13133014 0.192 0.019 0.792 0.885 1 0.778 1 1 0.771 0.948 -
Table 4.4 Linkage disequilibrium indices for association study markers. Above the diagonal are r2 values and below the diagonal 
are D’ values. The LD was calculated in Haploview from 444 individuals used in the control cohort for this study. The table is divided by 
dark grey gridlines according to the three LD blocks which were defined by solid spine of LD, D’>0.8 and merged at MAD≥0.95, as 
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4.2.3. Quality control measures
Genotyping error can have an appreciable effect on association results, where 
random genotyping error can reduce the power of an association study and 
systematic genotyping error can falsely attribute association (Hattersley and 
McCarthy 2005). Thus, several measures were undertaken in this study to ensure 
genotyping quality. Initial tests were performed to determine the quality of the 
seven Taqman assays for this study. They were checked for Mendelian segregation 
on 32 proband-patient trios, as described in section 2.1.1.4. . All seven markers 
segregated correctly in all trios. Each Taqman assay output was also visually 
inspected for correct differentiation of three clusters: two outer homozygote clusters 
and one central heterozygote cluster. All but one of the markers clustered into three 
groups. The genotyping assay for rs13133104 had only two clusters; homozygote CC 
and heterozygote CT and may be suspicious, however the genotypes segregated in a 
Mendelian fashion in the 32 trios. After the initial quality control tests, the case-
control DNA, which was randomly divided between four plates to avoid bias in 
genotype calling, were genotyped with seven Taqman SNP assays. The seven SNPs 
were successfully genotyped at an average locus success rate of 95% (range: 89-99%) 
in a total of 1212 individuals (93% sample success rate). The genotyping quality of 
the case-control sample set was checked by two independent people blind to each 
others results. The rs13133104 assay gave three different clusters when the larger 
number of samples was genotyped. Furthermore, duplicates were double-checked 
and one discrepant duplicate was removed and excluded from analysis. Table 4.3
shows that Hardy-Weinberg equilibrium was verified for all markers >0.01 cut-off, 
as another control measure.
4.2.4. Single allele results
Association analysis was performed using standard χ2 test, as shown in Figure 1.3. 
Single marker P-values were obtained for all cases against controls and then cases 
separated by diagnosis against controls. Figure 4.2 shows the single marker P-values 
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for the 11 markers in the PI4K2B region, seven of which were genotyped specifically 
for this study. Figure 4.2 shows there was no association between these seven SNPs 
and bipolar disorder or schizophrenia, or both illnesses combined, P-values>0.05. 
The only significant P-value (P<0.05), was for rs10939038 in the schizophrenia cases. 
This was a repeat association result of the previously reported finding 
(Christoforou, Le Hellard et al. 2007). Analysis performed in this study showed that 
the allelic association to this marker rs10939038 withstood permutation testing with 
1,000 simulations in schizophrenia cases (permutated P= 0.015, standard error (SE) = 
0.0038)











































BP Scz All cases
Figure 4.2 Distribution of single-marker allele P-values in PI4K2B region. The 
x-axis is the chromosome 4 physical position in base pairs (bp) according to the 
human genome map of UCSC May 2004, NCBI build 35. The y-axis is the P-values 
on a –log scale. The results are shown for bipolar disorder (BP), schizophrenia 
(SCZ) and both illness (All cases). The standard significance threshold is indicated 
with a dashed horizontal line at P=0.05. The LD blocks are indicated by a grey 
bracket and labelled by their respective number according to Table 4.3.
LD Block 2 LD Block 3LD Block 1
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4.2.5. Genotype results
Figure 4.3 shows the results at the genotype level. There were two markers 
associated with schizophrenia above the provisional significance threshold ≥ 0.05, 
rs10939038 and rs953305 with P-values 0.025 and 0.038 respectively. The association 
result of rs953305 with schizophrenia was potentially interesting as only PI4K2B lies 
within this LD block, as opposed to the other two LD blocks with SLA/LP and 
PI4K2B. However, rs953305 did not withstand permutation testing with 1,000 
simulations (permuted P=0.069, SE=0.008). Permutation analysis strengthened the
result for rs10939038 with 1,000 simulations (permuted P=0.039, SE=0.006). Thus, the 
association of rs10939038 was further investigated in this study.










































BP SCZ All Cases
Figure 4.3 Distribution of genotype P-values in PI4K2B region. The x-axis is the 
chromosome 4 physical position in base pairs (bp) according to the human genome 
map of UCSC May 2004, NCBI build 35. The y-axis is the P-values on a –log scale 
for each of the eleven markers. The results are separated according to illness, 
bipolar disorder (BP), schizophrenia (SCZ) and both illnesses (All cases). The 
standard significance threshold is indicated with a dashed horizontal line at P=0.05.
LD Block 2 LD Block 3LD Block 1
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4.2.6. Details of significant marker 
Table 4.5 presents further analyses of rs10939038, taking gender and both bipolar 
disorder and schizophrenia diagnoses into account. Analysis by gender was 
justified in bipolar disorder and schizophrenia, as there is reported evidence for 
gender differences in other candidate gene associations; for example a sex-specific 
association between bipolar disorder and the G-protein coupled receptor, GPR50
(Thomson, Wray et al. 2005). From Table 4.5 it is evident that rs10939038 is 
associated with schizophrenia (P=0.006, OR=1.314, 95% CI: 1.08-1.598).  This 
significant result was stronger for male patients with schizophrenia, P=0.009, than 
females, P=0.173.
SNP NAME DIAGNOSIS GENDER ALLELE (%) P-VALUE ORT/C GENOTYPE  (%) TOTAL P-VALUE ORTT/CC


































































(47.3) 62 (16.2) 383 0.025
1.72 (1.15-
2.55)










(50.5) 71 (16.5) 428 0.03
1.75 
(1.11-2.75)











68 (21.4) 317 0.664
1.06 
(0.64-1.76)

















































Table 4.5 Allele and genotype analysis of the significant SNP, rs109390387. The association results are separated by diagnosis, 
bipolar disorder (BP) and schizophrenia (SCZ) and by gender, male (M) and female (F). OR is the odds ratio. CI is the confidence 
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4.2.7. Results of model analysis
Each marker was tested for dominant and recessive inheritance models. The results 
for rs10939038 are shown in Table 4.6. The most significant P-value was the 
dominant model in the schizophrenia group, P=0.022.
Χ² DF P-VALUE
Genotype Counts
Bipolar Disorder 0.56 2 0.756
Schizophrenia 7.347 2 0.025
All cases 2.545 2 0.280
Dominant Model
Bipolar Disorder 0.271 1 0.602
Schizophrenia 5.269 1 0.022
All cases 1.198 1 0.274
Recessive Model
Bipolar Disorder 0.113 1 0.737
Schizophrenia 4.562 1 0.033
All cases 2.129 1 0.145
Table 4.6 rs10939038 results table for different inheritance models. The test 
results for each group compared to the control group are shown. DF is the degrees 
of freedom. P-values ≤0.05 are highlighted in yellow.
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The other markers were also tested. The results are not shown, but there were 
borderline significant association results for markers in LD block 2, rs313567 and 
rs6834255 in the bipolar disorder male group for the recessive model, P=0.04. Also, 
rs953305 in LD block 3 was associated in the schizophrenia group for the dominant 
model (P=0.01). However, these results were borderline significant and may not 
withstand permutation testing. Permutation analysis was not performed due to 
computational restraints, and the results were not considered further.
4.2.8. Association of haplotypes
Association analysis was performed on haplotypes to improve the information 
content of the PI4K2B genomic region (Ott and Rabinowitz 1997; Chapman and 
Wijsman 1998), with an aim to detect chromosomal segments that carry the true 
functional variant. This approach of estimating haplotypes was previously 
successful in identifying APOE predisposing haplotypes despite two obstacles i) 
without genotyping the true disease locus and ii) without positive association from 
the single SNP analysis to Alzheimer’s disease (Fallin, Cohen et al. 2001). In this 
study, the sliding windows analysis was limited to two-SNP haplotypes, separately 
for bipolar disorder and schizophrenia cases, due to computational restraints and to 
minimise the multiple-testing burden. Figure 4.4 illustrates the haplotype analysis of 
the markers in the PI4K2B genomic region with the global P-value, while Figure 4.5
illustrates the best individual P-values. The global test P-value assessed the 
significance of the overall difference in the distribution of haplotype frequencies 
between cases and controls, which was tested using the Likelihood Ratio Test (LRT). 
The P-value from the individual test represented the significance of the difference in 
frequency of an individual haplotype between cases and controls and was based on 
Χ2 test. 












































Figure 4.4 Distribution of global haplotype P-values from two-marker sliding 
window haplotype analysis. The x-axis is the chromosome 4 position according to 
UCSC genome browser, May 04 co-ordinates. The y-axis shows the P-values for 
two-marker sliding windows haplotype analysis using CoCaphase. The provisional 
significance threshold is indicated with a dashed horizontal line at P=0.05. The P-
value for the first two markers was the same for both bipolar disorder and 
schizophrenia and overlap so cannot be seen.
LD Block 2 LD Block 3LD Block 1
Chapter 4 PI4K2B Association Study
212
Figure 4.4 clearly shows two haplotypes from the two marker sliding-window 
analyses, which were above the provisional threshold level, P-value≥0.05. First, the 
haplotype of marker 3, rs17408391, in LD block 1 and marker 4, rs10939038, in LD 
block 2 were determined as significant in the schizophrenia cohort (global P= 0.005, 
permutated global P=0.039, SE:0.006). Second, the haplotype identified was from the 
original data; a two SNP haplotype of markers 4 and 5 in LD block 2; rs10939038 
and rs3756207 with a significant global test (P=0.01) in the schizophrenia cohort. 
Table 4.4 shows that marker 3, rs17408391 and marker 4, rs17408391 were in tight 
LD with each other; D’ 0.859 and also that marker 4, rs17408391 and marker 5, 
rs3756207 were in tight LD with each other; D’ 1.0. However, Table 4.4 also shows 
that markers 3 and markers 5, rs3756207 were not in LD with each other D’ 0.458.












































Figure 4.5 Distribution of individual haplotype P-values from two-marker 
sliding window haplotype analysis. The x-axis is the chromosome 4 position 
according to UCSC genome browser, May 04 co-ordinates. The y-axis shows the P-
values for two-marker sliding windows haplotype analysis using CoCaphase. The 
provisional significance threshold is indicated with a dashed horizontal line at 
P=0.05. 
LD Block 2 LD Block 3LD Block 1
BP SCZ
Chapter 4 PI4K2B Association Study
214
Figure 4.5 clearly shows six haplotypes with individual P-values that were above 
the provisional threshold level, P-value≥0.05. The best individual haplotype was for 
marker 3, rs17408391 in LD block 1 and marker 4, rs10939038 in LD block 2 
(P=0.0007; OR=1.52,1.21-1.91). The next significant haplotype was for neighbouring 
haplotype markers 4 and 5 in LD block 2; rs10939038 and rs3756207 (P=0.004; 
OR=1.41, 1.13-1.75). These corresponded to the significant global haplotypes 
reported in Figure 4.4. 
The other four individual P-values ≥0.05 were as follows;  for markers 5 (rs3756207) 
and 6 (rs313548) in LD block 2  (P=0.05, OR=1.45; 95%CI: 1.00-2.11); for markers 6 
(rs313548) and 7(rs313567) in LD block 2  (P=0.04, OR=1.46; 95%CI: 1.01-2.10); for 
markers 9 (rs1033102) and 10 (rs953305) in LD block (P=0.04); for markers 10 
(rs953305) and 11 (rs13133104) in LD block 3  (P=0.03, OR=0.81; 95%CI: 0.65-1.01). 
The most significant haplotype for markers 9 and 10 was very rare (frequency <0.5% 
in both cases and controls). Odds ratios were not estimated for this haplotype as 
they are unreliable for rare haplotypes.
4.3. Discussion
This study successfully reported that increasing marker coverage in the PI4K2B
region identified another significant haplotype, which showed greater significance 
than the original study and importantly, withstood permutation testing. 
It is worth noting that the information on the human genome and the 
understanding of association studies have improved greatly and continue to do so. 
The association results reported here could reflect association to any feature within 
the large >240kb genomic region investigated; such as either RefSeq gene SLA/LP or 
PI4K2B or any predicted, but yet confirmed gene or in fact, any regulatory or control 
region. The single marker that is significantly associated with schizophrenia, 
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rs10939038 is not located in a gene. It is, however, 1,614bp upstream of a human 
spliced EST isolated from adult cerebellum (AA323552), which potentially could be 
an alternative 5’ UTR for SLA/LP. Upon analysis of the genomic region on the UCSC 
genome browser (Kent, Sugnet et al. 2002), there was no evidence to suggest the 
SNP is involved in gene regulation as it was not in an area of cross-species 
conservation or regulatory potential area. Although, chromosome 4p15-16 is a hot-
spot for copy number variation, as will be discussed in section 6.5, there was no 
evidence for copy number variation or structural variation in the associated region. 
The other chromosome 4p15.2 marker, rs953305 is located within a human spliced 
EST isolated from adult testis (DB523474). It is also in an area of cross-species 
conservation with monkey, mouse, dog and horse sequence. The marker is >20kb 
downstream of PI4K2B and >13kb upstream of ZCCHC4 (zinc finger CCHC domain 
containing 4). Marker rs17408391, is also located outside of any gene coding region. 
The nearest unspliced EST which was isolated from human fetal liver spleen tissue 
(H54394), is 3,858bp away. It is in a highly conserved region, as illustrated by the 
“Vertebrate Multiz Alignment and Conservation” track on the UCSC genome 
browser. It shows sequence conservation with the rabbit, dog, armadillo, elephant 
and opossum but not with the mouse, rat, chicken or frog sequence. The other 
marker that is significant in the haplotype analysis, rs3756207, is located in intron 3 
of the SLA/LP gene. This marker is also in a highly conserved region with respect to 
rabbit, dog, armadillo, elephant and opossum sequence but not to mouse, rat, 
chicken or frog sequence. 
The significant result for association between rs10939038 and schizophrenia may be 
due to one of three possibilities; i) direct association, where the SNP allele directly 
affects the disease risk ii) indirect association, where rs10939038 is in LD with the 
true functional disease mutation or iii) spurious due to population stratification or 
random chance. Firstly, it is highly unlikely that direct association is involved, as 
bioinformatic analysis showed that the marker does not have any structural features 
to suggest such a role. 
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Secondly, the result may be spurious due to genotyping error or population sub-
structure. Indeed, genotyping error is a possibility which unfortunately cannot be 
tested comprehensively in a population study. The genotyping appears to have been 
robust as the average genotyping success rate was 95%. The success rate for 
rs17408391 was 98% and the average locus success rate was 95%. Duplication of the 
genotyping by another method would exclude this possibility. 
In addition, presence of population sub-structure can be problematic. Population 
stratification is due to difference in genotypes between cases and controls reflecting 
their population origin, not their disease status. Population stratification can only 
arise if different proportions of cases/controls are from each population and if 
populations differ in SNP allele frequency. There are many ways to deal with 
population stratification, for example genomic control (Devlin and Roeder 1999), 
structured association (Pritchard, Stephens et al. 2000) or to analyse by geographic 
origin (Clayton, Walker et al. 2005). Although the control group was matched 
carefully to have the same geographical background as the case group, hidden 
population sub-structure or relatedness may still be present. Initial studies on the 
control population using the structured association approach showed no evidence 
of population stratification in the control group, discussed in (Christoforou, Le 
Hellard et al. 2007). 
Finally, indirect association is possible. Figure 4.6 illustrates the proposed idea that 
the three markers, rs17408391, rs10939038 and rs3756207 are in fact, in LD with the 
actual functional variant, labelled in pink. Figure 4.6 also depicts the results of the 
individual haplotypes from 2-marker sliding window haplotype analysis for the 
significant SNPs. 
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Figure 4.6 Hypothesised indirect association of schizophrenia susceptibility 
variant. Results of the individual haplotypes from 2-marker sliding window 
haplotype analysis are shown for the significant markers. The odds ratio (OR), 95% 
confidence interval (CI) and the Χ2 P-value are listed.
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The indirect association result can be explained in two ways i) although the markers 
are not physically close to the candidate gene PI4K2B, markers rs10939038 and 
rs3756207 are in the same haplotype block and ii) despite the lack of association in 
bipolar disorder cases, association cannot be ruled out as there may have been a lack 
of power or differences in haplotype frequencies of the actual functional variant in 
the bipolar disorder cases. In the past, examination of haplotype information and 
LD in a region have confirmed association between the APOE locus and 
Alzheimer’s disease, without testing the actual E4 polymorphism (Fallin, Cohen et 
al. 2001). 
A particular caveat to this study is multiple testing. This study tested association at 
the gender, phenotype, allele, genotype and haplotype level. The significant 
association result was examined with respect to the gender of the cases and controls, 
as there is reported evidence for gender differences in candidate gene studies 
(Thomson, Wray et al. 2005) and in the age-of-onset, symptoms and treatment of 
both illnesses (Holden 2005).
To confirm an association, replication is highly recommended. A follow-up case-
control association study was performed by others, from a total of 391 schizophrenia 
cases, 397 bipolar disorder cases and 397 controls in the German population, with 
the aim of replicating the positive association findings on chromosome 4p15-p16 
(Christoforou et al., unpublished). There were over 300 SNPs chosen that tagged 
significant haplotypes in the Scottish population for the replication study. Of these 
SNPs, four of them cover the PI4K2B genomic region; SNP number 1, 2, 4 and 5 
according to Table 4.3 which are rs2324654, rs730061, rs10939038 and rs3756207. 
However, the significant marker for this study, rs10939038, was not found to be 
associated with schizophrenia in the German population (allele P=0.55, OR 1.18, 95% 
CI 0.79-1.77). Furthermore, there was no evidence for association, P-value <0.01, of 
any of these four markers with bipolar disorder or schizophrenia in this German 
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population, when testing for gender as a covariate and different inheritance 
patterns. This implies that the significant association reported here in the Scottish 
population is less likely to be real.
Although there was no replication of association in the German population and 
association does not rank highly with the other chromosome 4p15-16 results 
described in section 1.4.3, the result should not be completely discarded. Replication 
should be attempted in a different population, preferably one of Celtic origin.
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5. Design and Preparation for Linkage Study
5.1. Preface    
Appropriate design of a linkage study is essential to achieve meaningful results. In 
short, the genome must be comprehensively covered with informative markers, the 
family structure must be conducive for linkage and optimal linkage analysis 
methods are imperative to maximise the chance of detecting genetic risk variants.
To achieve this, three steps were taken. First, although in theory a large pedigree is 
ideal for linkage analysis (Clerget-Darpoux and Elston 2007), computation analysis 
is demanding and the capacity to handle very large families is limited. The family, 
as described in section 1.6, was therefore sub-divided in an informative manner. 
Second, careful error checking of genotype data is essential to prevent misleading 
results. There are many sources of error that can be encountered in a family-based 
linkage study, including errors in diagnoses, gender specification, marker allele 
frequencies, map order, map distances, genotype calling, DNA quality and family 
relationships. In this study, several approaches were employed to detect and resolve 
errors that can lead to misleading inferences about marker inheritance, haplotype 
frequencies and inflate genetic map length (reviewed in (Pompanon, Bonin et al. 
2005). In addition, pedigree structure errors were investigated and resolved. Finally, 
simulations were performed to estimate the threshold required to report suggestive 
and significant linkage results. The methods used to optimise the linkage study 
design, to perform the error checking and to validate the genotyping data are 
detailed below, with the aim to provide an optimal environment for linkage 
analysis.
5.1.1. Study design
In the initial stages of study design the genotyping platform, the marker panel and 
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the sample selection were surveyed. The Linkage IVb Panel from Illumina was 
chosen for three reasons, i) high genotyping quality at a level of 99.9% 
reproducibility and genotyping call rate 99.8% (Murray, Oliphant et al. 2004), ii) the 
6,008 SNP panel was informative for linkage analysis as the average genetic map 
spacing is 0.64cM, the average genotyping information content is 97.1%, the average 
minor allele frequency in the Caucasian population is 37% and the average 
heterozygosity is 43% (Murray, Oliphant et al. 2004) and iii) the panel has shown 
previous linkage analysis successes  in complex disease (Amos, Chen et al. 2006). 
The genotyping was performed using a GoldenGate Assay on an Illumina 
BeadStation platform, which requires a 96-well plate configuration. Cost 
considerations, therefore, limited the number of samples to 96 in this study. The 96
family samples were chosen by a number of criteria: to maximise the linkage 
information, to cover all branches of the pedigree, to include all affected individuals, 
DNA availability and to include a replicate sample of whole genome amplified and 
genomic DNA. Thus, 95 individuals from the family were genotyped with 6,008 
SNPs from the Illumina Linkage IVb Panel.
Technical replicates are often included in large-scale genotyping experiments. These 
replicates are the same sample, included multiple times in the same experiment, to 
test variability in the experiment.  However, technical replicates were not included 
in this linkage study. Instead, as this was a family study, errors could be easily 
detected by checking for deviation from Mendelian inheritance. Furthermore, 
Illumina have internal control measures that show confidence in their genotyping 
reproducibility at 99.9% and a low rate of Mendelian inconsistencies at 0.007%
(Murray, Oliphant et al. 2004). Nevertheless, a replicate sample with genomic and 
whole genome amplified DNA was included as a test of reliability of amplification.
No formal calculations of power were performed for this study due to 
computational burden and family complexity. However, the original detection of 
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linkage using microsatellite markers proves the ability of the pedigree to generate a 
significant LOD score and was an a priori reason to reinvestigate this family for 
linkage (Blackwood, He et al. 1996). An increase in the number of affected 
individuals available for linkage analysis and the comprehensive coverage of the 
genome by the Illumina IVb Linkage Panel should increase the power of this 
analysis, in comparison with the first study (Evans and Cardon 2004).
5.2. Pedigree Preparation
5.2.1. Phenotype definition
Linkage analysis was performed under two definitions of the phenotype i) a narrow 
phenotype model that included only individuals with bipolar I disorder and bipolar 
II disorder as “affected” and ii) a broad model that included individuals with 
bipolar I and II disorder and recurrent major depression. Individuals with a 
diagnosis of single episode depression, anxiety or alcoholism, or individuals with 
potential bilineal inherited illness were coded as unknown for linkage analysis. 
Thus, there were 12 individuals with bipolar disorder in the narrow phenotype 
category and 35 individuals (12 bipolar disorder and 23 recurrent major depression) 
in the broad phenotype category available for linkage analysis, as described in Table 
1.5. 
5.2.2. Splitting the pedigree
A clear advantage of this project was the availability of a large family. Software such 
as Simwalk2, that can perform linkage analysis on large pedigrees, was very slow 
and limited to a very small number of markers. The size restriction for the highly 
regarded MERLIN programme was (2n-f≤20, where n was the number of 
individuals in the pedigree and f was the number of founders). The large pedigree 
exceeded the size restriction; 2*180–52 = 308 and was thus computationally complex.
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In order to overcome this calculation burden and simultaneously maintain the 
useful information for linkage mapping, the family was split in a well-defined 
manner. This method was preferable to splitting the family by eye, which can be an 
arbitrary approach that may impact on power (Dyer, Blangero et al. 2001; Bourgain 
and Genin 2005). Sub-pedigrees were, therefore, extracted using GREFFA (Genetic 
Relationship Explorer for Familiality Aggregation) (Falchi, Forabosco et al. 2004).
GREFFA clustered individuals using pair-wise kinship coefficients, partitioned the 
individuals into optimal sub-groups and reconstructed the sub-pedigrees of each 
sub-group. To extract the optimal sub-pedigrees, the pairwise kinship coefficient 
chosen was the level of first-cousin relationship 1/16 (0.0625) and the maximum 
number of individuals was the limit for MERLIN analysis, <20, as described in 
section 2.5.4. This approach extracted one large informative family and five others, 
depicted in Figure 5.1.
Figure 5.1 Sub-pedigrees. Sub-pedigrees from the main family were extracted using GREFFA software. The most informative sub-
pedigree is highlighted in pink, and the other GREFFA extracted pedigrees are highlighted in blue. Further sub-pedigrees highlighted in 
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The most informative sub-pedigree is reproduced again in Figure 5.2. The other sub-
pedigrees extracted by GREFFA were illustrated from Figure 5.3 to Figure 5.7. As 
there was genotyping information available for other members, three further sub-
pedigrees were manually added, giving a total of nine sub-pedigrees. The additional 
three sub-pedigrees are shown from Figure 5.8 to Figure 5.10.  To provide phase 
information, it was sometimes necessary to include affected individuals in more 
than one sub-pedigree. This was the case for three samples with bipolar disorder 
diagnoses: sample 21 in sub-pedigrees 1 and 7, sample 29 in sub-pedigrees 1 and 8 
and sample 102 was in sub-pedigrees 4 and 6 and for five samples with recurrent 
major diagnoses: sample 44 and 63 in sub-pedigrees 1 and 2, sample 17 and 19 in 
sub-pedigrees 1 and 7 and sample 34 in sub-pedigrees 1 and 8. In order to avoid 
bias, the affection status for individuals in more than one sub-pedigree was set to 
unknown in every subsequent pedigree, and thus the individuals were not 
considered more than once for linkage analysis. 
Chapter 5 Design & Preparation for Linkage Study
228
=Genotyped on Illumina Linkage IVb Panel =Bipolar Disorder = Recurrent Major Depression
Figure 5.2 Sub-pedigree 1. This is the most informative pedigree for linkage 
analysis under both the broad and narrow phenotypic model. Samples 21, 29, 34, 
44 and 63 overlap with other sub-pedigrees.
=Genotyped on Illumina Linkage IVb Panel =Bipolar Disorder  = Recurrent Major Depression
Figure 5.3 Sub-pedigree 2. This pedigree is informative for linkage analysis under 
the broad phenotypic model. Samples 44 and 63 overlap with sub-pedigree 1.
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=Genotyped on Illumina Linkage IVb Panel =Bipolar Disorder = Recurrent Major Depression
Figure 5.4 Sub-pedigree 3. This pedigree is informative for linkage analysis under 
the broad phenotypic model.
=Genotyped on Illumina Linkage IVb Panel =Bipolar Disorder = Recurrent Major Depression
Figure 5.5  Sub-pedigree 4. This pedigree is informative for linkage analysis under 
the broad and narrow phenotypic model. Sample 102 overlaps with sub-pedigree 6.
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=Genotyped on Illumina Linkage IVb Panel =Bipolar Disorder = Recurrent Major Depression
Figure 5.6 Sub-pedigree 5. This pedigree is informative for linkage analysis under 
the broad phenotypic model. 
=Genotyped on Illumina Linkage IVb Panel =Bipolar Disorder = Recurrent Major Depression
Figure 5.7 Sub-pedigree 6. This pedigree is informative for linkage under the broad 
phenotypic model. Sample 102 overlaps with sub-pedigree 4.
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=Genotyped on Illumina Linkage IVb Panel =Bipolar Disorder = Recurrent Major Depression
Figure 5.8 Sub-pedigree 7. Samples 17 and 21 overlap with sub-pedigree 1.
=Genotyped on Illumina Linkage IVb Panel =Bipolar Disorder = Recurrent Major Depression
Figure 5.9 Sub-pedigree 8. Samples 29 and 34 overlap with sub-pedigree 1.
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=Genotyped on Illumina Linkage IVb Panel =Bipolar Disorder = Recurrent Major Depression
Figure 5.10 Sub-pedigree 9. This pedigree is informative for linkage analysis on the 
broad phenotypic model.
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5.3. Quality Control of Whole Genome Amplified DNA
5.3.1. Preface
Certain genomic DNA samples were subjected to whole genome amplification for 
the purpose of the linkage study and for future use. There were three important 
reasons to preserve these DNAs i) firstly, there was only a small quantity of DNA 
remaining, which would limit future experiments ii) secondly, the DNA was old, 
degraded and would benefit from preservation and iii) finally, certain DNA samples 
were from individuals now deceased. An established method to amplify DNA is 
whole genome amplification (Hosono, Faruqi et al. 2003). The amplification method 
used was based on multiple displacement amplification technology, which 
performed isothermal genome amplification utilizing a processive DNA polymerase 
capable of replicating up to 100kb without dissociating from the genome DNA 
template. The DNA polymerase had a 3’ to 5’ exonuclease proofreading activity to 
maintain high fidelity during replication and was used in the presence of 
exonuclease-resistant primers to achieve high yields of DNA product. This method 
was previously shown to provide highly uniform DNA amplification across the 
entire genome, with minimal sequence bias (Hosono, Faruqi et al. 2003). 
5.3.2. Whole genome amplification results
Whole genome amplification of DNA from two samples (samples 37 and 44) was 
attempted using the Qiagen REPLI-g Midi Kit, as described in section 2.2.6, in 
duplicate for each sample from different aliquots. Each amplification reaction was 
performed in duplicate, so there were four amplification samples for each 
individual. The duplication was important as any stochastic bias in amplification in 
one sample could be overcome by combining the two samples. The starting material 
is detailed in Table 5.1. The starting material was older than ten years, were either
apparently empty tubes or had a volume less than 2µl remaining.
Microsatellite Markers
Original [DNA] DNA remaining  WGA [DNA] Yield Chr1 Chr4p15-16
WGA Sample Agarose Gel Volume Agarose Gel Picogreen ug Successful PCR Successful Genotype Successful PCR Successful Genotype
37a #1 <100ng/µl 5/5 Yes 4/4 Yes
37a #2 >500ng/µl (smear) ~2µl <100ng/µl 211ng/µl 11 5/5 Yes 4/4 Yes
37b #1 5ng/µl ~2µl <100ng/µl 212ng/µl 11 5/5 Yes 4/4 Yes
37b #2 <100ng/µl 157ng/µl 8 5/5 Yes 4/4 Yes
Positive Ctrl (29) 151ng/µl 5/5 No 5/5 Yes
Positive Ctrl (34) 5ng/µl 126ng/µl 5/5 Yes 4/4 Yes
44a #1 5ng/µl ~2.5µl 100ng/µl 212ng/µl None No 1/4 Yes
44a #2 100ng/µl 219ng/µl None No 1/4 Yes
44b #1 10ng/µl ~1µl 100ng/µl 40ng/µl None No 0/4 No
44b #2 100ng/µl None No 0/4 No
44a 5ng/µl ~2.5µl 75ng/µl None No 2/5 No
44b 10ng/µl ~1µl 75ng/µl 207ng/µl None No 2/5 No
Negative Ctrl 100ng/µl None No None No
Negative Ctrl 75ng/µl None No None No
Table 5.1 Quantification and genotyping results for whole genome amplified (WGA) samples. The amplification of three DNA 
samples was attempted: 37 and 44. There were two genomic DNA samples, a and b, amplified with two replicates, 1 and 2. Positive 
controls of good-quality genomic DNA and negative controls of dH2O were included in the experiment. The DNA concentration was 
determined by agarose gel electrophoresis for the original DNA sample and also by picogreen for the WGA DNA.  Microsatellite markers 
were genotyped to determine the integrity of the DNA. The success of the PCR amplification step and genotyping step is shown for each 
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One sample was successfully whole genome amplified, as determined by DNA 
qualitative and quantitative analysis, supplemented by microsatellite genotyping. 
One sample, 44, did not amplify successfully. The quality of the DNA was assessed 
by agarose gel electrophoresis and the DNA yield was determined by picogreen 
analysis. The details of the DNA quantification and genotyping of the samples and 
replicates are also in Table 5.1. These quality controls tests were important factors in 
ensuring optimal DNA for downstream procedures.
Firstly, the initial quantification of the DNA was performed by agarose gel 
electrophoresis as shown in Figure 5.11. The concentration of the DNA can be 
estimated by comparing it to the λHindIII marker. The whole genome amplified 
DNA concentration ranged from 75ng to 200ng. The DNA concentration was also 
estimated by picogreen reagent and gave similar results. There was evidence of a 
band in the negative control for whole genome amplification in Figure 5.11. 
However, PCR amplification of this non-template control was unsuccessful. This 
may be DNA generated during REPLI-g reaction by random extension of primer 
dimers and should not effect the quality of actual samples or downstream assays 
(www.qiagen.com).
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Figure 5.11 Agarose gel of whole genome amplified products to quantify DNA. 
The amplification products of samples 37 and 44 are shown in (a) and a repeated 
attempt for sample 44 in (b). 1µl of a 1/10 dilution of the WGA DNA was run on a 
0.8% agarose gel stained with EtBr for 5 minutes at 40V. λHindIII is a marker for 
comparison to estimate the DNA concentration. There were two genomic samples 
for WGA from each individual, labelled A and B. Each was amplified in duplicate, 
labelled 1 and 2. The positive controls (+ve) were amplification of lymphoblastoid 
cell line sample 34 on gel A and 29 on gel B. The non-template control (-ve) was 
water. N/A means non-applicable and does not pertain to this study. Gel B shows 
the repeat amplification attempt for sample 44 by encouraging the remaining DNA in 
the eppendorf to dissolve at 65°C for 1 hour.
B
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Secondly, the quality of the whole genome amplified DNA was assessed by running 
the agarose gel for a longer time as shown in Figure 5.12. All samples had the 
expected genomic DNA band 10kb-12kb. There was smearing in all samples which 
indicated DNA degradation and/or shearing but as the bulk of DNA was >10kb it 
was sufficient quality for use. The yield for the successfully amplified samples 
ranged from 8-11µg. The manufacturers quoted an expected yield of 40µg
(www.qiagen.com), however starting DNA quality may have been a factor in the 
reduced yield for these samples.
It was not surprising that the genomic DNA aliquots for sample 44, as shown in 
Figure 5.12a, and the repeated attempt at DNA dissolution as shown in Figure 5.12b 
did not amplify. The recommended starting genomic DNA fragment size was 2kb to 
an optimal 10kb (www.qiagen.com), which was not evident in sample 44, Figure
5.12a. Also, the genomic DNA was low in quantity and thus did not serve as a good 
template for amplification.
Figure 5.12 Agarose gel of whole genome amplified products to determine DNA quality. The amplification products of samples 
37 and 44 are shown in (a) and a repeated attempt for sample 44 in (b).1µl of a 1/10 dilution of the WGA DNA was run on a 0.8% 
agarose gel stained with EtBr at 40V for 5 minutes, then 80V for 45 minutes (picture A) and 70 minutes (picture B) at 40V. The 
numbers correspond to ID numbers. There were two genomic samples for WGA from each individual labelled A and B. Each was 
amplified in duplicate, labelled 1 and 2. The positive controls (+ve) were lymphoblastoid cell line sample 34 on gel A and 29 on gel B. 
The non-template control (-ve) was water. N/A are samples that do not pertain to this study. Gel B shows the repeat amplification 
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A further test of whole genome amplified DNA integrity was microsatellite 
genotyping, as described in section 2.2.5.1. Successful and correct genotyping of 
polymorphic microsatellites, in all replicates, would lend credence to the whole 
genome amplification procedure and downstream use of the amplified DNA. The 
samples were thus genotyped with 11 microsatellite markers from chromosome 1 
and chromosome 4. 
The microsatellite genotyping results are shown in Table 5.1 and detailed in Table
5.2, showing successful genotyping for sample 37. Importantly, the genotyping 
matched between all replicate whole genome amplified DNA samples. For further 
confirmation, there were extra layers of genotype checking. The genotyping 
matched between genomic and whole genome amplified DNA for sample 37 on 
four microsatellites, D4S1533, stb131K9, D4S1609 and D4S2408, where data was 
available for both samples. Family members of sample 37, were also genotyped, and 
Mendelian segregation patterns were observed. The genotyping results were also 
checked from previous studies. An important final check was that nine of the 
microsatellite markers were heterozygous which would have allowed detection of 
allelic dropout if present. Crucially, the genotyping results matched between 
different samples, replicates, segregation patterns and previous known results.
Thus, there was no allelic drop-out observed and these results were sufficient to 
include the whole genome amplified samples in the linkage study.
D1S439 D1S103 D1S225 D1S229 D1S1621 D4S1599 D4S1533 STB131K9 D4S1609 D4S2408 D4S1546
Sample 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2
37a #1 249 251 77 89 124 124 196 196 163 169 F F 186 194 325 329 166 174 NA NA NA NA
37a #2 249 251 77 89 124 124 196 196 163 169 NA NA 186 194 325 329 166 174 NA NA NA NA
37b #1 249 251 77 89 124 124 196 196 163 169 NA NA 186 194 325 329 166 174 NA NA NA NA
37b #2 249 251 77 89 124 124 196 196 163 169 NA NA 186 194 325 ? 166 174 NA NA NA NA
37stock gDNA NA NA NA NA NA NA NA NA NA NA 150 154 186 194 325 329 F F 270 274 NA NA
37 diluted gDNA NA NA NA NA NA NA NA NA NA NA 150 154 186 194 325 329 166 174 270 274 NA NA
Key: F=Failed at genotyping, NA = Not attempted, ? = ambiguous results
Table 5.2 Genotyping results microsatellite markers on whole genome amplified DNA samples and genomic DNA samples. 
Samples 37 were successfully whole genome amplified. The samples were tested for genotyping accuracy by comparing results to 
replicate samples and other genomic DNA samples from the same individual. Eleven microsatellite markers were genotyped, five from 
chromosome 1 and six from chromsome 4. The genotyping matched between all replicate WGA DNA samples. The genotyping also 
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5.4. Metrics of Illumina Linkage IVb Mapping Panel 
For this study, 96 samples were genotyped on 6,008 SNPs from the Illumina Linkage 
IVb Panel. All samples were from 95 individuals in a large Scottish family. One of 
the samples was a whole-genome amplified replicate (sample 37). Measurements 
pertaining to the Illumina Linkage IVb Panel genotyping on the large Scottish 
family were detailed below.
5.4.1. Genotyping call rate success
The average genotyping success rate was 95%, which is lower than the expected rate 
of 99.8% published by Illumina (Murray, Oliphant et al. 2004) for the Linkage IVb 
Mapping Panel. The average percentage of missing genotypes per chromosome is 
shown in Figure 5.13 by the green line. Genotyping failed in samples 12, 15 and 19 
for >20% of markers and samples 25, 35 and 40 for > 30% of markers. The DNA from 
sample 83 failed for 55% of markers. This level of genotyping failure possibly 
indicates poor DNA sample quality or quantity. Upon further investigation it was 
found that the genotyping failures were specific to the primer mix from Illumina, 
named OPA (oligo pool all); sample 83 failed with OPA 6561, sample 25, 35, 40, 83 
failed with OPA 6562 and sample 12, 15, 19 failed with OPA 6564. Thus, poor OPA 
and DNA quality are the probable reasons for the missing genotypes. The 
genotyping results for sample 83 were removed from the linkage data. The other 
samples were included in the linkage analysis, as the genotyping failure was OPA 
specific. To ensure the accuracy of the genotypes, tests were carried out on the 
markers to check for Mendelian inheritance and Hardy-Weinberg equilibrium 
(HWE).



























WGA 37 gDNA 37 Average
Figure 5.13 Comparison of missing genotypes per chromosome, for 
individuals genotyped on the Illumina Linkage IVb Panel. The x-axis is the 
chromosome number; 1-22 are autosomes, 23-25 are X, XY and Y respectively. The 
y-axis shows the amount of missing data, which was calculated as a percentage of 
total genotyping performed for each sample that was genotyped on the Illumina 
Linkage IVb Panel. The whole genome amplified DNA sample is in pink (37). The 
results for 37 genotyped on genomic DNA are in blue. The average amount of 
missing data from all 96 samples is shown by the orange line. 
5.4.2. Reproducibility success of genomic DNA
From relationship analysis, as explained in section 5.5, there was evidence for a 
sample duplication of individual 97. The DNA aliquot labelled 105 was in fact, from 
sample 97. Analysis of the 3,998 markers that genotyped successfully for both 
samples showed that the data matched exactly and correlated significantly at the 
0.01 level, Pearson Correlation Significance (2-tailed) 1.000. This coincides with 
Illuminas published level of reproducibility of 99.6% (Murray, Oliphant et al. 2004)
for the Linkage IVb Mapping Panel.
5.4.3. Success of whole genome amplified DNA
As described in section 5.3.2, one sample (37) was successfully whole genome 
amplified and genotyped in the linkage study. A genomic DNA sample of 37 was 
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also genotyped to provide a duplicate data set. Table 5.4 shows that the three 
samples were genotyped successfully. Investigation of sample 37 genotyping results 
was performed by checking the correlation between the genomic and whole genome 







rs7559853 2 GG AG
rs1260658 6 AA AG
rs733342 17 AA AG
Table 5.3 Mismatch genotyping between a duplicate sample of genomic and 
whole genome amplified DNA. There were three mismatch genotypes between 37 
genomic and whole genome amplified (WGA) replicates. The total number of 
successful genotyping between both DNA samples was 5,304 SNPs.
The error rate per locus for sample 37 was 0.057%, calculated as shown in Appendix 
A, using an established method (Pompanon, Bonin et al. 2005). Under the 
assumption that the genotypes for genomic DNA were correct, it was interesting to 
note that the amplified DNA genotypes were called heterozygous but were in fact 
homozygous SNPs. The over-representation of heterozygous erroneous calls have 
been found by others to be a side-effect of the Illumina clustering algorithm 
(Personal Communication, Simon Heath, CNG, France, 23rd July 2006). Due to this 
prior reason, the cluster plots from the Illumina BeadStudio were examined for 
these three SNPs, and in fact, the whole genome amplified samples were outside of 
the majority of clustered genotyping and their genotypes were changed to 
unknown. The genotypes for the genomic DNA samples were positioned in the 
middle of the homozygote clusters. However, as it was not feasible to re-score all 
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SNPs it cannot be said that there was complete concordance between the whole 
genome amplified DNA and the genomic DNA. Nevertheless, the error rate per 
locus of 0.057% is low.
The genotyping call-rate for the whole genome amplified samples matched the 
genomic DNA samples. Table 5.4 shows the level of successful genotyping. 
SAMPLE % SUCCESSFUL GENOTYPING
All samples (average) 93
37 (genomic DNA) 94
37 (WGA DNA) 89
Table 5.4 Whole genome amplified products were successfully genotyped on 
the Illumina Linkage IVb Panel. The level of genotyping success for 6,008 SNPs 
on the Illumina Linkage IVb Panel was calculated for all samples, including whole 
genome amplified (WGA) samples on all autosomes and sex chromosomes. 
This can also be seen in Figure 5.13. Sample 37 has a lower than average success rate 
of 89% and it is clear from Figure 5.13 that many missing genotypes originate from 
chromosomes 16, 17, 19 and 22. There are three possible reasons for the greater 
missing genotypes on chromosomes 16, 17, 19 and 22: i) plate position, ii) OPA 
specific or iii) position of the failed markers in telomeric or centromeric repetitive 
sequences which are under-represented by the multiple displacement action (MDA)
method (Dean, Hosono et al. 2002). The position of whole genome amplified sample 
37 was B9, which was not on the edge on a 96-well plate. All markers for 
chromosomes 16, 17 and 19 were on OPA 6564 which completely failed for three 
other individuals, samples 12, 15 and 19. Therefore the OPA did not genotype 
robustly. 




UNKNOWN SNPS IN 
37 WGA SAMPLES










Table 5.5 The number of failed SNPs in the whole genome amplified DNA 
sample is not over-represented in genomic repeat regions. The SNPs that did 
not genotype for sample 37 on the WGA sample from OPA 6564 were investigated 
to see if the failed genotyping was due to the non-amplification of repetitive regions 
in WGA samples. However, only a small number of failed SNPs were from genomic 
repeat regions.
Furthermore, only 17% of the failed markers were located in repetitive regions, as 
shown in Table 5.5. Also, the missing alleles fall into a wide-range of genomic 
regions such as repetitive elements and regulatory regions, and do not have a 
specific function or locus region, as shown in Table 5.6. Thus, the missing 
genotyping from whole genome amplified sample 37 stems from the poor quality of 
OPA 6564.
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REPETITIVE ELEMENT DESCRIPTION # SNPS
DNA DNA repeat elements 4
LINE Long interspersed nuclear elements 12
LTRs Long terminal repeat elements, including retroposons 3
Satellite Satellite repeats 1




CpG Island Potential regulatory region 2
Conserved transcription 
factor binding site (TFBS)
Location & score of TFBS conserved in the 
human/mouse/rat alignment
2
Conserved region of 8-
genome alignment
Human/chimp/mouse/rat/dog/chicken/fugu/zebrafish 
conserved region from 8-genome multi-alignment
12
Function
Coding-NonSynon Change of peptide in contig sequence 3
Coding-Synon No change of peptide for allele in contig sequence 4
mRNA-UTR Variation in transcript, but not in coding region 
interval
22
Locus Region Variation in region of gene, but not in transcript 
(within 2kb flanking sequence of the mRNA)
16
Intron Variation in intron, but not in first 2 or last 2 bases of 
intron
66
Unknown No known functional classification 54
165
Table 5.6 Description of missing alleles in whole genome amplified DNA. The 
failed SNPs from the whole genome amplified sample (WGA) of 37 were 
investigated for any specific genomic location or property that may have affected the 
genotyping failure. The description of the SNPs was obtained from UCSC genome 
browser (March 2006 version, NCBI Build 36).
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5.4.4. Heterozygosity
The average heterozygosity in 5,398 Mendelian consistent markers was 44.6%. 
Marker heterozygosity was calculated using the descriptive statistics programme
Pedstats (Wigginton and Abecasis 2005). This is similar to >43% average 
heterozygosity in Caucasians published by Illumina (Murray, Oliphant et al. 2004)  
for the Linkage IVb Panel.
5.4.5. Mendelian inconsistencies
Genotyping errors were detected using Pedcheck, as described in section 2.5.3.4,
which identifies all Mendelian inconsistencies in pedigree data (O'Connell and 
Weeks 1998). Pedcheck inspected data for errors at four different levels. Level 1 
checked for simple errors in a nuclear family, such as the alleles of a child and 
parent that were incompatible, more than four alleles in a sibship, allele out of 
bounds of any specified range and more than three alleles in a sibship with a 
homozygous child. Level 2 looked for more subtle errors via a genotype elimination 
algorithm that, for each untyped individual, constructed the shortest possible list of 
genotypes that were mutually consistent with all genotypes of their relations. Level 
2 identified slight inconsistencies resulting from the elimination of certain 
genotypes, on the basis of more complex pedigree relations.  Level 3 tried to identify 
the possible error by “untyping” one individual at a time and applied genotype 
elimination to see if the inconsistency had been eliminated. Level 4 used an odds-
ratio algorithm to look at each critical genotype and computed the relative 
likelihood of different alternative valid genotypes (O'Connell and Weeks 1998). 
Thirty-eight Level 1 and 2 inconsistencies were found in the pedigree data; that was 
27 of the 5663 autosomal SNPs were inconsistent with Mendelian inheritance. No
errors were detected by Level 3 and 4 checks. This was a rate of 0.5% Mendelian 
inconsistencies which was higher than the expected rate of 0.006%, as published by 
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Illumina. The genotypes contributing to these errors were excluded from the linkage 
analysis, providing a “cleaned” dataset.
5.4.6. Hardy Weinberg equilibrium testing
Hardy Weinberg disequilibrium can occur for certain reasons including systematic 
genotyping errors, non-random mating and chance. Therefore, for quality control 
purposes, it was important to check for deviation from HWE. This was performed 
using the exact SNP test in the PedStats programme, as described in section 2.5.3.4,
on 14 unrelated individuals from the family (individuals 11, 13, 17, 20, 33, 38, 46, 49, 
98, 104, 146, 149, 160 and 180). 22 SNPs were excluded as a result of departure from 
HWE, P≤0.01 as recommended by the author (Wigginton, Cutler et al. 2005).
5.4.7. Mendelian-consistent genotyping errors
To test the data further for genotyping errors, sensitivity analysis of the likelihood 
of all genotypes was conducted, using the programme MERLIN, as described in 
section 2.5.3.4 (Abecasis, Cherny et al. 2002). MERLIN searches for genotypes that 
provide information about inheritance in a pedigree and that also contradict 
information provided by other genotyping data. MERLIN considers all of the 
pedigree data simultaneously (not just that for pairs of individuals) for error 
detection. MERLIN detected 355 errors in the whole-genome data on the 9 sub-
families. These putative erroneous genotypes were omitted. Furthermore, sample
107 proved problematic with an excess of genotyping errors, 13% compared to the 
average of 7%, detected by Pedcheck and MERLIN. Therefore, this unaffected 
individual was removed from the linkage analysis. 
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5.4.8. Linkage disequilibrium between markers
An assumption of most linkage analysis methods is that the markers under 
investigation are not in linkage disequilibrium (LD). This may not be the case for 
dense whole genome scans. LD between markers can lead to positive bias in linkage 
scores when founders are untyped (Josée Dupuis 2007) and if founders are typed, 
ignoring LD can lead to an inflation of false positive error rate (Yoonhee Kim 2008). 
For this study, LD between the SNPs on the Illumina Linkage IVb Panel was 
checked within the family. LD between autosomal markers was investigated in 
Haploview version 3.2 (Barrett, Fry et al. 2005). The default definition of LD, solid 
spine LD D’>0.8, for markers 500kb apart was used. Haploview chose 12 singletons 
and one trio called the “maximum unrelated subset” from the family. These were 12 
individuals married-in to the family (samples 11, 13, 20, 38, 46, 49, 98, 104, 146, 149, 
160, 180) and one trio (samples 29, 33, 35). There were 456 pair-wise comparisons 
with D’≥0.8 and LOD≥2. Figure 5.14 shows that the majority of SNPs are not in LD 
with each (D’<0.8).  Figure 5.14 also shows the presence of 456 markers in high D’ 
with each other in close distance <100kb. In each case, one of the two SNPs in pair-
wise LD was removed from the analysis. The SNP for removal was chosen on the 
basis of genotyping success: a lower genotyping error rate and then by lower 
heterozygosity. For SNPs in a cluster of LD, all but one marker was removed. In 
total, 455 SNPs were excluded from the linkage analysis.
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Figure 5.14 Distribution of pairwise D' values according to the pairwise 
distance of SNPs. The x-axis is the distance between a pair of SNPs in base pairs. 
The y-axis is the D’ value which measures linkage disequilibrium between SNPs, 
where D’=1 means complete LD.
To summarise, a “cleaned” genotyping dataset was prepared. This excluded many 
erroneous markers as listed in Table 5.7.
REASON EXCLUDED NUMBER SNPS EXCLUDED
Call rate per SNP <90% 266
Mendelian errors 27
MERLIN (haplotype) 355 genotypes
High LD with neighbouring SNPs 455
Failed HWE, P<0.01 22
Table 5.7 Reduction from 5,663 autosomal SNPs in the Illumina Linkage IVb 
Panel to 4,893 SNPs used in linkage analyses
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5.4.9. Information content
Information content is a measure of the information a panel of markers can provide
in a pedigree, which will extract the maximum amount of inheritance information 
for a linkage analysis. It is a function of marker heterozygosity and the number of 
meioses in a genetic study. To calculate the information content of the cleaned data, 
without the erroneous genotypes as shown in Table 5.7, the information content 
based on the Shannon entropy measure was calculated for all markers, on the sub-
families, using MERLIN software. The average information content over all 
chromosomes was 88% (±0.03 standard deviation) and the minimum value was 69%. 
This was lower than the published information content for the same marker panel, 
where the average information content was 97% and the minimum value was 83% 
(Murray, Oliphant et al. 2004). The information content may be greater if the whole 




To perform relatedness analysis in the family, three statistical methods were 
employed. They assessed whether the assumed relationship was likely, and if not, 
then predict a more likely relationship. The first statistical test determined whether 
the pattern of allele sharing by each pair of individuals was consistent with the 
indicated relationship and was performed using “PREST” (Pedigree RElationship 
Statistical Test) (McPeek and Sun 2000). This method was followed by ALTERTEST
(ALTERnative TEST) which determines the probability of a different hypothesised 
relationship (McPeek and Sun 2000). The third statistical method used a maximum 
likelihood approach to infer relationships between two individuals based on the 
genetic marker data provided. For this analysis, the programme “Relpair” was used 
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(Epstein, Duren et al. 2000). These statistical methods were different approaches to 
the same question and were chosen to compliment each other.
PREST estimates κ = (κ0, κ1, κ2), the probability of sharing zero, one or two alleles 
identical by descent (IBD) by a pair of individuals. Related individuals are similar to 
each other because they have variants that are IBD, which are copies of the same 
variant from a common ancestor, as illustrated and explained in Figure 1.6. PREST 
computes the expected IBD (EIBD), adjusted IBS (AIBS), IBS and maximised log-
likelihood ratio (MLLR) statistics and performs hypothesis tests for relationship 
misspecification, considering all relation pairs. The authors of PREST recommend 
initial screening of genome-wide data using the EIBD and AIBS test, followed by 
application of the MLLR test on problematic pairs. The EIBD test statistic is the 
“average of the conditional expected number of alleles shared IBD at each marker, 
conditional on the data for that marker, the null relationship and the allele 
frequencies”. The AIBS statistic is “an average over all markers m of Am, where Am is 
a sum over each shared allele of its null conditional probability of being shared IBD, 
given that the allele is shared IBS and under the assumption that the shared alleles 
results from a random draw of one allele from each of the individuals”. The MLLR 
statistic tests the “null relationship against a specific alternative relationship by 
calculating the likelihood of the data under the null and alternative relationships 
specified”.  The MLLR test is an extension of the likelihood calculations of Goring 
and Ott (Goring and Ott 1997) and Boehnke and Cox (Boehnke and Cox 1997) to 
more general relationship pairs, where the IBD test is not based on a Markov chain,
but a likelihood-ratio test. ALTERTEST is based on the same statistical tests.
Relpair is based on a maximum likelihood approach; that is to look at a large class of 
relationship distributions and then chooses the "best" distribution. For each 
distribution, likelihood is computed, and the best distribution is the one that 
maximizes this likelihood. This approach infers relationships between two 
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individuals based on the genetic marker data. This can be done within families, as in
this study, or across many pedigrees. The programme calculates and compares the 
multipoint probability of genetic marker data conditional on different pairwise 
genetic relationships and infers the relationship that makes the data most likely. 
Additionally, RELPAIR has two advantages over PREST i) X-linked data can be 
included to improve distinguishing of second-degree relationships, for example 
inferring paternal half-sisters and maternal half-brothers (Epstein, Duren et al. 2000)
and ii) improves identification of monozygotic twins and parent-offspring pairs by 
modelling genotyping error when classifying relationships.
5.5.2. Relationship testing results
Statistical tests using PREST and RELPAIR software were performed on the whole-
genome linkage data, as described in section 2.5.5, to determine whether the pattern 
of allele sharing by each pair of individuals was consistent with the indicated 
relationship provided from the originally published pedigree. 
5.5.2.1. PREST results
Pedigree errors were calculated over all relationship pairs known to PREST (parent-
offspring, full-siblings, half-siblings, avuncular, first cousins, grandparent-
grandchild, half-first-cousins, half-avuncular and unrelated). The results were 
plotted on a scatter diagram of estimated IBD probabilities κ0, κ1 and κ2 on 
relationship triangles. An explanation of relationship triangles, first devised by 
Elizabeth Thompson, is provided in Figure 5.15 (Thompson 2000). The results of all 
IBD tests are shown in Figure 5.16. For each mis-specified relationship, a MLLR test 
was performed for simulation using 100,000 replicates for each pair, to assess 
significance.
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Figure 5.15 The relationship triangle. The relationship triangle depicts the location 
of the expected results from allele sharing test and was first used to illustrate 
relationships by Elizabeth Thompson (Thompson 2000). Relationship triangles were 
used to display results from relationship testing using PREST software. Each vertex 
of the triangle represents sharing of genes IBD, zero alleles, κ0 =1, for unrelated at 
the top vertex, one allele, κ1 =1, for parent-offspring on the right vertex and both 
alleles, κ2 =1, for MZ twin on left vertex. Other levels of sharing are shown by 
crosses. DFC is double first cousin, QFC is quadruple first cousin. Please refer to
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Figure 5.16 Result of relationship analysis based on estimated IBDs using the 
PREST programme. Each coloured square represents the IBD probability between 
two individuals. All the tests, for each relationship, are displayed on the relevant 
relationship triangle. The expected location for each relationship is highlighted in 
yellow. Deviation from this location suggests an erroneous relationship. There were 
nine different relationship categories tested in the family. PO = Parent-offspring, FS 
=Full-sibling, HS = Half-sibling, U = Unrelated, MZ = monozygotic twin, π0, π 1, π 2 = 
the probability of sharing zero, one or two alleles IBD by the pair. Please refer to 








Chapter 5 Design & Preparation for Linkage Study
256
Figure 5.16 shows that the vast majority of relationships fall at the expected location 
highlighted in yellow in the relationship triangles, thus confirming pedigree 
structure. The test highlights, however, a number of relationship errors: two parent-
offspring errors, three full-sibling errors, four half-sibling errors and two unrelated 
errors. These errors are explained in detail in the following three figures: Figure
5.17, Figure 5.18 and Figure 5.19. 
The PREST results indicate that an incorrect sample was genotyped for sample 105, 
a duplicate of sample 97 as illustrated in Figure 5.17. Figure 5.17a shows the 
relationship triangles for each relationship of the nuclear family; parents 103 and 
104 and offspring 105, 106, 107 and 108. The actual PREST result, highlighted by the 
red circle, is not in the same position as the expected result, highlighted in yellow 
and falls at the “unrelated” position in each case. Figure 5.17b shows the number of 
markers that were tested for each relationship test, approximately 5,000 SNPs. 
Figure 5.17c shows the pedigree of the large Scottish family, where the nuclear 
family, including sample 105 and the position of the duplicated sample 97, can be 
located within the pedigree.  
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Figure 5.17 Incorrect sample for sample 105 identified by relationship testing 
in PREST. Analysis by PREST is shown in (a). The expected relationship result of 
parent-offspring relationships between parents 103, 104 and offspring 105 or full-
sibs 106, 107 and 108 are highlighted in yellow, whereas the actual unrelated 
relationship result from PREST is circled in red. The PREST results used to prepare 
the relationship triangles are tabulated in (b). κ0, κ1, κ2 is the probability of sharing 
0, 1 or 2 alleles IBD result for the specified relationship. The pedigree is a snapshot 
of the full pedigree showing the original relationship information. 
ID 1 ID 2 ASSUMED RELATIONSHIP NUMBER OF MARKERS Κ0 Κ1 Κ2
103 105 Parent-offspring 5375 0.892 0.108 0.000
104 105 Parent-offspring 5377 1 0.000 0.000
105 106 Full-sibling 5372 0.998 0.000 0.002
105 107 Full-sibling 4919 0.999 0.000 0.000
105 108 Full-sibling 5363 0.999 0.000 0.000
103 & 105 104 & 105
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Figure 5.18 illustrates the resolution of paternity in a trio, samples 44, 46, and 69. 
The initial pedigree structure listed the parents of sample 69 as samples 46 and 173. 
However, the relationship test results with over 5,000 markers, as shown in the 
relationship triangles in Figure 5.18a, shows that the parents of sample 69 are in fact, 
samples 44 and 46 (Figure 5.18b). Furthermore, Figure 5.18 demonstrates 
relationship testing of samples 83 and 84 and shows that they are not full-siblings as 
originally assumed, but half-siblings. However, Figure 5.18b shows the number of 
markers that deduced this relationship was 2,521, only half the number of markers 
used for testing relationships between all other individuals. This was a consequence 
of sample 83 failing to genotype with 50% of the markers, and thus all genotypes 
were set to unknown for this sample and the relationship error was not taken into 
account. 
Figure 5.18 Non-paternity resolved. Relationship testing results (a) show that 69 is related to both 44 and 46 at the parent-offspring 
level circled in red at the bottom right vertex in (a). This differs from putative pedigree (c) where 46 is not a parent. Relationship results 
also suggest that 83 and 84 are not full sibs. However, sample 83 failed for 50% genotyping so all genotyping was set to unknown. The 
expected results for each pair of individuals are highlighted in yellow and the actual results are circled in red in the relationship triangles 
(a). The PREST results are tabulated in (b) κ0, κ1, κ2 is the probability of sharing 0, 1 or 2 alleles IBD result for the specified 
relationship and number of markers tested. The pedigree is a snapshot of the full pedigree showing the original relationship information 
and the altered pedigree. Blue circles show the individuals genotyped for this linkage study. 
ID1 ID2 ASSUMED RELATIONSHIP NUMBER OF MARKERS Κ 0 Κ 1 Κ 2
44 69 Parent-offspring 5253 0.004 0.996 0
46 69 Unrelated 5348 0 1 0
83 84 Full-siblings 2521 0.554 0.446 0
c)
a)
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Figure 5.19 demonstrates that sample 11, an assumed unrelated individual, married 
into the family, may be related to sample 161. The relationship triangles in Figure
5.19a present the PREST results for sample 11 with the assumed unrelated nuclear 
family, samples 161, 162, 163, 164 and 166, from analysis on over 5,000 markers in 
Figure 5.19. The results circled in red, deviate from the expected location 
highlighted in yellow on the relationship triangles. Thus, revealing excess sharing in 
assumed unrelated individuals (11 and 161), as denoted by the blue circles in Figure
5.19c.
ID1 ID2 ASSUMED RELATIONSHIP NUMBER OF MARKERS Κ0 Κ1 Κ2
11 161 Unrelated 5352 0.565 0.435 0.000
11 166 Unrelated 5038 0.564 0.436 0.000
11 162 Unrelated 5344 0.75 0.25 0.000
11 163 Unrelated 5351 0.809 0.181 0.010
11 164 Unrelated 5351 0.781 0.219 0.000
Figure 5.19 Excess sharing detected between unrelated individuals. Analysis by PREST is illustrated in relationship triangles 
(a).The expected relationship result for the two individuals is highlighted in yellow, whereas the actual relationship result is circled in 
red. The PREST results are tabulated in (b), κ0, κ1, κ2 is the probability of sharing 0, 1 or 2 alleles IBD result for the specified 
relationship. The original pedigree is shown with the position of samples 11 and 161 highlighted by blue circles, to the left and right
respectively. 
11 & 161 11 & 166
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5.5.2.2. ALTERTEST results
Alternative relationships were indicated on the relationship triangles for the 
problematic relationships detected by PREST. These alternative relationships were 
tested as a null hypothesis using ALTERTEST, performing the EIBD, AIBS and IBS 
tests on problematic relationship pairs, to see if the alternative was compatible with 
the data. The results are shown in Table 5.8 and confirm the newly hypothesised 
relationships. Firstly, samples 97 and 105 share markers to the same degree as an 
alternative relationship of monozyogotic twins, indicating sample duplication. This 
was also confirmed by testing sample 105 (duplicated sample 97) with family 
members of sample 97, where the relationships concur with a sample duplication of 
97. Secondly, non-paternity was resolved for parents 44 and 46 and offspring 69. 
Again, this relationship was confirmed, by alternative relationship testing the 
offspring of samples 44 and 46 (sample 47, 59 and 165), to show they are full-siblings 
and not half-siblings. The second case of non-paternity was investigated, by 
estimating the alternative relationship of half-siblings for samples 83 and 84. 
Although the number of markers is less than tested for the other alternative 
relationships, a relationship at the half-sibling level is disclosed. Thirdly, excess 
sharing was also confirmed by the alternative relationship of half-sibling, 
grandparent or avuncular, between the assumed unrelated samples 11 and 161, and 
11 and 166.










5371 NA 0 0 1
105 150 Full-sibling 5380 0.8782 0.6431 0.3568 0
97 145 Full-sibling 5360 0.9808 0.3302 0.449 0.2208
Sample 
mix-up








5348 NA 0 1 0
47 69 Full-sibling 5355 0.9617 0.3909 0.4314 0.1778
59 69 Full-sibling 5367 1.0082 0.2471 0.4724 0.2805
Non-
paternity
165 69 Full-sibling 5367 0.9641 0.3956 0.4135 0.1909
Non-
paternity
83 84 Half-sibling 2521 0.4963 0.5536 0.4464 0
11 161 Half-sibling 5352 0.4952 0.5646 0.4354 0Excess 
sharing 11 166 Half-sibling 5038 0.4955 0.5636 0.4362 0.0002
Table 5.8 Relationship errors detected using the ALTERTEST. The results from 
testing alternative relationships between individuals where relationship errors were 
detected by PREST analysis. The test hypothesises the likelihood of a null 
hypothesis relationship, indicating the estimated IBD (EIBD) value and the estimated 
probability of sharing 0, 1 or 2 alleles by descent (κ0, κ1, κ2). Please refer to Table 
1.2 for theoretical IBD values. NA = Non Applicable.
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5.5.2.3. Relpair results
Relpair was used as an alternative method to PREST and helped confirm the results. 
Due to memory constraints in the use of Relpair, the test was performed on 
chromosomes 1, 13, 16 and X with 489, 191, 197 and 301 SNPs respectively. The 
Relpair limit for the number of markers was initially set at 200, thus the choice of 
chromosomes 13 and 16. Altering the limit constraints, as shown in Table 2.11, 
allowed the use of chromosome 1 and more importantly the X chromosome, which 
can help define second-degree relationships. The results were deemed noteworthy if 
they were confirmed for all four chromosomes under study. The critical value 
parameter was set to 1000, which is recommended for large data sets. This value 
reports the likelihood ratio between putative and inferred relationships (INF/PUT). 
The likelihood ratio is the ratio of two probabilities for the same observations, 
calculated under alternative hypotheses. In the context of relatedness analysis, the 
likelihood ratio is formed by dividing the probability of the observed pair of 
genotypes using the IBD probabilities for one possible relationship by the 
probability of the genotypes using IBD probabilities for the other possible 
relationships. The likelihood ratio is a continuous variable that can take any non-
negative value and values greater than one support the relationship used for the 
numerator (Weir, Anderson et al. 2006). Only the results for close relationships of 
parent-offspring, full-siblings and half-siblings were considered, as this method is 
not reliable for inferring distantly related individuals. Examining all pairs across a 
large dataset, the great majority of pairs will be putatively unrelated, so the false 
positive rate is high (Epstein, Duren et al. 2000). 
As shown in Table 5.9, Relpair inferred a monozygotic twin relationship between
sample 97 and 105 at INF/PUT ratio of >106 for chromosome 1, 13, 16 and X. This 
was confirmed with results from the rest of the family, where sample 105 was 
unrelated to its putative parents 103 and 104, but related to sample 97. It also 
showed that the parents of sample 69 are samples 44 and 46. Furthermore it showed 
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that sample 11 was related to samples 161, 162, 163, 164, 166 to some degree.  Thus 
the results from all three statistical methods using the PREST, ALTERTEST and 











97 105 Unrelated MZ twin >106
99 105 Unrelated Parent offspring >106
103 105 Parent offspring Grandparent >106
Sample 
duplication
104 105 Parent offspring Unrelated >106
46 69 Unrelated Parent offspring >106
47 69 Half-sib Full-sib >106
59 69 Half-sib Full-sib >106
Non paternity
69 165 Half-sib Full-sib >106
11 161 Unrelated AV/HS/CO >0.7x106
11 162 Unrelated AV/HS >106
Excess sharing in 
unrelated 
individuals 11 166 Unrelated GG/CO >106
Table 5.9 Relationship testing results using Relpair software. Relpair detected 
three relationship errors in the putative pedigree: a sample duplication, non-paternity 
and excess sharing in unrelated individuals. Furthermore, Relpair inferred a 
relationship from the level of IBD sharing in the genotype data. AV is avuncular, HS 
is half-sibling, CO is cousin and GG is grandparent, grandchild relationship. The 
results for Relpair analysis inferring a relationship between a pair of individuals is 
reported as a likelihood ratio of inferred relationships compared to the putative 
relationship (INF/PUT Ratio). Each value above is the average result from markers 
on all chromosomes analysed (chromosome 1, 13, 16 and X).
The results of the three statistical methods were summarised in Table 5.10. For each 
relationship error that was detected, the consequence to the pedigree structure was 
noted.
Error 
No ID 1 ID 2
Putative
Relationship








(permuted) Confirmed 1, 13, 16, X No conclusive information
2 83 84 Full sibs
Autosomes
(permuted) Confirmed 13, X
Set genotyping to zero for 
83 as failed >50% 
genotyping
3 46 69 Unrelated Autosomes Confirmed 1, 13, 16, X Pedigree change - Parent




5 97 105 MZ twin NA Confirmed 1, 13, 16, X
Set genotyping to zero for 
105 as duplicate sample
6 97 145 Half-sibs Autosomes Confirmed 1, 16, X Pedigree change - Full-sibs
7 97 150 Full-sibs
Autosomes
(permuted)
Confirmed None Pedigree change - Half sibs
Table 5.10 Summary of Pedigree Errors. There were seven pedigree errors confirmed by three different methods of relationship 
testing. The putative relationship according to the original pedigree is stated for the individuals in question. The result of relationship 
test for each putative relationship is shown from PREST, ALTERTEST and Relpair. Those results that withstood permutation testing in 
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The appropriate adjustments were made to the pedigree according to Table 5.11. For 
samples that failed genotyping or a sample error occurred as described in section 
5.4, the genotyping information was labelled as unknown. For samples that were 
shown to deviate from their assumed relationships, the pedigree structure was 
adjusted.
NUMBER PEDIGREE STRUCTURE ADJUSTMENT
1 Genotyping for 25, 35, 40, 83, 105 set to unknown
2 The parents of 69 are 46 & 44
3 173 is removed
4 Parents of 97 & 145 are 91 & 96
5 Parents of 150 are 91 & 172
Table 5.11 List of adjustments to pedigree. There were five categories of 
adjustments made to the pedigree data for linkage analysis.
After correction of the pedigree, both PREST and Relpair were rerun to confirm that 
family relationships reassignments were consistent with estimated IBD patterns and 
no other relationship errors were conclusively detected. In brief, all three methods 
were successful in identifying and resolving several pedigree errors. 
There were a number of repercussions from the error checking to the linkage 
analysis. First, samples with a bipolar disorder diagnosis (105) and with recurrent 
major depression diagnoses (40 and 83) failed genotyping and were removed from 
the linkage analysis. A sample duplication of 97 was identified, which was 
originally thought to be 105. Upon further investigation in the lab, previous tube 
mislabelling was the source of the error. This loss of information for 105 was 
unfortunate and the power to detect linkage using the genome screen will be 
reduced by omission of this individual. Second, non-paternity of 69 was resolved
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and the trio of 44, 46 and 69 was resolved from analysis of the whole genome data. 
The previous finding of non-paternity of sample 69 was due to genotyping of the 
wrong sample prior to this study. Last, there was a suggestion of excess allele 
sharing between apparently unrelated sample 11 and 161. It was important to note 
that the nature of the relationship of 11 to 166 and other samples could not be 
deciphered. Also, a clear answer was not obtained when the analysis was rerun with 
the adjustments made to the pedigree. The statistical methods used are not capable 
of accurately determining distant relationships, so the pedigree was left unchanged. 
However, this relationship between both these unaffected individuals was borne in 
mind when examining the results of the linkage analysis in chapter 6.
5.6. Determination of Significance Thresholds
5.6.1. Introduction
To determine the criteria for suggestive and significant linkage, simulations of the 
dataset was performed. Genome-wide significant levels were estimated by 
simulating replicates of the genotype of each marker on each autosomal 
chromosome, while maintaining the actual sub-pedigree structures, phenotypes, 
allele frequencies, marker maps and missing data structure. There were 10,000 
replicates performed for the broad phenotype and 1,000 replicates for the narrow 
phenotype. The marker data was simulated under the null hypothesis of no linkage 
to observed phenotypes. Each replicate was subject to non-parametric linkage
analysis in the same way as the real data. For parametric linkage analysis, the true 
disease model was unknown, so simulations based upon the assumed disease 
model may not provide a true reflection of the null distribution. This, together with 
computational limitations and a redundancy between methods, led to the decision 
to perform linkage analysis on the replicated datasets using non-parametric 
methods, in order to determine significance thresholds. 
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5.6.2. Result for significance thresholds
The peak non-parametric LOD scores from each replicate were noted for each whole 
genome scan and their distribution analysed. The distribution for all 22 autosomes 
is shown in Figure 5.20. 
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Figure 5.20 Distribution of highest Z and LOD scores for each replicate for  
simulation of non-parametric linkage analysis on broad and narrow 
phenotypic model. Genotype data was simulated 10,000 times for the broad 
phenotype (blue) and 1,000 times for the narrow phenotype (orange) for the sub-
pedigrees. Non-parametric linkage analysis was performed on the data. For each 
whole genome scan, the highest Z (a) and LOD (b) scores were retrieved. The 
distribution of the Z and LOD scores are shown, where the x-axis is the Z score (a) 
and LOD score (b) and the y-axis is the counts of the scores. The normal distribution 
is shown by the curved line. 
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These distributions were used to determine the threshold at which a finding is 
observed once in every genome scan which is the mean, once in every 20 genome 
scans, which is the 95% level and once in every 1000 genome scans for the more 
stringent 99.9% level. These are the criteria for suggestive, significant or highly 
significant linkage respectively.
STATISTIC BROAD NARROW
Z-score LOD Z-score LOD
Mean 4.23 2 4.21 2.11
Std. Error of Mean 0.0088 0.00657 0.02 0.02
95 Percentile 5.79 3.21 4.72 2.41
99.9 Percentile 7.55 5.32 4.72 2.41
Coefficient of Skewness 0.428 1.019 -0.905 -1.34
Std. Error of Skewness 0.024 0.024 0.077 0.077
Kurtosis 0.182 2.234 -0.806 0.238
Std. Error of Kurtosis 0.049 0.049 0.155 0.155
Table 5.12 Statistics of simulated linkage analysis. The relevant statistics on 
non-parametric linkage analyses on the broad and narrow phenotype models 
simulated datasets.
It was important that the data should have a normal distribution, as many statistical 
methods make this assumption. The shape and symmetry of the simulated data was 
characterised by comparing the shape of the observed frequency distribution with 
that of the normal distribution, as shown in Figure 5.20. Two measures are used to 
assess departures from normality: skewness and kurtosis, which are explained in 
full in Appendix A.
The whole genome simulation results followed a normal distribution. Figure 5.20
showed that the Z-score for the broad phenotype model follows the normal 
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distribution in shape and symmetry with coefficients of skewness and kurtosis close 
to zero. The corresponding maximum Kong and Cox exponential LOD score for the 
broad phenotype was slightly positively skewed (coefficient of skewness = 1.019) 
with a long right tail (coefficient of kurtosis = 2.234), but fits the normal distribution 
more than any other distribution, such as Χ2 for example. However, it is clear from 
the histogram that the simulation data for the narrow phenotypic model with both 
scores, Z- and LOD respectively, was negatively skewed with a long left tail 
(coefficient of skewness = -0.9, -1.3) and a longer tail than the normal distribution 
(coefficient of kurtosis = -0.8, 0.2). This negatively skewed distribution, with no 
values less than zero, follows a Χ2 distribution; Χ2 test 489.8, degrees of freedom 259, 
asymptotic P-value 0.000, which was expected for LOD scores when N is large 
(Lander and Kruglyak 1995). The reason for this was the power available in the 
narrow phenotypic model was limited to a Z-score 4.72 and LOD 2.41, as discussed 
in section 6.2.2. Therefore, the data from the narrow phenotypic model did not 
extend on the right tail, limited at LOD 2.41 and Z-score 4.72 and was hence, not 
ideal for confidently measuring highly significance thresholds.
The thresholds for suggestive, significant and highly significant for the broad model 
are 2, 3.21, and 5.32 respectively and for the narrow model are 2.11, 2.41 and 2.41 
respectively. The threshold levels for significance were as expected and comply with 
the gold-standard Lander and Krugylak suggestions, as shown in Table 1.8. The 
simulation result for the broad phenotype model for whole genome analysis 
followed a normal distribution. The other simulation results for the narrow model 
should be regarded with caution as their distributions are slightly skewed. 
Empirical P-values for each reported non-parametric LOD score, under the broad 
and narrow phenotypic model, were calculated from this data. These P-values were 
computed by dividing the number of replicates that exceeded LOD score by the 
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number of replicates.  This allowed examination of the LOD scores in context with 
the whole genome scan.
5.7. Discussion
The examination of data on 6,008 SNPs for 96 DNA samples led to some interesting 
observations. The whole genome amplified DNA was consistent with its genomic 
DNA duplicate, thus ensuring confidence in the other amplified DNA sample. The 
metrics of the genotyping success were acceptable, although less than the published 
Illumina success rates (Murray, Oliphant et al. 2004). The failures in genotyping can 
be attributed to poor quality DNA samples and emphasises the importance of high-
quality, intact DNA to generate the best results. Also, information content analysis 
showed that there was adequate information in the “cleaned” data to detect linkage. 
In addition, the confirmation of the pedigree structure based on relatedness analysis
ensures an accurate platform for linkage analysis. Splitting of the pedigree 
simplified the error-checking process and the linkage analysis. The LOD scores 
required for significant linkage were derived empirically for non-parametric linkage 
analysis and were in keeping with current literature recommendations. It was 
hoped that these efforts would maximise the power to detect linkage, while not 
discarding any useful information that may help linkage detection.
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6. Results of Linkage Analysis
6.1. Preface
6.1.1. Background
Previous linkage analysis performed on this large Scottish family showed evidence 
for a bipolar disorder locus on chromosome 4p15-p16 with a maximum LOD score 
of 4 (Blackwood, He et al. 1996). The initial linkage analysis was subsequently 
updated with additional chromosome 4 markers and family members confirming 
linkage with a maximum LOD score of 4.4 (Le Hellard, Lee et al. 2007). The first 
linkage analysis employed 193 markers that were unevenly spaced across the whole 
genome, omitting large proportions of chromosomes. The second linkage analysis 
used 24 markers on chromosome 4p. As these initial linkage studies had incomplete 
coverage of the genome, a re-evaluation of the linkage evidence was deemed 
important. This was timely for two reasons i) the recruitment of extra family 
members, including some affected individuals without the chromosome 4p15-p16 
linked haplotype and ii) new technology that enables dense coverage of the whole 
genome. Here, I describe whole-genome linkage analysis performed on this family, 
to reassess the chromosome 4p linkage and to test for other genetic loci co-
segregating with bipolar disorder and recurrent major depression.
There are several issues that determine the approach to linkage studies of bipolar 
disorder and recurrent major depression. Firstly, the mode of inheritance is 
unknown. The analyses should therefore test both parametric (to examine dominant 
and recessive inheritance) and non-parametric models. Secondly, psychiatric 
symptoms are assessed by a psychiatrist during a diagnostic interview and a 
phenotype reached according to the DSM-IV criteria. The lack of diagnostic 
biological markers means that there is always a subjective element regarding the 
diagnosis. Also, the overlap between bipolar disorder and recurrent major 
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depression is unclear. Some patients with depression will develop mania symptoms 
at a future date and will change diagnosis. Others will have only brief episodes of 
mania, insufficient to trigger a final diagnosis of bipolar disorder. Therefore linkage 
analysis was performed under two definitions of phenotype, a narrow model of 
bipolar disorder and a broad model that includes recurrent major depression. 
Thirdly, the size of this family and the number of SNP markers used was 
computationally demanding and only certain linkage programmes could be used. 
There were two options available; i) analysing the whole family for a few markers 
using programmes such as Simwalk2 (Sobel and Lange 1996) and Fastlink 
(Cottingham, Idury et al. 1993) or ii) splitting the family to analyse all markers using 
the programme MERLIN (Abecasis, Cherny et al. 2002). The attributes of each 
linkage analysis programme are detailed in section 1.4.3. As the aim of this study 
was to scan the whole genome for linkage peaks, the latter option was chosen. The 
family was split, using an informative method performed by the programme 
GREFFA (Falchi, Forabosco et al. 2004) that extracted the most informative sub-
pedigrees for linkage analysis. These sub-pedigrees were then tested for linkage to 
bipolar disorder and recurrent major depression by a whole genome scan. As LOD 
scores are additive, linkage evidence from each sub-pedigree was added to provide 
a LOD score for the whole family. Phenotype information for individuals that 
overlap between the sub-pedigrees was included in one sub-pedigree and noted as 
unknown in the other sub-pedigrees, to avoid bias. Thus, there were several layers 
of complexity to this linkage analysis, with many obstacles circumvented and 
assumptions made, to increase the power to detect genetic loci for bipolar disorder 
and recurrent major depression. 
Here I report two methods of linkage analysis, parametric and non-parametric for 
two phenotypic models. For parametric linkage analysis, a genetic model was 
defined. As the misspecification of the model can lead to a loss of power to detect 
linkage, non-parametric linkage analysis was also performed to test for increased 
marker sharing between affected relations. Suggestive regions of linkage to 
Chapter 6 Results of Linkage Analysis
278
psychiatric illness are described. Haplotype analysis on these regions is also 
performed.
6.1.2. Description of phenotypic models
Linkage analysis was performed under two definitions of the disease phenotype. 
The “narrow” model included only individuals diagnosed with bipolar I disorder or 
bipolar II disorder as affected individuals. Individuals with recurrent major 
depression and other minor psychiatric diagnoses were labelled as unknown.  The 
“broad” model included individuals diagnosed with bipolar I disorder, bipolar II 
disorder and recurrent major depression. Individuals with other psychiatric 
diagnoses or an uncertain diagnosis were labelled as unknown. A description of the 
phenotypes is provided in section 1.1. Branches of the family with evidence for 
bilineal inheritance of psychiatric illness, as assessed by a psychiatrist through 
interview and family history, were also labelled as unknown.
Division of the family meant that only certain sub-pedigrees were informative for 
linkage analysis. For the narrow model, the two sub-pedigrees with the greatest 
information were sub-pedigree 1 with four affected individuals and sub-pedigree 4
with three affected individuals. There was one affected individual in each of sub-
pedigrees 2, 6 and 7. For the broad model, the more informative sub-pedigrees were
sub-pedigree 1, with ten affected individuals; sub-pedigree 2, with four affected 
individuals; sub-pedigree 3, with two affected individuals; sub-pedigree 4, with five
affected individuals; sub-pedigree 5, with four affected individuals; sub-pedigree 6,
with two affected individuals and sub-pedigree 9, with three affected individuals.
Sub-pedigree 8 has one affected individual.
An autosomal dominant mode of inheritance was primarily considered for the 
family because visual inspection of the segregation of the illness did not fit with the 
features of recessive or X-linked inheritance. However, recessive analysis was 
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performed as a precautionary measure (Hodge, Durner et al. 1993) as 
misspecification of a dominant disease model has the greatest effect to reduce 
power to detect linkage (Clerget-Darpoux, Bonaiti-Pellie et al. 1986).
6.1.3. Genetic marker information
Linkage analysis requires an accurate knowledge of marker allele frequencies in the 
population. The allele frequencies were estimated from the family itself, as the 
family was large and all members were from the Scottish population. The allele 
frequencies were determined by counting the alleles from every genotyped 
individual in the family, using the RECODE facility provided by the MEGA2 
programme, as described in section 2.5.3.3 (Mukhopadhyay, Almasy et al. 2005).
Linkage was also analysed using allele frequencies derived from the CEPH 
pedigrees and under a model of equal allele frequencies, for a marker with n alleles, 
all frequencies were 1/n. The genetic position of the markers was obtained from a 
high-resolution sex-averaged published map by deCODE genetics (Kong, 
Gudbjartsson et al. 2002). 
6.1.4. Parametric linkage 
The parameters for parametric linkage analysis under the narrow and broad 
phenotypic model were the same as previously published (Blackwood, He et al. 
1996; Le Hellard, Lee et al. 2007). The narrow phenotypic model details inheritance 
for bipolar disorder and the broad phenotypic model details inheritance for bipolar 
disorder and recurrent major depression. The models are detailed in full in 
Appendix B, explained in section 1.4.1.2, and important aspects are discussed below. 
As the true disease model is not known for either bipolar disorder or recurrent 
major depression, the model choice was based on a number of assumptions from
population genetic data. The disease allele frequency refers to the population 
frequency of the allele that causes the psychiatric illness. This was not known for 
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certain and the aim was to make assumptions about a model that best fit the 
population genetic data. Thus, the values were based on the assumption of a 
lifetime risk of 0.005-0.01 for bipolar disorder and 0.05-0.1 for recurrent major 
depression in the general population (McGuffin, Owen et al. 2002). The disease 
allele frequency was assumed to be 0.007 for the narrow model, which was 
midpoint of the lifetime risk for bipolar disorder, and 0.03 for the broad model, 
which takes into account the lifetime risk for both bipolar disorder and recurrent 
major depression. 
Each individual in good mental health was assigned one of four age dependent 
liability classes; <20 years, 20-30 years, 31-40 years and >40 years.  These liability 
classes were used to specify variation in disease risk, with respect to age. The age-
dependent penetrance values for each the liability class were 4.6%, 19.5%, 23% and 
29% for the narrow model and 25%, 39%, 61% and 75% for the broad model. These 
were calculated for the original study from the family itself, according to established 
principles described by Jurg Ott (Ott 1999). The use of penetrance measures allowed
for reduced penetrance, where some mutation carriers who do not have a 
psychiatric diagnosis may develop a psychiatric illness post-interview, due to late 
age-of-onset for bipolar disorder. As explained in section 1.4.1.2, the penetrance 
vectors for disease allele heterozygotes and homozygotes were equal when a model 
of autosomal dominant inheritance was assumed.
As linkage tests for one putative disease locus, disease penetrance attributed to any 
other locus or sporadic mutation must be accounted for with a phenocopy rate. The 
phenocopy rate is the rate at which affected individuals without a mutation in the 
region of linkage, occur in the sample. The phenocopy rate relates to population 
prevalence. The phenocopy rates from the original study were used; a rate of 0.1 for 
the narrow model and 0.5 for the broad model. These values were calculated
according to principles described by Jurg Ott and Joseph Terwilliger (Terwilliger 
and Ott 1994; Ott 1999).
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In summary, the genetic parameters for the parametric linkage analysis were taken 
from the original study. The calculations are based on the following assumptions i) 
that the population lifetime risk of 0.005 for bipolar disorder and 0.05 for recurrent 
major depression ii) age dependent penetrances for both the disease susceptibility 
genotypes and iii) phenocopy rates of 10% for the narrow model and 50% for the 
broad model. However, it must be reiterated that this calculated model was based 
on many assumptions and may not reflect the true nature of psychiatric illness.
Linkage is measured by the LOD score method described in section 1.4. Here, the 
score reported is the multipoint LOD score for each marker, as described in section 
1.4.4, with the corresponding α value which is the proportion families linked to the 
marker and the HLOD, which is the heterogeneous LOD, taking genetic 
heterogeneity into account. However, as this study investigated bipolar disorder in 
a single family, the LOD will be reported in graph form. The tabulated results show 
the LOD, α and HLOD for interest. 
6.1.5. Non-parametric linkage analysis 
As previously described in section 1.4.2, the aim of the non-parametric linkage 
analysis was to identify the disease locus by identifying markers where affected 
individuals are more alike than expected by chance. In this study, the Sall sharing 
statistic was reported. This favoured the sharing of a single allele by a large number 
of affected individuals, as hypothesised for the family described here. To evaluate 
this sharing, the Kong and Cox δ (delta) parameter with the exponential model was 
used. The exponential model was designed to identify a large increase in allele 
sharing in a small number of families and is a better test if a large increase in allele 
sharing among affected individuals is expected, but is more computationally 
intensive (Abecasis, Cherny et al. 2002). The Kong and Cox exponential model 
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approach generates more accurate P-values than those obtained by other methods, 
and thus was reported here.
6.1.6. Significance thresholds for non-parametric linkage 
The thresholds for suggestive and significant linkage were determined by 
simulating the broad dataset 10,000 times and the narrow dataset 1,000 times and 
analyzing the data by non-parametric linkage analysis. The threshold levels are 
reproduced in Table 6.1. 












Broad Suggestive Mean 4.23 2





Narrow Suggestive Mean 4.21 2.11





Table 6.1 Significance levels for whole genome linkage analysis. These are the 
levels required for significant linkage analysis in the broad and narrow phenotypic 
model under non-parametric linkage analysis. They are calculated from the 
distribution of LOD scores from linkage analysis for 10,000 simulated genotyping 
datasets on the broad model and 1,000 simulated genotyping datasets on the 
narrow model, as shown in section 5.6.
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6.2. Results of Whole-Genome Linkage Analysis
6.2.1. Parametric linkage results
The family was split to accommodate whole-genome linkage analysis, as described 
in section 5.2.2. The family sub-pedigrees were tested for linkage across all 
autosomal markers in both the broad and narrow model using the quality controlled 
dataset, as discussed in chapter 5. The marker list, genetic position, physical 
position and allele frequencies are available from Illumina
(http://www.illumina.com/pages.ilmn?ID=191). Parametric linkage analysis was 
performed, as defined by the genetic model, Appendix B, using MERLIN software, 
described in section 2.5.7. Each of the 22 autosomes was scanned for linkage. The 
results of linkage scan are shown in Figure 6.1 and Figure 6.2. The majority of 
chromosomes show negative linkage (LOD <-2) or inconclusive linkage (LOD~0). 
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Figure 6.1 Results of parametric linkage analysis under broad phenotypic 
model. Continued on the next page.
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Figure 6.1 Results of parametric linkage analysis under broad phenotypic 
model. The x-axis shows the chromosome positions according to deCODE cM. The 
y-axis shows the LOD score. The grey lines show a threshold for significant linkage, 
LOD=3, and for negative linkage, LOD=-2.
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Figure 6.2 Results of parametric linkage analysis under narrow phenotypic 
model. Continued on the next page.
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Figure 6.2 Results of parametric linkage analysis under narrow phenotypic 
model. The x-axis shows the chromosome positions according to deCODE cM. The 
y-axis shows the LOD score. The grey lines show a threshold for significant linkage,
LOD=3, and for negative linkage, LOD=-2.
Chapter 6 Results of Linkage Analysis
289
Regions of suggestive linkage are detailed in Table 6.2. Although simulation studies 
were not performed for parametric linkage analysis, the cut-offs determined by non-
parametric linkage analysis can be applied here as they are comparable with those 
suggested by Lander and Kruglyak for parametric linkage analysis (Lander and 
Kruglyak 1995). LODs >2 are deemed suggestive for linkage and warrant further 
study. In brief, regions of suggestive linkage in the narrow category are 
chromosomes 4p14-p16 (LOD 2.4) and 1p36 (LOD 1.9) and in the broad diagnostic 
category chromosome 4p15-p14 (LOD 3) were identified. In Table 6.2 and Table 6.3, 
the maximum LOD score at the particular genetic marker was noted. The 
corresponding HLOD and the estimate proportion of linked families (α, alpha) at 
the particular genetic marker are provided. Additionally, a 1-LOD support interval 
is reported. The width of the 1-LOD support interval is R-L, where L and R are the 
first positions at which the LOD score is less than the maximum LOD score minus 1 
to the left and right of the position of the maximum LOD score respectively. It is 
evident from Table 6.2 that the chromosome 4 loci overlap between the narrow and 
broad phenotypic model. However, the peak was much wider in the narrow model 
(43cM) than the broad model (25cM) which was consistent with more affected 
individuals (a greater number of meioses) in the broad model (34) than the narrow 
model (11). Additionally, genetic heterogeneity was not detected, as the α score was 
1 and the HLOD was the same as the LOD score. This result argues against the 
presence of genetic heterogeneity with this large family. The linkage evidence for 
chromosome 1p36 in the narrow phenotypic model was reported, as LOD 1.9 
approximates to that for suggestive linkage LOD 2. Although it was not suggestive, 





















43 34.78, 34.88 rs1477898, 
rs1850548
2.4 1 2.4





24 40.15 rs1476880 3 1
3
Table 6.2 Regions of suggestive linkage from parametric linkage analysis on the whole genome SNP scan on sub-pedigrees. 
Both broad and narrow phenotypic models were analysed. The chromosome position of the linkage peak is from the UCSC genome 
browser (May04). The support interval is based on the Max 1-LOD rule, LODMAX ≥ 2. The highest LOD for each peak is shown at the 
particular marker position, where more than one marker at the same LOD the both are mentioned. Alpha is the estimated proportion of 
linked families and the HLOD is the corresponding maximum heterogeneity LOD score. The table is separated by phenotypic model 
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Regions of nominal interest, LOD≥1 are described in Table 6.3. Although these loci 
did not reach suggestive levels of significance, they are worth reporting as potential 
loci linked to illness in the whole family or in individual sub-families. It is worth 
noting that the potential linkage evidence for chromosome 1p36 (LOD 1.3) for the 
broad model shown in Table 6.3, overlaps with the region of suggestive linkage 
(LOD 1.9) in the narrow model as Table 6.2. This lends more support to this locus. 
The linkage evidence on chromosome 13q was a wide linkage peak (27cM) in both 
phenotypic models (LOD 1 in the narrow model and LOD 1.4 in the broad model). 
However, the evidence for linkage comes only from sub-pedigree 4 (LOD 1.77) and 
9 (LOD 0.4) suggesting heterogeneity in the broad phenotypic model (LOD 1.4, α 
0.7, HLOD1.5). Linkage to a small region of 9cM on chromosome 8p21 (LOD 1.7, α 
































41 48.03 rs1408875 1.4 0.7 1.5







rs10594 1 0.6 1.4
Table 6.3 Regions of nominal linkage from parametric linkage analysis on the whole genome SNP scan on sub-pedigrees. 
Both broad and narrow phenotypic models were analysed. The chromosome position of the linkage peak is from the UCSC genome 
browser (May04). The support interval is based on the Max 1-LOD rule, LOD ≥ 1. It is defined by the first and last position at which the 
LOD score is less than the maximum score minus 1. The highest LOD for each peak is shown at the particular marker position, where 
more than one marker at the same LOD the both are mentioned. Alpha is the estimated proportion of linked families and the HLOD is 
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Linkage analysis was performed under a recessive model for the broad phenotypic 
model. There were no LOD scores > 0.9 and the recessive mode of inheritance was 
not considered further.
6.2.2. Non-parametric linkage results
Non-parametric linkage analysis was performed on whole genome SNP data for 
each sub-pedigree. The preparation of the quality controlled genotyping data and 
the sub-pedigrees are described in chapter 5. Non-parametric linkage analysis was 
performed on both the broad and narrow phenotypes, as described in section 2.5.8.
The maximum possible scores obtainable, considering the number of genetic 
markers and the number of affected individuals per sub-pedigree, are shown in 
Table 6.4.
PHENOTYPE Z MEAN P-VALUE EXP DELTA LOD P-VALUE
Narrow 4.72 0.0000 9.999 2.41 0.0004
Broad 8.68 0.0000 9.999 7.72 0.0000
Table 6.4 Maximum LOD scores obtainable for non-parametric linkage 
analysis. The Z mean score is mean-sharing score for affected members in a 
pedigree with the corresponding P-value. The exponential delta measures the 
amount of deviation of the inheritance vector distribution from it’s null distribution, 
with the corresponding LOD score and P-value.
The maximum obtainable LOD score was 2.41 for the narrow phenotypic model and 
7.72 for the broad model. Linkage analysis on the broad phenotype model had more 
power as expected, given that there were a greater number of affected individuals. It 
was important to emphasis that non-parametric linkage analysis cannot achieve 
LOD scores greater than 2.41, under the narrow phenotypic model.
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The analysis was performed using MERLIN software to calculate the Whittemore 
and Halpern non-parametric linkage analysis Sall statistics, alongside the Kong and 
Cox LOD scores. The results for the whole genome scan are presented in Figure 6.3.
As the exponential model was a better test for a large increase in allele sharing 
expected among affected individuals, these results were shown. 
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Figure 6.3 Result of non-parametric linkage analysis. The x-axis is the 
chromosome position according to deCODE cM. The y-axis is Kong and Cox 
exponential LOD score for the broad phenotype model (blue line) and the narrow 
phenotype model (orange line).
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It is clear from Figure 6.3 that many autosomes show no evidence for linkage 
(LOD<1) or negative non-parametric LOD scores that indicate less than expected 
allele sharing in the family. There was evidence for suggestive linkage, as defined 
by Table 6.1, LOD>2 for the broad phenotype model and LOD>2.11 for the narrow 
phenotype model. The suggestive linkage results for non-parametric linkage 
analysis are shown in detail in Table 6.5. There was evidence for suggestive linkage 
on chromosome 4p14-p16 supported by both the narrow (LOD 2.4) and broad (LOD 
2.52) phenotypic model. There was also suggestive linkage on chromosome 8p21 
(LOD 2.22). Again, the peak on chromosome 1p36 (LOD 1.9), in the narrow 
phenotypic model was reported as it is of potential interest. Table 6.5 also details the 
empirical P-values calculated from 10,000 simulations of the broad phenotypic 
model and 1,000 simulations of the narrow phenotypic model. This assessed the 
genome-wide significance of the results. None of the linkage results met a genome-
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53 60.32 rs278973 2.52 3.59 0.0002 0.842 0.0003 0.187
Table 6.5 Regions of suggestive linkage from non-parametric linkage analysis. The chromosome position of the linkage peak is 
from the UCSC genome browser (May04). The support interval is based on the Max 1-LOD rule, LOD ≥ 2 which is the threshold for 
suggestive linkage as determined by simulations. The LOD score shown is the maximum LOD score for the SNP markers listed. The Z 
score, P-value assuming normal approximation and the Kong and Cox P-value are also listed. The empirical P-values were calculated 
from 10,000 simulated datasets for the broad model and 1,000 simulated datasets for the narrow model. The data is separated 
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Figure 6.3 and Table 6.6 display results of nominal linkage, LOD≥1 that did not meet 
the criteria for suggestive linkage (LOD ≥2.11 for the narrow phenotypic model and 
LOD≥2 for the broad phenotypic model). It was important to note these positions, 
without making any substantial claims and to clearly present the LOD scores. It is of 
interest that the linkage peak on chromosome 1p13-q23, under the broad phenotypic 
model (LOD 1.03), overlaps with the peak of suggestive linkage under the narrow 
phenotypic model (LOD 1.9) in Table 6.5. The linkage peak on chromosome 19p13 
was also interesting as the peak overlaps in both the broad (LOD 1.77) and narrow 





































































































1.03 2.84 0.002 0.522 0.015 0.966
Table 6.6 Regions of nominal linkage from non-parametric linkage analysis. The chromosome position of the linkage peak is from 
the UCSC genome browser (May04). The support interval is based on the Max 1-LOD rule, LOD ≥ 1. The LOD score shown is the 
maximum LOD score for the SNP markers listed. The Z score, P-value assuming normal approximation and the Kong and Cox P-value 
are also listed. The empirical P-values were calculated from 10,000 (broad) and 1,000 (narrow) simulated datasets. The data is sorted 
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In conclusion, parametric and non-parametric linkage analysis provided evidence 
for suggestive linkage on chromosome 4p14-p16 and 1p36 for both the narrow and 
broad model and chromosome 8p21 for the narrow model. To confirm these results, 
the following sections test the reliability of the linkage scores.
6.2.3. Robustness of linkage results
The robustness of the linkage results, obtained using family-based allele 
frequencies, was tested by varying the allele frequencies. Parametric and non-
parametric linkage analyses, on both broad and narrow phenotypic models, were 
performed using allele frequencies from CEPH population and equal allele 
frequencies. This whole genome analysis did not reveal any chromosomal regions of 
interest, other than those specified on chromosome 1p36, 4p14-p16 and 8p21 and 
those shown in Table 6.3 and Table 6.6. The linkage results for chromosome 4p are 
illustrated in Figure 6.4, for chromosome 1 in Figure 6.5 and chromosome 8 in 
Figure 6.6.  In addition, Figure 6.4, Figure 6.5 and Figure 6.6 demonstrate that for 
parametric and non-parametric linkage analysis, the linkage results based on the
various sets of allele frequency data mirrored each other. Importantly, varying the 
allele frequencies did not alter the chromosomal position of the linkage peaks, the 
size of the linkage peaks and the position of the maximum LOD scores, thus
suggesting the linkage analysis results were robust.
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Figure 6.4 Chromosome 4p linkage results are robust to allele frequency testing 
for the broad phenotypic model and narrow phenotypic model. Linkage analysis 
was performed with various allele frequencies under the broad (a) and narrow (b) 
phenotypic model. Chromosome 4, from the start of p-terminal to marker rs895615 
at 70.64cM is displayed on the x-axis. There are no linkage peaks after this marker. 
The y-axis shows the LOD score. Each line represents the linkage result for a 
particular analysis. Parametric linkage (PL) analysis LOD is shown by a continuous 
line and non-parametric linkage (NPL) analysis Kong & Cox Exponential LOD score 
by a dotted line. Each analysis was performed using different allele frequencies, 
denoted by a different colour; allele frequencies obtained from the family in blue for 
the broad phenotypic model and orange for the narrow phenotypic model, equal 
allele frequencies in green and from the CEPH population in red. The blue, orange 
and green lines are not continuously visible as they are masked by the red line. 
a)
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Figure 6.5 Chromosome 1 linkage results are robust to allele frequency testing 
for the broad phenotypic model and narrow phenotype model. Linkage analysis 
was performed with different allele frequencies under the broad (a) and narrow (b) 
phenotypic model. Chromosome 1, from the start of p-terminal to marker rs7513 at 
200cM is displayed on the x-axis. The whole chromosome is not shown as there is 
no LOD >0 past this marker. The y-axis shows the LOD score. Each line represents 
the linkage result for a particular analysis. Parametric linkage (PL) analysis LOD is 
shown by a continuous line and non-parametric linkage (NPL) analysis Kong & Cox 
Exponential LOD score is shown by a dotted line. Each analysis was performed 
using different allele frequencies, denoted by a different colour; allele frequencies 
obtained from the family in blue for the broad phenotype and orange for the narrow 
phenotype. Equal allele frequencies are in green and from the CEPH population in 
red. The blue, orange and green lines are not continuously visible as they are 
masked by the red line.
a)
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Figure 6.6 Chromosome 8 linkage results are robust to allele frequency testing 
for the narrow phenotype model. Linkage analysis was performed with different 
allele frequencies. Chromosome 8, from the start of p-terminal to marker rs1051624 
at 99.5cM is displayed on the x-axis. The whole chromosome is not shown as there 
is no LOD >0 past this marker. The y-axis shows the LOD score. Each line 
represents the linkage result for a particular analysis. Parametric linkage (PL) 
analysis LOD is shown by a continuous line and non-parametric linkage (NPL) 
analysis Kong & Cox Exponential LOD score is shown by a dotted line. Each 
analysis was performed using different allele frequencies, denoted by a different 
colour; allele frequencies obtained from the family in orange, equal allele 
frequencies in green and from the CEPH population in red. The orange and green 
lines are not continuously visible as they are masked by the red line. 
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6.3. Suggestive Linkage Results
6.3.1. Chromosome 4p15-p16
6.3.1.1. Parametric & non-parametric linkage analyses combined
The chromosome 4p15-p16 linkage regions are illustrated in Figure 6.1 to Figure 6.3
and detailed in Table 6.2 and Table 6.5. Figure 6.7 shows the parametric and non-
parametric linkage evidence on chromosome 4p15-p16 illustrated together. Firstly, it 
is evident that both methods of analysis detected linkage to the same locus, as the 
full line for parametric analysis is mirrored by the dotted line for non-parametric 
analysis. There was an exception for the broad phenotypic model at 30-60cM, where 
the evidence peaked in the parametric analysis and dipped in the non-parametric 
analysis. As discussed previously in section 1.10, linkage analysis has the ability to 
detect linkage to a region of ~20cM and thus, the whole region was considered a 
linkage peak. The information content of the SNP genetic markers was consistent 
across the region. 
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Figure 6.7 Parametric and non-parametric linkage analysis on chromosome 
4p14-p16. The x-axis is the genetic position on chromosome 4 from start of p-
terminal to marker rs895615 at 70.64cM. There is no linkage evidence LOD>0 
beyond this marker. The y-axis shows the LOD score. The result of parametric (PL) 
and non-parametric analysis (NPL) for the narrow model is shown by the orange 
and yellow respectively  and by the dark blue and light blue line respectively (b) for 
the broad model. Linkage analysis was performed on all SNP markers. The grey bar 
shows the linked haplotype region as defined by previous work to highlight the 
chromosomal region that segregates with bipolar disorder in the family.
Linked Haplotype
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6.3.1.2. Increased marker coverage on chromosome 4p14-p16
To improve marker coverage in the chromosome 4p15-p16 region, microsatellites 
from the previous linkage study were added (Le Hellard, Lee et al. 2007). There 
were 24 microsatellites available, typed on a range of individuals from the family, as 
listed in Table 2.10. Figure 6.8 shows that the addition of microsatellite data on 
chromosome 4 provided greater information, increasing LOD scores in both 
parametric and non-parametric linkage analysis in the narrow and broad 
phenotypic model. The LOD scores increased in the narrow model to LOD 2.7 over 
a wide linkage peak and in the broad model to LOD 3.6 at rs1476880 (40.15cM) for 
parametric linkage analysis and LOD 3.6 at stb448G15.ca2 (22.17cM) for non-
parametric linkage analysis. The dip in linkage at position 22cM in both models and 
analyses was due to the addition of microsatellite information for some, but not all 
individuals. These missing genotypes contributed to a loss of linkage information. 
The position of the linkage peak corresponded to the position of the linked 
haplotype previously defined by our group for bipolar disorder, shown by the grey
bar. In Figure 6.8a, there was a linkage peak outside of the previously linked 
haplotype at chromosome 4p14, however this was not present in the narrow 
phenotypic region and was likely due to a different spectrum of recombination 
events in individuals with recurrent major depression.
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Figure 6.8 Addition of microsatellite markers increases the linkage evidence 
on chromosome 4p14-p16 under the narrow (a) and broad (b) phenotypic 
model. The x-axis is the genetic position on chromosome 4 from start of p-terminal 
to marker rs895615 at 70.64cM. There is no linkage evidence (LOD>0) beyond this 
marker. The y-axis shows the LOD score. The result of parametric (PL) and non-
parametric analysis (NPL) under the narrow model, is shown by the orange and 
dotted orange line respectively and under the broad model, by the blue and dotted 
blue line respectively. Linkage analysis was performed on all SNP markers, shown 
by grey lines and with SNP and microsatellite markers, shown by the coloured lines. 
The information content for all available markers, both SNPs (dark blue diamond) 
and microsatellites (red diamond) are marked. The grey bar shows the linked 
haplotype region, as defined by previous work to highlight the chromosomal region 
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Figure 6.9 shows the linkage evidence for both phenotypic models combined. 
Although, addition of extra markers did not narrow down the linkage region, it 
does provide support for this locus by increasing the LOD score. Table 6.7 details 
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Figure 6.9 Suggestive evidence for linkage on chromosome 4p. The x-axis the genetic position on chromosome 4 from start of p-
terminal to marker rs1866989 at 65.9cM. There is no linkage evidence LOD>0 beyond this marker. The y-axis shows the LOD score. 
The result of parametric (PL) and non-parametric (NPL) analysis for the broad model is shown by the blue and dotted blue line 
respectively. The result of PL and NPL for the narrow model is shown by the orange and dotted orange line respectively. Linkage 
analysis was performed on all markers available for chromosome 4p, including SNPs and microsatellites. The information content is 
shown for SNPs (blue diamonds) and microsatellites (red diamonds). The grey bar shows the linked haplotype region as defined by 


























MARKER WITH MAXIMUM 
LOD SCORE
LOD ALPHA HLOD
Narrow 4p14-p16 14.11→55.81 62 34.78→ 38.72 rs1477898→rs216113 (10 markers) 2.7 1 2.7
Broad 4p16 17.271→25.34 18 22.17 stb448G15.ca2 3.3 1 3.2
Broad 4p15 29.611→ 55.81 26 40.15 rs1476880 3.6 1 3.6
Table 6.7 Regions of suggestive linkage on chromosome 4 scan using both SNP and microsatellite markers. Both broad and 
narrow phenotypic models were analysed using parametric (a) and non-parametric linkage analysis (b). The chromosome position of 
the linkage peak is from the UCSC genome browser (May04). The support interval is based on the Max 1-LOD rule, LODMAX ≥ 2 which 
is the threshold for suggestive linkage as determined by simulations. It is defined by the first and last position at which the LOD score is 
less than the maximum score minus 1. The highest LOD for each peak is shown at the particular marker position, where more than one 
marker at the same LOD the both are mentioned. Alpha is the estimated proportion of linked families and the HLOD is the 
corresponding maximum LOD. In table b, the LOD score shown is the maximum LOD score for the SNP markers listed. The Z score, 
P-value assuming normal approximation and the Kong and Cox P-value are also listed. The data is sorted according to descending 






















OF Z SCORE DELTA
PROBABILITY OF 
KONG & COX 
LOD SCORE




(mean) 0 9.999 0.0002
Broad 4p16 12.86 →25.34 22 22.17 stb448G15.ca2 3.6 7.99 0 0.789 0.00002
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6.3.1.3. Contribution of each sub-pedigree
The contribution of each sub-pedigree to the linkage result is shown in Figure 6.10. 
It is clear that sub-pedigree 1 contributed principally to the LOD scores, as shown in
Table 6.8. Sub-pedigrees 2 and 4 also contributed to the linkage peak. Table 6.8
shows the LOD scores from each sub-pedigree that were added together to give a 
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Figure 6.10 Parametric analysis on broad phenotypic model per sub-pedigree on chromosome 4. The x-axis is the position on 
chromosome 4 position from the p-terminal to rs1866989 at 65.7cM. The linkage result per sub-pedigree is shown by a different 






























1 10 1.7 1.25 1.7
2 4 0.7 0.725 0.7
3 2 0.1 -0.2 -0.1
4 5 0.8 0.725 -1.08
5 4 0.3 0.2 0.15
6 2 0.2 0.4 0.4
7 1 0.1 0.06 0.09
8 1 -0.1 0.04 0.04
9 3 -0.5 0.4 0.4
Total 32 3.3 3.6 2.3
Table 6.8 Chromosome 4p linkage results from sub-pedigree. The linkage 
results for the sub-pedigrees that are informative for linkage in the broad phenotypic 
model are listed. There are three linkage peaks in the chromosome 4p14-p16 
region. The marker with the highest LOD score in each of the peaks is shown for 
each sub-pedigree.
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6.3.1.4. Contribution of a single affected individual
The linkage results were also tested to see if the peaks were a consequence of one 
individual only, and therefore an artefact of linkage analysis. There are many 
reasons for artefactual linkage peaks for example: interval mapping of widely 
spaced markers can cause problems, as do random fluctuations in marker 
informativeness and erroneous genotypes that give a false impression of a 
recombination event (Ott 1999). The analysis chosen to perform this test was non-
parametric linkage analysis for the narrow phenotypic model, because non-
parametric linkage analysis was not dependent on genetic model assumptions and 
also, the individuals in the narrow model with a diagnosis of bipolar disorder were
most informative. For each linkage analysis, the affection status was set to unknown 
for one individual with a bipolar disorder diagnosis at a time. The LOD score 
reached a limit according to the calculated maximum obtainable LOD score as 
shown in Table 6.9. The maximum LOD score that was obtainable was dependent 
on the informativeness of each individual. For example, removing samples without 
parental information; 29, 102 and 150, the maximum obtainable LOD score was 2.11. 
Conversely, removing more informative samples with parental (inheritance) 
information; 21, 47, 57 and 99, lead to a decrease in the maximum obtainable LOD 
score (1.81).













Table 6.9 Maximum LOD scores obtainable for analysis when removing 
selected affected individuals. The maximum obtainable Kong and Cox 
exponential LOD scores for non-parametric linkage analysis are displayed above. 
The analysis including all seven individuals with a bipolar disorder diagnosis in the 
narrow phenotypic model. The other  results are for analysis with the affection status 
changed to unknown for the individuals specified.
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Figure 6.11 showed the linkage results for chromosome 4, after removing selected 
individuals. Each coloured line showed linkage analysis with one bipolar disorder 
affection status sample removed at a time. These lines can be compared to the 
orange line which showed the linkage analysis for all individuals with bipolar 
disorder diagnoses. It is clear that all individuals contribute to the chromosome 
4p15-p16 peak, and that each analysis reached their maximum obtainable LOD 
score in this region, as shown in Table 6.4. This showed that LOD score was robust 
to removal of single affected individuals. The LOD 1.13 peak at 114cM shows that 
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Figure 6.11 Contribution of a single individual to the linkage results on chromosome 4. The x-axis is the chromosome 4 genetic 
position. The y-axis is the Kong and Cox exponential LOD score from non-parametric linkage analysis. The orange line is the result 
including all seven affected individuals from the informative sub-pedigrees 1 and 4.  The other coloured lines are linkage analysis 
performed with the individual specified affection status set to unknown. The coral and green line for ID29 and ID102 respectively is 
masked by blue line for ID150 at the 4p15-p16 peak. The turquoise line for ID99 masks the lines for ID21, ID47 and ID57 at the 4p15-
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6.3.2. Chromosome 1p36
6.3.2.1. Parametric & non-parametric linkage analyses combined
Another instance of suggestive linkage is illustrated in Figure 6.12, which shows a 
peak on chromosome 1p36 in both narrow (orange) and broad (blue) phenotype in 
both parametric (full line) and non-parametric linkage analysis (dotted line) analysis 
methods. The greatest evidence for linkage at chromosome 1p36 stemmed from the 
narrow phenotypic model. Both methods of analysis, parametric and non-
parametric, had the same linkage peak at chromosome 1p36. The peak was in the 
same location for the broad phenotypic model, but smaller. The bipolar disorder 
candidate gene on chromosome 1p36.22 methylenetetrahydrofolate reductase (MTHFR)
(Gilbody, Lewis et al. 2007), the schizophrenia candidate gene DISC1 (Chubb,
Bradshaw et al. 2008) and region 1q21 (Brzustowicz, Hodgkinson et al. 2000) are 
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Figure 6.12  Parametric and non-parametric linkage analysis on chromosome 1. The x-axis is the position on chromosome 1. The 
y-axis is the LOD score from parametric linkage analysis (PL) and the Kong and Cox exponential LOD score from non-parametric 
linkage analysis (NPL). The information content was calculated for each marker and is shown by a blue-filled square. The results for 
linkage analysis performed using both PL (full line) and NPL (dotted line) analysis methods on both broad (blue) and narrow (orange) 
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6.3.2.2. Contribution of each sub-pedigree
Closer examination of the chromosome 1p36 peak from parametric linkage analysis 
on the narrow phenotype (LOD 1.9) in Figure 6.13 shows the majority of linkage 
evidence stems from sub-pedigree 1 (LOD 1.45), with a contribution from sub-
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Figure 6.13 Parametric linkage analysis in sub-pedigrees 1 and 4 on chromosome 1p36 for narrow phenotype.  The x-axis is 
the position on chromosome 1 from the p-terminal to the q-terminal. The y-axis is the LOD score at each location on chromosome 1. 
The sub-pedigrees informative for the narrow model were sub-pedigree 1 and 4. The grey arrow points to the position of the maximum 
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6.3.2.3. Contribution of a single affected individual
Figure 6.14 illustrates that the linkage peak on chromosome 1p36 was not affected 
by the removal of any single affected individual from the linkage analysis. Six of the 
affected individuals contributed to the linkage peak. However, sample 102 did not 
contribute to the linkage peak at 6.4-8.6cM, as the LOD score increased from LOD 
1.9 (orange line) to LOD 2.11 (green line) with removal of sample 102 from the 
linkage analysis.  With the removal of sample 150 (blue line), there was a linkage 
peak at 136cM [LOD 1.1 rs360636 (136.73cM, 115,132,947bp) - rs2057127 (137.05cM, 
115,525,807bp)] and with the removal of sample 47 (violet line), there was a linkage 
peak at 150cM [LOD 1.8 rs2317232 (151.4cM, 154,501,115bp) – rs1062174 (159.68cM, 
159,224,667bp)]. Both peaks were considered linkage artefacts as they were 





























































NPL Narrow ID 21 ID 29 ID 47 ID 57 ID 99 ID 102 ID 150
Figure 6.14 Contribution of a single affected individual to the linkage results on chromosome 1. The x-axis is the chromosomal 
genetic position from p-terminal to q-terminal. The y-axis is the Kong and Cox exponential LOD score from non-parametric linkage 
analysis (NPL). The orange line is the result including all seven affected individuals from the informative sub-pedigrees 1 and 4.  The 
other coloured lines are linkage analysis performed with the individual specified affection status set to unknown. At the chromosome 
1p36 peak the pink line for ID21, the lavender line for ID 47 and the violet line for ID57 are masked by the turquoise line for ID99, the 
coral line for ID29 is masked by the blue line for ID150. Individuals 21, 29, 47 and 57 are in sub-pedigree 1 and individuals 99, 102 and 
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6.3.3.  Chromosome 8p21
6.3.3.1. Parametric & non-parametric linkage analyses combined
The peak on chromosome 8 overlaps in the parametric and non-parametric linkage 
analysis for the narrow phenotypic model as shown in Figure 6.15. Greater evidence 
was provided by the non-parametric linkage analysis (dotted line), with both 
methods of analysis showing evidence for linkage to the same chromosomal 
location. The information content was consistent across the maximum linkage peak 
at 40cM. Within this chromosomal location are three candidate genes for psychiatric 
illness; a pericentriolar material 1 gene (PCM1) and a calcineurin γ catalytic subunit 
(PPP3CC) which are discussed further in section 6.5, and neuregulin-1 (NRG1) which 








0 20 40 60 80 100 120 140 160 180




PL NPL Information PCM1 PPP3CC NRG1
Figure 6.15 Parametric and non-parametric linkage analysis on chromosome 8. The x-axis is the chromosome 8 genetic position. 
The y-axis is the LOD score from parametric linkage (PL) analysis and the Kong and Cox exponential LOD score from non-parametric 
linkage (NPL) analysis. The information content was calculated for each marker and is shown by a blue-filled square. The location of 
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6.3.3.2. Contribution of each sub-pedigree
To establish the robustness of the linkage results, two checks were performed by 
investigating the contribution of each sub-pedigree and each affected individual to 
the linkage result. Figure 6.16 shows the two sub-pedigrees that contribute to the 
linkage peak on chromosome 8p21. There were two regions i) 20-50cM for sub-
pedigree 1 by the blue line and ii) 40-80cM for sub-pedigree 4 by the turquoise line, 
that overlap at 40cM to produce the linkage peak. This linkage peak at rs2466216 
was produced from a LOD 1.1 from sub-pedigree 1 (four affected individuals) and a 
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Figure 6.16 Parametric linkage analysis in sub-pedigrees 1 and 4 on chromosome 8 under the narrow phenotype model. Two 
families were informative for linkage analysis in the narrow model, sub-pedigree 1 (dark blue) and sub-pedigree 4 (turquoise). The x-
axis is the position on chromosome 8. The y-axis is the LOD score at each location on chromosome 8. The grey arrow points to the 
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6.3.3.3. Contribution of a single affected individual
Figure 6.17 shows the contribution of each affected individual to non-parametric 
linkage analysis on chromosome 8p. Each coloured line shows linkage analysis with 
one bipolar disorder affection status sample removed at a time. These lines can be 
compared to the orange line which shows the non-parametric linkage analysis for 
all individuals with bipolar disorder diagnoses. It is clear that all individuals 
contributed to the maximum LOD score at rs2466216 (40.75cM), where the LOD 
score decreased when each individual was removed. This showed that the 
maximum LOD score was robust to removal of single affected individuals.  
However, the positional effects were not the same; for example removal of sample 
99 (turquoise line) extends the location of the linkage peak by 6cM (15.64cM-
21.74cM) to the p-terminus and removal of sample 21 (pink line) extend the location 
of the linkage peak by 5cM (45.88-50.87cM) in the direction of the q-terminal. The 
position of the candidate gene NRG1 was marked on Figure 6.17 to compare its 
position to the linkage peaks. However, the linkage peaks do not extend to the gene. 
In addition, removal of samples 99 (turquoise line) and 150 (dark blue line), 
produced a linkage peak of LOD 2.1 at three markers; rs2028806 (22.15cM, 
8,967,448bp), rs753012 (22.17cM, 9,019,806bp) and rs735449 (22.22cM, 9,140,857bp) 
that was greater than the linkage peak when all individuals were included (orange 
line), showing that this linkage peak was less robust. This is likely to be due to a 
different spectrum of recombination events in individuals affected with bipolar 
disorder at this chromosomal location. The LOD 1.05 peak at 164cM shows that 
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Figure 6.17 Contribution of a single individual to the linkage results on chromosome 8. The x-axis is the chromosomal genetic 
position from p-terminal to q-terminal. The y-axis is the Kong and Cox exponential LOD score from non-parametric linkage (NPL) 
analysis. The orange line is the result including all seven affected individuals from the informative sub-pedigrees 1 and 4.  The other 
coloured lines are linkage analysis performed with the individual specified affection status set to unknown. At the chromosome 8p21 
peak the coral and green line for ID 29 and 102 respectively is masked by the blue line for ID 150 and the lavender line for ID 47 is 
masked by the violet line for sample 57. The location of the candidate gene NRG1 is indicated. Individuals 21, 29, 47 and 57 are in 
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6.4. Inspection of Haplotypes
6.4.1. Preface
The aim of haplotype analysis was to estimate the haplotypes segregating with 
disease through the family, to position recombination breakpoints and thus define 
the minimum interval that should contain the disease gene. Haplotypes were 
estimated for the regions with suggestive evidence for linkage on chromosomes 
4p14-p16, 1p36 and 8p21. MERLIN estimated the haplotypes corresponding to the 
most likely pattern of gene flow in the sub-pedigrees, as described in section 2.5.9. 
Visual inspection of the marker genotypes was then used to check the construction 
of the estimated haplotype by MERLIN. The haplotype that segregated with bipolar 
disorder samples was defined as the “linked haplotype” for each locus. The samples 
with recurrent major depression were not used to define the linked haplotype, as 
the risk of phenocopies was greater, because recurrent major depression is more 
frequent than bipolar disorder in the general population. The presence or absence of 
the linked haplotype was noted for 10 samples with bipolar disorder diagnoses and 
22 samples with recurrent major depression diagnoses. Three samples were not 
included in the haplotype analysis: sample 19 (recurrent major depression) and 105 
(bipolar disorder) failed to genotype and sample 176 (bipolar disorder) had no 
parental or offspring genotyping information that could be used to define haplotype 
phase. 
6.4.2. Definition of chromosome 4p14-p16 haplotype 
segregating with illness.
Prior to performing the haplotype analysis, there were two types of evidence to 
consider on chromosome 4p14-p16. Firstly, Figure 6.9 shows the linkage evidence 
for chromosome 4p15-p16 [LOD=2.7, parametric and non-parametric linkage 
analysis under the narrow phenotypic model (bipolar disorder samples only)]. As 
shown in Table 6.7, the predicted location of the disease gene according to the 1-
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LOD support interval, for both parametric and non-parametric linkage analysis 
under the narrow phenotypic model, conservatively, was a region of 43.35cM on 
4p14-p15, from rs878283 (6,539,741bp, 12.46cM) to rs725292 (36,965,713bp, 55.81cM). 
In addition, from the parametric linkage analysis under the narrow phenotypic 
model, no locus heterogeneity was detected (α=1) for 41.8cM from rs726111 
(6,030,055bp, 10.85cM) to rs902659 (32,011,211bp, 52.65cM). Secondly, haplotype 
analysis with microsatellite markers and visual construction of the haplotypes had 
been performed before this study (Le Hellard, Lee et al. 2007). This defined a 
haplotype that segregated with bipolar disorder diagnoses. The telomeric boundary 
of the linked haplotype was defined by a recombination event in sample 48
(recurrent major depression) that was inherited by samples 55 (recurrent major 
depression) and 57 (bipolar disorder) distal to rs5017682 (6,633,843bp, 12.6cM). The 
centromeric recombination event was defined by a recombination event before 
microsatellite marker, stb131K9.p1 (26,279,795bp, 46cM) in sample 102 (bipolar 
disorder) and inherited by the bipolar disorder samples 143 and also is samples 99 
and 150. The position of the linked haplotype is marked on Figure 6.18 as 
“previously defined linked haplotype.”
Haplotype analysis was performed within the sub-pedigrees for all SNP markers on 
chromosome 4, as illustrated in Figure 5.1-Figure 5.10. The microsatellite markers 
were not included in the current haplotype analysis, as data were not available for 
many of the samples. Missing data causes difficulties when resolving haplotypes, 
and haplotype analysis with missing data can be error-prone (Schaid, McDonnell et 
al. 2002). Figure 6.18 illustrates the results of the haplotype analysis and shows the 
estimated haplotypes for all affected individuals in the sub-pedigrees. The linked 
haplotype, labelled in orange, segregated with the 10 samples from individuals with 
bipolar disorder. 
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Figure 6.18 Illustration of haplotype analysis on chromosome 4p14-p16 
linkage peak. Haplotype analysis was performed on 10 individuals with a diagnosis 
of bipolar disorder (a) from the p-terminal of chromosome 4 and beyond the linkage 
peak. The haplotype that segregates with illness in each individual is illustrated by 
the orange bar. Haplotype analysis was also performed on 22 individuals diagnosed 
with recurrent major depression (b). 
a)
b)
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At the telomeric end of the chromosome 4 linkage region, a recombination event 
after rs875864 (6,504,754bp, 12.37cM), was observed in sample 48, that was inherited 
by samples 55 and 57. A recombination event at this position was also observed in 
sample 170. Towards the centromere on chromosome 4, there was a recombination 
event observed in sample 102 before rs1456087 (27,180,675bp, 47.14cM) that was 
inherited by sample 143. The recombination event was observed in sample 99 and 
also, sample 150 that was inherited by sample 151. The recombination events in 
samples 57 and 102 conservatively defined the minimum interval of the linked 
haplotype segregating with bipolar disorder. Taking the predicted recombination 
events from haplotype analysis on the SNP data into account, the haplotype that 
segregates with bipolar disorder on chromosome 4 spanned a region of 34.78cM 
(12.37cM-47.15cM).
There were many obstacles relating to the haplotype analysis. One problem was that 
the recombination events predicted by MERLIN were not entirely correct and 
required validation by visual inspection. For example, the recombination event that 
MERLIN predicted at the telomeric region of chromosome 4p15-p16 was not 
accurate. Visual inspection of the designated haplotypes showed that MERLIN was 
not sufficiently conservative in predicting the breakpoint. MERLIN predicted a 
recombination event between markers rs11734660 (15.49cM) and rs1557816 
(19.02cM). However, the preceding two markers, rs875579 (12.86cM) and rs13147693 
(14.11cM), were not informative for haplotype phase determination and so the 
location of the recombination breakpoint could only confidently determined after 
marker rs875864 (12.37cM).
Another difficulty was that samples were contained in more that one sub-pedigree. 
For example, three samples diagnosed with bipolar disorder were in different sub-
pedigrees; sample 21 (sub-pedigrees 1 and 7), sample 29 (sub-pedigrees 1 and 8) and 
sample 102 (sub-pedigrees four and six).  The same haplotype should be estimated 
regardless of the sub-pedigree. However, this was not necessarily the case. The 
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same haplotype was estimated for samples 21 and 29 in both their respective sub-
pedigrees. However, the haplotype for sample 102 was not the same in sub-
pedigrees 4 and 6. A recombination event between 44.72cM and 47.14cM was 
predicted in sample 102 in sub-pedigree 4, but not in sub-pedigree 6. Visual 
inspection of this region showed there was indeed a recombination event in sample 
102 at this position, which was inherited by its descendents (samples 103, 143, 144 
and 156). 
As described above, the individuals with recurrent major depression were not used 
to define the linked haplotype. It was, however, interesting to investigate how many 
carried the linked haplotype as shown in Figure 6.18 (b). Previous microsatellite 
information had shown that 11 samples with recurrent major depression carried the 
linked haplotype (samples 17, 44, 45, 48, 55, 62, 63, 108, 151, 161 and 163) and 11 did 
not have the linked haplotype (samples 12, 34, 40, 59, 83, 84, 124, 125, 152 and 164).
Haplotype analysis in this study showed that eight samples with recurrent major 
depression carried the linked haplotype. The haplotype analysis could not 
determine whether the linked haplotype was carried by samples 108 (sub-pedigree 
6), 161 and 163 (sub-pedigree 9) due to insufficient information. The samples with 
recurrent major depression: 17, 44, 45, 48 and 63 transmitted the defined linked 
haplotype to an affected offspring, ensuring greater confidence in haplotype 
analysis. There were no recombination events that would help to narrow down the 
minimum interval of the linked haplotype (12.6-46cM). 
6.4.3. Definition of chromosome 1p36 haplotype segregating 
with illness
To define the chromosome 1p36 linked haplotype, several pieces of linkage evidence 
were considered. Firstly, there was a region of suggestive linkage on chromosome 
1p36 for the narrow phenotypic model (maximum non-parametric LOD 1.9), as 
shown in Figure 6.12. Secondly, the 1-LOD support interval, from both parametric 
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and non-parametric linkage analyses, narrowed the region of interest to 9.6cM 
(1.72cM-11.33cM). Thirdly, the location of genetic homogeneity under the linkage 
region (α=1) was 9.75cM (0.33cM-10.08cM). Finally, all but one individual (sample 
102) contributed to linkage in this region, as shown in Figure 6.14.
Haplotype analysis covering >60cM on chromosome 1p36, was performed on the 
sub-pedigrees using MERLIN and by visual inspection. Within each sub-pedigree, 
the affected individuals shared a haplotype. Figure 6.19 shows the haplotype 
analysis for seven markers under the chromosome 1p36 linkage peak for three sub-
pedigrees. Four of these markers, rs1870509-rs912991, resulted in the maximum 
LOD 1.9. Figure 6.19a shows that the haplotype which segregates with bipolar 
disorder in samples 21, 29, 47 and 57 is 1-1-2-1-1-1-1 (coloured in purple). Figure
6.19b shows that the haplotype that segregates with bipolar disorder in sub-
pedigree 4, with samples, 102, 150 and 99 is 1-2-2-1-2-2-2 (coloured in pink). 
However, Figure 6.19c shows that the haplotype that segregates with bipolar 
disorder in sub-pedigree 6, with sample 102 again and sample 143 is coloured in 
green, 1-1-2-1-2-2-2. This green haplotype in sub-pedigree 6 is different from the 
pink haplotype segregating with illness in sub-pedigree 4. It is evident that one 
chromosome (pink) from 102, segregates with bipolar disorder in sub-pedigree 4 
and the other chromosome (green) segregates with bipolar disorder, in sub-pedigree 
6. The definition of the haplotypes in sub-pedigrees 4 and 6 for sample 102 rests on 
one marker, rs1870509, that is heterozygous. Comparison of these haplotypes
between the sub-pedigrees, indicates sharing of four consecutive markers (1-1-2-1; 
rs4654522, rs1870509, rs2035453 and rs557477) between sub-pedigrees 1 and 6 and 
indicates sharing of the last three markers (2-2-2; rs912991, rs1570964, rs729206) 
between sub-pedigrees 4 and 6.
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Figure 6.19 Haplotype analysis on chromosome 1p36 linkage peak in sub-
pedigree 1 (a), 4 (b) and 6 (c). Continued on the next page.
b)
a)
Chapter 6 Results of Linkage Analysis
337
Figure 6.19 Haplotype analysis on chromosome 1p36 linkage peak in sub-
pedigree 1, 4 and 6. The name and position in deCODE cM of the seven markers 
tested are listed to the left of the pictures with sub-pedigree 1 (a), 4 (b) and 6 (c).The 
haplotypes were predicted using MERLIN software and the pedigrees were drawn 
with Haplopainter. The gender is disguised by triangles (the usual diamonds were 
not used as they could not disguise the symbols fully) and Haplopainter requires 
gender information to draw pedigree. The filled symbols indicate a diagnosis of 
bipolar disorder. 
c)
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The other samples with a diagnosis of bipolar disorder do not have haplotypes that 
segregate with bipolar disorder in sub-pedigrees 1, 4 and 6. Sample 61 in sub-
pedigree 2 does not inherit the haplotype segregating with disease from sample 44. 
Sample 44 is the sample which is contained in both sub-pedigrees 1 and 2. Sample 
170 in sub-pedigree 7 does not inherit the haplotype segregating with disease from 
sample 17. Sample 17 is contained in both sub-pedigree 1 and 7.
The linkage peak on chromosome 1p36 seems to be a result of the four markers in 
common between sub-pedigree 1 and 6, and the three markers in common between 
sub-pedigree 4 and 6. However, upon investigation at the chromosome level, the 
haplotypes segregating with illness are not the same. The most probable explanation 
is that the markers are identical by state (IBS) and not identical by descent (IBD), 
possibly resulting in the positive linkage results. This is difficult to establish 
conclusively with biallelic markers, but future analysis with multiallelic 
microsatellite markers would resolve this issue.
6.4.4. Definition of chromosome 8p21 haplotype segregating 
with illness
Several aspects of the linkage investigations were collated to assist in the definition 
of a haplotype segregating with illness on chromosome 8p21. In the first instance, 
the linkage evidence for chromosome 8 was solely present in the narrow phenotype 
for both parametric and non-parametric linkage analysis as shown in Figure 6.15
(maximum non-parametric LOD 2.2). The 1-LOD support interval defined a region 
of 8.82cM (38.02cM-46.84cM) in parametric linkage analysis as Table 6.3 and a 
region of 25.1cM (21.74cM-46.84cM) in non-parametric linkage analysis. Secondly, 
genetic homogeneity (α=1) from the parametric linkage analysis was present for a 
region of 7.63cM (38.25cM-45.88cM). Finally, all individuals from sub-pedigrees 1 
and 4 contributed to the linkage peak on chromosome 8p21 as shown in Figure 6.17. 
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Haplotype analysis was performed within the sub-pedigrees, to include the linkage 
peak and beyond using MERLIN and by visual inspection. Haplotypes were also 
analysed at a finer level, in a region defined by the five markers where non-
parametric LOD scores were greater than two: rs900267 (39.34cM), rs2466216 
(40.75cM), rs3924018 (41.21cM), rs310319 (41.91cM) and rs879958 (43.58cM). It was 
difficult to obtain phase for all five markers in many of the bipolar disorder cases. 
MERLIN did not predict the same haplotype phase for the same individual that was 
in two sub-pedigrees (sample 21 in sub-pedigrees 1 and 7). Furthermore, 
examination of the pedigree as a whole did not provide any extra phase 
information.  It did show, however, that three samples were phased: samples 99 and 
150 were phased 1-1-1-1-2, and sample 61 was phased 1-1-1-2-1. The remaining 
seven samples could not be phased. Of these samples, five samples (samples 21, 29, 
57, 102 and 143) were compatible with haplotype 1-1-1-1-2, and seven samples 
(samples 21, 29, 47, 57, 102 and 170) were compatible with haplotype 1-1-1-2-1. 
However, all ten samples with a diagnosis of bipolar disorder are 1-1-1 for the first 
three markers (rs900267, rs2466216 and rs3924018). These markers that are IBS 
possibly contributed to the linkage result. Of the samples that were unable to be 
phased, four samples (samples 21, 29, 57 and 102) are homozygous at the three 
markers. 
In summary, the establishment of haplotypes segregating with bipolar disorder was 
inconclusive for chromosome 1p36 and chromosome 8p21. The reason for this was 
the uninformative nature of biallelic SNPs. Although the markers themselves singly 
had sufficient informativeness: the average information content (IC) of the seven 
markers on chromosome 1p36 is IC=0.89 (range: 0.86-0.90) and the average 
information content over the five markers on chromosome 8p21 is IC=0.86 (range: 
0.83-0.87), they did not provide enough diversity when segregated through the 
family. An ideal situation to establish haplotype phase is when for example, within 
a trio, where both parents are homozygous, but different to each other, for one 
marker (and of course, the more markers the better), transmit one chromosome each 
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to offspring that are heterozygous at this marker. Thus, this enables the source of 
the chromosome to be established and the phase of said chromosome. Undoubtedly, 
conclusive definition of the haplotypes could be achieved with more informative 
microsatellite markers in the future.
6.4.5. Limitations of haplotype analysis
One limitation of this haplotype analysis was the recombination events were 
detected by MERLIN. Although the haplotypes were visually inspected for 
consistencies and segregation, the apparent recombination event, may not be the 
location of the real recombination event, as the surrounding markers may not be 
informative (Speed and Waterman 1996). Conversely, recombination events may be 
missed due to uninformative markers (Hodge, Boehnke et al. 1999). Furthermore, 
MERLIN estimated the most likely haplotype, while this was useful there may have 
been other haplotypes almost as likely. This was one of the major drawbacks of 
using biallelic markers for linkage analysis. 
A further impediment to haplotype construction for this large family was that its 
large size prevented haplotype construction as a whole. Naturally, estimating the 
gene flow in a pedigree would be more informative if the pedigree as a whole was 
considered. Despite this, the chromosome 4p14-p16 haplotype confirmed 
knowledge previously obtained through microsatellite analysis. However, 
appropriate interpretation of this haplotype analysis is important as the linkage 
peaks on chromosome 1p36 and 8p21 may be an artefact of allele frequencies or 
alleles shared IBS but not IBD.
The presence or absence of the linked haplotype on chromosome 4p15-p16 was not 
taken into account for healthy individuals. Bipolar disorder is not a fully penetrant 
disease so the presence of the linked haplotype in unaffected individuals could not 
be used to exclude chromosomal regions. Also the sample 176, which was not 
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included in the haplotype analysis, may carry the linked haplotype on 
chromosomes 4p15 and either potential haplotypes on chromosomes 1p36 and 8p21.
6.5.  Discussion
6.5.1. Preface
The linkage analysis was successful in confirming linkage to chromosome 4p15-p16 
and suggesting other regions of linkage on chromosome 1p36 and 8p21. Reinforcing 
the genetic evidence for chromosome 4 was important, considering the recruitment 
of new individuals to the study and the updated phenotypes. The key benefit of the 
analysis was to exclude other loci of major effect, while suggesting other minor risk 
factor loci. 
Optimisation of the linkage study was of prime concern. Great care was taken to 
ensure well-defined affected individuals were used, by thorough review of case-
notes and repeat interviews. In addition, a “cleaned” genotyping dataset was 
prepared, parameters for significant linkage were established and the robustness of 
reported linkage results was validated. The linkage results were robust to 
perturbations in the data, such as excluding affected individuals in turn and altering 
the allele frequencies. This was important as the allele frequencies were obtained by 
counting all genotyped individuals, which did not take into account family 
information. This could potentially bias towards one chromosome, if many 
offspring from one parent were genotyped. The linkage results were robust to 
changes in allele-frequencies, in turn making the results more credible. This is a 
noteworthy point as misspecification of a genetic model and allele frequencies can 
produce a false-positive LOD score (Clerget-Darpoux, Bonaiti-Pellie et al. 1986). 
Conversely, an over-dogmatic approach to the disease loci hunt may lead to an 
unfortunate oversight which hopefully has not occurred in this study. Finally, the 
effectiveness of any particular technique in linkage analysis, parametric and non-
parametric linkage analysis will usually depend upon the true, but unknown, 
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genetic model applicable to the disease. The evidence for linkage to chromosomes 
4p15-p16, 1p36 and 8p21 as loci of potential importance was supported by both 
parametric and non-parametric linkage analyses. 
Notably, the linkage evidence was greatest in sub-pedigree 1, which had the 
maximum linkage information and the linkage evidence was present in the narrow 
phenotypic model. The linkage evidence for chromosome 4p14-p15 was increased, 
with the addition of microsatellite markers and has support in independent 
samples. The litmus test for chromosome 1p36 and 8p21 will be maintaining the 
linkage evidence and determination of a consistent haplotype that segregates with 
illness in the family. Firstly, addition of informative microsatellites on chromosomes 
1p36 and 8p21 could increase the linkage evidence as shown in this study for 
chromosome 4 and resolve haplotype construction ambiguities. Secondly, 
genotyping of additional families would help discern whether the result is spurious 
or significant. Neither of these chromosomal regions was covered in the original 
genome scan. There were no markers on the p-terminal arm of chromosome 1 and 
only three microsatellite markers on the p-terminal arm of chromosome 8, with the 
nearest marker 20cM away from the linkage peak reported in this study 
(Blackwood, He et al. 1996). 
6.5.2. Chromosome 4p15-p16 linkage evidence
Figure 6.20 illustrates the past and present genetic analyses on this family, which 
have shown the primary locus for susceptibility to bipolar disorder is chromosome 
4p15-p16. The linkage peak defined in this study overlapped with the previously 
known “linked haplotype”, which includes the candidate genes GPR78 and PI4K2B, 
the “allele-sharing region” and the regions of association, as previously discussed in 
section 1.4. Although the LOD score did not reach 4 as originally reported in 1996 
and again in 2006, it still met the genome-wide significance criteria (NPL LOD 3.6
under broad phenotypic model, as listed in Table 6.7). The reason for a decrease in 
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LOD score may be due to many factors including, splitting the family, reduced 
informativeness of SNPs compared to microsatellite markers and the addition of 
affected family members without the chromosome 4p haplotype.
Figure 6.20 Hallmarks of the chromosome 4p15-p16 linkage region. The linkage 
region is defined by the haplotype analysis in Figure 6.18. The positions of the 
markers on the boundary of the region are marked by their genetic position with 
respect to deCODE cM and physical distance with respect to UCSC May 2004, 
NCBI Build 35 assembly of the human genome. The approximate location of 
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In the future, it would be interesting to investigate this family for copy number 
variants as the chromosome 4p arm has many CNV hotspots (Redon, Ishikawa et al. 
2006). Bioinformatic investigation of this region on chromosome 4p16.1 revealed 
eleven CNV loci on this band from the Database of Genomic Variants (Iafrate, Feuk 
et al. 2004). Furthermore, investigation of the DECIPHER database revealed four 
patients with chromosomal abnormalities and with CNV change 
(https://decipher.sanger.ac.uk/). There was phenotype information for one of the 
patients (610) with a copy number change indicating a deletion on chromosome 
4p16.1;p16.3. This individual has neurological, thorax and stature abnormalities. 
With respect to the neurological phenotype, there were mental and cognitive 
abnormalities with mental retardation and developmental delay. 
6.5.3. Chromosome 1p36 linkage evidence
In support of these candidate loci on chromosome 1p36 and 8p21, previous work 
has implicated them in susceptibility to psychiatric illness (Kato 2007). Recent 
evidence has supported an association between methylenetetrahydrofolate reductase 
(MTHFR) on chromosome 1p36 and bipolar disorder, recurrent major depression 
and schizophrenia (Gilbody, Lewis et al. 2007).  In addition, chromosome 1p36 was 
implicated in linkage studies for recurrent major depression. For example, McGuffin 
et al, 2005 performed a genome-wide linkage analysis on 497 sib-pairs concordant 
for recurrent major depression and found suggestive linkage on chromosome 1p36 
(13.8cM-21.8cM) where the LOD score for female-female pairs >3 (McGuffin, Knight 
et al. 2005). This region is just centromeric to the region reported here. Also, a report 
of a chromosome 1p36 peak in four European bipolar disorder families is outside of 
this support interval (LOD 3.3) (Schumacher, Kaneva et al. 2005).  However, there 
are other linkage reports to chromosome 1p36 that overlap with the region, such as
those described for mood disorders (maximum LOD 3.6) (Zubenko, Maher et al. 
2003) and bipolar disorder in a single family (LOD 3.1) (Curtis, Kalsi et al. 2003). 
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This region was also identified in IBD haplotype sharing analysis in psychotic 
patients from Israel (LOD 1.5) (Kohn, Danilovich et al. 2004).
Below the chromosome 1p linkage peak are 22 known genes. The known genes were 
those genes with RefSeq status that are protein-coding genes taken from the NCBI 
mRNA reference sequences collection. None of these 22 genes show immediate 
potential for candidacy to psychiatric illness. The maximum LOD score falls at a 
predicted gene, adherens junction associated protein 1 (AJAP1), also known by its 
Ensembl name as SHREW1, and the gene product is involved in cell invasion 
(Schreiner, Ruonala et al. 2007). An interesting candidate may be KCNAB2 (a 
potassium voltage-gated channel shaker-related) gene that has putative functions 
including regulating neurotransmitter release and neuronal excitability. WDR8 was 
also noteworthy, as this gene encodes a member of the WD repeat protein family. 
WD repeats are minimally conserved regions of approximately 40 amino acids, 
which may facilitate formation of heterotrimeric or multiprotein complexes. 
Members of this family are involved in a variety of cellular processes; including cell 
cycle progression, signal transduction, apoptosis and gene regulation. Although this 
chromosome 1p36 locus did not reach whole-genome wide significance levels, it 
should be subjected to further investigation.
6.5.4. Chromosome 8p21 linkage evidence
As illustrated in Figure 6.15, the chromosome 8 linkage peak is in the same location 
as candidate genes PCM1 and PPP3CC. PCM1 is a pericentriolar material 1 gene that 
is significantly linked to schizophrenia, is associated with orbitofrontal grey matter 
volumetric deficits (Gurling, Critchley et al. 2006) and has been shown to bind to 
kendrin (PCNT) (Li, Hansen et al. 2001) and NUDEL (Guo, Yang et al. 2006), which 
are both binding partners of DISC1. PPP3CC is a calcineurin γ catalytic subunit on 
8p21.3 that is associated with schizophrenia in a United States and South African 
dataset (Gerber, Hall et al. 2003), in a Taiwanese dataset (Liu, Fann et al. 2007) and 
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associated with bipolar disorder in a French cohort (115 bipolar disorder cases and 
97 controls) (Mathieu, Miot et al. 2008). There was a negative association reported 
with PPP3CC to schizophrenia in a Japanese cohort (457 schizophrenia cases and 
429 controls) (Kinoshita, Suzuki et al. 2005) and in a cohort of European descent 
(1,870 schizophrenia and schizoaffective disorder cases and 2,002 controls) (Sanders, 
Duan et al. 2008).
This region was also highlighted from linkage analysis on 40 families from the US 
and Israel on bipolar disorder with psychotic features (multipoint LOD score 3.46) 
(Park, Juo et al. 2004). Furthermore, many linkage studies have implicated this 
region in schizophrenia (reviewed in (Blackwood, Pickard et al. 2007). In particular, 
a recent linkage study on expression of the susceptibility gene for schizophrenia, 
dystrobrevin binding protein (DTNBP1) in the CEPH pedigrees showed genome-wide 
suggestive evidence for linkage to chromosome 8p (maximum LOD 2.77). The 
authors suggest this locus on chromosome 8p12-8p21.1 (rs2169315-rs726908), that 
overlaps with the 1-LOD support interval reported here, exerts a trans-acting effect 
on DTNBP1 expression (Bray, Holmans et al. 2008).
In fact, there were 156 known genes under this linkage peak.  The maximum LOD 
score on chromosome 8p21 was at rs2466215 which falls within the PEBP4
(phosphatidylethanolamine-binding protein 4) gene and the same arguments apply 
to this gene which is involved in the PI pathway, for a candidacy for susceptibility 
to bipolar disorder as does PI4K2B, described in chapter 1. In short, the PI pathway 
is inhibited by lithium for therapeutic effect in bipolar disorder.
6.5.5. Caveats
As in any statistical study, there are many caveats. Firstly, the failure of certain 
samples to genotype reduced the power of the linkage study. For example, 
individual 105 with a diagnosis of bipolar disorder was not genotyped successfully 
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on the Illumina IVb panel. Experiments performed in-house showed the individual 
did not have the chromosome 4p defined linkage haplotype. It would be interesting 
to determine if the person increased linkage evidence to chromosome 1p36 or 8p21. 
Individuals 12, 15 and 19 failed genotyping on one quarter of the 6,008 SNP 
Illumina IVb panels, which meant there was missing genotype information on 
chromosome 4 for these three individuals with recurrent major depression 
diagnoses. Thus, the missing samples and genotyping information may cause a 
reduction in the power to detect linkage and it would be prudent to consider re-
genotyping the individuals for further information.  
Secondly, the decision to split the family was based on the capacity of current 
linkage analysis programs. The linkage analysis may be improved considering the 
family as a whole, as these linkage programmes develop to give exact linkage 
results for large families (Tong and Thompson 2008), as opposed to the estimated 
results produced by programmes such as Simwalk2.
Thirdly, the simulation results would benefit from an increased number of 
simulations, which were not performed due to computational limitations. A 
desirable number of simulations would be 10,000 replicates for both parametric and 
non-parametric linkage analysis, which would ensure stringent significant level 
estimations. It must be noted that the simulations were performed on the initial 
whole genome screen marker data and do not supply significance levels for linkage 
analysis when the marker coverage was increased with microsatellites on 
chromosome 4. According to Lander and Kruglyak “increasing marker density 
around linkage hits has a strong effect on the false-positive rate”(Kruglyak and Daly 
1998). More simulations should be performed to evaluate the level of significance as 
the addition of microsatellites to chromosome 4p14-p16 pushed the LOD scores over 
the suggestive linkage threshold into the significant linkage category Furthermore, 
the results do not reach a Bonferroni significance threshold level for this study 
where, P=0.05/n, where n is the number of independent associations, such that n (m-
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1) for the testing of n loci with m alleles each correction factor. For this study, a P-
value of 8x10-6 would be required for evidence of significant linkage and no markers 
remotely achieved this. However, Bonferroni correction is recognized to be overly 
conservative (Perneger 1998; Ott 1999).
A final argument involves the widespread use of sex-averaged maps for the genetic 
distance of markers. The ratio of male and female genetic map distances vary across 
the human genome. One multipoint linkage study showed that when either all or no 
parental genotypes are available, there was no important difference in the expected 
maximum LOD score or location estimates of the disease locus between the sex-
averaged map and true sex-specific maps (Fingerlin, Abecasis et al. 2006). However, 
if there are genotypes available for only one parent and the recombination rate is 
higher in females, then the LOD score using the sex-averaged map was inflated 
compared to the sex-specific map if only the mothers were genotyped and deflated 
if the fathers were genotyped.  Conversely when the recombination rate was higher 
in males, the LOD was inflated if only the fathers were genotyped and deflated if 
the mothers were genotyped. In this study, the majority of affected trios have either 
both or neither parents genotyped [13 (3 bipolar disorder) affected individuals with 
both parents genotypes and 11 (5 bipolar disorder) affected individuals with no 
parents genotyped].  There are 9 (2 bipolar disorder) individuals where the 
genotyping information is from the mother and 1 bipolar disorder individual where 
only the father is genotyped. However, without knowing the recombination rate 
over the whole-genome, it is not easy to predict the effect on LOD scores.
6.5.6. Future work
As previously discussed, bipolar disorder is thought to be a complex genetic 
disorder. The primary aim of this study was to investigate this family for a single 
susceptibility genetic factor for bipolar disorder and recurrent major depression. In 
keeping with this hypothesis, chromosome 4 remains the most significant region for 
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susceptibility to bipolar disorder and recurrent major depression. The loci on 
chromosome 8p21 and 1p36 may contribute to the hypothesis in the following ways:
i) they may be false positives, a result that could be confirmed by further linkage 
and haplotype analysis, using more informative markers ii) the loci may combine to 
contribute to illness with chromosome 4p15-16 and finally, iii) they are single risk 
factors. However, the latter is not the case as it appears that the chromosome 4 locus
contributes to psychiatric illness in the family.
It would be interesting to investigate the loci revealed in this study for additive, 
multiplicative or epistatic effects. For example, a linkage study for Hirschsprung 
disease (a complex genetic disease that is a common heritable cause of intestinal 
obstruction) have found evidence for oliogenic inheritance with one major loci and 
two other contributing loci (Gabriel, Salomon et al. 2002). This study investigated 
the magnitude of the genetic effects from the three loci to estimate how they 
interact, whether in an additive, multiplicative, mixed multiplicative or epistatic 
fashion. They found that all loci were involved in the manifestation of the illness. 
Application of these notions to this study may prove beneficial in dissecting 
complex mental illness. At present, this analysis requires expensive computational 
resources. Recently novel score statistics have been developed to simultaneously 
scan for two disease susceptibility loci in pedigree data and these may be interesting 
to apply to this dataset in the future (Schaid, McDonnell et al. 2007). It also would be 
interesting to condition the family for the presence of the chromosome 4p15-p16 
linked haplotype and re-analyse the whole genome linkage scan on the basis of this 
stratification. This method was successful in identifying additional risk loci in a 
family with DISC1 risk alleles (Hennah, Tomppo et al. 2007).
6.5.7. Summary
To summarise, it is worth reiterating the importance of studying the genetics of 
large families for complex disorders (Venken and Del-Favero 2007). Any one family 
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is likely carry a single gene variant of major effect or multiple rare genes. The ability 
to identify DISC1 from linkage analysis of a single Scottish family was a proof in 
point. Negative whole-genome association studies and whole-genome linkage meta-
analyses on chromosome 4p should not detract from the evidence provided here. 
These studies by definition, look for common variants whereas, large families lend 
themselves to identification of a rare variants of large effect, as in the case of the 
DISC1 locus (Macgregor, Visscher et al. 2002). This study demonstrated that the 
focus of the hunt for a disease locus for bipolar disorder and the related phenotype,
recurrent major disorder in this family, remains on chromosome 4p15-p16. This 
study has also hinted at other suggestive genetic risk factors that should also be 
considered. It remains to be seen whether these statistically suggestive linkage 
findings yield any findings of biological importance.








Bipolar disorder and recurrent major depression are complex psychiatric illnesses. 
Studies to uncover the genetic component of these disorders are in their early 
stages. Linkage analysis has identified evidence of linkage to bipolar disorder and 
recurrent major depression with markers on chromosome 4p15-p16 in a large 
Scottish family and three smaller families (Blackwood, He et al. 1996; Le Hellard, 
Lee et al. 2007). High-resolution haplotype analysis of this region defined a linked 
haplotype that segregates with bipolar disorder. This region was also supported by 
allele-sharing analysis and a case-control association study (Christoforou, Le 
Hellard et al. 2007; Le Hellard, Lee et al. 2007). This study contributes to this 
research by adopting two approaches i) a candidate gene study and ii) a high 
resolution whole-genome linkage scan.
7.2. Candidate Gene Study
PI4K2B was a worthy candidate gene in many respects. Positional evidence from 
linkage, allele sharing and association analyses had implicated this genomic region 
on chromosome 4p15. Genetic evidence has also suggested other members of the 
phosphoinositide signalling pathway as susceptibility factors for bipolar disorder, 
schizophrenia and recurrent major depression (Kato 2007). Additionally, functional 
evidence supported members of the phosphoinositide signalling pathway as 
candidate genes, as components of the phosphoinositide pathway are inhibited by 
lithium for therapeutic effect in bipolar disorder (Berridge, Downes et al. 1989). The 
salient advantage of this study was the opportunity to investigate this candidate 
gene, in lymphoblastoid cell lines from a large Scottish family with bipolar disorder. 
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PI4K2B expression studies at the allele-specific mRNA and protein level were 
performed using lymphoblastoid cell lines. RNA expression was measured at the 
allele-specific level using Taqman assays. The advantage of this method was the 
sensitivity obtained by comparing the linked haplotype to a series of different 
control alleles from related individuals.  Three PI4K2B SNPs were used to measure 
gene expression levels. Initially, standard curves of homozygote gDNA dilutions 
were created, to look for a deviation from the expected 1:1 allelic ratio in cDNA. 
Despite optimisation attempts, the standard curves did not achieve the required 
sensitivity to detect small differences. However, the standard curves were useful to 
show that a gross deviation in allele-specific expression was not present. A second 
method, which compared expression in cDNA to that seen in gDNA from 
heterozygous samples, proved more sensitive. There was, however, no evidence for 
a difference between samples with the linked haplotype and those without. PI4K2B 
protein expression was also quantified. This method required much optimisation, to 
ensure the specificity of antibodies, the sensitivity of protein detection and the 
reliability of quantification methods. At the protein level, there was no evidence to 
suggest a difference in PI4K2B expression between samples with the linked 
haplotype and those without.
Although the expression studies showed no evidence for abnormal PI4K2B RNA 
and protein levels, it must be stated that there were a number of technical 
limitations to this study. Firstly, the number of heterozygotes available for two of 
the SNPs used to measure allele-specific expression was small and therefore, not 
well powered to detect an expression difference between groups. Secondly, 
regardless of efforts to maintain constant protocols for RNA, DNA and protein 
preparations throughout the study, experimental variation was an inevitable side-
effect. Thirdly, and despite efforts to find alternatives (PeakPicker method in place 
of Taqman Assays and fluorescent antibody detection to improve Western blotting), 
no technique was sufficiently sensitive or reliable to measure PI4K2B expression 
differences. 
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The candidacy of PI4K2B was also tested by increasing the marker density in the 
PI4K2B genomic region in a case-control association study. This study showed 
evidence for association of schizophrenia, but not bipolar disorder, with tagging 
SNPs from the PI4K2B genomic region. Two-marker haplotypes were also 
associated with bipolar disorder and schizophrenia. The association of SNP 
rs313548 with schizophrenia withstood permutation analysis and may suggest the 
presence of disease susceptibility variant in this region, but replication studies are 
required to confirm or refute this. 
7.3. Whole Genome Linkage Study
The evidence for a bipolar disorder locus on chromosome 4 arose from linkage 
analysis on a large Scottish family, performed in 1996. Here, the linkage evidence for 
bipolar disorder and recurrent major depression was re-examined in the same 
family. This was important because additional affected family members had been 
recruited and advances in technology made it feasible to cover all chromosome 
regions more uniformly and more densely than had been previously possible. 
Stringent genotyping and pedigree error checks were performed to ensure an 
optimised dataset for analysis. Markers that could potentially inflate linkage 
evidence were removed, such as markers in LD with each other, markers that failed 
a proportion of genotyping, markers that failed Mendelian segregation checks and 
markers that failed Hardy-Weinberg equilibrium tests. Pedigree errors, including 
sample duplication, were also detected and resolved. Additionally, computation 
constraints necessitated sub-dividing the whole family for linkage analysis.
A whole-genome linkage scan was performed using both parametric and non-
parametric methods. Two phenotypic models were tested; a narrow phenotypic 
model with only bipolar disorder cases and a broad phenotypic model with bipolar 
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disorder and recurrent major depression cases. Genome-wide suggestive evidence 
was observed on chromosomes 4p15-p16, 8p21 and 1p36 (non-parametric LOD for 
narrow phenotypic model 2.4, 1.9 and 2.2 respectively). Following the addition of 
chromosome 4 microsatellite markers genome-wide evidence for significant linkage 
was observed on chromosome 4p15-p16 (non-parametric LOD 3.6 for broad 
phenotypic model). The robustness of the linkage evidence was tested by varying 
allele frequencies, by removing one affected individual at a time and by performing 
simulation analysis to determine the significance of the results. The three linkage 
peaks withstood these tests. Importantly, there are previous linkage and association 
studies to bipolar disorder, schizophrenia and recurrent major depression that 
support these three loci. Haplotype analysis demonstrated that a consistent 
haplotype segregated with bipolar disorder on chromosome 4p15-p16. Haplotypes 
that segregated with bipolar disorder on chromosome 1p36 and 8p21 were also 
defined. This analysis provided stronger evidence for the segregation of a consistent 
haplotype with most cases of bipolar disorder on chromosome 8, than on 
chromosome 1. However, no firm conclusions can be drawn without further 
analysis with more informative microsatellite markers.
The analysis clearly supported the evidence for a susceptibility locus of bipolar 
disorder and recurrent major depression on chromosome 4p15-p16 and identified 
other genetic loci that may confer risk to psychiatric illness. The lack of evidence 
supporting chromosome 4p15-p16, 1p36 and 8p21 from whole-genome association 
studies should not depreciate the data provided here. These studies by definition 
look for common variants and were successful in identifying association of SNPs for 
Crohn’s disease, diabetes and cancer. One reason for this success was the ability to 
define reliable and valid phenotypes, which is not yet feasible for bipolar disorder. 
There are many caveats to linkage analysis. Firstly, the three linkage peaks did not 
reach the threshold required for highly significant linkage, as established by the 
permutation analysis (LOD>5.32) and may be false positive results. Linkage 
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artefacts can occur for many reasons including errors in diagnoses, gender 
specification, marker allele frequencies, map order, map distances, genotype calling, 
DNA quality and family relationships. Despite testing extensively for these 
inaccuracies, some errors are almost undetectable and may have been present 
(Pompanon, Bonin et al. 2005). Secondly, the linkage results did not narrow the 
search for the disease gene as the 1-LOD support regions cover large regions of 
chromosome 4p15-p16, 1p36 and 8p21. 
7.4. Future Work
This study showed that there was no direct evidence for a role of PI4K2B in 
susceptibility to bipolar disorder from lymphoblastoid cell lines. However, the 
technical methods and analyses developed could be applied to other candidate 
genes. Nevertheless, this candidate gene still merits further investigation to assess 
its potential role in psychiatric illness, because of the significant case-control 
association study result that withstood permutation testing. In the future, PI4K2B
could be tested for association to bipolar disorder and schizophrenia in other 
Scottish samples, as well as those derived from other populations. A replication 
study should follow stringent criteria to allow clear and unambiguous 
interpretation of the results, to establish or refute association (Chanock, Manolio et 
al. 2007). Furthermore, sequencing of the risk haplotypes in samples with 
schizophrenia could be applied to search for functional variants.
The linkage evidence could be enhanced by performing linkage analysis using new 
computational methods, that promise accurate LOD score calculations, when the 
pedigree size and marker number are large (Tong and Thompson 2008). In addition, 
it would be interesting to perform a more comprehensive analysis on interacting 
genetic loci. Also, it would be prudent to re-genotype the samples that failed 
genotyping as they may provide additional information. Moreover, it is imperative 
to follow-up the linkage peaks, by performing haplotype analysis using multiallelic 
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microsatellite markers, to establish inheritance of a consistent haplotype with 
illness. 
Indeed new technologies can be embraced in the search for the genetic basis to 
bipolar disorder. In particular, the linkage peaks reported in this study are ideal 
candidates for genome resequencing. Recent technological advances make genome 
resequencing a salient prospect for the near future, incorporating sequencing 
technologies such as Solexa from Illumina, SOLiD™ from Applied Biosystems and 
454 Life Sciences™ from Roche Applied Science. Sequencing of the large genomic 
regions could survey protein coding, intronic and intergenic sequences for 
structural variations and point mutations (Stratton 2008). 
The availability of large-scale, high-throughput and high-quality assays should 
enable the discovery of crucial disease variants. For example, microarray gene 
expression analysis aims to understand complex functional mechanisms and can be 
applied to the search of unknown exons, protein-DNA interactions, protein-RNA 
interactions and structural analysis (Hoheisel 2006). In the future, gene expression 
profiles for bipolar disorder patients would be tremendous to understand the 
biological process of the illness, such has been performed previously in studies of 
cancer analysis where gene expression profiling helped to identify new subtypes 
and predict clinical outcomes (Nevins and Potti 2007). Access to relevant biological 
tissue, specific for the illness itself or a reliable proxy, will be key to the long-term 
applicability of these methods.
Emerging technologies also allow investigations beyond the present capabilities. 
One example is the ability to assay for chromosomal inversions by single-molecule 
haplotyping, which is an improvement on current cytogenetic techniques (Turner, 
Shendure et al. 2006). Another example is the inclusion of copy number variants 
probes on whole genome SNP arrays, such as the Genome-wide Human SNP Array 
6.0 from Affymetrix or the Human 1M BeadChip from Illumina. Both technologies 
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have greater than one million SNP and CNV probes for whole genome genotyping 
applications, which is double the coverage than was available 12 months ago. 
Prudent application of this technology to genetic studies of bipolar disorder will 
hopefully improve the understanding of the biological basis of the illness.
7.5. Conclusions
The search for genetic susceptibility to bipolar disorder and recurrent major 
depression is still in its infancy. This study has made a contribution to this search in 
two respects, i) PI4K2B is no longer a preferred candidate gene in the large Scottish 
family, as there was no evidence for a difference in allele-specific and protein 
expression between samples, with the linked haplotype and those without the 
linked haplotype and ii) chromosome 4p15-p16 remains the priority location for a 
genetic susceptibility factor to bipolar disorder in this family, as there are no other 
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Constructs new data points from a discrete 
set of known data points
y=ya + ((x-xa)(yb-ya)/(xb-
xa)) at the point (x,y) 




Mean error rate 
per locus
Ratio between ml, the number of single-locus 
genotypes including at least one allelic 





Calculate a desired significance level from 
simulations
(#>T)/(Total #) = 0.05 or 
0.01
Nth moment





A measure of the asymmetry of a 
distribution. For a symmetrical distribution, 
the coefficient is zero. Significant positive 
values have a long right tail. Significant 
negative values have a long left tail. A 
skewness value more than twice it’s 
standard error indicates a departure from 





A measure of the spread of the distribution. 
For a normal distribution the coefficient of 
kurtosis is zero. Positive kurtosis indicates 
the observations cluster more and have 
longer tails than those in normal 
distribution. Negative kurtosis indicates the 
observations cluster less and have shorter 






Parameters for Parametric Linkage Analysis
Parametric linkage analysis required disease locus parameters to be specified. Below 
are the files for each of the three disease models evaluated. The first line for each 
model notes the name “Trait” and the trait/disease frequency in the population. The 
following nine lines specify the penetrance function for each liability class, one to 
eight. Liability class one to four applies to individual in good mental health in age
classes: <20 years, 20-30 years, 31-40 years and >40 years. Liability class five pertains
to founder individuals who are married into the family. Liability class six relates to 
individuals with a bipolar disorder diagnosis and liability class seven to individuals 
with a recurrent major depression diagnosis. Liability class eight applies to 
individuals diagnosed with other psychiatric illness including anxiety states, 
alcoholism, single episode depression or minor depression. Please refer to chapter 1 
and 6 for further explanation of the disease models.
a) Dominant model under the broad phenotypic model
TRAIT 0.03
LIABILITY = 1 0.016,0.250,0.250 
LIABILITY = 2 0.024,0.390,0.390
LIABILITY = 3 0.038,0.610,0.610
LIABILITY = 4 0.047,0.750,0.750
LIABILITY = 5 0.047,0.750,0.750 
LIABILITY = 6 0.005,0.290,0.290 
LIABILITY = 7 0.047,0.750,0.750 
LIABILITY = 8 0.500,0.500,0.500 
OTHERWISE 0.500,0.500,0.500
b) Dominant model under the narrow phenotypic model
TRAIT 0.007
LIABILITY = 1 0.001,0.046,0.046 
LIABILITY = 2 0.003,0.195,0.195
LIABILITY = 3 0.004,0.230,0.230
LIABILITY = 4 0.005,0.290,0.290
LIABILITY = 5 0.005,0.290,0.290 
LIABILITY = 6 0.005,0.290,0.290 
LIABILITY = 7 0.500,0.500,0.500




c) Recessive model under the broad phenotypic model
TRAIT 0.12 * DB_Recessive
LIABILITY = 1 0.001,0.001,0.150 
LIABILITY = 2 0.001,0.001,0.620
LIABILITY = 3 0.001,0.001,0.700
LIABILITY = 4 0.001,0.001,0.700
LIABILITY = 5 0.001,0.001,0.700 
LIABILITY = 6 0.001,0.001,0.700 
LIABILITY = 7 0.001,0.001,0.700 
LIABILITY = 8 0.500,0.500,0.500
OTHERWISE 0.500,0.500,0.500
Appendix
387
11. Appendix C
Published Paper
